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 1     Introduction 
1. Introduction 
1.1 Diabetes mellitus: classification, diagnosis and pathophysiology 
 
Diabetes mellitus (DM) represents a group of metabolic disorders with the lead symptom 
hyperglycemia [1]; the loss of glycemic control is induced by a dysfunction in the metabolism 
of the hormone insulin which is responsible for blood glucose regulation; hyperglycemia is 
characterized either by a defective insulin secretion (insulin deficiency) of the beta cells of the 
pancreas or an impaired pharmacodynamic of insulin on its target organs, mainly muscle and 
liver cells (insulin resistance), or both. According to the etiological classification of the 
American Diabetes Association (ADA) diabetes mellitus is sub-divided into four main 
categories: type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), other specific 
types and gestational diabetes mellitus [2] (see Table 1).  
 
Table 1: Etiologic classification of diabetes mellitus [2] 
Type 1 diabetes (beta-cell destruction, usually leading to absolute insulin deficiency) 
A. Immune mediated 
B. Idiopathic 
Type 2 diabetes (may range from predominantly insulin resistance with relative insulin 
deficiency to a predominantly secretory defect with insulin resistance) 
Other specific types 
A. Genetic defects of beta-cell function 
B. Genetic defects in insulin action 
C. Diseases of the exocrine pancreas 
D. Endocrinopathies 
E. Drug- or chemical-induced 
F. Infections 
G. Uncommon forms of immune-mediated diabetes 
H. Other genetic syndromes sometimes associated with diabetes 
Gestational diabetes mellitus  
 
T1DM, also called insulin dependent diabetes mellitus accounts for approximately 6-7% of 
diagnosed cases in Germany and is mediated by an autoimmune destruction of the ß-cells of 
the pancreas. Its acute manifestation is accompanied with symptoms of glucose induced 
diuresis, exsiccation and polydipsia [3].  
T2DM, also referred to as non-insulin dependent diabetes mellitus or adult-onset diabetes 
mellitus is characterized by insulin resistance and a relative insulin deficiency; at the onset of 
the disease insulin secretion is predominantly insufficient and delayed in the early 
postprandial phase, whereas the basal blood levels are normal or can even be elevated in the 
late phase. However, during the course of disease insulin secretion can worsen and lead to an 
absolute insulin deficiency. Apart from lack of physical activity, hypertension and 
dyslipoproteinemia, adipositas, especially affecting the visceral fat tissue, are the main drivers 
of the insulin resistance [1]. Onset of T2DM is usually subtle and epidemiologic studies show 
that the metabolic dysfunction precedes the clinical diagnosis for years. Manifestation of 
T2DM occurs if the insulin resistance is no longer compensated by the impaired insulin 
secretion; individuals exhibit abnormal plasma glucose concentrations but are usually free of 
symptoms. According to the ADA recommendations diabetes mellitus can be diagnosed as 
described in Table 2 [2]; unless hyperglycemia is unambiguous, diagnosis must be confirmed 
on a subsequent day by any of the three other methods given.  
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Table 2: Criteria for the diagnosis of diabetes mellitus [2] 
HbA1C ≥6.5%. The test should be performed in a laboratory using a method that is NGSP certified 
and standardized to the DCCT assaya. 
FPG ≥126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 ha. 
2-h plasma glucose ≥200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as 
described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose 
dissolved in watera. 
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma 
glucose ≥200 mg/dl (11.1 mmol/l). 
a In the absence of unequivocal hyperglycemia, criteria 1–3 should be confirmed by repeat testing. 
HbA1c, glycated haemoglobin. FPG, fasting plasma glucose. OGTT, oral glucose tolerance test. WHO, World 
Health Organization. 
 
The prediabetic stages of impaired glucose tolerance (IGT) and impaired fasting glucose 
(IFG) are defined by a 2-hour postprandial glucose level of 7.8 to 11.1 mmol/l and a fasting 
blood glucose level of 5.6 to 7 mmol/l, respectively. Individuals suffering from these 
conditions are at high risk and should be monitored tightly and offered measures to eliminate 
factors that promote development of diabetes mellitus [1]. 
 
All forms of diabetes lead to microvascular and macrovascular complications. 
Hyperglycemia-induced injury of blood vessels is mediated by upregulated pathological 
sideways of glucose metabolism. The damaged endothelial cells and pericytes trigger 
atherosclerotic transformations which eventually lead to microangiopathies such as 
retinopathy, neuropathy and nephropathy and macroangiopathies of the heart, brain and 
extremities translating into coronary heart disease, heart failure, heart attack, stroke, 
(peripheral) artery disease, amputation of diabetic foot and more [3]. 
 
1.2 Epidemiology and burden of disease of type 2 diabetes mellitus 
 
Growing levels of obesity and physical inactivity together with an ageing population and a 
greater longevity among patients with T2DM account for the increasing rise of this emerging 
pandemic worldwide. Globally the prevalence of T2DM  rose from 171 million people in 
2000 to 220 million people in 2004 and estimates predict an increase to 380 million for the 
year 2025 [4]. National surveillance data from the United States showed that from 1980 to 
2011 the age-adjusted incidence for all forms of diabetes increased from 3.5 to7.6 cases per 
1,000 population per year [5]. This menacing trend is reflected in numbers on a national level, 
too. In Germany the prevalence for DM lies between 7-8% of the general population, of 
which T2DM accounts for  80-90% of all cases [1,6]. According to data from a nationwide 
statutory health insurance (SHI) record the prevalence is expected to rise from 4.7% to 6.7% 
from 2008 to 2020; the one year incidence per 1,000 population is estimated to step up from 
2.2 to 3.1 cases in that period [7]. These figures may even underestimate the real burden of 
disease since numbers refer only to diagnosed patients and definition of T2DM for identifying 
eligible patients in the database was rather restrictive. 
 
The mean age of newly diagnosed patients equals approximately 60 years [1,7]. The main 
hazard for developing T2DM is summarized by the term metabolic syndrome which is 
defined by visceral adiposity plus two additional items from the following elements: abnormal 
trigylcerides, decreased high density lipoprotein cholesterol, hypertension or impaired fasting 
glucose [1]. Further risks are a positive familial anamnesis, higher age, lifestyle factors such 
as socioeconomic status, lack of physical activity, nutrition with a high fat content and 
smoking, drugs that interfere with glucose metabolism, gestational diabetes mellitus and other 
endocrine disorders [8]. 
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About 80% of patients with T2DM develop cardiovascular complications which are by far the 
main drivers of morbidity and mortality [1]. Almost every second patient with T2DM dies 
from a cardiovascular cause; angina pectoris, myocardial infarction, stroke, peripheral artery 
disease, and congestive heart failure are associated with T2DM [4]. Evidence shows that the 
risk of myocardial infarction in people suffering from diabetes equals that of non-diabetic 
persons with a history of myocardial infarction [9]. Even in the context of the metabolic 
syndrome where patients exhibit multiple cardiovascular risk factors evidence suggests that 
type 2 diabetes acts as an independent predictor. Thus, the adjusted risk for the development 
of myocardial infarction and stroke of diabetics compared with healthy controls was increased 
1.5- to 4.5- fold in women and 1.5- to 2- fold in men and 2- to 6.5- fold in women and 1.5- to 
2- fold in men, respectively [10]. 
 
Regarding the microvascular complications T2DM is the main reason for end-stage renal 
disease and accounts for up to 50% of patients undergoing renal replacement therapy [4]. 
Incidence rates of renal failure average 6 events per 1000 person years; of these patients one 
third dies and the others require dialysis [11]. Moreover diabetic retinopathy is the most 
common cause of blindness among people aged 30-69 years. It is estimated to account for 5% 
of all cases of blindness globally [4]. Furthermore, regarding T2DM the prevalence of 
diabetic neuropathy is in the range of 13-46% [1].  Affected patients have a more than 25- 
fold increased risk of amputation compared to people without diabetes [4]. The prognosis of 
patients already having diabetic complications is fairly poor. For example the median survival 
of patients referred to a diabetes clinic was only 61 months; likewise, odds ratios for all cause 
and cardiovascular mortality in patients with diabetic retinopathy compared with non-diabetic 
controls were 5.1 and 5.6, respectively [12]. 
 
Astonishingly a substantial proportion of newly diagnosed patients already suffer diabetic 
complications. For instance, data from an evaluation of a disease management program in 
Germany revealed several comorbidities already present at the time of diagnosis such as 
hypertension (83.8%), dyslipidemia (65.2%), coronary heart disease (27.1%), peripheral 
artery disease (10%), heart failure (8%), heart attack (6.9%) and stroke (5.8%). Even the 
diabetes related complications neuropathy, retinopathy and nephropathy existed to a 
considerable degree at baseline affecting 20.4, 10.7 and 9.9% of patients, respectively [13]. 
 
T2DM also has an important impact on health-related quality of life (HRQoL). A pooled 
analysis of four population based surveys showed that HRQoL measured by the physical 
components of the 36-item Short Form Health Survey (SF-36) was significantly decreased in 
diabetics [14]. 
 
The impact of premature death in patients with T2DM is well documented. It is assumed that 
life expectancy on average is shortened by 5-10 years [15]. A German cohort study estimates 
that life years lost in diabetics depending on the socio-economic status range from 4.88-7.97 
[16]. 
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1.3 Health economic burden of disease of type 2 diabetes mellitus 
 
Apart from the burden of disease the care and treatment of patients with DM has a substantial 
economic impact on health care expenditures. In the US alone, treatment of diabetic patients 
is estimated to exceed 100 billion dollars each year [17]. Regarding T2DM a cost of illness 
study focusing on the diabetes-related complications revealed that costs per year increased by  
USD ($) 1,087(50%), $ 7,352 (360%), and $15,675(771%) for patients with cardiovascular 
drug therapy, after a major cardiovascular event and for end stage renal disease, respectively, 
compared to patients with T2DM without any complications [18].  
A Germany costing study estimated the direct medical excess costs of individuals with T2DM 
(diagnosed and undiagnosed) compared with individuals without the condition from a societal 
perspective including indirect cost such as productivity losses to rise from EUR (€) 11.8 
billion in 2010 to €21.1 billion in 2040 [19]. Even if the indirect costs are ignored, another 
study indicates that patients with T2DM incur more than four times higher direct costs than 
patients without the disease mainly due to inpatient costs of diabetic-related complications 
and that these costs account for 14.2% of total health care costs in Germany [20].   
 
1.4 Oral antidiabetic drugs as monotherapy for the treatment of type 2 
diabetes mellitus 
 
An comprehensive and effective diabetes care should encompass several aspects: reduction of 
morbidity and mortality including the cardiovascular risk, avoiding diabetes-related acute and 
chronic complications, elimination or relief of symptoms by optimizing metabolic control 
with respect to blood glucose, glycated haemoglobin, lipids, body-mass index (BMI) and 
blood pressure (see Table 3), treatment of comorbidities and improvement of HRQoL [6].  
 
Table 3: Therapeutic targets of metabolic control for diabetics [6] 
Indicator Therapeutic range 
Blood glucose 
- fasting 
- 2 hour postprandial 
 
90–120 mg/dl (5.0–6.7 mmol/l) 
130–160 mg/dl (7.2–8.9 mmol/l) 
HbA1c 6.5% 
Lipids LDL-C < 100 mg/dl (< 2.5 mmol/l) 
Secondary goals: 
HDL-C > 40 mg/dl (> 1.0 mmol/l) 
Fasting TG < 150 mg/dl (< 1.7 mmol/l) 
BMI < 25kg/m2 
Blood pressure Systolic <130 mmHg 
Diastolic < 80 mmHg 
HbA1c,  glycated haemoglobin. LDL-C, low density lipoprotein cholesterol. HDL-C, high density lipoprotein 
cholesterol. Tg, triglycerides. BMI, body-mass index. mmHg, unit of blood pressure.  
 
To achieve these goals a multifaceted approach is necessary which goes far beyond the 
pharmacological management of hyperglycemia. However, since the scope of this work 
focuses on the relative efficacy and safety of oral antidiabetic drugs as monotherapy the other 
aspects of disease management and therapeutic regimes other than oral monotherapy will only 
be outlined shortly. 
Non pharmacological interventions such as patient education, increased physical activity, 
low-caloric diet and weight decrease constitute always essential components of every 
treatment strategy.  
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In randomized controlled trials (RCT) such lifestyle interventions have proven to be able to 
reduce the incidence of T2DM in people with impaired glucose tolerance [21,22]. Moreover, 
smoking is a further risk factor for nephropathy an retinopathy [1].  
Thus, diabetic patients should be motivated to give up smoking. Self-monitoring of blood 
glucose (SMBG) is another integral part of diabetes self-management. However it must be 
differentiated which subgroups of diabetics benefit from SMBG. There is consensus that 
patients with insulin therapy profit from self-measurement the frequency of it depending on 
the intensiveness of drug regimen [1,23]. For patients with T2DM on oral antidiabetic drugs 
the evidence is controversial. A benefit assessment of the Institute for Quality and Efficiency 
in Health Care (IQWiG) a German health technology assessment body which is 
commissioned by the Federal Joint Committee (GBA) which is the highest decision-making 
body of the joint self-government of physicians, dentists, hospitals and the statutory health 
insurance in Germany concluded that there is no proof of benefit [24]. Neither observational 
studies yielded an association between SMBG and decreased mortality or morbidity, nor did 
interventional studies show a considerable effect of the intervention. Although SMBG showed 
a statistically significant but clinically non-relevant difference in lowering glycated 
haemoglobin (HbA1c) (the difference in means (MD) was -0.23% in favour of SMBG; 0.95 
confidence interval (CI0.95):[-0.12;-0.34]), there were no statistically significant differences 
regarding hypoglycemia, body weight or HRQoL. As a consequence of this assessment the 
GBA decided that SMBG is no longer reimbursed by the SHI apart from some exceptions 
[25]. 
 
The control of existent risk factors predominantly hypertension and dyslipidemia as well as 
the treatment of comorbidities such as heart failure, chronic kidney disease, retinopathy, 
neuropathy and foot ulcers play a vital role in the medical management of diabetics. For 
hypertension and dyslipidemia it has been shown that they are independent predictors that  
increase the incidence of nephro- and neuropathy and coronary heart disease, respectively 
[26-28]. Thus it is advisable to treat diabetics with blood pressure lowering agents such as 
angiotensin converting enzyme- inhibitors or angiotensin II receptor blockers which show 
additional renal benefit and lipid lowering agents, especially statins to therapeutic targets [1]; 
nevertheless excessive lowering of blood pressure and lipids did not improve cardiovascular 
outcomes [29,30]. Furthermore, patients at high risk for cardiovascular events should receive 
antiplatelet therapy with low dose acetylsalicylic acid or Clopidogrel. 
The incidence of heart failure is 2-4- fold higher in diabetics than people without; patients 
should be treated according to clinical guideline algorithms with special regard to the 
adequate selection of drugs due to diabetic-related complications, e.g. renal dysfunction. 
For the prevention of microangiopathies like chronic kidney disease, retinopathy, neuropathy 
and food problems tight metabolic control (blood glucose, lipids and blood pressure) together 
with screening for complications like albuminuria, decrease of renal function, altered vision, 
peripheral loss of sensitivity and food examination are fundamental [23]. 
 
Based upon the symptoms and the level of hyperglycemia at diagnosis and after non-
pharmacological interventions are not sufficient anymore pharmacological treatment of 
T2DM is usually initiated with an oral antidiabetic drug (OAD) as monotherapy (see chapter 
1.5) if hyperglycemia is moderate; given that hyperglycemia is pronounced or patients present 
with symptoms and metabolic decompensation, oral combination therapy or initiating insulin 
therapy may be considered [6,23,31]. Due to the progressive nature of disease adaption of 
therapeutic strategies is necessary if glycemic targets are no longer met. Usually oral 
monotherapy is extended by a second and third antihyperglycemic agent; after glycemic 
failure of oral treatment the transition to injectable therapy takes place.  
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This is the domain of rapid-, short-, intermediate-, long acting and premixed insulin analogues 
as well as the newer generation of glucagon-like peptide 1(GLP-1) receptor agonists, e.g. 
Exenatide, Liraglutide and Lixisenatide. These drugs can be administered in a variety of 
therapeutic regimes such as monotherapy, combination therapy among each other or 
combination therapy with OAD which is displayed by the different therapeutic algorithms of 
the corresponding clinical guidelines [1,23,31]. 
 
Epidemiological studies have shown a correlation between the surrogate HbA1c and micro- 
and macrovascular risk. For example, in the UKPDS 35 study each 1% reduction in HbA1c 
was associated with a reduction of the risk for diabetes related death, myocardial infarction 
and microvascular complications of 21%, 14% and 37%, respectively [32].  
 
Moreover, several interventional studies confirmed the positive effect of hyperglycemic 
control on the reduction of microvascular complications. In a large clinical trial intensive 
glucose control of Gliclazide plus other OAD to achieve HbA1c targets below 6.5% versus 
normal glucose control reduced the risk for microvascular events (hazard ratio (HR):0.86; 
CI0.95:[0.77;0.97]; p-value (p)=0.01), a finding which was mainly driven by the reduced 
incidence of nephropathy (HR:0.79; CI0.95:[0.66;0.93]; p=0.006); indeed the benefit was 
narrowed by weight gain (MD:0.7kg; p<0.001) and an increased incidence of severe 
hypoglycemia (HR:1.86; CI0.95:[1.42;2.40]; p<0.001) in the intensive glucose control group 
[33]. In the UKPDS 33 study, after a follow-up of 10 years patients with T2DM who were 
administered an intensive antihyperglycemic treatment (sulfonylurea or insulin) displayed  a 
reduced incidence of a combined microvascular endpoint, including the risk of retinal 
photocoagulation, compared to patients treated with diet only (relative risk (RR):0.75; CI0.95: 
[0.6;0.93]) [34]. Evidence for a prevention of macrovascular events by drug intervention is 
scarce, only one trial in obese patients yielded a positive effect [35] (see Metformin).  
 
On the other hand the approach to aim at very tight glucose control bears risks for patient 
safety, too. In a trial with a very ambitious glycemic target of HbA1c < 6% the higher 
mortality in the intensive-therapy group led to early discontinuation [36]. 
 
Thus, clinical guidelines are determined by the positive effect of drugs mainly on 
microvascular complications on the one hand and of reservation against a too restrictive 
lowering due to excess mortality on the other hand and recommendations suggest a range of 
6.5-7.5% as target for HbA1c [1,23,31]. The decision required shared decision making 
involving the patient and should always balance potential benefits against the risks of therapy. 
A target close to an HbA1c of 6.5% should only be considered if it can be achieved by 
lifestyle modification or drugs with a low risk of severe adverse events, e.g. Metformin. If 
factors like age, life expectancy and comorbidities argue against an aggressive glucose control 
therapeutic goals should be eased and an HbA1c of 7.5% or above seems reasonable. 
 
Alpha-glucosidase inhibitors: Acarbose, Miglitol 
 
Acarbose and Miglitol exhibit their antihyperglycemic effect by inhibiting gastrointestinal 
enzymes that metabolize carbohydrates; thus digestion and absorption of carbohydrates is 
delayed and reduced; this cellular mechanism is unlikely to cause hypoglycemia and to affect 
body weight [3]. A systematic Cochrane review resumed that compared to placebo Acarbose 
and Miglitol reduce HbA1c levels by approximately 0.8% (CI0.95:[ 0.6;0.9]) and 0.7% 
(CI0.95:[0.4;0.9]), respectively [37]. Due to their pharmacodynamic profile this drug class is 
especially efficacious in reducing postprandial glucose; however, there is no proof that in 
RCT the reduction of the surrogate postprandial glucose is correlated with clinical relevant 
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endpoints [1].There is a lack of evidence regarding clinical endpoints due to micro- and 
macrovascular complications. The approved dose ranges from 150-300mg and 50-600mg per 
day for Miglitol and Acarbose, respectively. Gastrointestinal side effects such as diarrhea and 
flatulence occur frequently and impair compliance; they can be mitigated if therapy is 
initiated at 50mg and dose escalation is accomplished carefully. The drugs should not be used 
in people with severe gastrointestinal disorders, chronic inflammations, ulcers and 
malabsorption. Voglibose was not part of this investigation since it did not meet the eligibility 
criteria (see 3.1.1).  
 
Dipeptidylpeptidase-4 (DPP-4) inhibitors (gliptins): Sitagliptin, Saxagliptin, Vildagliptin, 
Linagliptin  
 
The DPP-4 inhibitors Sitagliptin, Saxagliptin, Vildagliptin and Linagliptin belong besides the 
GLP-1 receptor agonists to the group of incretin agents. Upon glucose stimulation incretins 
like GLP-1 act as potent insulinotropic hormones by suppressing glucagon secretion and 
delaying gastric emptying and secretion, thus reducing postprandial glucose. Since the 
biological half-life of GLP-1 is relatively short DPP-4 inhibitors can sustain its 
antihyperglycemic effects by inhibiting degradation. Compared to placebo therapy, Sitagliptin 
and Vildagliptin resulted in an HbA1c reduction of approximately 0.7% and 0.6%, 
respectively [38]. Similarly, clinical reviews of Linagliptin and Saxagliptin yielded 
comparable results for their antihyperglycemic efficacy; their placebo subtracted change in 
reduction of HbA1c levels ranged from 0.5%-0.7% and 0.5%-0.6%, respectively [39,40]. 
Long-term outcome trials are currently ongoing to determine whether gliptins reduce 
cardiovascular risk in T2DM [41]. The approved doses are 25-100mg, 50-100mg, 2.5-5mg 
and 5mg for Sitagliptin, Vildagliptin, Saxagliptin and Linagliptin, respectively. Due to the 
glucose dependent effect of gliptins they are unlikely to cause profound hypoglycemia. Apart 
from manageable side effects such as nausea and headache gliptins display fair tolerability; 
anyway gliptins may be associated with a higher risk for upper respiratory infections and 
pancreatitis which is not finally resolved [38]. Care must be taken if these drugs are given to 
diabetics with renal disease; renal elimination of the drugs may lead to accumulation and 
clinical experience is limited. However, Sitagliptin may be given at a dose of 25mg per day 
even if patients have end stage renal disease or a creatinin clearance less than 30ml/min; 
Linagliptin is hardly renally eliminated and can be given to patients for whom Metformin is 
contraindicated due to renal impairment. 
Alogliptin was not part of this investigation since it did not meet the eligibility criteria (see 
3.1.1). 
 
Metformin 
 
Metformin exerts its pharmacodynamic effect by inhibiting hepatic glucose production and 
improving peripheral insulin sensitivity. Moreover, it positively effects dyslipidemia and 
activated hemostasis two pathological processes often present in diabetics which may 
contribute to its protective cardiovascular effect [42]. Its mode of action does not seem to be 
associated with extensive hypoglycemia or weight gain [3]. In placebo controlled trials 
Metformin reduced mean HbA1c levels by 0.9% (CI0.95:[0.6;1.1]) [43]; the glucose-lowering 
effect is maintained even after a follow-up of 10 years; in the UKPDS-34 study the difference 
in means in obese patients receiving Metformin compared to diet alone was -0.6%. For now, 
Metformin is the only OAD reducing the incidence of macrovascular complications [35].  
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Trialed against placebo, Metformin reduced the incidence of any diabetes-related endpoints 
(including macrovascular and microvascular complications), diabetes-related death, all-cause 
mortality and myocardial infarction by 0.32% (RR:0.68; CI0.95:[0.58;0.87]), 0.42% (RR:0.58; 
CI0.95:[0.37;0.91]), 0.36 (RR:0.64; CI0.95:[0.45;0.91]) and 0.39% (RR:0.61; CI0.95:[0.41;0.89]), 
respectively; compared with an active control consisting of Chlorpropamide, Glibenclamide 
or Insulin, Metformin significantly reduced the risk of any diabetes-related endpoints, all-
cause mortality and stroke (RR:0.74 (per 1000 patient-years); p=0.0034, RR:0.72; p=0.021 
and RR:0.53; p=0.032, respectively). The approved dose ranges from 500-3000mg per day. 
According to the Summary of Product Characteristic (SmPC) gastrointestinal side effects like 
nausea, vomiting and diarrhea are common (> 10%) but can be handled by careful dose 
escalation. A rare but often fatal complication is lactate acidosis (< 0.01%). Metformin is 
contraindicated in patients with renal dysfunction (creatinin clearance < 60ml/min) a 
complication which occurs frequently in diabetics, especially within the geriatric patients. 
Therefore, Metformin is not suited for a considerable share of patients; there is some evidence 
that Metformin can even be used in patients with a creatinin clearance > 30ml/min [44]. 
However, this approach is not supported by clinical trials with renal safety endpoints; thus, in 
this patient collective, Metformin should be administered with caution and renal function 
must be monitored. 
 
Insulin secretagogues –sulfonylureas: Glibenclamide, Gliclazide, Glimepiride, Glipizide, 
Tolbutamide (Gliquidone, Chlorpropamide) 
 
Sulfonylureas promote their glucose lowering effect by stimulating insulin secretion through 
inhibition of potassium dependent channels of the beta cells of the pancreas. As a 
consequence they tend to induce hypoglycemia and weight gain and are more prone to induce 
secondary therapeutic failure due to increasing insulin deficiency of the beta cells compared 
to other OAD [3,45]. All sulfonylureas reduce glycemia similarly; a meta-analysis yielded a 
placebo subtracted mean change in HbA1c of -1.51% (CI0.95:[-1.78;-1.25]) [23,46]. As 
mentioned before, the treatment with Chlorpropamide and Glibenclamide seems to be 
associated with  reduced incidence of microvascular complications and after 10 year follow-
up the risk reduction became even significant for macrovascular complications such as 
myocardial infarction and death from any cause due to an increased number of events [34,47]; 
however the results should be interpreted with caution since the study has been criticized for 
several reasons. For example, patients were randomized to an active control group consisting 
of Chlorpropamide, Glibenclamide and Insulin and compared to therapy with diet alone; thus 
the assignment was rather adequate for comparing intensive vs. conventional therapy and not 
for inference about certain drugs. The validity of results may be challenged due to several 
amendments of power calculation and specification of endpoints and it cannot be ruled out 
definitely that reporting was driven by intermediate results. Moreover, co-medication and 
additional glucose lowering therapies beyond therapy failure have not been assessed 
rigorously enough and particularly after such a long follow-up it is difficult to draw 
conclusions about the initially assigned therapies [1]. The administered doses are 1.75-
10.5mg, 30-120mg, 1-6mg, 2.5-40mg and 250-300mg per day for Glibenclamide, Gliclazide, 
Glimepiride, Glipizide and Tolbutamide, respectively. Frequent side effects are nausea, 
emesis, weight gain and hypoglycemia. However, hypoglycemia is often caused by 
medication errors (overdose, omitting a meal, alcohol consumption, etc.) and the incidence of 
clinically relevant severe hypoglycemias or major hypoglycemic events (nightly or sustained 
events) is elevated but baseline risk is rare [33,34]. The excess mortality of the combination of 
Glibenclamide and Metformin in subgroup analysis of the UKPS-34 raised concerns over the 
safety of this combination; epidemiological studies show conflicting results [6]; even if this 
question is not finally settled this combination should be avoided.  
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Gliquidone and Chlorpropamide were not part of this investigation since retrieved studies did 
not meet the eligibility criteria (see 3.1.1). 
 
Insulin secretagogues – meglitinides (glinides): Repaglinide, Nateglinide 
 
Like sulfonylureas meglitinides act as betazytotropic substances and increase insulin 
secretion. However, onset of action occurs earlier and half-life is shorter compared to 
sulfonylureas; this phenomenon leads to fair control of postprandial glucose and their flexible 
dosing makes them an attractive option for food uptake adapted therapy and for patients with 
irregular eating behaviour; on the other hand, due to their insulinotropic effect they are likely 
to cause hypoglycemia and weight gain, just as sulfonylureas [3,6]. Compared to placebo, 
Repaglinide reduced mean HbA1c levels by 1.08% (CI0.95:[0.43;1.73]). Repaglinide may be 
more beneficial than Nateglinide; in a head to head trial the difference in means was -0.53% 
(CI0.95:[-0.93;-0.13]) [48]. There is no evidence for a benefit of meglitinides on micro- or 
macrovascular outcomes. The approved doses are 0.5-16mg and 180-540mg per day for 
Repaglinide and Nateglinide, respectively. The side effect profile is similar to that of the 
sulfonylureas: main adverse events are gastrointestinal disorders, hypoglycemia and weight 
gain, the latter less pronounced compared to sulfonylureas [6]. 
 
Thiazolidindiones: Pioglitazone  
 
Pioglitazone is a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist. 
It enhances insulin sensitivity („insulin-sensitizer“) of the target organs like muscle-, liver- 
and fat cells resulting in an  inhibition of hepatic glucose production, a reduction of 
abdominal fat tissue and an increased glucose uptake and glycogen synthesis [3]. Its mode of 
action and effect on lowering HbA1c is promising whereas it clinical safety profile and recent 
pharmacovigilance data limit a widespread use. The reduction of HbA1c for Pioglitazone lies 
within the range of 0.5-1.4% [6]. Clinical data regarding cardiovascular outcomes raises 
doubts about a positive benefit-risk balance of Pioglitazone. In a randomized controlled trial 
Pioglitazone 45mg per day vs. placebo in addition to baseline antihyperglycemic medication 
did not affect the primary endpoint positively (composite of all-cause mortality, non-fatal 
myocardial infarction (including silent myocardial infarction), stroke, acute coronary 
syndrome, endovascular or surgical intervention in the coronary or leg arteries, and 
amputation above the ankle; HR:0.90; CI0.95:[0.80;1.02]; p=0.095) [49]. A secondary main 
endpoint (composite of all-cause mortality, myocardial infarction and stroke), which was not 
specified in the study protocol was reported to yield a statistical significant benefit in favour 
of Pioglitazone vs. placebo (incidence: 11.6 vs. 13.6%; HR: 0,84; CI0.95:[0.72;0.98]; p=0.027; 
number needed to treat (NNT) =50), whereas the risk of developing heart failure was elevated 
in patients taking Pioglitazone (incidence: 10.8 vs. 7.5%; p<0.0001; number needed to harm 
(NNH )= 30). In a subgroup analysis of patients with previous myocardial infarction 
Pioglitazone had a beneficial effect on the pre-specified endpoint of fatal and non-fatal 
myocardial infarction (incidence: 5.3 vs. 7.2%; HR:0.72; CI0.95:[0.52;0.99]; p=0.045;  
NNT=53). Anew, Pioglitazone increased the risk of heart failure (incidence: 13.5 vs. 9.6%; 
HR: 1.43; CI0.95: [1.13;1.81]; p=0.003; NNH= 26) [50]. The results must be scrutinized; as 
mentioned, in the core publication the main secondary endpoint was not pre-specified and 
analyzed post-hoc; thus a reporting bias driven by favourable results for some arbitrarily 
chosen endpoint cannot be excluded.  The benefit-risk ratio seems to be unfavourable since 
the NNT exceeds the NNH in both studies. Moreover, in the second study randomization was 
not stratified by previous myocardial infarction to ensure that potential effect modifiers are 
distributed evenly among intervention groups. In addition, the authors do not state whether 
they adjusted for multiple testing; since the reported p-value displays marginal statistical 
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significance the inference may be misleading due to an uncorrected inflation of the alpha 
error. Based upon these results the Federal Joint Committee denied further reimbursement of 
Pioglitazone for SHI insurants. The approved dose range is 15-45mg per day. Side effects 
apart from heart failure are weight gain, fluid retention and edema and an increased incidence 
of peripheral fractures. Recently, pharmacovigilance data from the Food and Drug 
Administration (FDA)  found a potential association between the exposure to Pioglitazone 
and bladder carcinoma; for the whole cohort there was a numerical trend towards a higher risk 
of  incident bladder carcinoma in patients taking Pioglitazone compared to controls (HR: 1.2; 
CI0.95: [0.9;1.5]) , which reached statistical significance in the stratum of patients being 
exposed to the drug for more than 2 years [51]. 
Rosiglitazone was not part of this investigation since it did not meet the eligibility criteria (see 
3.1.1). 
 
Other drugs: Colesevelam, Dapagliflozin 
 
Colesevelam is is a bile acid sequestrant which binds bile acids in the intestinal tract. Its 
glucose lowering efficacy is modest with a reduction of HbA1c levels of approximately 0.5%; 
however it was only investigated as add-on therapy in patients who maintained their pre-
existing antidiabetic regimen. Dapaglifozin is the first agent of a novel class of OAD known 
as sodium-glucose co-transporter-2 (SGLT2) inhibitors. Its mode of action is insulin 
independent; by inhibiting the SGLT2 protein in the kidneys, Dapagliflozin reduces renal 
glucose reabsorption, leading to urinary glucose excretion and a blood glucose reduction [52]. 
According to the pivotal studies submitted for approval its efficacy is moderate; mean HbA1c 
levels were reduced by 0.5%-0.7%; data on clinically relevant endpoints isn´t available yet 
[53]. In patients with moderate renal insufficiency Dapagliflozin loses its glucose lowering 
effect. Frequent side effects are infections of the urinary tract. Concerns about hepatotoxicity 
and a potential association with an increased incidence of bladder and prostate carcinoma led 
to rejection of approval by the FDA until these safety issues are answered by the manufacturer 
[54,55]. 
Both drugs were not part of this investigation. Colesevelam did not meet the eligibility criteria 
and Dapagliflozin was only approved in Europe after the updated literature research [53] (see 
3.1.1).  
1.5 Clinical guidelines for treatment of type 2 diabetes mellitus with 
oral antidiabetic drugs as monotherapy 
 
The recommendations of the different clinical guidelines relating to the decision which OAD 
should be used initially to start monotherapy in patients with T2DM are reflected in the 
corresponding therapy algorithms. There is consensus that Metformin is the standard of care 
as initiating agent due to its beneficial effects regarding cardiovascular protection, especially 
in overweight diabetics [1,23,31,56,57]. Only the clinical guideline from the National Institute 
for Health and Care Excellence (NICE) suggests considering a sulfonylurea as an option for 
first-line therapy in not overweight patients or if a rapid response is required due to 
hyperglycemic symptoms. Though, there is debate about which OAD should be used as initial 
therapy if Metformin is contraindicated or not tolerated. For example, the Canadian Diabetes 
Association (CDA) doesn´t favour any specific drug but advises against Pioglitazone due to 
its disadvantageous safety profile [23]. Some guidelines recommend only a subset of 
candidates: the NICE guideline mentions only glinides and Acarbose whereas the joint 
position statement of the American Diabetes Association (ADA) and the European 
Association for the Study of Diabetes (EASD) names sulfonylureas, glinides, gliptins and 
Pioglitazone as alternatives to Metformin [31,56].  
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Interestingly, the German Disease Management Guideline for T2DM provides no consistent 
recommendation but provides instead to different therapy algorithms: the one issued by the 
Drug Commission of the German Medical Association (AKDÄ) and the German College of 
General Practitioners and 
Family Physicians (DEGAM) discriminates between drug classes with proven clinical benefit 
regarding clinically relevant endpoints (sulfonylureas) and without benefit (alpha-glucosidase 
inhibitors, gliptins and glinides) advocating indirectly sulfonylureas as second-line therapy, 
whereas the one of the German Diabetes Association (DDG) has no explicit recommendations 
for second-line therapy and schedules all other OAD equal to another [1].  
1.6 Indirect comparisons of health care interventions 
 
In medicine today it is uncommon that there exists solely one therapeutic intervention for 
patients with a certain condition. In fact, health care professionals often have to make 
decisions between different competing treatments for the question at hand to select the best 
option and to ensure optimal care for their patients. Usually, systematic reviews and meta-
analyses from randomized controlled trials focusing on pairwise direct comparisons are the 
most reliable sources of evidence. Ideally, there are one or several RCT including every 
relevant treatment option so that judgment can be based on direct evidence, which is an 
unrealistic scenario if the competing interventions are numerous [58]. For example, in clinical 
trials of new drugs they are often compared to placebo or standard care which is sufficient to 
gain approval of regulatory authorities. However, demonstrating effectiveness against other 
relevant competitors and cost-effectiveness by means of health economic evaluation becomes 
nowadays an important task for market access and successful reimbursement. Since a decision 
has to be made anyway, in the absence of direct evidence this is when indirect treatment 
comparisons (ITC) are of great value to enable decision makers to draw the required 
conclusions. Moreover, if direct evidence is of poor methodological quality or inconclusive 
indirect comparisons provide an additional piece of information so that the decision has not to 
rely solely on the questionable direct evidence. Even if direct evidence is conclusive the 
combination of direct and indirect evidence can strengthen the results of direct comparisons 
only by increasing the precision of estimates and by lending more external validity to the 
analysis due to a broadened population sample [59]. For a systematic approach it is even 
mandatory to encompass the whole body of evidence by considering indirect evidence, too. 
Anyway it is a pivotal issue to decide under which circumstances direct and indirect evidence 
should be combined (see chapter 3.2.3). Another disadvantage of classical meta-analysis is 
that results are limited to pairwise comparisons making it difficult to come to an overall 
conclusion which treatment is the best if several treatment options are available. The methods 
underlying indirect comparison are able to produce such rankings and probability statements 
which treatment is the best and can ease decision making across a range of interventions. 
Thus, indirect comparisons are an important tool in the field of evidence research synthesis 
and are becoming more popular a fact that is reflected by the increasing number of 
publications of systematic reviews using statistical methods of indirect comparisons [60].  
In the simplest case intervention A has been compared to intervention B in a A-B trial and to 
intervention C in an A-C trial but there is no B-C trial; thus, an estimate of the relative effect 
of C vs. B dBC can be derived from the indirect comparison of the effect of B vs. A (dAB) and 
the effect of C vs. A (dAC) via the common comparator A (see Figure 1, first network on the 
left) 
 
  ABACBC ddd −=                                                                                             (1.1)    
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Since the relative treatment effects add together the appropriate scale of measurement must be 
chosen (e.g. the outcome measure must be normally distributed such as odds ratios, hazard 
ratios and relative risks on a log scale or difference in means) [58]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structures of different evidence networks of network meta-analysis [59] 
 
The indirect comparison is anchored on treatment A as bridging comparator, what is called an 
adjusted indirect comparison, too. It is fundamental that indirect comparisons do not break 
randomization. An unadjusted comparison of B vs. C which is only based on the results of the 
B arm of the A-B trial and the C arm of the A-C trial also called “naïve indirect comparison” 
ignores randomization and is no more valid than a comparison based on single arm from 
observational studies and should therefore be avoided [61]. A common critique about indirect 
comparisons is the assumption that they suffer from observational biases. As long as the 
indirect evidence is based on relative treatment effects and randomization is preserved they 
suffer from unobserved effect modifiers since patients are randomized within trials but not 
across trials, just as pairwise meta-analyses do. Both give unbiased estimates as long as the 
effect modifiers have similar distributions across pairwise comparisons or across the whole 
set of comparisons in the network (see chapter 3.2.3). Thus, both are superior compared to 
observational studies since they are based on RCT [62].  
As long as the network is connected (e.g. each contrast has a path from one to the other) an 
indirect comparison of each intervention with any other is possible (see 2nd and 3rd network, 
Figure 1), although comparisons with longer paths will have less precision [59]. The fourth 
and fifth network in Figure 1 contains closed loops. In the fourth network the comparison B-C 
has direct evidence from the B-C trial and indirect evidence from the A-B and A-C trials; in 
the fifth network there are two closed loops, triangle ABC and diamond ACEF, both 
supported by direct and indirect evidence. Networks containing such loops are called mixed 
treatment comparisons (MTC) or multiple treatment meta-analysis (MTM). For such networks 
an important assumption for pooling all the evidence is that indirect comparisons are 
consistent with direct comparisons (see chapter 3.2.3). Sometimes there is confusion about the 
terminology regarding indirect comparisons. This work refers to the proposed definitions by 
Jansen et al., 2011 (see Figure 1): a network meta-analysis (NMA) is any synthesis where the 
Anchored Indirect Treatment Comparison 
 (or „adjusted“ ITC) 
Mixed Treatment 
Comparison 
Network Meta- Analysis 
(> 2 studies in the network comparing > 2 comparators) 
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evidence base comprises two or more than two RCT connecting more than two interventions. 
An MTC or MTM consists of at least one closed loop in the network, for any other analysis of 
an open loop network the term ITC is appropriate [59]. 
 
1.7 Comparative effectiveness research within the framework of 
benefit assessment, reimbursement and health economic evaluation 
 
Since pressure on efficient allocations of resources within health care systems is rising there is 
an demanding increase for comparative effectiveness research including the whole set of 
relevant treatments which in turn lays the foundation for  health economic evaluation of these 
interventions. For instance, the Cochrane Collaboration introduced a new form of reviews 
assessing the relative effectiveness of several interventions for the same condition and 
established a methods group to enhance diffusion of this technology [63].  
In the United Kingdom the NICE has a strong record of technical appraisal of new health care 
interventions; in its guide to the methods of technology appraisal it embraces MTC if it adds 
information that is not available from head-to-head comparisons or if direct evidence is 
lacking at all [64]. Moreover, the NICE maintains the Decision Support Unit an institution 
supporting the institute's technology appraisal program by providing useful technical support 
documents for evidence synthesis, utilities and other topics [65]. Other countries for instance 
the United States, Canada or Australia are undertaking similar efforts to improve efficiency of 
their health care delivery; thus their evidence bodies and health technology assessment (HTA) 
authorities appreciate methods of indirect comparisons in their methods guides, too [66-68]. 
In Germany, with the Act on the Reform of the Market for Medicinal Products (AMNOG) a 
benefit assessment of pharmaceuticals according to German Social Code V (SGB V) was 
introduced. Within three months after market authorisation the market authorisation holder 
(MAH) has to submit a dossier to the GBA who is in charge of conducting the benefit 
assessment - usually by commissioning the IQWiG. This assessment is the basis for the 
negotiations of reimbursement prices between the SHI and manufacturers. In case of 
disagreement a cost-benefit assessment can be initiated to derive adequate pricing levels of 
pharmaceuticals [69]. In this setting, both the GBA in its rules of procedure as well as the 
IQWiG in their methods papers on benefit assessment and on health economic evaluation 
acknowledge the need for indirect comparisons. For health economic evaluation the IQWiG 
admits that assessments are generally impractical without indirect comparisons. For benefit 
assessment the institute concedes that consideration of indirect comparisons may be 
appropriate but its use automatically downgrades the certainty of findings. Only adjusted 
indirect comparisons are considered and the homogeneity of pairwise comparisons as well as 
the consistency in the network has to be assessed. Furthermore the statistical model and code 
and the underlying assumptions have to be fully reported [69-71]. Already two oral 
antidiabetic drugs, Linagliptin and Dapagliflozin have undergone the process of benefit 
assessment in Germany. For both drugs the IQWiG concluded that due to a lack of evidence 
benefit with respect to the appropriate comparator could not be established. The MAH could 
have overcome this issue by making use of indirect comparisons to meet the requirements of 
the dossier, which wasn´t done. As a consequence Linagliptin will not be accessible for 
diabetic patients in Germany.  
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2. Research objective 
 
T2DM is increasingly becoming a global pandemic and especially in developed countries 
increasing levels of obesity and sedentary lifestyle enhance its dissemination. The burden of 
disease in terms of micro- and macrovascular complications, loss of HRQoL and premature 
death as well as the socioeconomic burden is substantial.  Therefore, identifying effective 
strategies including lifestyle interventions and pharmacological treatment that control diabetes 
and its complications are strongly needed to improve outcomes of affected patients and to 
keep health care expenditures manageable. Clinical guidelines tend to provide insufficient 
guidance on the sequential therapy when T2DM progresses. For example most guidelines 
don´t have clear preferences for combination therapy regarding the second or third 
antihyperglycemic agent [1,23,31]. However, there is evidence from MTC which double or 
triple combination therapy might be favoured [72,73]. For oral monotherapy clinical 
guidelines agree that Metformin is the gold standard but no statements are made which OAD 
should be used second line if Metformin is contraindicated or not well tolerated. This is an 
important question since gastrointestinal intolerance may limit its use in some patients and a 
substantial share of patients with T2DM already suffers from chronic kidney disease at time 
of diagnosis and can´t be treated with Metformin [13,74]. The lack of recommendation may 
be attributed to the fact that not all OAD have been trialed directly against each other and no 
indirect comparisons have been made yet. Moreover, it is unfortunate that patients don´t get 
access to new drugs due to the inability or reluctance to use indirect comparisons for benefit 
assessment providing the rationale for this work. Thus, the objective of this thesis is a 
systematic review and mixed treatment comparison assessing the comparative effectiveness 
and safety of oral antihyperglycemic drugs as monotherapy in patients with type 2 diabetes 
mellitus. 
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3. Methods 
 
Although there exists more literature about conducting systematic reviews especially 
regarding different quality appraisal tools for assessing the risk of bias of studies, the single 
steps of this systematic review including the definition of the eligibility criteria, the search for 
records, the study selection and data collection and the assessment of the risk of bias were 
performed in close dependence on the Cochrane Handbook for Systematic Reviews of 
Interventions, since it represents one of the most elaborated and sophisticated guides for this 
kind of research. Unless otherwise stated, the section 3.1 of this work refers to the Cochrane 
Handbook Part 2 Chapter 5-8 [75]. Furthermore the conducting and reporting of the 
systematic review, meta-analysis and mixed treatment comparison will follow the methods of 
the PRISMA  (preferred reporting items for systematic reviews and meta-analyses) statement 
and the guidance of the ISPOR (International Society of Pharmacoeconomics and Outcome 
Research) task force on indirect treatment comparisons, respectively [76,77].  
 
Since reviews are by nature retrospective the used methods should be established and 
documented prior to the review process. The publication of a review protocol reduces the 
impact of review authors’ biases and provides transparency of methods and processes. Every 
effort should be undertaken to comply with the predetermined protocol. However, changes in 
a review protocol are sometimes necessary due to unanticipated circumstances such as issues 
with data collection or reporting of data and justifiable, as long as they are not made on the 
basis of how they affect the outcome. Thus, amendments of the protocol and their underlying 
rationale should be reported in the review.  Section three is written in the form of such a 
protocol pre-specifying the applied methods of systematic review and the statistical analysis 
plan. 
3.1 Systematic Review 
3.1.1 Defining the scope of the review by eligibility criteria 
 
A systematic review in contrast to a narrative approach is characterized by a focused and 
clearly defined objective: the research question. This research question (see 2.) translates into 
pre-specified eligibility criteria. Based on them the inclusion and exclusion of studies for the 
review is accomplished. The PICOS (participants, interventions, comparisons, outcomes and 
study design) scheme was applied to cover all relevant aspects of the research question and 
develop the single eligibility criteria. A systematic review should contain all relevant 
outcomes focusing on 2-3 primary endpoints including beneficial effects and adverse events. 
However, the choice of endpoints determines how broad or narrow the scope of the review 
gets; the broader the eligibility criteria are defined the bigger is the evidence base to be 
included and the higher is the external validity in terms of generalizability of findings; on the 
other hand heterogeneity might be increased due to mixing „apples and oranges“ which makes 
interpretation of results difficult (for narrowing the eligibility criteria, it is just the other way 
around). Thus, the analyst has to make a tradeoff between these opposites, has to balance their 
assets and drawbacks pragmatically and whatever approach is taken, must be transparent by 
pointing out how decisions are derived.  
The eligibility criteria will be piloted against a sample of reports (including ones that are 
thought (not) eligible) to refine and clarify them if necessary. 
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3.1.1.1 Participants 
 
Studies will be eligible for inclusion if they were conducted in adults aged 18 years or older 
with type 2 diabetes. To be consistent with changes in classification and diagnostic criteria of 
type 2 diabetes mellitus through the years, the diagnosis should have been established using 
the standard criteria valid at the time of the beginning of the trial (see 3.1.3.3).  
3.1.1.2 Interventions/ Comparators 
 
Studies will be valid for inclusion if patients were assigned to oral monotherapy (non-
pharmacological lifestyle measures such as diet or physical activity were allowed; previous 
therapy itself was no criterion for exclusion as long as all other drugs than the interventions 
were discontinued at time of randomization) and one of the following drugs holding a market 
authorisation within the European Union or the United States alone were compared with each 
other or with placebo: Metformin, sulfonylureas (Gliclazide, Gliquidone, 
Glimepiride/Glyburide, Glibenclamide, Chlorpropamide, Glipizide, Tolbutamide or 
Tolazamide), Pioglitazone, meglitinides (Repaglinide or Nateglinide), alpha-glucosidase 
inhibitors (Miglitol or Acarbose) or DPP-4 inhibitors (Sitagliptin, Vildagliptin, Linagliptin, or 
Saxagliptin). Rosiglitazone will not be considered since it has been withdrawn from the 
market (association with an increased risk of myocardial infarction and cardiovascular death). 
Colesevelam was only investigated as combination therapy and is therefore not meeting the 
eligibility criteria. Dapagliflozin was only approved (2012/11/12) after the updated literature 
research (2012/07/30) and hence could not be considered. 
 
One vital question regarding the definition of nodes in a network is whether treatments, 
especially drugs of the same class should be pooled or if each single drug should be analyzed 
separately. The lumping of treatments seems justified if the treatment effects of drugs within a 
drug class are comparable enough to make the assumption of a group effect. A benefit is that 
in a complex network with many nodes assessing drug classes rather than single drugs eases 
reading and conveying of key findings and results become more precise. On the other hand, if 
the treatment effects within a drug classes differ considerably and the assumption of a group 
effect may not hold, analyzing drug classes can introduce an amount of heterogeneity into the 
network which may complicate interpretation of results.  
Based upon evidence from the existing literature in this thesis the assumption is made that the 
treatment effects of the single sulfonylureas, meglitinides, alpha-glucosidase inhibitors and 
DPP-4 inhibitors are comparable enough to analyze them as drug classes [23,37-40,46,48]; 
moreover, in the stage of conceptualization, either seven treatments (drug classes) or 20 
treatments (single drugs) would yield an outcome matrix of T*(T-1)/2= 21 or 190 relative 
effect estimates, the latter making interpretation of results almost impractical. As a 
consequence, studies comparing drugs from the same class against each other are not eligible 
for inclusion.  
Another method applied by the IQWiG in its first health economic evaluation of 
antidepressants is to use a top down approach [78]. The IQWiG rejects the assumption of drug 
classes if measures of heterogeneity of pairwise meta-analyses exceed a threshold value (p-
value for heterogeneity < 0.2 or I2>50%). If heterogeneity in meta-analyses of single drugs is 
still present the IQWiG excludes this evidence trying to keep the amount of heterogeneity in 
the network low. This approach seems too restrictive since it downsizes the whole body of 
evidence. Anyway, careful attention will be given to this issue by assessing heterogeneity in 
pairwise meta-analyses and MTC by the corresponding statistical measures and by meta-
regression.  
 
 17     Methods 
In line with the aggregation of similar drugs into drug classes for trials including arms with 
different doses of the same drug these arms were aggregated into one for data entry 
(see 3.1.3.4). Dose dependent effects were not modeled, but overly high or low doses of the 
single drugs which may bias the results were subjected to sensitivity analysis. 
From multi arm studies, only the eligible intervention arms were selected for inclusion. Single 
eligible arms were not included since they will break the principle of randomization of 
pairwise comparisons. 
3.1.1.3 Outcomes 
 
As mentioned before it would have been desirable to choose clinically relevant endpoints such 
as mortality (all-cause mortality or diabetes-related death), morbidity (impact on micro- and 
macrovascular complications) or HRQoL. However, due to the lack of evidence there are 
almost no studies that have investigated these endpoints [34,35,49]. The network structure 
would only consist of a few RCT and neglect the majority of diabetes drug trials that had 
other endpoints. Therefore studies were entitled to inclusion if they reported all of the three 
following outcomes: HbA1c, body weight and hypoglycemia. 
Hypoglycemia was selected as third outcome since especially severe, prolonged and nightly 
events cause recurrent morbidity and are sometimes fatal [79]. It has to be acknowledged that 
not all treatments in the analysis are prone to cause hypoglycemia (e.g. gliptins, Metformin or 
alpha-glucosidase inhibitors). For those other treatment-specific adverse events like gastro-
intestinal side effects (Metformin or alpha-glucosidase inhibitors) or upper respiratory 
infections (gliptins) are primarily of interest but these endpoints in turn are not relevant for 
other treatments. One alternative might be the frequency of adverse events (AE) and severe 
adverse events (SAE) and their corresponding discontinuation rates, respectively; this data 
was extracted but these safety endpoints are less frequent reported as hypoglycemias; 
moreover, they suffer from the same concerns as hypoglycemia (see below) and reporting is 
selective due to different thresholds of incidence of AE/SAE in the included studies (AE/SAE 
below these thresholds are usually not reported). Finally this safety endpoint is not very 
informative since it aggregates all kinds of AE/SAE and definition varies significantly 
between trials. Taken together, hypoglycemia appears to be the most reasonable trade-off. The 
rationale for including only studies that report all three outcomes simultaneously is that these 
studies may be less affected from selective reporting bias [80,81], acknowledging that this 
ruling is put up with a loss of evidence. Nevertheless this cumulative condition of reporting 
outcomes for inclusion allows for external cross-validation against some of the excluded 
studies for contrasts that are not supported by direct evidence in the network (see 3.2.3.6). 
 
HbA1c  
 
As outlined before HbA1c is a well analyzed surrogate for clinically relevant endpoints and 
accepted by regulatory authorities, even if the correlation with the relevant endpoint has not 
been demonstrated for every single drug [82]. Studies will be eligible for inclusion if they 
report the mean change from baseline along with standard error of the mean (SEM) for each 
eligible intervention arm (for transformation of other summary data and imputation, see 
3.1.3.4). 
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Body weight  
 
Weight gain is an undesired adverse effect in diabetics since dyslipidemia is associated with 
an increased risk for micro- and macrovascular complications. Studies will be eligible for 
inclusion if they report the mean change from baseline in kilogram (KG) and the SEM for 
each eligible intervention arm (for transformation of other summary data and imputation, see 
3.1.3.4). 
 
Hypoglycemia  
 
Unfortunately the reporting of hypoglycemic episodes - despite existing guidelines and 
recommendations of regulatory bodies [79,82] – lacks consistency and completeness and 
differs considerably between trials.  According to the working paper of  the ADA working 
group on hypoglycemia data should be reported as followed: 1.) frequency: the workgroup 
recommends that both the proportion (percentage) of patients experiencing at least one 
episode and the event rates (e.g., episodes per patient-year) for each of the categories of 
hypoglycemic events should be reported;  2.) categories: to consider differences in severity of 
hypoglycemic episodes the ADA suggests that events should be reported separately for each 
of the five categories (see Table 4). At a minimum, hypoglycemic events should be reported 
in each of the first three categories. Thus, data was extracted for each category separately. As 
it was already foreseeable upfront that due to the scarcity of data within each category and the 
fact that the categories of clinical relevance (1 and 2) were rare in all trials (most trials 
reported zero event rates) and that some events as reported by the investigator could not be 
classified into one of the category because of different definitions, the original approach to 
analyze this outcome for each category had to be abandoned. Moreover, only a few studies 
reported episodes per patient-years in addition to the proportion of patients experiencing at 
least one episode, thus unfortunately, count data which would have accounted for multiple 
episodes could not be considered as unit of analysis.   
Therefore studies will be eligible for inclusion if they reported the number of patients 
suffering at least one episode of any hypoglycemia for each eligible intervention arm; the trial 
specific definition of a hypoglycemic episode will be detailed to facilitate interpretability. 
 
Table 4: Categories of hypoglycemia [79] 
Category Definition 
1.) Severe hypoglycemia An event requiring assistance of another person to 
actively administer carbohydrate, glucagons, or other 
resuscitative actions. 
2.) Documented symptomatic 
hypoglycemia 
An event during which typical symptoms of 
hypoglycemia are accompanied by a measured plasma 
glucose concentration < 70 mg/dl (3.9 mmol/l) 
3.) Asymptomatic hypoglycemia An event not accompanied by typical symptoms 
of hypoglycemia but with a measured 
plasma glucose concentration < 70 mg/dl (3.9 mmol/l). 
4.) Probable symptomatic hypoglycemia An event during which symptoms of hypoglycemia are 
not accompanied by a plasma glucose determination (but 
that was presumably caused by a plasma glucose 
concentration  < 70 mg/dl (3.9mmol/l). 
5.) Relative hypoglycemia An event during which the person with diabetes reports 
any of the typical symptoms of hypoglycemia, 
and interprets those as indicative of hypoglycemia, but 
with a measured plasma glucose concentration 
> 70 mg/dl (3.9 mmol/l). 
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Regarding the time frame studies will be considered for inclusion if the duration of the 
intervention (follow-up of trial drug exposure) was at least 12 weeks. Due to the progressive 
course of disease and the majority of studies having a follow-up between 12 and 36 weeks 
studies lasting longer than three years were excluded to ensure a certain degree of 
comparability within the study set (even though meta-regression was performed to account for 
potential effect modification by the covariate length of follow-up). Due to the limited 
glycemic durability of some of the drugs, longer studies may bias the efficacy of the results 
downwards.  
3.1.1.4 Study design 
 
Studies will only be considered for inclusion if they were randomized controlled trials. Cross-
over studies were eligible too, if patients were randomized to intervention arms and a wash-
out phase of at least 8 weeks was planned to avoid potential bias induced by time by treatment 
interaction and carry-over effects, respectively. 
3.1.2 Searching for records 
3.1.2.1 Sources to search 
 
To design a comprehensive literature search the following sources were searched: 1.) 
bibliographic databases: Medline, Embase and the Cochrane Central Register for Controlled 
Trials (CENTRAL); 2.) clinical trials registers: ClinicalTrials.gov register and trials registers 
of the market authorisation holder of the relevant drugs; 3.) reviews of the assessment reports 
of the regulatory authorities FDA and the European Medicines Agency (EMA). Since the 
screening of all retrieved records is time consuming an update of the initial search will be 
done to capture the records that appeared in the meantime. The completeness of the retrieved 
records will be validated against a randomly drawn test set of trials fulfilling the search 
criteria.  
 
Bibliographic databases 
 
Medline 
 
Medline is the U.S. National Library of Medicine premier bibliographic database from the 
National Institutes of Health. It can be accessed by several interfaces like Pubmed. 
To date it contains more than 22 millions of records and more than 5,200 journals in 37 
languages are indexed in Medline. 
 
Embase 
 
Embase is a biomedical bibliographic database run from the publishing company Elsevier; it 
can be accessed via the interface Ovid. Embase currently contains over 11 million records 
from 1974 onwards. Currently 4,800 journals are indexed for Embase in 30 languages. 
 
CENTRAL 
 
CENTRAL, which is part of the Cochrane Library serves as a comprehensive source of 
reports of controlled trials. It contains more than 530,000 citations a lot of them stemming 
from Medline and Embase. 
 
 20     Methods 
Even if there is a huge overlap between the three sources it is unsatisfactory to search only 
one database. For example of the 4,800 journals in Embase more than 1,800 are not indexed 
in Medline. The other way around of all the journals in Medline more than 1,800 are not 
indexed in Embase. Moreover, approximately a third of records in CENTRAL are from other 
databases or hand-searching. Thus a comprehensive literature search should at least contain 
these three important databases. 
 
Clinical trial registers (public and pharmaceutical industry) 
 
Clinical trials register become an increasingly important part of the literature research. For 
example the ClinicalTrials.gov register contains all clinical studies conducted in the United 
States that require registration by law. Currently, more than 143,500 studies are listed [83]. 
Nowadays, expanded requirements make more trial information and results available from the 
database. Unfortunately the European Union lags behind and the publicly accessible parts of 
the clinical trial registers like EudraCT, the EU Clinical Trials Register and EudraPharm 
provide no relevant trial information [84-86]. Thus, in addition the trial registers from the 
following pharmaceutical companies were searched for records, too: Astra Zeneca, Bristol 
Myers Squibb, Eli Lilly, GlaxoSmithKline, Novartis and Roche [87-92].  
 
Regulatory approval authorities 
 
The EMA and FDA provide explicit information about the drug approval process on their 
homepage [93,94]. For every drug licensed in the U.S. the FDA provides access to the clinical 
and statistical reviews; likewise the European public assessment reports (EPAR) provide 
approval information about drugs holding a central market authorisation within the EU. 
3.1.2.2 Defining a search strategy for bibliographic databases 
 
For developing a search strategy it is not necessary to search for every aspect of the research 
question. It is common to divide the search in three domains: the condition of interest, the 
intervention of interest and the study design. These three domains are usually connected by 
the Boolean operator AND whereas a variety of different search terms within each domain are 
combined with the Boolean operator OR.  
Searches for systematic reviews should be as extensive as possible to identify every relevant 
record; anyway it is necessary to balance comprehensiveness against efficiency and 
maintaining relevance by developing the search strategy. The quality of a literature search is 
defined by its sensitivity and precision. Sensitivity is defined as the number of relevant reports 
identified divided by the total number of relevant reports in existence and measures the degree 
of comprehensiveness. Precision is defined as the number of relevant reports identified 
divided by the total number of reports identified and measures the degree of relevance. 
Increasing the comprehensiveness (or sensitivity) of a search will reduce its precision and will 
retrieve more irrelevant articles. Anyway for systematic reviews it is accepted to apply a 
highly sensitive search strategy. Thus, validated and highly sensitive filters for the domain 
study design (RCT) were applied for Medline and Embase [95,96]. Furthermore, no limits 
regarding the time period or languages were set. With the help of native speakers records not 
published in English were also considered for inclusion. However since mistakes with respect 
to data extraction and bias assessment due to language barriers can´t be ruled out completely 
these records were excluded from sensitivity analysis. Abstracts without a full text publication 
were handled in the same way (see 3.1.4.4). 
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Medline and Embase can be searched using standardized subject terms generated by indexers. 
This thesaurus named MeSH (medical subject heading) in Medline and CENTRAL  as well as 
Emtree in Embase is helpful to identify articles that may use different words to describe the 
same aspect going beyond the content of the title and abstract. However, one can´t rely only 
on this controlled vocabulary since authors not always are explicit in their scientific notation, 
indexers may not be familiar with every subject and not all search concepts are matched by 
the indexing terms. Thus, it is crucial to combine indexing and free text terms for a broad 
search approach. Since CENTRAL exhibits a considerable overlap with records from Medline 
and Embase it is possible to exclude these sources with an appropriate operator. The full 
search for each source including date, search strategy, syntax guide and retrieved records will 
be detailed in the appendix. 
3.1.2.3 Managing references 
 
The reference management software Endnote®  Version X.4.0.2  was used to import and 
merge retrieved records with abstracts and titles from each database by customized filters 
[97]. Duplicate records were removed by using a filter and by manual screening. Each record 
was indexed by a unique record number. 
3.1.2.4 Missing data 
 
In case that outcome data is not reported in the desired format (e.g. body-mass index instead 
of kg or median change instead of mean change), only partly reported (e.g. outcome data only 
reported for some arms or the mean change reported without the measure of uncertainty) or 
that information is missing to judge if the study meets the eligibility criteria (e.g. ongoing 
antidiabetic medication apart from trial drugs) when possible the first author was addressed by 
email to obtain the requested information.  
3.1.3. Study selection and data collection 
 
In the review process the decision which study to include is very crucial. Even if eligibility 
criteria are clearly defined it involves individual judgement of the reviewer. Thus, the steps of 
assessment of inclusion, data collection and assessment of the risk of bias should always be 
undertaken by two independent reviewers for two reasons. First, careless errors that have just 
been overseen can be detected more easily; second if agreement can´t be achieved 
disagreement can be settled by a third investigator. For this thesis all steps mentioned above 
(except from the search of the clinical trials registers and regulatory bodies which will be 
conducted only by one reviewer (TB)) will be done independently by two reviewers (TB and 
SK); in case of disagreement this will be resolved by a third author (UM) (see 3.1.5). To 
account for the uncertainty included studies based upon judgement from the third author will 
be excluded from sensitivity analysis (see 3.1.4.4). 
3.1.3.1 Screening of studies 
 
After the removal of duplicates in the database of records, these will be screened for 
compliance with the eligibility criteria. This first screen serves to exclude obviously irrelevant 
records; at this stage reviewers should be „over-inclusive“ meaning that the eligibility criteria 
should not be applied to restrictive in order not to miss any relevant record upfront.  
For reviews the unit of interest is the study; sometimes there may exist more reports 
originating from the same study either containing additional information (from other articles, 
abstracts or reports) or being published again with the same content.  
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Whereas the former may yield helpful information like missing data the latter can introduce 
serious bias if identical studies are appearing twice in the review. Therefore, supplementary 
data from different records (including the records of the search of the web sites of regulatory 
authorities and clinical trials registers)  providing additional information will be linked 
together and records that are in effect duplicates will be removed.  
After identifying the potentially eligible records their full text will be evaluated rigorously and 
a final decision regarding inclusion will be made. For the whole process of study selection, 
assessment of eligibility and inclusion, a study flow diagram will be provided. For both steps 
interrater agreement will be assessed (see 3.1.5).  
3.1.3.2 Rationale for excluding studies 
 
An overview of studies that have been assessed for full text but have been deemed ineligible 
will be provided by giving the primary reason for exclusion. It will encompass all studies that 
seem to meet the eligibility criteria on first sight but on further inspection do not, and also 
studies that are not eligible but are well known and likely to be expected among the selected 
studies.  
3.1.3.3 Defining the relevant parameters and their coding for collection of data 
 
After completion of the study selection process it is important to decide which data should be 
collected and which coding should be used for the different variables. The data that is 
required for the review is of course outcome data for the pre-specified endpoints, descriptive 
data to depict included studies and patient characteristics, data of observed covariates that 
may be potential effect modifiers and data about the methodological quality to facilitate 
assessment of the risk of bias (see 3.1.4). To ensure a structured and comprehensive data 
extraction a data collection form was designed. It covers all relevant parameters and their 
coding or explanation, respectively. A template will be piloted against three randomly 
selected studies for testing feasibility and consistent coding between reviewers. 
For this work the parameters with the corresponding units, coding, measure or explanation 
that will be extracted are displayed in Table 5. 
 
Table 5: Parameters for data collection 
Parameter Explanation/ unit/ measure / coding 
Source 
Record identifiyera Explanation: record number assigned in the database of 
records from literature search (Endnote). 
Study identifiyera Explanation: study number assigned for indexing the 
studies included in quantitative synthesis. 
First author - 
Year of publication - 
Study duration  Explanation: time of trial drug exposure starting from time 
of randomization. 
Unit: weeks 
Coding: complete follow-up (core study/ extension). 
 
NCT numberb Explanation: record the trial number from 
ClinicalTrials.gov. 
Participants 
Number of randomized patientsc - 
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Diagnostic criteria of T2DMb Explanation: criteria that were applied to confirm existence 
of T2DM. 
Coding: 
1 ADA 1997 
2 ADA 1999 
3 WHO 1980 
4 WHO 1985 
5 WHO 1998 
6 Else (state definition) 
7 NR 
Agec/d Unit: years 
Measure: mean, SD 
Sexc/e Explanation: number of male patients per arm. 
Dietb Explanation: record if patients got any dietary advice in 
addition to the intervention.  
Coding: 
1 Yes 
2 No 
3 NR 
Duration of existing T2DMc Explanation: record how long did the disease already exist 
at the time patients were enrolled for the trial. 
Unit: years 
Measure: mean, SD 
Previous therapy Explanation: record if patients did receive any antidiabetic 
therapy before the beginning of the study. 
Coding: 
1 Therapy naive 
2 No OAD at least 8 wks before randomization 
3 Else 
Baseline HbA1cc Unit: % 
Measure:mean, SD 
Baseline body weightc Unit: kg 
Measure:mean, SD 
Comorbiditiesb Explanation: record if the trial was conducted in a 
population suffering from a special condition. 
Coding: 
1 Hypertension 
2 End stage renal disease 
3 Chronic renal insufficiency 
4 Else (state other conditions) 
 
Interventions 
Treatment Explanation: record the intervention with the cumulative 
dose per day and the dosing frequency: q.d; b.i.d.; t.i.d..  
If reported, indicate dosing escalation and mean or median 
received dose. 
Unit: mg/d 
Coding 
(dose/d; frequency) 
 
Number of armsf Explanation: record the number of eligible intervention 
arms. 
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Coding of treatmentsf Explanation: record the single interventions or the drug 
classes according to the following scheme. 
Coding: 
A 1 Placebo 
B 2 Metformin 
C 3 Sulfonylurea 
D 4 Pioglitazone 
E 5 Glinides 
F 6 Alpha-glucosidase inhibitors 
G 7 Gliptins 
Outcomes 
HbA1c 
Number of analyzed patientsc Explanation: record the number of analyzed patients per 
arm. 
Populationb Explanation: record in which population the analysis was 
done, e.g. ITT analysis, pp analysis, OC analysis or as 
defined by the investigator. If reported, state the imputation 
method for missing values. 
Mean change from baselinec Explanation: record the mean change from baseline for each 
arm. 
Unit: % 
Measure: mean, SD 
 
Body weight  
Number of analyzed patientsc Explanation: record the number of analyzed patients per 
arm. 
Populationb Explanation: record in which population the analysis was 
done, e.g. ITT analysis, pp analysis, OC analysis or as 
defined by the investigator. If reported, state the imputation 
method for missing values. 
Mean change from baselinec Explanation: record the mean change from baseline for each 
arm. 
Unit: kg 
Measure: mean, SD 
 
Hypoglycemia  
Populationb Explanation: record in which population the safety analysis 
was done. 
Patients with any hypoglycemia Explanation: number of patients experiencing at least one 
event of any hypoglycemia. 
Patients with severe hypoglycemiag Explanation: number of patients experiencing at least one 
event of severe hypoglycemia. 
Patients with documented symptomatic 
hypoglycemiag 
Explanation: number of patients experiencing at least one 
event of documented symptomatic hypoglycemia. 
Patients with asymptomatic 
hypoglycemiag 
Explanation: number of patients experiencing at least one 
event of asymptomatic hypoglycemia. 
Patients with probable symptomatic 
hypoglycemiag 
Explanation: number of patients experiencing at least one 
event of probable symptomatic hypoglycemia. 
Patients with relative hypoglycemiag Explanation: number of patients experiencing at least one 
event of relative hypoglycemia. 
Patients at risk Explanation: number of patients at risk in the safety 
population. 
Definition of hypoglycemia Explanation: definition of hypoglycemia as reported in the 
study. 
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Further safety outcomesb,h 
Definition of AE Explanation: definition of AE as reported in the study. 
Patients with AE Explanation: number of patients experiencing at least one 
AE. 
Patients discontinued due to AE Explanation: number of patients who were discontinued 
from the trial due to an AE. 
Definition of SAE Explanation: definition of SAE as reported in the study. 
Patients with SAE Explanation: number of patients experiencing at least one 
SAE. 
Patients discontinued due to SAE Explanation: number of patients who were discontinued 
from the trial due to an SAE. 
Miscellaneous 
Remarks Explanation: state any information important for evidence 
synthesis. 
a The record number indexed from Endnote® wasn´t continued. Instead the study number indexing the studies 
included in evidence synthesis was used. 
b For clarity purposes, only the most relevant data was displayed in the main table. Additional parameters were 
listed in a further table. 
c Data was collected for each eligible arm. 
d  If the desired measure wasn´t reported the confidence interval, standard error of the mean, p-value or t-value 
was extracted from each intervention group, from the final value or from effect estimates between intervention 
groups. 
e In the table trial and patients characteristics of included studies the proportion of men (%) was displayed. 
f 
 For setting up the data for MTC in a matrix containing one study per row it is necessary to denote the number 
of arms and to index the different treatments (see 3.2.3). 
g  Due to the scarcity of data for the different categories of hypoglycemia only the events of any hypoglycemia 
along with the trial specific definition were reported. 
h Data was extracted but no analysis was performed on these endpoints (see 3.1.1.3). 
HbA1c, glycated haemoglobin. T2DM, diabetes mellitus type 2. ADA, American Diabetes Association. WHO, 
World Health Organization. NR, not reported. SD, standard deviation. OAD, oral antidiabetic agent. Q.d., once 
daily. B.i.d., twice daily.  T.i.d. thrice daily. Wks, weeks. Kg, kilogram. ITT, intention to treat. PP, per protocol. 
OC, observed cases. AE, adverse events. SAE, severe adverse events.  
 
A table summarizing the most important trial and patient characteristics will be provided; in 
addition, the remaining parameters that were collected will be detailed in additional table.  
Amongst other things the trial information regarding the efficacy and safety populations was 
considered to rate the risk of bias of incomplete outcome data (see 3.1.4.2). 
3.1.3.4 Transformation and imputation of data 
 
Ideally for performing the statistical analyses outcome data should be reported as mentioned 
before (see 3.1.1.3). However this is not always the case, since data is missing or is reported 
differently. For missing data it is worthwhile to contact the authors to get the lacking 
information. If no data is provided for some measures like the standard deviation (SD) of the 
mean change from baseline imputation methods can be applied. Other target measures can be 
derived by transformation of reported data. Below, the procedure how to handle these issues 
in this thesis is described.  
 
The standard error of the mean can be derived from the standard deviation and the sample  
size N.  
 
  
N
SDSEM =                      (3.1) 
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If the sample size was not reported, for analysis or necessary transformations requiring the 
sample size the number of randomized patients or from the intention-to-treat population was 
taken as an approximation. For group means the standard deviations can be obtained from a 
confidence interval (3.2) or a p-value (3.3) and equation (3.1). For large sample sizes (x > 60) 
the 95% confidence interval is 3.92 standard errors wide (3.92 = 2 × 1.96). For other (1-ɑ) % 
CI intervals the value 3.92 has to be replaced by the corresponding z quantile of the normal 
distribution. If the sample size is small (x < 60) the quantiles of the heavier tailed t-
distribution should be applied; thus the value 3.92 is replaced by 2 * tdf (N-1);(1-ɑ), df indicating 
the degrees of freedom and 1-ɑ the quantile of the two-tailed distribution for the 
corresponding level of Type 1 error. 
 
 
 
  
92.3
)limlim( itloweritupperNSD −⋅=      (3.2) 
 
  t
MDSEM =
          (3.3) 
The t-value that corresponds with the p-value is read from a two-tailed t-table as follows:  
tdf (N-1);(1-α).  
 
If no measure of uncertainty was available for the group mean but the effect estimate (MD) 
with a CI (3.4) or p-value was reported a within-group standard deviation as the average of 
the intervention arms was calculated. 
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Again, for a small sample size the value 3.92 is replaced by 2*tdf (N1+N2-2);(1-ɑ). From a p-value 
the t-value is derived as follows: tdf(N1+N2-2);(1-α). Applying formula 3.3 and 3.4b yields the 
average within-group standard deviation. If a threshold of a p-value (such as p < 0.05) rather 
than the exact value is reported an conservative approach is to take the p-value at the upper 
limit (e.g. for p < 0.05, p=0.05); though, this assumption might increase the uncertainty 
artificially.  
 
For combining continuous data from different arms (e.g. aggregating arms of different doses 
of one drug or aggregating all study arms to derive study level data for potential effect 
modifiers in meta-regression) the following formula was used. 
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Furthermore where possible data reported in different units (e.g. pounds instead of kg) was 
transformed to the unit of analysis. 
 
When there is no sufficient information to calculate the SD for the mean change from 
baseline, it can be imputed; for this thesis a correlation coefficient was used for imputation. 
However it must be borne in mind that this kind of imputation is only appropriate if the 
assumption holds that the set of studies being used for deriving a correlation coefficient is 
comparable to the study where the missing SD will be imputed (since correlations will differ 
due to different time of follow-up, interventions or patient characteristics). Thus, similar 
studies were selected to meet this assumption. The correlation coefficient (corr) describes how 
similar baseline and final measurements are across intervention groups.  
It lies between -1 and 1. For each arm, it can be derived as follows:  
 
  
fbl
chfbl
SDSD
SDSDSDCorr
2
222 −+
=                   (3.6) 
 
in which SDbl, SDf and SDch denote the standard deviation of the baseline, final value and the 
mean change, respectively. 
When either the baseline or final SD is missing, it may be substituted by the other, if it´s 
reasonable to assume that the intervention doesn´t impact the variability of the outcome. 
If the correlation coefficients between the arms are similar they were averaged and pooled 
across the set of studies to obtain a global correlation coefficient. 
Now, for the study with the missing SD for the mean change, it can be imputed for each 
intervention arm.  
 
  )2(22 fblfblch SDCorrSDSDSDSD −+=       (3.7) 
 
Again, missing baseline or final SD may be substituted by each other.  
If calculation of a correlation coefficient seemed inappropriate (if values of less than 0.5 are 
obtained or correlation coefficients from two intervention groups differed obviously), a SD 
for the mean change from baseline from another study in the review can be taken. However, 
the appropriateness of this approach relies again on the similarity assumption between studies. 
Nevertheless, to account for the uncertainty of the latter procedure these studies were 
subjected to sensitivity analysis (SA) to assess the robustness of results (see 3.1.4.4).  
Finally, if measures of uncertainty were not reported but displayed in a figure with its error 
bars, they were read from the graph. 
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For HbA1c and body weight, the following approach was made in subsequent order to obtain 
the required data according to the formulas above: preferably, the mean change from baseline 
together with the measure of uncertainty (SEM, SD, CI or p-value) were extracted for each 
eligible intervention arm; all measures of uncertainty were transformed to the SEM. 
Alternatively, the effect estimate and its corresponding measure of uncertainty (SEM, CI or p-
value) was extracted and transformed to arm-level data. If no effect estimate was available 
and the measure of uncertainty for the mean change was missing this value was imputed using 
a correlation coefficient. If calculation of a correlation coefficient is inappropriate final values 
together with their measure of uncertainty (SEM, SD, CI or p-value) were extracted. If - 
despite randomization - baseline values differed to obviously for a valid comparison a SEM 
from a comparable study was taken as approximation.  
 
For hypoglycemia, preferably, the number of patients or the proportion (%) experiencing at 
least one episode of any hypoglycemia and the patients at risk (sample size of the safety 
population) were extracted for each eligible intervention arm. Alternatively the effect estimate 
(odds ratio (OR)) and its corresponding measure of uncertainty (SEM, CI or p-value) was 
extracted and transformed to arm-level data. The odds ratio was chosen over the relative risk 
as unit of analysis. Under the so called “rare disease assumption” the OR provides an 
adequate approximation of the RR.  For the incidence, a percentage of 10 % is a frequently 
mentioned as cut-off point to ensure a close correspondence between both measures, but even 
this threshold is arbitrary [98]. The non-equivalence of the risk ratio and odds ratio for 
common events does not indicate that either is wrong: both are entirely valid ways of 
describing an intervention effect, as long as they are not misinterpreted. 
 
3.1.4 Assessing the risk of bias in included studies 
 
The conclusions that are drawn in systematic reviews rely heavily on the validity of the data 
and results of the single studies. Assessing the risk of bias relates to the internal validity of 
study, namely if the study answers its research question accurately and is free of bias. On the 
other hand, external validity which will not be further addressed here means if the results of 
the study can be generalized and its findings can be applied to different settings (other 
populations, treatments, etc.).  
  
There are two types of errors potentially affecting results, random and systematic errors. 
Imprecision underlying  the random error means that several studies will yield different 
results because of sampling error but give the right answer on average (if no systematic error 
is present at the same time). Smaller studies are stronger affected by sampling variation and 
are less precise (hence have a greater SEM and confidence interval). On the other hand bias is 
causing systematic errors or deviations from the truth meaning that several studies biased 
towards the same direction would reach a wrong answer on average. The extent of bias can 
vary in the direction and dimension. Bias can act in both direction thus leading to an under- or 
overestimation of the true effect. Furthermore bias can vary in magnitude; small bias is 
unlikely to affect the observed effect overly, whereas a finding might be entirely attributed to 
a pronounced bias. Thus in meta-analysis, exploration of bias can help to prevent false 
positive (claiming wrongly an intervention is effective) and negative conclusions (concluding 
wrongly no effect)  if the methodologically less rigorous studies are overestimating or 
underestimating the true effect, respectively; moreover its assessment can help to explain 
heterogeneity of the included studies. In conclusion, invalid studies may lead to misleading 
inferences thus it is an essential part of a systematic review to carry out a thorough assessment 
of the risk of bias of included studies. 
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3.1.4.1 Tools for assessing study quality and risk of bias 
 
There exist a lot of quality appraisal tools for RCT in the medical literature; a review 
identified more than 25 scales and 9 checklists that have been proposed to assess the internal 
validity of trials [99]. Scales are instruments, in which various items are rated and combined 
to give an overall summary score of the risk of bias, whereas checklists contain different 
questions relating to different aspects of the risk of bias enabling operators to screen if these 
items were sufficiently considered or not. The disadvantage of applying scores is that they are 
giving different weights to the various items of the risk of bias; it´s difficult to find a 
justification so that assigning weights seems to be an arbitrary approach. Moreover, scales 
may provide unreliable assessments and are less transparent for readers of  the review [100]. 
Although checklists avoid the issue of weighting and summarizing different components, they 
are incapable to rate the degree of bias within each item; thus, both tools were deemed 
inappropriate and hence not used in this work.  
3.1.4.2 The Cochrane Collaboration's tool for assessing risk of bias 
 
The Cochrane Collaboration's tool for assessing risk of bias is neither a scale nor a checklist. 
The risk of bias is assessed within seven different domains, either at study- or endpoint 
specific level. For each entry in the corresponding domain the assessment is split into two 
parts. The first part is the support for judgment which outlines what was reported in the study 
to enable the judgment itself. The second part, the judgment rates the risk of bias for each 
entry as low, high or unclear, the latter denoting either lack of information or uncertainty over 
the potential for bias for items that are sufficiently reported. 
 
Domains of bias  
 
Table 6 displays the most common types of bias occurring in RCT and shows how they 
translate into the corresponding domains of the Cochrane Collaboration's tool for assessing 
risk of bias which will be used in this work. The different domains are illustrated shortly. 
 
Table 6: Classification scheme of bias in randomized controlled trials 
Type of bias Description Domains of the Cochrane 
Collaboration's tool for 
assessing risk of bias 
Selection bias Systematic differences between 
baseline characteristics of the 
groups that are compared. 
- Sequence generation 
- Allocation of concealment 
Performance bias Systematic differences between 
groups in the care that is pro-
vided, or in exposure to factors 
other than the interventions of 
interest. 
 
- Blinding of participants and   
  personnel 
Detection bias Systematic differences between 
groups in how outcomes are 
determined 
- Blinding of outcome  
   assessment 
Attrition bias Systematic differences between 
groups in withdrawals from a 
study. 
 
- Incomplete outcome data 
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Reporting bias Systematic differences between 
reported and unreported 
findings 
- Selective outcome reporting 
Other bias Other potential threats to 
interval validity 
- Other bias 
 
Sequence generation 
 
An adequate sequence generation is the first step in the allocation process ensuring that 
baseline characteristics and prognostic factors are evenly distributed between intervention 
groups. The use of a random component generates an unpredictable sequence and is therefore 
usually sufficient to provide adequate sequence generation. Alternation methods like 
assignment based on date of birth, case record number and date of presentation should be 
avoided since sequences may be anticipated or are known and selection bias can occur due to 
selective enrolment. 
 
Allocation of concealment 
 
Random sequence generation is a necessary but not a sufficient protection against selection 
bias. An appropriate sequence is likely to be worthless if it is not protected by adequate 
concealment of the allocation sequence from those involved in the enrolment and assignment 
of participants. On the other hand, a proper allocation of concealment alone may be 
insufficient, too, if the sequence is not generated at random. Due to different prognoses of 
patients or different beliefs of the efficacy of the compared interventions some trialists may 
have preferences which patient should be allocated to which arm. If this assignment becomes 
foreseeable patients may be rejected or delayed from study entry to meet these preferences 
and thereby directed to the „appropriate“ intervention. 
Thus, the second step in the allocation process must guarantee that those persons involved in 
enrolment into the trial have no foreknowledge of future intervention assignments; adequate 
methods are central randomization by a third party or the use of sequentially numbered, 
opaque, sealed envelopes. 
 
Blinding of participants and personnel 
 
After enrolment into the study, blinding of study participants and personnel may prevent that 
the knowledge of which intervention was received, rather than the intervention itself, affects 
outcomes.  
Lack of blinding of participants or healthcare providers, especially for patient reported 
outcomes like pain or depression scales could bias results whereas measured outcomes are 
less likely to be affected. This may be due to a lack of expectations in a control group, or due 
to differential drop-out, cross-over to an alternative intervention, or differential co-
medication. However, for some interventions like surgery, blinding can´t be implemented. 
Even if the interventions are administered in a blinded fashion, unblinding can occur for 
example due to certain characteristic side effects enabling individuals to guess the received 
intervention.  
 
Blinding of outcome assessment 
 
Outcome assessment can be made by patients, health care providers or independent assessors. 
The most outcomes can be impacted by lack of blinding, although the risk of bias increases 
with PRO´s being more subjective. On the other hand, for example laboratory measured 
outcomes are less likely to be affected and some outcomes like all-cause mortality are not 
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affected at all. It is therefore important to consider how subjective or objective an outcome is 
when this item is evaluated. Within one study it can occur that the relevance of blinding of 
patients and personnel and outcome assessors is dependent on the endpoints.  The risk of bias 
may be high for some outcomes and low for others, even if the same people were unblinded in 
the study. For example, knowledge of the assigned intervention may bias PRO´s such as 
reported hypoglycemia while not distorting other outcomes like HbA1c or body weight. Thus, 
the risk of bias resulting from lack of blinding for both categories will be made separately for 
the selected outcomes. However, since both HbA1c and body weight represent measured and 
objective outcomes and carry similar risks of bias they are grouped together.  
 
Incomplete outcome data 
 
Missing outcome data refers to drop-outs or exclusion of patients in a study. Attritions can 
arise when patients withdraw from a study, are lost to follow-up, or don´t attend follow-up 
visits. Exclusion can occur when patients are deemed ineligible after assignment or a certain 
kind of analysis like per-protocol (only patients that complied with the study protocol are 
included in analysis) is conducted. Missing outcome data may lead to biased results if its 
nature is informative implying that there are systematic differences in outcomes between 
patients remaining in the trial and patients leaving the trial. Uninformative missing outcome 
without any association between these groups will only affect precision but not magnitude in 
terms of direction and dimension of results. Apart from the informativeness of the missing 
data it is important to assess the total amount, the distribution among intervention groups and 
the reasons for incomplete outcome data as well as what solutions were provided by the 
authors to overcome this issue in the reported analyses. An intention-to-treat (ITT) analysis 
which analyzes patients as randomized regardless of the treatment that was finally 
administered is often recommended to be least biased; however, if there is substantial attrition 
an ITT analysis can hardly be performed without any imputation method like substituting the 
mean outcome (or minimum or maximum in sensitivity analyses) of an intervention group or 
for dichotomous outcomes assigning treatment success or failure. Even techniques like the 
last observation carried forward method (LOCF) (where the most recently observed outcome 
measure substitutes all subsequent outcome assessments) can bear a risk of bias for example 
in degenerative diseases with a long time period between last available measurement and end 
of follow-up. Generally there exists no consistent definition for the different populations 
analyzed. It is therefore not enough only to denote an analysis as ITT, modified ITT or per-
protocol; authors should rather report their trial-specific definitions so that all relevant 
information for bias assessment is provided to reviewers. 
Generally the risk of bias will be low, if the overall attrition rate is low, the reasons for 
missing outcome data are unlikely to be related to the true outcome (non-informative), 
informative missing data is balanced in numbers and reasons across intervention groups, per 
protocol analyses are done without any substantial attrition and if missing data for ITT 
analyses have been imputed with appropriate methods. 
 
Again, the incompleteness of missing outcome data and its potential bias can vary among 
outcomes. Thus, analogous to the domains of blinding, the assessment was done separately 
for hypoglycemia and together for HbA1c and body weight; however, if necessary, the degree 
of bias for HbA1c and body weight will be reported separately. 
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Selective outcome reporting 
 
Selective outcome reporting is defined as the selection of a subset of the original variables 
recorded and intended for reporting, on the basis of the results, for inclusion in publication of 
trials [101]. A main reason is that statistically non-significant results might be selectively 
withheld from publication. There is evidence that statistically significant outcomes had a 
higher odds ratio of being fully reported when compared with non-significant outcomes, both 
for efficacy (OR:2.4; CI0.95:[1.4;4.0]) and for harms (OR:4.7; CI0.95: [1.8;12]) data. Moreover, 
the comparison of publications with protocols revealed that 62% of trials had at least one 
primary outcome that was changed, introduced or omitted [80,102]. The most common 
reasons for non-publication of results were “lack of clinical importance” or lack of statistical 
significance. Thus, meta-analyses excluding unpublished outcomes are at risk to 
systematically over- or underestimate treatment effects.  
Sometimes for reviewers it may be hard to distinguish why some outcomes are not reported, 
due to selective omission or due to the fact that data just has not been collected. Selective 
choice of data for the same outcome (such as different points in time or the use of different 
instruments or scales) may result in bias if authors deviate from pre-specified criteria and 
make decisions depending on seeing the results. Moreover, selective reporting of analyses 
using the same data may have an impact on results. For example, decisions about analyzing 
continuous outcomes as final values or mean change from baseline or dichotomizing them 
with different cut-off points should be defined upfront and not be driven by its findings. 
Another reason for selective outcome reporting is underreporting of data in inadequate detail 
such as p-value threshold (which requires reviewers to make assumption if they want to 
include the study) or just mentioning that there were no differences in results rendering a 
quantitative analysis impossible. A study is unlikely to be biased, if the reviewer can access 
the study protocol and all endpoints relevant to the review have been reported as pre-
specified. Unfortunately, the study protocol isn´t always available so that reviewers have to 
rely on their common sense which of the relevant endpoints they reasonably expect to be 
reported or compare the methods section with the results section to assess the integrity of pre-
specified endpoints by means of number and way of reporting (however the latter approach 
will only detect obvious discrepancy in the publication itself and not detect intentional data 
manipulation). 
 
Other bias 
 
The category other bias accumulates all remaining sources of bias that can impact internal 
validity. Some are related to specific trial designs such as a carry-over effect or naïve pre-post 
comparisons in cross-over trials or recruitment bias in cluster-randomized trials, whereas 
others can arise trial specific such as asymmetric designs favouring one of the interventions 
(e.g. insufficient dose escalation impairing efficacy or forced dose titration triggering side 
effects) or unadjusted analyses for baseline values of continuous outcomes if the baseline 
variables are imbalanced and may modify the treatment effect. 
3.1.4.3 Presentation and summary of the assessment of risk of bias 
 
For each study the domains sequence generation, allocation of concealment, selective 
outcome reporting and other bias will be assessed at the study level, whereas the remaining 
domains will be appraised at the outcome level (jointly for HbA1c and body weight).  Each 
entry will comprise a judgment of the risk of bias as „low”, “high” or „unclear“ along with a 
support for the judgment  - a quote from the source of information and/ or a comment from 
the reviewers. Assessment of bias will be done independently by two reviewers (TB and SK); 
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in case of disagreement this issue will be overcome by a third reviewer (UM). The risk of bias 
for the primary outcomes will be summarized according to the following decision rule:  
The overall risk of bias for an outcome within a study will be deemed high in the presence of 
high bias in any domain, low if all key domains (all domains except random sequence 
generation and allocation concealment) will be of low bias, and unclear in all other cases. The 
risk of bias for each study at the study- and outcome level together with the support for 
judgment will be presented in a risk of bias table. 
Moreover, a figure will be provided displaying the distribution of the risk of bias for all 
domains at study- or endpoint level across all studies. 
3.1.4.4 Accounting for risk of bias in analysis 
 
When performing and presenting meta-analyses and mixed treatment comparisons, review 
authors must address the risk of bias in the results of included studies. There are several ways 
how the risk of bias assessment can be incorporated into the statistical analysis. One 
possibility of visually exploring a relationship between outcomes and risks of bias is to 
present forest plots for the pooled treatment effects stratified according to the different 
categories of risk of bias. A further approach is to include a covariate for the risk of bias in 
meta-regression and to test if the treatment by covariate interaction is statistically significant; 
alternatively a test for differences across subgroups representing the different categories of 
risk of bias can be applied. However the last two methods suffer from low power if the 
number of studies is small; based on a non-significant p value, it should not be concluded that 
there is no association between the results and bias categories. Furthermore, studies can be 
weighted in evidence synthesis according to their validity [103], as it is commonly done for 
combining results of multiple studies by the inverse variances of their effect estimates, which 
gives studies with more precise results more weight. The main concern is that it requires a 
measure of validity for each study, and there is no established method how to weight the 
different domains of bias for aggregation. Bayesian approaches allow incorporating beliefs of 
bias from external evidence, expert opinion or reasonable guess in prior distributions driving 
together with the data the posterior results. However, these methods are subject of current 
research and are not sufficiently well developed for widespread use.   
 
A further alternative is to evaluate the risk of bias by conducting sensitivity analyses. 
If studies are of mixed quality regarding the risk of bias the different approaches to analysis 
involve a trade-off between bias and precision. A meta-analysis that includes all eligible 
studies may produce a result with high precision but bears the risks of yielding a biased 
estimate of the treatment effect. On the other hand, restricting the analysis to studies at low 
risk of bias in all domains may produce an unbiased result but ignores some of the evidence. 
 
In this thesis the former approach will be selected for the primary analysis reporting data on 
all included studies; furthermore, the robustness of the results will be explored by sensitivity 
analysis excluding biased observations. In summary, these are  
• entire studies or single endpoints according to the riks of bias assessment 
• studies with disagreement regarding study inclusion, data collection and the risk of 
bias assessment 
• studies for which only an abstract is available or which are not published in English 
(see 3.1.2.2) 
•  studies for which the SD for the mean change from baseline was borrowed from 
another study and  
• studies reporting different categories of hypoglycemia (see Table 12b). 
 34     Methods 
3.1.4.5 Publication bias 
 
There is evidence that studies arguing a beneficial effect or a larger effect size are more often 
published than data showing a harmful effect or no effect at all. Hopewell et al. showed that 
positive results vs. negative results or results with no difference as well as significant vs. not 
significant results were more likely to be published (OR:3.36; CI0.95:[1.73;6.53] and OR:3.58; 
CI0.95:[1.84;6.99], respectively) [104].This issue is commonly referred to as publication bias 
which is somehow related to selective outcome reporting bias. 
 
Given this situation, any evidence synthesis relying only on published results will lead to 
biased and spurious results. Thus it is crucial part of systematic review to explore if 
publication bias may be present and is likely to affect the findings. 
 
One way to judge potential publication bias is the use of a funnel plot. 
It illustrates the scatter of the intervention effect estimates on the horizontal axis against a 
measure of the precision of the study, usually the standard error of the mean. 
The name ‘funnel plot’ arises from the fact that the precision of the treatment effect is 
positively correlated with the size of study. Effect estimates from small studies will therefore 
scatter more widely at the bottom, with the spread decreasing in larger studies. In the absence 
of publication bias the plot should approximately resemble a symmetrical inverted funnel. 
 
If for example smaller studies without statistically significant effects are not published, this 
introduces bias and will lead to an asymmetrical appearance of the funnel plot with a gap in a 
bottom of the figure (usually at one corner of the scatter). Ratio measures should be plotted on 
a logarithmic scale. This ensures equidistance from opposite effects from the null effect. 
 
However, the visual inspection of the funnel plot alone is subjective and insufficient to draw 
conclusions about publication bias. Thus it should only be made in combination with a 
statistical test of funnel plot asymmetry. 
A test for funnel plot asymmetry examines whether there is a statistical significant association 
between estimated intervention effects and the corresponding measure of uncertainty like the 
standard error of the mean. Egger et al. propose a linear regression of the intervention effect 
estimates on their standard errors. Under the null hypothesis of no publication bias such a line 
would be vertical. The greater the association between intervention effect and standard error 
the more the slope moves towards the horizontal [105]. 
Since the power of such tests to detect asymmetry is rather low they should only be used if 
enough amount of information is available. Even if the number of studies seems adequate one 
should not infer that due to a non-significant result of the test publication bias is absent 
keeping in mind that „absence of evidence is not evidence of absence“ [106]. 
 
Thus, in this work publication bias will only be assessed for pairwise comparisons informed 
by ten or more studies by using contour enhanced funnel plots which display different areas of 
statistical significance to ease assessment of potential asymmetry and the Eggers test for 
funnel plot asymmetry.  
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3.1.5 Agreement and handling of disagreement 
 
As mentioned before, critical steps of a systematic review involving subjective judgment 
should be done by two independent reviewers. In addition the quantification of the amount of 
interrater agreement is helpful to assess the goodness of independent review. If agreement is 
low this for example can be due to vague formulated eligibility criteria or less sophisticated 
data collection forms which may be revised. If disagreement is still substantial without any 
obvious reason this may alert reviewers that this very step of the review procedure is 
susceptible to subjective judgments which must be considered by interpreting the results.  
 
The kappa statistic is helpful tool for measuring the extent of agreement by two raters 
exceeding that just by chance alone. Consider the following 2x2 contingency table for two 
reviewers R1 and R2 making judgment about inclusion of studies (which can readily be 
extended to more than two values for the rated variable): 
 
  R2  
  I E  
R1 
I a b I1 
E c d E1 
  I2 E2 n 
 
From the observed and expected agreement just by chance, kappa (κ ) and its confidence 
interval can be derived (3.8). 
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Pe denotes the agreement by chance, I and E stands for included and excluded studies, 
respectively, po is the observed agreement and n indicates the total number of studies. 
Values of kappa between 0.40 and 0.59 may be considered to correspond to fair agreement, 
between 0.60 and 0.74 to good agreement and 0.75 or more to reflect excellent agreement. 
The kappa statistic will be applied to measure agreement of inclusion of studies based upon 
title and abstract as well as full text, of data collection and of assessing the risk of bias.  
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3.2. Evidence synthesis 
3.2.1 Bayesian Statistic 
3.2.1.1 Inference 
 
Bayesian statistical methods of inference combine a prior belief expressed by a prior 
probability distribution (which depicts possible values of a unknown parameter of interest) 
with a distribution based on the observed data (the likelihood)  to yield a posterior probability 
distribution of the unknown parameter of interest [107]. The principle idea behind it goes 
back to 1763 when the Bayes Theorem was published. Thomas Bayes, an English 
mathematician and presbyterian pastor showed how existing beliefs are modified by new 
information to posterior results. A familiar application of its theorem today is diagnostic 
testing where a physician´s prior belief that a patient suffers from a disease (based on 
prevalence data and patients symptoms) will be modified by new information (by means of a 
diagnostic test) to result in the physicians posterior belief about the patient having the disease 
[108]. 
Imagine the following 2x2 contingency table where D+, D-, T+ and T- denote people with 
disease and without disease, positive test and negative test results, respectively. A test has a 
sensitivity (probability that the test is positive given that the patient is ill; p (T+|D+)) and a 
specificity (probability that the test is negative given that patient is healthy; p (T-|D-)) of 
0.95and 0.98, respectively, and the prevalence (p (D+)) in a population of 100,000 individuals 
is 0.001. 
  
 D+ D-  
T+ 95 1,998 2,093 
T- 5 97,902 97,907 
 100 99,900 100,000 
 
 
Thus the posterior probability that a patient has the disease, given that the test result is 
positive (also called positive predictive value (PPV)) is derived as follows: 
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TDp                                                                 (3.9) 
 
In this case the PPV is 0.045 arguing that more than 95% of test positives don´t have the 
disease revealing that even when the discriminatory power of the test is adequate but the prior 
probability is low the posterior probability will still be relatively small [109].  
 
Generally spoken, suppose that θ is some unknown quantity, for example the treatment effect 
of a new drug and let p (θ) denote the prior distribution of θ. Now there is some observed 
evidence y, whose probability of occurrence is assumed to be dependent on θ, which is 
formalized by p (y|θ), the likelihood. It is the extent to which different values of θ are 
supported by the data. The new posterior probability for different values of θ, taking into 
account the evidence y, p (θ|y) is derived as follows: 
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Generally, p (y) is just a normalizing constant to ensure that ʃ p (θ|y) dθ = 1; thus Bayes 
theorem is often written as in formula 3.10b) which implicates that the posterior distribution is 
proportional to the product of the likelihood and the prior [109].  
 
For Bayesian inference it is important to assume that random variables are independent and 
identically distributed (i.i.d.). This refers to the broader term of exchangeability; it assumes 
that the random variables Y1,…..,Yn are exchangeable if their joint probability function 
p(y1,.....yn) is not dependent on the permutation of its indices, which is described by the 
theorem from De Finetti: 
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From left to right it argues, that „exchangeable random quantities can be thought of as being 
i.i.d. variables drawn from some common distribution depending on an unknown parameter θ, 
which itself has a prior distribution.“ [109]. 
 
The main differences between the Bayesian and frequentist approach are outlined in Table 7. 
 
Table 7: Comparison of the Bayesian and frequentist approach [108] 
Issue Frequentist methods Bayesian methods 
Data Data are repeated random 
events with a certain frequency 
Data are observed  from the 
sample and fixed 
Parameters Unknown parameters are treated 
as having fixed but unknown 
values 
Parameters are unknown 
quantities and are described 
probabilistically 
Prior information other than 
in the study analyzed 
Informally used in design Used formally by specifying a 
prior probability distribution 
Basic question „How likely is the data, given a 
particular value of the 
parameter?“ 
„How likely is a particular value 
of the parameter given the 
data?“ 
Presentation of results Likelihood functions, p values, 
confidence intervals 
Plots of posterior distributions, 
calculation of probabilities of 
interest, credible intervals 
 
Especially the probability statements differ between the two methods: whereas a frequentist 
probability in terms of a confidence interval implies that in repeated sampling x% of realized 
samples cover the true parameter the Bayesian probability yields credible intervals for 
posterior distributions that can be interpreted more intuitively like „there is a x% probability 
that the true parameter is in this interval“; often confidence intervals are wrongly interpreted 
in a Bayesian way. Another advantage of the Bayesian method is that uncertainty or 
scepticism about the unknown random variable can be incorporated into the model by 
specifying adequate priors. For example a sceptical prior about large treatment effects in a 
RCT might prevent to stop a trial too early due to fortuitously good interim results [108]; in 
random effects meta-analysis the heterogeneity variance is given a prior distribution fully 
acknowledging the uncertainty in this parameter whereas the frequentist approach ignores it 
and thus underestimates uncertainty [107].  
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Moreover, making predictive distributions yielding the prediction of an outcome in a future 
trial in a Bayesian setting is straightforward and inference from the posterior distribution leads 
naturally into a decision making framework. Finally Bayesian methods allow generating 
probability statements and ranking of treatments for different outcomes which go beyond 
pairwise comparisons which assists health care professionals in medical decision making. 
 
Only in few simple examples one can derive the posterior distribution in a standard analytic 
form. With Markov chain Monte Carlo methods (MCMC) simulations of random numbers are 
estimable by iterative processes, expecting to draw from a posterior distribution p (θ|y) after a 
convergence time.  If Xt denotes a random variable at time t and the state space s refers to the 
range of possible X values. The random variable is a Markov process if the transition 
probabilities between different values in the state space depend only on the current state 
 p (si → ji) of the random variable  
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Thus, for a Markov random variable the only information about the past needed 
to predict the future is the current state of the random variable, knowledge of the 
value of an earlier state does not change the transition probability. A Markov chain 
refers to a sequence of random variables (X0,…, Xn) generated by a Markov process [110]. 
For computation of Bayesian models in this thesis the open source version WinBUGS of the 
BUGS program (Bayesian inference using Gibbs sampling) is used [111]. The Gibbs sampler 
is a special case of the Metropolis-Hastings algorithm and generates Markov chains to get a 
sample from the posterior distribution after a burn-in sample (the time before the Markov 
chain has reached a stationary distribution and has converged, see 3.2.1.2). After starting from 
an initial value random numbers are iteratively drawn from the conditional distribution given 
all other components [110]. 
 
 
For Gibbs sampling the parameter vector θ is separated in S components, θ = (θ1,…, θS) 
Let p (θ|y) denote the density of the posterior distribution, from which random numbers 
should be drawn. 
 
1.) Define the initial values θ1(0),…, θS(0) and the number of iterations T. set t = 1.  
2.) For s = 1,…,S: draw random numbers θs(t) from the full conditionals 
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       using the current state of the other parameters 
3.) if t = T, the algorithm stops, otherwise continue with step 2 and increase t by one. 
 
After a convergence phase of t0 iterations the random numbers can be seen as realizations 
θs(t0+1),…,θs(T) from the marginal distribution of θS|y, s = 1,…, S [112]. 
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3.2.1.2 Convergence diagnostics 
 
A crucial question is to determine whether the MCMC sampler has reached its stationary 
distribution. If convergence is slow and the number of iterations is not enough the drawn 
samples will not be representative for the target posterior distribution since the Markov chain 
can get stuck in a region heavily influenced by the starting distribution thus yielding 
misleading inferences [110]. However, it is very difficult to say conclusively that a chain 
(simulation) has converged, only to diagnose when it hasn´t yet. Thus, for each scalar 
summary of interest (all unknown quantities of interest in the model) two or more chains 
should be run in parallel and convergence can be assessed formally and visually [110,113].  
If after the burn-in phase of the sampler, convergence has been achieved, the simulation 
should be run for further iterations to obtain samples that can be used for posterior inference. 
 
The potential scale reduction factor R̂  
 
For each parameter the scale reduction factor R̂  is essentially the square root of the 
variances for all simulated sequences mixed together divided by the average of the variances 
within the separate sequences. In the limit, when the number of iterations approaches infinity    
R̂ approaches 1, but if the sequences fail to reach convergence, R̂  can be much larger. It 
is recommended  to continue simulation until R̂ is close to 1 [110]. 
 
Monitoring trace plots visually 
 
For each simulated chain of the parameter adequate mixing can be assessed by monitoring of 
a trace plot of the sample values versus iteration. Convergence seems reasonable if all the 
chains appear to be overlapping one another [114] (see Figure 2, top). On the other hand, poor 
convergence (see Figure 2, bottom) requires extending the burn-in phase before sampling 
results from the posterior distribution.  
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Figure 2: Trace plots for assessing convergence [114] 
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3.2.1.3 Model diagnostics 
 
To check if a model fits the data well the overall residual deviance resD will be considered, 
which is the posterior mean of the deviance under the current model minus the deviance for 
the saturated model. Table 8 illustrates the residual deviance for binomial and normal 
likelihoods which are used for the Bayesian models in this thesis.  
 
Table 8: Formulas for the residual deviance, prediction and likelihoods [113] 
Likelihood Prediction Residual Deviance 
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For a Binomial Likelihood, rik and nik are the observed number of events and patients from 
each trial arm, ikr̂ = nikpik  is the expected number of events at each iteration; for a Normal 
Likelihood yik and seik are the observed mean and its standard error from each trial arm and 
iky  is the expected mean at each iteration; ikdev  is the posterior mean of the deviance residual 
for each data point which is summarized by the posterior mean resD  [113]. 
 
Leverage statistics assess the influence of each data point on the model outcomes. The 
leverage of each data point, leverageik, is derived as the posterior mean of the residual 
deviance ikdev minus the deviance at the posterior mean of the fitted values devik; this is 
summarized by pD which is a term for model complexity and is equal to the effective number 
of parameters in the model [113]. 
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As an equivalent to Akaike´s Criterion (AIC) in Bayesian statistics, the Deviance Information 
Criterion (DIC) is the sum of the posterior mean of the residual deviance, resD , and the 
effective number of parameters, pD. It provides a measure for the goodness of fit for the 
model that penalizes middle complexity and lower values of the DIC suggest a more 
parsimonious model. Hence, the trade-off is to use a parsimonious model that sufficiently fits 
the data but that provides stable parameter estimates [59]. 
It is helpful for model selection between different models with the same likelihood and data 
such as comparing fixed effects and random effects models or meta-regression models which 
are extended by covariates [113].  
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Leverage vs. residual plots can provide further information whether poorly fitting data points 
are substantially affecting the model parameters. Each data point´s contribution to the 
leverageik on the vertical axis is plotted against wik, its contribution to ikdev  on the horizontal 
axis, which is expressed by ikik devw = . Parabolas of the form x
2 + y = c, c=1,2,3…, where 
x denotes wik and y denotes the leverage can be labeled on the plot and points lying on these 
curves contribute an amount c to the DIC [115]. Points which lie outside the line with c=3 can 
be identified as highly contributing to the models poor fit. Data points with a high leverage 
are influential, implicating that they have a strong influence on the model parameters [113]. In 
this work, the DIC will be used for model comparison and selection and studies whose arms 
contribute to poor model fit (that is, the data points lie outside the line with c=3) will be 
subjected to sensitivity analysis.  
3.2.1.4 Implementation in WinBUGS and R 
 
For computation of Bayesian models (pairwise MA, MTC, meta-regression, assessment of 
inconsistency, ranking of treatments and validation) the software WinBUGS was used [111]. 
All remaining analyses were done with the statistical software R version 2.15.2 [116]. Setting 
up a model and running an analysis in WinBUGS usually requires the following steps. First a 
model in the BUGS language has to be specified to providing all probabilistic and 
deterministic information such as the likelihood, the linear predictor and prior distributions. In 
the Bayesian setting for a normal distribution the uncertainty is parametrized by the precision 
tau (1/variance). Secondly, the data has to be loaded. Thirdly, the number of Markov chains 
which will be run in parallel to yield samples of the posterior distribution for all unknown 
parameters has to be determined; then, the model will be compiled. Fourthly, for each Markov 
chain different sets of initial values for each probabilistic parent node have to be specified. It 
is recommended that overdispersed starting points are used for the initial values in order to 
detect a potential lack of convergence and ensure that all regions of the target distribution are 
covered sufficiently [113]. 
Fifthly, the model can be run for the burn-in phase and convergence has to be monitored as 
mentioned above. Sixthly, after reaching convergence the model will generate values from the 
posterior distributions. Burn-in and posterior samples should be conservatively large enough. 
As a rule of thumb, iterations should be run until the Monte Carlo error which reflects both 
the number of iterations and autocorrelation and is an estimate of the difference between the 
mean of the sampled values and the true posterior mean is less than 5% of the posterior 
standard deviation of the parameters of interest [113]. 
A substantial autocorrelation of consecutively drawn parameters can impair precision of 
results. A thin out function using only every k-th iteration as realisation from the posterior 
distribution can be set-up to prevent autocorrelation. Moreover, autocorrelation plots can 
provide information if autocorrelation over the iterations decreases rapidly enough against 
null to generate uncorrelated random numbers [117]. Since a multitude of models will be run 
and computation in WinBUGS becomes very time consuming and cumbersome, the 
R2WinBUGS package will be used. It allows to call a WinBUGS model from R, summarize 
inferences and convergence in a table and graph, and save the simulations in arrays [118].  
 
In this thesis the default settings for running WinBUGS models are as follows: for each model 
two Markov chains will be run with a burn-in phase of 30,000 iterations and a sampling phase 
of the posterior distribution of 70,000 iterations. A thin out function saving only every 10th 
sample from the posterior distribution will be used to prevent autocorrelation, thus yielding 
14,000 samples from both chains for each parameter. Convergence will be assessed by 
monitoring trace plots for all parameters of interest.  
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Autocorrelation plots will be inspected at random to check if the thin out safeguards 
efficiently against correlation. For each parameter the Monte Carlo error is required to be less 
than 5% of the SD to ensure the accuracy of posterior estimates.  
For DIC calculation and the construction of the leverage vs. residual plots a R function 
formula provided by the MTM group of the University of Ioannina was applied [119]. All 
relevant R and WinBUGS codes, data matrices and ancillary outputs not presented in the 
manuscript will be detailed as supplementary material on an electronic data carrier.  
3.2.2 Pairwise meta-analysis (Bayesian and frequentistic) 
 
Meta-analysis is used to synthesize study estimates of a particular effect of interest from 
related studies to obtain a summary estimate of the effect [120]; a fixed or a random effects 
model can be applied and meta-analysis can be performed in a frequentist or Bayesian way 
(see 3.2.2.1). 
The advantages of conducting a MA are amongst others [121] 
• To increase power. Power is the chance of detecting a real effect as statistically 
significant if it exists. Single studies may be too small to detect significant effects, but 
when several studies are combined there is a higher chance of detecting an overall 
significant effect. 
• A gain of precision. The estimation of an intervention effect can be improved when it 
is based on more information rather than single studies. 
• To provide answers not settled by single studies. Primary studies often involve 
different types of patients, received interventions, length of follow-up or other clinical 
characteristics. A set of studies in which these factors differ allows investigation of the 
consistency of effect and its generalizability, or allows reasons for differences in effect 
estimates to be explored. 
• Conflicting results of single studies might be overcome by evidence synthesis. 
 
 
However there also concerns raised when a meta-analysis might not be appropriate [121]. 
 
• A common criticism is the pooling of incomparable studies, also known as the „apples 
and oranges“ problem. If studies are clinically too diverse, then a meta-analysis may 
be meaningless, and genuine differences in effects may be masked. “This is true if 
apples and oranges are of intrinsic interest on their own, but may not be if they are 
used to contribute to a wider question about fruit” [121]. Decisions are subjective and 
require discussion and clinical judgment (see 3.1.1.2). However its appropriateness 
can be judged by statistical measures of heterogeneity (see 3.2.2.2). 
• Inference of meta-analyses of studies that bear a high risk of bias may be deceptive. 
Present bias will compound the errors, yielding a ‘wrong’ result that may be 
interpreted as being more reliable.  
• Serious publication and/or reporting biases are likely to produce an inappropriate 
summary estimate. 
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3.2.2.1 Fixed effects and random effects models 
 
In a fixed effects (FE) model the underlying assumption is that all studies iθ̂  are estimating 
the same common treatment effect θ, which implies that there is no between study 
heterogeneity in the true treatment effect and the observed treatment effect estimates vary 
only because of chance, namely their different variances sdi2. Thus, given that all studies had 
infinite sample size there would be no differences due to chance and the differences in study 
estimates would completely disappear [120]. The question behind any given comparison is:  
“What is the true treatment effect?” [121]. 
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A random effects (RE) model assumes that in addition to sampling error differences across 
studies are caused by heterogeneity between studies. The underlying assumption is that the 
study specific treatment effects θi are exchangeable meaning that the information provided by 
each study is independent of the order in which they were conducted [113].  Thus, a RE 
model assumes that the study specific treatment effects θi are drawn from a normal 
distribution; yielding an estimate of the average treatment effect θ and the heterogeneity 
variance τ2 [107]. If all studies were infinitely large, the observed study effects would still 
vary because of the real differences in treatment effects, which can be caused by differences 
in study populations, received interventions, length of follow-up and other clinical 
characteristics [120]. The question for any given comparison is: “What is the average of the 
true treatment effects, and how much do these effects vary across trials?” [121]. 
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If heterogeneity is present the confidence interval of the pooled effect estimate from the 
random effects model is wider than that of the fixed effects model since it incorporates both 
sampling error from individual studies and between-study variance.  
Often for a random effects model, only the pooled estimate and its confidence interval are 
reported, which is insufficient. The confidence interval for the mean treatment effect θ from a 
random effects meta-analysis only describes uncertainty in the estimation of the pooled effect 
but not the degree of heterogeneity among studies. Thus, the between-study variance in a 
random effects meta-analysis known as tau-squared (τ2) should be reported, too. The square 
root of it is the estimated standard deviation of underlying effects across studies and 
prediction intervals can incorporate this between-study variance to give a range for a 
parameter value in a new study [120,121]. 
 
Frequentistic Approach  
 
Meta-analysis typically consists of a two-stage process. First, based upon arm level data, a 
summary statistic is calculated for each study, to describe the observed intervention effect.  
Secondly, a summary intervention effect estimate is calculated as a weighted average of the 
intervention effects estimated in the individual studies [122]. For binary data consider the 
following 2x2 table for each study i. 
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Study i Event No event Total 
Treatment 1 ai bi n1i 
Treatment 2 ci di n2i 
 
The odds ratio of treatment 1 vs. treatment 2 and its standard error are derived as follows:  
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For continuous data consider the following table for each study i 
 
Study i Group size Mean Standard deviation 
Treatment 1 n1i m1i sd1i 
Treatment 2 n2i m2i sd2i 
 
The difference in means and its standard error are derived as follows: 
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Next, the pooled effect estimate over i studies is estimated. There are different statistical 
methods for summarizing the evidence such as the Mantel-Haenszel-, the Peto or the inverse- 
variance method. In this work, the inverse-variance method will be applied for both fixed 
effects and random effects models. Inverse-variance methods are used to pool effect measures 
like the log odds ratio (since meta-analysis requires the effect estimate to follow a normal 
distribution) or mean differences. The intervention effect estimate is denoted by θi and the 
effects from the single studies are given weights wi according to the reciprocal of their 
variance [122]. For a fixed effects model the summary estimate θ̂  and its standard error are 
derived as follows:  
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For a random effects model the study specific treatment effects are drawn from 
superpopulation of effects ~ N(θ, τ2) [123]. The DerSimonian-Laird estimator DLθ̂ , its 
standard error and the heterogeneity variance 
2τ̂  are derived as follows:  
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where )ˆ( DLiw τ  denotes the weights which are the inverse of the study specific variance sdi
2 
and the heterogeneity variance τ2 and Q denotes the heterogeneity statistic (see 3.2.2.2). If the 
Q statistic is less than or equal to its degrees of freedom, τ2 is zero and the weights correspond 
to those of the inverse-variance fixed effects model.  
 
With the package meta meta-analysis with R can be performed. For binary and continuous 
outcomes arm-level data has to contain the number of events ri and the patients at risk ni and 
the mean change mi, the standard deviation sdi and the number of patients analyzed ni for each 
study i, respectively. Since zero cells (e.g. no events in one group) cause problems with 
computation of estimates, increments of 0.5 for any affected study are added automatically to 
each cell of the 2×2 table as correction. Multiple arm trials are entered repeatedly into the data 
matrix to estimate all possible pairwise comparisons.  
 
For frequentistic meta-analysis outcome data (the point estimate, CI0.95 and the between-study 
variation τ) for fixed- and random effects models will be presented. The corresponding forest 
plots will be provided in the appendix. 
 
Bayesian Approach 
 
Bayesian meta-analysis as well as Bayesian MTC can be considered as Generalized Linear 
Models where the link function and the likelihood can change due to the nature of the data. 
For binary and continuous data, Table 9 displays the relationship. 
 
Table 9: Link functions and their inverse for likelihoods [113] 
Link Link function 
)(yg=θ   
Inverse link function 
)(1 θ−= gy  
Likelihood 
Identity y θ  Normal 
Logit 
)1(ln( y
y
−  )exp(1
)exp(
θ
θ
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The generalized linear model for pairwise meta-analysis over i studies can be written as: 
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where g is an appropriate link function, y the likelihood of the unknown parameter y, θik the 
linear predictor of a treatment effect in arm k of trial i (k=1,2; for pairwise meta-analysis), µi 
are the trial specific baseline effects in trial i, treated as nuisance parameters and 12,iδ  are the 
trial specific treatment effects  of treatment group (2) compared to control (1). For a random 
effects model the trial specific treatment effects are drawn from a normal distribution with 
mean d12 and variance σ122. 
 
  ),(~ 2121212, σδ dNi                                                                                      (3.23)                     
 
For a fixed effects model, the heterogeneity variance is set to zero assuming all studies are 
estimating the same common treatment effect d12 [113]; formula 3.22 can be written as:  
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Binary and continuous data is modeled assuming a binomial (using logit link function to map 
the probabilities on a plus/minus infinity range) and a normal likelihood, respectively. The 
generic equation (3.22) can be written as 
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for RE models with binary data (3.25a/b) and continuous data (3.25c/d), respectively; usually 
the uncertainty of normally distributed data in Bayesian models is expressed by the precision, 
which is one over the variance. If the heterogeneity variance is set to zero, the corresponding 
FE models are derived [113]. 
Special consideration must be given to the parametrization of priors for d12 and σ122. Unless 
there is no reason for an informative prior, flat (non-informative) priors should be used to 
ensure that the posterior distribution is not influenced by the prior but totally driven by the 
data [107]. However, „there is no such thing as an uninformative prior“ and even flat priors 
should be reasonably selected [109]; especially the posterior of the heterogeneity variance is 
likely to be sensitive to its prior, and vague priors are likely to result in posteriors which allow 
for unrealistically high levels of heterogeneity if the amount of evidence is small [62].  
In this thesis for the core analysis the treatment effects and the trial specific baseline effects  
are given a vague normal prior (d~N(0,1.0e-6) and µi~N(0,1.0e-5), respectively) and the 
standard deviation of the heterogeneity variance σ is believed to follow a uniform distribution 
(σ~unif(0,10); to account for the susceptibility of results, in MTC different priors for the 
between-study variance will be assessed in sensitivity analysis (see 3.2.3.4).  
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No model is assumed for the trial-specific baselines, they are treated as nuisance parameters 
which are estimated in the model [113]. Alternatively, one could place a second hierarchical 
model on the trial baselines. However, this approach is in keeping with frequentist methods in 
which relative effect estimates are treated as data and baselines eliminated entirely. 
 
For analysis, WinBUGS requires binary and continuous arm-level data, namely the number of 
events ri and the patients at risk ni and the mean change mi, and the standard error sei for each 
study i, respectively. Multiple arm trials are entered repeatedly into the data matrix to estimate 
all possible pairwise comparisons. It must be acknowledged, that this approach ignores 
correlation among the effect estimates for the pairs of arms since the input data for the three 
direct comparisons in a three-arm trial is treated like coming from three separate studies. 
However, correlation will be taken into account for MTC models (see 3.2.3.1). Finally the 
number of studies informing each comparison must be specified. The models run for meta-
analysis are adapted from the WinBUGS code provided from Dias et al. in their Technical 
Support Document 2 [113]. 
 
For Bayesian meta-analysis, both fixed and random effects models will be reported with the 
mean (if necessary the median, given a skewed posterior distribution) and the CrI0.95; in 
addition, for random effects models the posterior mean of the between-trials standard 
deviation will be reported. 
3.2.2.2 Assessment of heterogeneity 
 
Higgins et al. proposed the following definition for heterogeneity: „…Statistical heterogeneity 
exists when the true effects being evaluated differ between studies, and may be detectable if 
the variation between the results of the studies is above that expected by chance…“ [124]. 
To common measures for assessment are the heterogeneity statistic Q and the quantity I2 
[123,124]. The heterogeneity test refers to the following statistic: 
 
  1~)ˆˆ( 22 −=Χ−= ∑ kwQ dfii θθ                                                                (3.26) 
 
Q is the heterogeneity statistic which is assuming that under the null hypothesis all studies 
share a common treatment ):( 210 θθθθ ==== kH  effect and follows a Chi-Square 
distribution with k-1 degrees of freedom. Under the alternative hypothesis, at least two studies 
differ { } { }),...,1,;:( ktrtrH A ⊂≠ θθ . However, if the number of studies is small, the power of 
the test is low to detect a significant heterogeneity. In this setting a non-significant result 
should not be interpreted as evidence of homogeneity [125].  
 
The quantity I2 describes the percentage of total variation across studies that is due to 
heterogeneity and goes beyond chance [124]. 
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Even if there are no fixed categories I2 values of 0.25, 0.5 and 0.75 may refer to low, 
moderate and high heterogeneity. The advantage of I2 is that it can be interpreted similarly 
irrespective of the type of outcome data and choice of effect measure and it doesn´t depend 
inherently on the number of studies. 
 48     Methods 
Thus, in a meta-analysis of only eight studies where the study specific odds ratios ranged 
from 0.07 to 0.84 the p-value of test for heterogeneity was 0.09 indicating no heterogeneity, 
whereas I2 = 0.44 indicated a considerable amount of heterogeneity [125].  
 
In this work the Q statistic for an alpha error level of 0.05 and I2 will be used for assessing 
heterogeneity. 
3.2.3 Mixed treatment comparison analysis (only Bayesian) 
 
As outlined before (see chapter 1.6) network meta-analysis is an extension to classical 
pairwise meta-analysis and for connected networks it provides relative treatment effects for 
any possible contrast either by indirect treatment comparisons for open loop networks where 
either direct or indirect evidence informs evidence synthesis or by mixed treatment 
comparisons for networks with at least one closed loop where direct and indirect evidence 
(via one or several anchor treatments) yield mixed estimates. The idea of network meta-
analysis in a Bayesian context was first brought up by Higgins et al. who revealed that 
„borrowing strength from external trials“ in a meta-analysis by jointly estimating all possible 
treatment effects leads to more precise posterior estimates especially with regard to the 
heterogeneity parameter [126]. For a simple triangular network, Bucher et al. provided the 
statistics to derive an indirect treatment estimate, a test for consistency to assess if direct and 
indirect evidence are in agreement and a mixed estimate as a weighted average of both 
evidence sources [127]. The rank-ordering of treatments to assign probabilities which 
treatment is best by relating all treatments to an overall baseline was introduced by Lu et al. in 
2006 [128]. With the spread of applications and methods papers further approaches to address 
the issue of consistency such as the node splitting procedure or the inconsistency model were 
developed [128,129]; recent developments for example focus on the combination of 
aggregated level and individual patient data or how bias of small study effects can be 
accounted for in NMA reflecting that this evidence synthesis method becomes more 
elaborated and sophisticated [130,131]. Due to its appealing features network meta-analysis is  
increasingly accepted amongst researchers, health technology assessment agencies and 
funding bodies [60]. 
3.2.3.1 Fixed effects and random effects models 
 
For simultaneously estimating all possible contrasts a statistical model can be derived that 
takes into account all the direct and indirect comparisons in the complete network.  
 
When the network from equation (1.1) is generalized to any network with multiple different 
comparisons, it yields the following consistency equation: 
 
   
0=
−=
AA
AbAkbk
d
ddd
                                                                         (3.28) 
 
 
K denotes the intervention and b the baseline treatment for that trial. As long as k is 
alphabetically after b, in a connected network any estimate for a particular pairwise 
comparison can be expressed by the effect estimate of the intervention k relative to the 
baseline b expressing them in terms of effects in relation to an overall reference treatment A 
[59].  
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Db = (dAB, dAC, dAD, . . . , dAk) is the vector of basic parameters of the model that are estimated 
based on the available studies. Df = (dBC, dBD, dCD,…) is the vector of functional parameters 
and can be calculated based on the estimates for the basic parameters [128].  
For a network involving K treatments, there are T= K (K-1)/2 potential types of comparisons, 
K-1 basic parameters and T-K+1 functional parameters. In conclusion, a network meta-
analysis extends a traditional meta-analysis model from one to K-1 parameters that need to be 
estimated to allow for multiple pairwise comparisons across the range of K interventions [59].  
A fixed effects model assumes that relative treatment effects across the whole set of studies 
are identical. 
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A random effects model assumes that the relative treatment effects relative effects across the 
whole set of studies are considered exchangeable and are drawn from a normal distribution. 
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In this work it is assumed that between-study variances for all treatment contrast are equal, 
thus σbk2=σ2. For heterogeneous variance models refer to Lu and Ades [132]. Multi arm trials 
induce a between arm correlation that has to be taken into account while estimating the 
random effects [113]. Pbk denotes the within trial correlation which in case of homogeneous 
variance is 0.5 for any two treatment comparisons from a multi-arm trial. 
The vector of random effects δi estimated for multi arm trials follows a multivariate normal 
distribution: 
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where ai denotes the number of arms in trial i (ai=2,3,…) and dti1,tik = d1,tik-d1,ti1. Then, the 
conditional univariate distributions for the random effects of arm k > 2 given all other arms 
from 2 to k-1 is [113] 
  ( ) ( )[ ] 





−
−−
−
+−










∑
−
=
−
2
1
1
,1,11,,1,1
)1(1,
12,
1, )1(2
,
1
1~
11
σδ
δ
δ
δ
k
kdd
k
ddN
k
j
ttjitt
ki
i
ki iijiik
  
                                                                                                                                             (3.32) 
 
For multi-arm trial correction in the calculated models equation (3.32) is applied to account 
for between-arm correlations. 
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For running MTC models with WinBUGS the data input consists of two components: a list 
containing the number of treatments and the number of studies and a data matrix that has to be 
set-up as follows: each row contains one study with k arms; treatment number identifiers and 
the number of arms are indexed as described in Table 5. Moreover, for each arm 1 to k 
treatment indices and data for binary and continuous outcomes are provided as described in 
section 3.2.2.1. Studywise for each arm treatments are always presented in ascending 
numerical order and treatment 1 is taken as the reference treatment. This rule is essential for  
MTC to make sure that the correct relative effects are estimated. Treatment A is chosen as the 
overall reference treatment and the studies are arranged consecutively as follows [133]: 
 
a.) all A trials with AB trials first, then AC, AD, etc. 
b.) all B trials not containing A in the same order 
c.) all C trials not containing A or B, etc. 
 
For all pairwise comparisons the outcomes for FE and RE models for MTC will be reported 
as described in section 3.2.2.1 together with the DIC for model comparison purposes. The 
between- study standard deviation will be reported with its mean and CrI0.95. The MTC 
models are adapted from the WinBUGS code provided from Dias et al. [113]. 
3.2.3.2 Assessment of consistency and transitivity 
 
The different assumptions underlying NMA and pairwise meta-analysis are displayed in 
Figure 3. 
 
Figure 3: Assumptions underlying network meta-analysis and pairwise meta-analysis [134] 
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The assumption that different trials are sufficiently (not necessarily completely) homogeneous 
and that they estimate the same single treatment effect (fixed effect model) or different 
treatment effects distributed around a typical value (random effects model) holds for both, 
NMA and MA. For NMA, two additional assumptions must be postulated. First, the 
transitivity assumption implies that an indirect comparison validly estimates an unobserved 
head-to head comparison; thus the assumption that studies may be considered identical or 
exchangeable must hold across the whole set of trials in the network [60,134]. One can 
imagine transitivity as a network of M trials with S treatments originating from M S-arm trials, 
but that some of the arms are missing at random, meaning that the missingness of arms is not 
associated with the relative efficacy of the interventions [113]. Another conceivability is that 
transitivity is given if the distribution of effect modifiers doesn´t differ across comparisons. 
Transitivity can´t be tackled statistically, but reasonability can be assessed epidemiologically. 
Finally the consistency assumption that direct and indirect evidence are not contradictory is 
the prerequisite for the calculation of a mixed estimate. Consistency is the extension of 
transitivity to closed loops of evidence and statistical methods are at hand for verifying it [60]. 
Lu et al. propose the following definition: "If the discrepancy in the results of the studies goes 
beyond that explained by sampling error and between trial heterogeneity, then we may say the 
direct and indirect evidence are inconsistent as sources of effect size estimation“ [128]. 
Transitivity doesn´t automatically imply consistency; even if an indirect comparison via a 
transitive comparator C (e.g. A-C and B-C trials have the same distribution regarding the 
effect modifier age) yields an valid estimate but direct A-B trials are conducted in a different 
population regarding age, both estimates A-Bindir and A-Bdir are valid but a mixed estimate 
will be meaningless, since the consistency assumption is violated [60]. 
 
Lu et Ades suggest an inconsistency model where the consistency assumptions are relaxed by 
a random quantity ω, the inconsistency factor (ICF) and both models are compared for better 
model fit [128]. The number of ICF is determined by the inconsistency degrees of freedom 
(ICDF) which can be described by the number of independent three-way loops in the network; 
thus, it is derived from the number of functional parameters minus the number of loops S 
informed from a multi-arm trial alone, ICDF=df-S [135]. In their fully connected network of 
four interventions A represents the reference treatment, db= (dAB,dAC,dAD), df= (dBC,dBD,dCD) 
and the number of independent three way loops ICDF=3. The inconsistency equations can be 
parametrized as follows [128]: 
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ddd
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                                                                              (3.33) 
 
Plots of the posterior mean deviance of each data point for the consistency model against the 
inconsistency model might allow detection of inconsistent loops in the network. Moreover, an 
inconsistency p-value can be derived expressing the probability given the full data y  that the 
inconsistency variance σω2 exceeds the between trial heterogeneity σ2 with a high value 
pointing to potential inconsistency (Pr(σω2 > σ2 | y)) [128]. However for networks with a small 
number of ICDF measure of variance will have wide credible intervals which 
handicaps detecting inconsistency [135]. 
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The back calculation introduced by Dias et al. is an extension of the Bucher method to any 
network. Manipulating the basic formula for weighted averages the direct estimate DirXYd̂  and 
the MTC estimate MTCXYd̂ for a contrast (x,y) can be transposed to derive the indirect 
estimate stXYd
Reˆ  and its variance stXYV
Re : 
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Assuming a normal distribution of stXYd
Reˆ  an inconsistency factor XYω̂ and its variance 
XYVarω  can be derived; for the null hypothesis that there is no inconsistency (H0: XYω̂ = 0) a 
test statistic ZXY which follows a standard normal distribution can be applied [129]: 
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The node splitting method separates direct from indirect evidence for each contrast informed 
by both direct and indirect evidence for assessing inconsistency between the posterior 
distributions of DirXYd̂  and 
Ind
XYd̂  [129]. Consider the following directed acyclic graph 
(DAG) which reflects a random effects model for binary data for a contrast (x,y): 
 
 
Figure 4: Directed acyclic graph for MTC for node split [129] 
MTC, mixed treatment comparison. 
 
The left side contains trials, indexed i, providing direct evidence; on the right sight the 
remaining MTC model is displayed with data from all other studies except XY trials. K 
denotes the arm of each study, b the trial specific baseline. Boxes represent constants, ellipses 
denote variables, either deterministic (dashed arrow indicating functional dependence) or 
stochastic (solid arrow) ones.  
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Stochastic nodes are either child nodes or parent nodes the former depending on the latter. 
Thus, by giving the parent nodes prior distributions the model is fully specified [117,129].  
The node splitting approach draws the posterior distributions from two separate sources 
),(~ 2σδ DirXYiXY dN , based only on studies comparing the treatments X and Y directly and 
),(~ 2σδ IndXYiXY dN based on all remaining studies in the MTC model, assuming the variance 
σ2 be equal for both distributions estimated from all data.  
The inconsistency parameter 
Ind
XY
Dir
XYXY dd ˆˆˆ −=ω  is examined for each node if the 
consistency assumption is reasonably supported by the data. A Bayesian p-value indicates   
the probability that 
Dir
XYd̂  exceeds 
Ind
XYd̂  (or XYω̂  > 0); for symmetric unimodal distributions 
this is implemented by MCMC sampling and estimating this probability by  
p=2xmin (prob,1-prob) [129].   
In multi-arm trials, the splitted node is used for the direct evidence 
Dir
XYd̂ whereas the 
remaining arms are incorporated in the indirect comparison making full use of the available 
evidence. For trials with more than three arms, the correlation for the unsplitted arms must be 
taken into account. Thus, the model for an ACD trial splitting node A-C is:  
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Thus, the A-D and C-D information contributes to the indirect evidence of dAD and dCD if 
there are other A-D and C-D trials, since a three arm trial alone cannot be inconsistent [129].  
 
The flat prior for the direct comparison parameter is assumed to follow a normal distribution 
(dDir~N (0,1.0e-4)). The posterior mean of the deviance ( resD ), the DIC, the heterogeneity 
parameter σ2and the Bayesian p-value will be examined for comparing the full MTC model 
with the node split models for assessing model inconsistency. The R code for data 
manipulation and the MTC models for node split are adapted from Dias et al. [129]. 
Depending on the DIC for the FE/RE MTC core models the node split will only be conducted 
for the model that fits the data better. 
 
In this work transitivity for loops supported by indirect evidence only will be assessed by 
comparing potential effect modifiers between the sets of studies informing the indirect 
comparison. Consistency will be tested by the node splitting method initially and after meta-
regression and sensitivity analysis to analyze if measures of reducing inconsistency have been 
successful. 
3.2.3.3 Meta-regression of potential effect modifiers 
 
Although a random effects model allows for incorporating heterogeneity, it doesn´t explain it.  
As mentioned before, MTC results will be biased if there are differences in covariates that act 
as treatment modifiers across the network. Thus, by incorporating covariates and modeling 
treatment-by-covariate interactions in a meta-regression model the impact of bias due to the 
violation of the similarity and/or consistency assumption might be reduced [59]. 
 
It has to be acknowledged that meta-regression suffers the limitations of observational studies, 
including possible bias through confounding by other study-level characteristics.  
 54     Methods 
Even if individuals are randomized within trials, they are not randomized to covariate values 
[121]. Thus it is impossible to infer a causality from the association since an identified 
association may in reality reflect a true association with another (unobserved) covariate [136]. 
Moreover, meta-regression is vulnerable to aggregation bias, also called ecological bias or 
ecological fallacy. It can occur if the relationship with patient averages across trials may not 
be the same as the relationship for patients within trials. Thus, a within trial relationship may 
be masked at the study level or a study level association may not be present within the single 
studies each of the scenarios leading to misleading results [136]. This issue can only be 
overcome by performing meta-regression with individual patient data (IPD) which is 
generally preferable due to other features like its higher power in detecting statistic significant 
effects of the covariate and the possibility to re-analyze other covariates not reported at the 
study-level. Although meta-analysis and meta-regression on an IPD level might serve as the 
gold-standard it´s often unfeasible due to the unavailability of individual patient data and 
often the analyst has to resort to aggregated level data (AGD) [137].  
 
Due to its low power if the number of studies in the network is limited meta-regression should 
only be undertaken if as a rule of thumb there are at least ten studies for each modeled 
covariate in the study set [121]. To keep the number of covariates at a reasonable level and to 
avoid „data dredging“ (namely that covariates are selected after seeing the data since the 
likelihood of a false positive result increases with the number of characteristics investigated), 
covariates that will be subjected to meta-regression should be pre-specified. Ideally, the 
selection of characteristics should be based on clinical grounds or supported by external 
evidence. 
  
For this thesis, the following covariates were selected since it is assumed that they are likely 
to act as effect modifiers: for HbA1c and body weight, the covariate at baseline, the length of 
follow-up and the previous therapy will be evaluated; for HbA1c it is known that lower 
baseline levels result in a smaller treatment-induced change in HbA1c and previous therapy 
induces a similar effect since patients with drug history exhibit lower baseline values [138]. 
Moreover for some OAD´s  it has been shown that they lose their efficacy and lead to 
secondary therapeutic failure the longer they are administered [45]; thus since length of 
follow-up according to the eligibility criteria ranges from 12 weeks to 3 years it may affect 
the relative treatment effects if it is unevenly distributed between the comparisons. For body 
weight, the same considerations seem plausible. For hypoglycemia, the year of study and the 
length of follow-up are considered for meta-regression. The rationale is that older studies may 
exhibit lower standards regarding the reporting of hypoglycemia compared to more recent 
studies (see 3.1.1.3) and that the frequency of hypoglycemia may increase with longer drug 
exposure especially when drugs that are prone to induce such events are compared to placebo 
or drugs that are unlikely to trigger hypoglycemia. 
The meta-regression models for fixed (3.37) - and random effects models (3.38) are derived 
as follows: 
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Xi denotes the trial-level covariate (either categorical or continuous) and ßbk=ß is the 
regression coefficient and for continuous and categorical variables, it describes, how the 
outcome variable (the intervention effect) changes with a unit increase in the explanatory 
variable and how the intervention effect differs from a reference group, respectively. Here, 
one common regression coefficient which assumes an identical interaction effect across all 
treatments with regard to the reference treatment is estimated since there is no evidence from 
the literature that provides a rationale for assuming independent or related regression 
coefficients; for those models refer to Dias et al [62]. This means all treatments related to the 
reference treatment exhibit the same treatment by covariate interaction and the treatment 
effects of functional parameters relative to each other are the same because interaction terms 
then cancel out (brackets for ß in equation 3.37 and 3.38 dissolve) [62].  
 
Continuous covariates will be centered around their mean by subtracting the mean covariate 
value, x , from each xi to improve the mixing of the MCMC chains; thus, the treatment 
effects are estimated at the mean covariate value. Uncentering for any covariate value z is 
achieved by d-ß( x - z) [62]. The categorical variable previous therapy with three values (see 
Table 5) is coded with k-1=2 dummy variables (d1, d2) with therapy naive as reference 
category and d1 and d2 taking the value 1 for no OAD at least 8 weeks before randomization 
and the category else, respectively. For each outcome all potential effect modifiers will be 
included in the full model. Variable selection will be based on the significance at an alpha 
level of 0.05. Thus, only covariates of which the CrI0.95 doesn´t contain the null effect and the 
null hypothesis of no treatment- by- covariate interaction can be rejected will be maintained in 
the model. Missing values for continuous covariates will be imputed with the mean of the 
remaining studies. No imputation will be made for measures of uncertainty for covariate 
values which appear to be poorly reported since assumptions for imputation might be too 
strong if the proportion of missing data is substantial; therefore meta-regression for 
continuous covariates will be unweighted. A vague normally distributed prior will be assumed 
for all regression coefficients (ß~N (0,1.0e-4)). 
 
Depending on the DIC for the FE/RE MTC models meta-regression will only be conducted 
for the model that fits the data better. To ease the assessment of plausibility of a meta-
regression relationship covariate vs. outcome scatterplots will be designed for statistically 
significant regression coefficients. The meta-regression models provided by Dias et al. [62] 
were adapted and applied to the data. For all meta-regression MTC models the regression 
coefficients (point estimate, CrI0.95) for all covariates will be reported to illustrate variable 
selection. For statistically significant treatment-by-covariate interactions the pairwise 
comparisons will be reported as described in section 3.2.2.1 together with the regression 
coefficients (point estimate, CrI0.95) and the DIC for model comparison purposes. 
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3.2.3.4 Sensitivity analyses 
 
The conduct of a systematic review involves several decisions and assumptions [121]. While 
many of these decisions are clearly objective, some are arbitrary or unclear and some 
assumptions are challengeable. It is worthwhile to prove that the results from a systematic 
review are not dependent on such issues. A sensitivity analysis is a repeat of the core analysis, 
substituting alternative decisions or ranges of values for decisions that were arbitrary or 
unclear or making different assumptions. A sensitivity analysis asks the question, “Are the 
findings robust to the decisions made in the process of obtaining them?” [121]. If core and 
sensitivity analyses are consistent or are conflicting, the results may be more reliable or must 
be interpreted more cautiously, respectively. In this review the following sensitivity analyses 
will be performed: 
 
• for the endpoint HbA1c, all treatments will be assessed in SA for the appropriateness 
of serving as overall baseline; for each overall baseline the mean and standard 
deviation for the absolute efficacy and the probability of being the best treatment will 
be provided (see 3.2.3.5). 
• the impact of the risk of bias on the robustness of results will be analyzed as described 
in chapter 3.1.4.4 
• outliers, as described in 3.2.1.3 will be subjected to SA 
• for RE models the impact of different priors on the heterogeneity parameter will be 
assessed. Since the posterior of the between trial standard deviation is highly sensitive 
to its prior and will exhibit higher heterogeneity the more vague a prior is it is 
advisable to subject prior assumptions to sensitivity analysis. Priors might be derived 
from external data like using predictive distributions from former meta-analysis on the 
same topic or by eliciting priors from clinical experts [109]. In this work a rather 
vague prior (σ~unif (0,10) reflecting a belief in a large degree of uncertainty (see 
3.2.2.1) will be used in the core analysis. Tighter priors on σ (i.) (σ~unif (0,5);  
ii.) (σ~unif (0,2)) and a prior on the precision which follows a gamma distribution 
(τ~gamma (0.001,0.001)) and puts more weight on values of σ near to zero will be 
evaluated in sensitivity analysis [113]. 
3.2.3.5 Ranking of treatments  
 
Classical MA only provides estimates of a set of pairwise comparisons and can´t yield 
indirect comparisons or a ranking of treatments. The output of MTC contains all possible 
comparisons but the outcome matrix can become confusing and difficult to interpret when the 
number of treatments increases.  
Thus, it is helpful to provide a summary based on probabilities addressing the following 
questions: „What is the probability that each treatment is the best“? „What is the probability 
that each treatment is among the n best options“? [139]. In some cases, it may be sufficient to 
know which treatment is best. However, this may not be comprehensive enough. For example, 
the most effective treatment may be unavailable, too expensive, or associated with serious 
adverse effects outweighing its benefits. Moreover, a treatment may have low (high) 
probability to be the best but very high (low) probability of being second or third best. Also, 
two treatments may have similar probabilities to be the best but may have very different 
ranking thereafter. Thus it is important to see, what the other alternatives are and how they 
rank altogether.  
In a Bayesian setting the ranking of treatments is implemented by choosing on overall 
baseline, which should ideally be connected with every other node in the network forming a 
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spanning tree [128]. For the baseline a separate meta-analysis is conducted including all arms 
with the baseline treatment to derive its absolute efficacy. Together with the estimated 
treatment effects for the basic parameters the arm-specific treatment effect for each node is 
derived and ranked; aggregation over all iterations yields the probability of each treatment for 
every rank. While the overall baseline isn´t interfering with the calculation of the relative 
treatment effects it can affect the ranking. The overall baseline is connecting the treatments 
across the network, so the treatments become comparable; if the baseline is poorly chosen 
either that it is not connected with all treatments (no spanning tree) or that the number of 
observations informing the absolute efficacy of the baseline treatment is low this can impact 
the ranking since basic parameters are missing and the baseline calculation may be instable, 
respectively. Moreover, choosing the treatment that has been trialed against the highest 
number of other treatments reduces strong correlations that may otherwise be induced 
between mean treatment effects for each pair of treatments which can slow convergence 
[113].  
 
In this work the treatment that forms a spanning tree and includes the most observations for 
the calculation of the overall baseline, will be chosen as overall reference treatment. FE and 
RE meta-analysis will be carried out for the calculation and the DIC will be used for model 
selection; the predictive distributions of these posterior estimates will be used as prior for the 
calculation of T[k] and rank [k], the absolute efficacy and overall ranking of each treatment 
by adapting a code of Dias et al. [113]. The ranking of treatments will only be performed for 
the apparently best fitting model from preceding analyses. Depending on the outcome (if 
higher or lower values of T[k] are superior) the code for being the best treatment must be 
adapted or yields the worst treatment.  The impact of different overall baselines will be 
evaluated exemplary for the endpoint HbA1c (see 3.2.3.4) in sensitivity analysis. 
3.2.3.6 Validation of the mixed treatment comparison models 
 
Model diagnostic by means of the DIC only allows to judge if the model fits the data well. 
Internal validation can be performed for the detection of outliers by the „leave one out” 
method or by dividing the whole study set into a test- and trainings set and calculate a 
prediction error. However, if the whole study set is used afterwards for estimating outcomes, 
it doesn´t allow to evaluate the goodness of prediction of the model regarding independent 
data. If the study set remains splitted, prediction is independent but a considerable amount of 
information is lost. Ideally, a model may be externally validated by checking its prediction 
against future studies within the same setting. In this work a similar approach will be 
accomplished; studies that don´t report all three outcomes at once will be excluded (see 
3.1.1.3) from the review and can be used like having external evidence for validation. For the 
contrasts and outcomes that are not supported by direct evidence in the network and for which 
this kind of external evidence is available an external validation will be conducted by means 
of the „leave one out“ approach. 
 
The procedure is to compare the observed treatment effect of the excluded studies to the 
predictive distribution of effects that one expects based on the network analysis [62]. First the 
predictive treatment effect in a future trial newδ  is estimated from the posterior distributions of 
the summary estimate d and the heterogeneity parameter σ ( newδ ~ N(d,σ
2)). To account for 
the correlation of predictive effects induced by multiple treatments and multi-arm trials a 
series of conditional univariate normal distributions must be used as described before (see 
3.2.3.1). Predictive distributions of functional parameters are derived from the consistency 
equations:
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Now, the predictive treatment effect newδ is applied to the baseline arm of the external trial.  
A flat prior is placed on the baseline risk to reflect the uncertainty about this parameter [62]. 
For binomial (hypoglycemia and continuous data (HbA1c and body weight), this is 
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where pbase denotes the baseline probability of suffering a hypoglycemic event and a and b 
(numbers of events and non-events in the baseline arm of the external trial) represent the 
shape parameters and the mcbase is the mean change in HbA1c/ body weight of the control arm 
following a normal distribution with its mean d and precision 1/σ2 , respectively.  
The predictive outcome for the experimental arm is given by 
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The predicted number of events and the mean change in HbA1c/ body weight in the 
experimental arm will be compared with the observed number of events and the mean change 
in HbA1c/ body weight of the experimental arm of the external trial. A Bayesian p-value (see 
3.2.3.2) will be set-up by a step function to monitor if the predicted results are in agreement 
with the observed result from the external trial [62]. In addition a CrI0.95 for the external trials 
will be constructed to assess if the predictive effects lie within this interval or if both CrI0.95 
overlap at least. The validation will only be performed for the apparently best fitting model 
from preceding analyses. The models were adapted from a code provided by Dias et al. [62].  
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3.2.3.7 Overview of models 
 
Figure 5 provides on outlook over the implemented models in this thesis. 
 
Figure 5: Model diagram 
All models are run for all three outcomes HbA1c, body weight and hypoglycemia, unless otherwise specified. 
a For frequentist models a forest plot is provided for all direct comparisons; a contour enhanced funnel plot is 
provided with a test for funnel plot asymmetry for direct comparisons which are supported by > 10 studies (A-G 
and B-G). 
b For random effects models a homogeneous variance is assumed. 
c For meta-regression a common regression coefficient which assumes an identical interaction effect across all 
treatments with regard to the reference treatment was used. 
d The apparently best fitting model from sensitivity analyses was used for ranking of treatments and validation 
and reanalyzing of node splitting to assess if inconsistency resolved. 
MA, meta-analysis. MTC, mixed treatment comparison. DIC, deviance information criterion. 
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4. Results and Discussion 
4.1. Systematic review 
 
Literature search, study selection and data collection 
 
The piloting of the eligibility criteria against a sample of clearly eligible/ not eligible studies 
resulted in complete agreement reasoning that eligibility criteria were precisely and 
adequately pre-specified. Moreover, the search strategy appeared to be comprehensive since 
all records from a randomly drawn test set of trials clearly fulfilling the search criteria were 
identified in the database of retrieved records. The literature search strategy including all 
information sources, the databases, the search concepts, operators and syntax is provided in 
Table 10 of the Appendix. 
 
Figure 6 summarizes the flow of information from the core and updated literature research 
over identification of eligible trials to inclusion into evidence synthesis. 
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Figure 6: Flow of information through the different phases of the systematic review [76] 
a The following bibliographic databases were searched: MEDLINE via PubMed, EMBASE and the Cochrane 
Central Register for controlled trials. 
b The following additional sources were searched: ClinicalTrials.gov register, European Public Assessment 
Reports of the European Medicines Agency and reviews of approval of the Food and Drug Administration as 
well as the pharmaceutical industry trials registers of the market authorisation holder of the relevant drugs 
[83,87-94]. 
c One full-text article (Record No. 4945) reports two single studies, which were separately included in 
quantitative synthesis (Study No. 2/32). 
MA, meta-analysis. MTC, mixed treatment comparison. 
Records identified through 
database searchinga; initial 
search: 2012/04/02 
n=12,968 
Duplicate records removed 
n=1,753 
 
Records screened 
n=12,247 
 
Records excluded based on 
title and abstract 
n=11,990 
 
Full-text articles assessed for 
eligibility 
n=257 
Studies included in 
quantitative synthesis 
n=62c 
(MA and MTC, 
respectively) 
Full-text articles excluded 
n=196 
• Non eligible intervention  
n=28 
• Inadequate study design 
n=15 
• Study duration inadequate 
n=5 
• Duplicate data 
n=34 
• Data required for analysis 
not reported/ not 
obtainable from authors 
n=112 
• Full text publication not 
available 
n=2 
 
Records identified through 
database searchinga; 
updated search: 
2012/07/30 
n=990 
Additional records 
identified through other 
sourcesb 
n=42 
Id
en
tif
ic
at
io
n 
Sc
re
en
in
g 
E
lig
ib
ili
ty
 
In
cl
ud
ed
 
 62     Results and discussion 
12,968 and 990 records were retrieved from the initial and updated literature research, 
respectively. Moreover, the search of other record sources resulted in 42 additional records. 
After removing duplicates from the merged database of all records 12,247 records were 
screened by study title and abstract by two reviewers (TB and SK). Finally, 257 full texts 
were assessed for inclusion; Japanese, Chinese, Spanish, Russian and Italian publications 
were evaluated with the help of native speaking scientists. 196 records had to be excluded 
after evaluating the full text; in Table 11 of the appendix the excluded studies are listed with 
the reason and a rationale for exclusion. 62 studies were eventually included in evidence 
synthesis. 
 
For the majority of excluded studies (n=112) the outcome data required for analysis was not 
reported adequately and could not be obtained upon request from the first author (see 3.1.2.4). 
Nevertheless, 52 Authors were contacted to obtain missing data or information, and in 5 cases 
the requested piece of information was provided revealing that it is worthwhile to undertake 
this effort. A substantial proportion of studies (n=20) could be included by transforming the 
reported data to the required format or by imputation (see 3.1.3.4); therefore, it is important to 
consider these possibilities of data manipulation and imputation to maximize the body of 
evidence. The second most common reason for exclusion was duplicate data (n=34): on the 
one hand some records were identical assuming that the automatic removal of duplicates in 
the reference management software could not identify all duplicates. On the other hand some 
of the excluded duplicates were published twice (another journal, time of publication and 
study title) showing that it is enormously important to identify true duplicates in order to 
avoid biased outcomes. Non eligible interventions (especially due to combination therapy or 
studies comparing two drugs from one drug class; n=28), inadequate study design (no 
randomization, reviews or cross-over studies without wash out phase potentially biasing 
results by carry over effects; n=15), and inadequate study duration (n=5) were further reasons 
for exclusion. Two studies were not accessible for full-text. The well-known UKPDS 33 and 
34 studies which report outcome data matching the eligibility criteria for placebo, Metformin 
and sulfonylureas for a follow-up of ten years were excluded since no data was obtained from 
the authors for the interim analysis at three years, which was set as the upper limit of eligible 
time frame. Since the mean follow-up of included studies is clearly shorter and below one 
year and most of the OAD show impaired glycemic durability due to secondary therapeutic 
failure, the UKPDS studies were deemed ineligible due to the distinct differences in length of 
follow-up. 
 
Interestingly, the search of additional records like public and corporate clinical trial registers 
and regulatory authorities yielded 42 additional records some of them contributing 
information to other records and therefore enabling their inclusion and others providing whole 
summaries of clinical studies not published at all. Thus, regulatory bodies and clinical trial 
registers represent a useful additional source for a systematic literature search and may help to 
detect or avoid publication bias.  
 
Three extension studies (study No. 31 from core study No. 30 and studies No. 44 and 45 from 
core study No. 43) were included, too; however regarding the latter extension studies, study 
arms that were switched from placebo to Metformin were not considered due to potential 
confounding of placebo given during core phase. Two trials with cross-over design were 
included (study No. 34 and 39). The former trial did not comprise a wash-out phase but 
outcome data was obtained from the author for the first sequence. One abstract provided 
sufficient information for inclusion (No. 58) and a Chinese publication could be included due 
to the assistance of the native speaker (No. 61). 
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The piloting of the data extraction form of three randomly selected studies displayed no 
difficulties so that the parameters and their coding could be operationalized as pre-specified 
and consistently between the two reviewers (TB and SK). Table 12 of the appendix depicts 
the core trial and patients baseline characteristics as well as the outcome data on HbA1c, body 
weight and hypoglycemia along with its trial-specific definition. 
 
Overall the whole study set for quantitative analysis included 21,302 patients with a mean age 
of 56 (SD: 4.2) years and thereof 56% being male patients. On average, the mean duration of 
T2DM was 4.2 years (SD: 1.54) reflecting the fact that only a few studies included therapy 
naive patients (13%) and the majority of studies included patients with previous antidiabetic 
therapy suffering already a longer time from diabetes (87% of patients either had a pre-
therapy with a wash-out of 8 weeks of their previous drug before randomization or a even 
shorter or no wash-out period at all). Mean baseline HbA1c and body weight were 8.2% (SD: 
0.88) and 82.6 kg (SD: 8.12), respectively. Incomplete reporting for all categories of 
hypoglycemia (see 3.1.1.3) allowed only the analysis of data for patients suffering at least one 
event of any hypoglycemia; thus the other categories were not reported in this review. The trial-
specific definition of hypoglycemia illustrates how inconsistently events are reported; even if 
probable symptomatic hypoglycemia appeared to be the prevailing category the symptoms 
constituting an event were often not specified. Around a quarter of all studies provided no 
definition at all making it difficult to assess the comparability of events between studies.  
Some studies reported different categories of hypoglycemia (apart from severe hypoglycemia 
which was reported in a lot of studies but due to rare or zero events was not adequate for 
analysis). Aggregation of different categories is only methodologically appropriate, if 
different patients are affected. Since this was never confirmed upon request from the author 
no aggregation was applied. If studies reported two different categories, probable 
symptomatic hypoglycemia (category 4) was chosen for the core analysis to ensure a certain 
degree of comparability since this definition occurred most often used in the included studies; 
to account for the potential bias, the other reported category was explored in sensitivity 
analysis. The mean length of follow-up was 32 weeks.  
The dosing scheme of administered drugs, especially for Metformin, alpha-glucosidase 
inhibitors and sulfonylureas exhibited a dose titration phase and a maintenance phase which is 
common to increase tolerability and enhance patient compliance. Data transformation for the 
corresponding studies is commented in the legend of Table 12.  
Table 13 of the appendix contains further parameters that were collected but are of minor 
importance.  
 
Briefly, most studies did not state the criteria used to diagnose T2DM. Dietary advice was 
given in most of the studies which is common for study protocols in clinical diabetes trials. 
Diet alone was not an eligible intervention and only studies that offered dietary counseling to 
patients in all arms were included to avoid biased results. Clinical trials that were entirely 
conducted in patients with a certain condition were rare except from a few trials conducted in 
patients with end stage renal disease or chronic renal insufficiency since renal disorders are 
frequently associated with T2DM and drug elimination may be impaired. The kind of (severe) 
adverse events was not specified and patients discontinued for this reason were rarely reported 
confirming that this endpoint is less adequate for analysis.  
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Risk of bias and agreement 
 
The risk of bias was assessed independently by two reviewers (TB and SK). Figure 7 
illustrates the proportions of ratings of the risk of bias for all domains across all studies.  
 
 
Figure 7: Methodological quality graph 
Judgments about each domain of bias presented as percentages across all included studies. 
If the degree of bias within one domain was reported endpoint specific the highest risk of bias (H-->U-->L) was 
taken for presentation. 
 
For the domains allocation of concealment and sequence generation the risk of bias could 
almost never be assessed since it was not reported. Although generally accepted 
recommendations like the CONSORT statement clearly request authors to report the type of 
randomization or details of any restriction as well as mechanisms used to implement the 
sequence and describing the steps taken to conceal the sequence until interventions were 
assigned this information is still lacking in a lot of publications, even recent ones [140]. Thus, 
it is unclear if these points were handled properly but were just not reported or if inadequate 
methods possibly introduce selection bias into the analysis. The risk of bias for selective 
reporting was most frequently judged as low. However, the appraisal was mostly made based 
on whether pre-specified endpoints from the method section were fully and consistently 
reported in the results section. It would have been preferable to check study protocols for 
consistency with publication; however, there were almost no protocols available, although this 
is another suggestion from the CONSORT  
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statement. The risk of bias for HbA1c and body weight regarding the domains blinding of 
participants, personnel and outcome assessors was rated as low since it is unlikely to imagine 
that inadequate blinding or unblinding could bias these measurements. In the most studies 
hypoglycemia was a patient-reported outcome requiring patients to record symptoms and 
trialists to confirm episodes of hypoglycemia. Therefore, if drug-specific adverse events or 
other effects lead to unblinding, patients, personnel or outcome assessors might be influenced 
in recording hypoglycemic events through knowledge or belief which drug was administered. 
Therefore, the risk of for performance or detection bias was considered as unclear for the 
majority of studies.  
 
The risk of bias for each study at the study- and outcome level together with the support for 
judgment is presented in Table 14 of the appendix. 
 
In summary, according to the pre-specified criteria for the exclusion of studies at high risk for 
bias in sensitivity analysis (see 3.1.4.4), 17 studies were identified for HbA1c and body 
weight and 14 for hypoglycemia. The most common reasons for HbA1c and body weight 
were presumably underdosed or overdosed trial drugs impairing efficacy or enforcing side 
effects, respectively (HbA1c: n=6; body weight: n=1), imbalanced baseline values (HbA1c: 
n=3; body weight: n=6) between intervention arms (without knowledge if an adjustment was 
made in the statistical model for the baseline value as explanatory variable) and ongoing 
therapy (HbA1c/body weight: n=2) with one of the trial drugs potentially decreasing its 
therapeutic efficacy. For hypoglycemia, most often open label studies were assigned with a 
high risk of bias (n=5); other reasons were events occurring under rescue therapy (when 
glycemic targets weren´t met some protocols allowed adding another OAD) or an inadequate 
definition of the safety population potentially underestimating frequency of events (n=4).  
 
The judgment of the risk of bias for the domain incomplete outcome data for all three 
outcomes was predominantly rated unclear. Although the efficacy populations and safety 
populations seemed to be adequately specified for most of the studies (ITT-analysis for 
HbA1c and body weight for patients that received the trial drug at least once and who had 
both baseline and at least one post-baseline measurement and safety analysis for 
hypoglycemia for all patients who received the trial drug at least once) the number of 
dropouts wasn´t reported in several studies. Even if reported numbers and reasons for each 
trial arm were imbalanced which might cause attrition bias due to systematic differences 
between groups in withdrawals from a study it was unclear if the reasons were likely to affect 
the outcome. For continuous outcome data the LOCF method is commonly applied for 
imputation to enable an ITT analysis; however its appropriateness is questionable. Early 
values from the trough of lowering HbA1c carried forward may overestimate the drugs 
efficacy in studies with long follow-up when T2DM progresses and glycemic durability of 
drugs is lost. On the other hand some drugs like the insulin sensitizer Pioglitazon unfold their 
full efficacy only after 4 weeks; thus earlier readings of HbA1c carried forward might bias its 
efficacy downwards. Due to this remaining uncertainty the risk of bias was deemed unclear.  
Some studies with substantial loss to follow-up were analyzed per protocol or only for 
observed cases; for HbA1c and body weight, the risk of bias was therefore considered high. 
 
Finally two studies - one abstract and Chinese publication - were entirely excluded from 
sensitivity analysis, since the abstract didn´t provide enough information for appraisal and 
misunderstandings in the cooperation with the native speaker can´t be completely ruled out, 
respectively. 
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Interrater agreement for study selection based upon title and abstract, full-text, data collection 
and for assessing the risk of bias was measured using the kappa statistic. For the first three 
items agreement was complete with no need of involvement of the third reviewer. For the 
appraisal of methodological quality, interrater agreement on all domains apart other bias was 
complete. Still, the kappa statistic was quite high (κ=0.89; CI0.95(κ):[0.82;0.95]) reflecting 
reliable agreement. 
For this domain the disagreement was resolved by judgment of the third reviewer (UM). The 
influence of disagreement was analyzed by excluding these studies from sensitivity analysis. 
4.2 Evidence synthesis 
4.2.1 Pairwise meta-analysis 
4.2.1.1 Fixed effects and random effects models 
 
The results of the direct pairwise frequentist and Bayesian meta-analyses are presented in 
Table 15 (for the corresponding forest plots, see Figure 8 of the appendix).
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Table 15: Fixed effects- and random effects Bayesian and frequentist direct pairwise meta-analysis 
Comparison Frequentist MA Bayesian MA 
1. HbA1c, % FE: MD [CI0.95] RE: MD [CI0.95]; tau FE: MD [CrI0.95] RE: MD [CrI0.95]; sigma 
A-B -1.14 [-1.27;-1.01] -1.18 [-1.62;-0.74]; 0.47 -1.14 [-1.28;-1.01] -1.18 [-1.95;-0.39]; 0.73 
A-C -1.07 [-1.21;-0.93] -1.18 [-1.48;-0.88]; 0.29 -1.07 [-1.21;-0.93] -1.2 [-1.73;-0.74]; 0.47 
A-D -0.97 [-1.2;-0.75] -1 [-1.36;-0.65]; 0.24 -0.96 [-1.21;-0.74] -1.03 [-3.02;0.76]; 1.02 
A-Ea -0.6 [-0.95;-0.25] -0.6 [-0.95;-0.25] 
A-F -0.7 [-0.91;-0.49] -0.79 [-1.33;-0.25]; 0.5 -0.7 [-0.91;-0.49] -0.8 [-2.1;0.47]; 0.98 
A-G -0.73 [-0.78;-0.68] -0.69 [-0.8;-0.58]; 0.2  -0.73 [-0.76;-0.68] -0.69 [-0.81;-0.56]; 0.23 
B-C 0.23 [0.06;0.4] 0.11 [-0.26;0.47]; 0.34 0.23 [0.06;0.4] 0,09 [-0.58;0.7]; 0.55 
B-Da -0.15 [-0.36;0.06] -0.15 [-0.36;0.06] 
B-E -0.15 [-0.41;0.11] -0.15 [-0.41;0.11]; 0 -0.15 [-0.41;0.11] -0.17 [-5.5;5.11]; 2.231 
B-F 0.5 [0.26;0.74] 0.39 [-0.56;1.34]; 0.66 0.5 [0.26;0.74] 0.39 [-6.35;7.12]; 3.31 
B-G 0.23 [0.17;0.28] 0.26 [0.18;0.35]; 0.08 0.23 [0.18;0.28] 0.26 [0.16;0.37]; 0.1 
C-D -0.05 [-0.2;0.1] -0.05 [-0.2;0.1]; 0 -0.05 [-0.2;0.1] -0.05 [-0.35;0.23]; 0.17 
C-E -0.03 [-0.13;0.08] -0.08 [-0.31;0.15]; 0.19 -0.03 [-0.13;0.09] -0.09 [-0,81;0.6]; 0.51 
C-F 0.52 [0.2;0.83] 0.52 [0.2;0.83]; 0 0.51 [0.19;0.83] 0.52 [-1.41;2.34]; 0.95 
C-G 0.2 [0.1;0.31] 0.17 [-0.09;0.44]; 0.21 0.2 [0.1;0.31] 0.16 [-1.46;1.72]; 0.88 
D-G 0.41 [0.24;0.58] 0.41 [0.24;0.58]; 0 0.41 [0.24;0.58] 0.38 [-4.99;5.7]; 2.13 
E-Fa 0.07 [-0.16;0.3] 0.07 [-0.16;0.3] 
F-Ga -0.1 [-0.38;0.18] -0.1 [-0.38;0.18] 
2. Body weight, 
kg 
FE: MD [CI0.95] RE: MD [CI0.95]; tau FE: MD [CrI0.95] RE: MD [CrI0.95]; sigma 
A-B 0.04 [-0.35;0.43] 0.04 [-0.35;0.43]; 0 0.04 [-0.35;0.43] 0.01 [-0.67;0.63]; 0.43 
A-C 1.95 [1.61;2.29] 2.28 [1.33;3.23]; 1.05 1.95 [1.61;2.29] 2.34 [0.78;4.07]; 1.7 
A-D 2.53 [1.97;3.09] 2.53 [1.87;3.19]; 0.3 2.53 [1.96;3.09] 2.55 [-0.33;5.49]; 1.52 
A-Ea 0.1 [-0.48;0.68] 0.1 [-0.48;0.68] 
A-F -0,03 [-0.59;0.52] -0,03 [-0.59;0.52]; 0 -0.03 [-0.6;0.51] -0.13 [-2.1;1.68]; 1.05 
A-G 0.53 [0.4;0.66] 0.52 [0.37;0.67]; 0.15 0.53 [0.4;0.66] 0.52 [0.34;0.68]; 0.16 
B-C 2.66 [2.31;3.02] 2.56 [1.69;3.43]; 0.87 2.66 [2.3;3.02] 2.57 [1.19;4.02]; 1.27 
B-Da 3.5 [2.79;4.21] 3.5 [2.81;4.21] 
B-E 2.16 [1.46;2.87] 2.64 [0.43;4.85]; 1.49 2.16 [1.45;2.87] 2.67 [-4.93;10.27]; 4.1 
B-F 0.13 [-0.56;0.82] 0.13 [-0.56;0.82]; 0 0.13 [-0.56;0.81] 0.06 [-6.28;6.28]; 2.85 
B-G 1.21 [1.01;1.41] 1.34 [0.95;1.73]; 0.5 1.21 [1.01;1.41] 1.37 [0.86;1.95]; 0.7 
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C-D 1.3 [0.68;1.91] 1.25 [0.5;2.01]; 0.42 1.3 [0.68;1.9] 1.2 [-0.68;2.9]; 1.17 
C-E -0.32 [-0.68;0.04] -0.32 [-0.68;.0.04]; 0 -0.32 [-0.68;0.05] -0.3 [-1.09;0.55]; 0.52 
C-F -2.52 [-3.21;-1.82] -2.3 [-3.87;-0.72]; 1.24 -2.52 [-3.22;-1.83] -2.25 [-6.63;2.32]; 2.8 
C-G -1.13 [-1.47;-0.8] -1.17 [-1.62;-0.71]; 0.25 -1.14 [-1.47;-0.8] -1.2 [-3.46;1.07]; 1.23 
D-G -1.8 [-2.39;-1.21] -1.8 [-2.78;-0.82]; 0.57 -1.8 [-2.4;-1.22] -1.82 [-8.46;4.77]; 3.14 
E-Fa -1.4 [-1.88;-0.92] -1.4 [-1.88;-0.92] 
F-Ga 1.3 [0.86;1.74] 1.3 [0.86;1.74] 
3.  Hypoglycemia FE: OR [CI0.95] REb: OR [CI0.95]; tau FE: OR [CrI0.95] REb: OR [CrI0.95]; sigma 
A-B 1.35 [0.64;2.84] 1.35 [0.64;2.84]; 0 1.49 [0.69;3.34] 1.61 [0.38;8.2]; 0.91 
A-C 5.15 [2.51;10.58] 5.15 [2.51;10.58]; 0 7.03 [3.44;15.36] 7.93 [2.08;40.37]; 1.02 
A-D 2.0 [0.3;13.36] 2.0 [0.3;13.36]; 0 2.42 [0.4;26.66] 2.74 [0.02;470.6]; 2.65 
A-Ea 0.92 [0.02;50.37] 1.02 [0.001;665.8] 
A-F 1.16 [0.53;2.52] 1.16 [0.53;2.52]; 0 1.18 [0.52;2.64] 1.18 [0.16;7.9]; 1.04 
A-G 0.99 [0.6;1.63] 0.99 [0.6;1.63]; 0 1.16 [0.72;1.93] 1.13 [0.64;2.05]; 0.38 
B-C 1.38 [0.8;2.37] 1.38 [0.8;2.37]; 0 1.41 [0.81;2.49] 1.35 [0.42;3.5]; 0.62 
B-Da 0.9 [0.32;2.53] 0.87 [0.28;2.5] 
B-E 3.27 [1.78;6.03] 3.27 [1.78;6.03]; 0 3.4 [1.86;6.35] 5.69 [0.01;10,667]; 3.384 
B-F 0.89 [0.33;2.42] 0.89 [0.33;2.42]; 0 0.88 [0.3;2.53] 0.87 [0.001;1,458]; 3.5 
B-G 0.61 [0.39;0.94] 0.61 [0.39;0.94]; 0 0.54 [0.34;0.84] 0.55 [0.31;0.97]; 0.35  
C-D 0.23 [0.15;0.35] 0.21 [0.1;0.45]; 0.56 0.21 [0.14;0.31] 0.2 [0.03;1.5]; 1.35 
C-E 0.94 [0.73;1.21] 0.94 [0.73;1.21]; 0 0.94 [0.73;1.22] 0.92 [0.49;1.62]; 0.39 
C-F 0.27 [0.12;0.59] 0.23 [0.07;0.75]; 0.67 0.2 [0.09;0.44] 0.15 [0.002;9.37]; 2.51 
C-G 0.22 [0.14;0.34] 0.22 [0.11;0.42]; 0.41 0.21 [0.13;0.33] 0.21 [0.01;3.3]; 1.47 
D-G 0.86 [0.28;2.6] 0.86 [0.28;2.6]; 0 0.85 [0.27;2.67] 0.94 [0.001;873]; 3.17 
E-Fa 0.28 [0.08;1.06] 0.25 [0.05;0.92] 
F-Ga 0.5 [0.01;25.3] 0.51 [0.001;339] 
For frequentist and Bayesian meta-analysis the point estimate, the CI0.95 and the heterogeneity standard deviation tau  and the point estimate,  the CrI0.95 and the heterogeneity 
standard  deviation sigma are reported, respectively.  
The contrasts D-E, D-F and E-G are missing since these comparisons are not supported by direct evidence.  
a  No meta-analysis since only one study exists for these comparisons. 
b For hypoglycemia the heterogeneity standard deviation tau and sigma are reported on the log scale, respectively. 
HbA1c, glycated haemoglobin. MA, meta-analysis. FE, fixed effects model. RE, random-effects model. MD, difference in means. CI, confidence interval, CrI, credible interval. 
OR, odds ratio. 
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The comparisons D-E, D-F and E-G were not informed by direct evidence and for the 
contrasts A-E (Nateglinide vs. placebo), B-D (Pioglitazone vs. Metformin), E-F (Acarbose vs. 
Nateglinide) and F-G (Vildagliptin vs. Acarbose) only one study was available; thus meta-
analysis was performed for the remaining 14 comparisons. For the drug class meglitinides and 
alpha-glucosidase inhibitors, the comparisons B-E, C-E and C-F were only conducted with 
Repaglinide and Acarbose, respectively. 
 
Because binomial likelihoods with zero cells are tolerated, usually, no precautions need to be 
taken in the case of an occasional trial with a zero cell count within the Bayesian setting 
[113]. This is an advantage, because some frequentist methods add for log odds ratios an 
arbitrary constant, usually 0.5, to cells in order to obtain non-infinite estimates of treatment 
effects and non-infinite variance, but in so doing they might introduce bias. 
However, in extreme cases of many small trials and when several trials have zero cells, 
models can be numerically unstable, either failing to converge, or converging to a posterior 
with very high standard deviation or can´t be run at all. Since for some of the comparisons 
WinBUGS produced an error message and didn´t run increments of 0.5 for each cell of 
studies containing zero events were added for all forthcoming analyses to enable computation. 
 
For every Bayesian MA and all of the other subsequent Bayesian models convergence and the 
MCMC error were monitored for all relevant parameters. The corresponding trace plots 
displayed good mixing of the two Markov chains indicating sufficient convergence so that it 
can be assumed that the 14,000 iterations from the sampling phase yield reliable estimates 
from the posterior distributions. The MCMC error for all parameters was below 5% so that 
the number of iterations from the sampling phase is likely to produce stable estimates. 
Randomly inspected autocorrelation plots exhibited a fast decrease of correlation over 
iterations towards zero so that the thin-out function seems to prevent autocorrelation 
effectively. Density plots of the posterior distribution of outcome parameters appeared to be 
normally distributed. All the ancillary output together with the data matrices is provided as 
supplementary material (see electronic data carrier).  
 
In general frequentist and Bayesian estimates were in agreement; for RE models Bayesian 
credible intervals were always wider than the corresponding frequentist confidence intervals 
since the former take into account the uncertainty in terms of a prior for the heterogeneity 
parameter whereas the latter ignore it and therefore underestimate the uncertainty of the 
pooled treatment effect and the between-study variance. 
 
HbA1c 
 
Compared to placebo all treatments showed a statistically significant difference in means; 
Metformin, sulfonylureas and Pioglitazone exhibited a stronger effect than Nateglinide, alpha-
glucosidase inhibitors and gliptins lowering HbA1c levels by 1% and 0.6-0.7%, respectively, 
which is consistent with findings from other systematic reviews [6,23,37-40,43,46,48]. 
Contrasted against Metformin, sulfonylureas, alpha-glucosidase inhibitors and gliptins were 
less beneficial resulting in an moderate increase of HbA1c; for sulfonylureas and alpha-
glucosidase inhibitors the difference was only statistically significant for FE models (either 
frequentist or Bayesian) whereas for gliptins statistical significant inferiority was proven for 
all models due to the large number of trials (n=17) yielding narrower CI0.95/CrI0.95 for RE 
models. Moreover, Acarbose was likely to be inferior to sulfonylureas and gliptins were less 
efficacious than Pioglitazone resulting in an increase in HbA1c of approximately 0.52% and 
0.41%, respectively, which was significant for all models apart from the Bayesian RE model 
that had a very wide CrI0.95 due to the small number of underlying studies. 
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The pooled treatment effects of comparisons A-B, A-C, A-F, A-G, B-C, B-F, C-E and C-G 
exhibited considerable heterogeneity with statistically significant tests for heterogeneity and 
values of I2 between 0.69-0.93 (see Figure 8, appendix). For those comparisons, RE models 
provide more reliable and conservative estimates than FE models since they allow for 
heterogeneity. For the comparison A-D based upon the statistical test the null hypothesis 
(p=0.09) couldn´t be rejected, whereas the value for I2 (0.58) pointed to a moderate extent of 
heterogeneity underscoring the fact that the test might sometimes be underpowered in 
detecting heterogeneity if the number of studies is mall.  
 
By examining the outlying observations in the forest plots of comparisons with a high degree 
of heterogeneity it can be noticed that most outliers are due to unusual dosing of trial drugs or 
ongoing therapy with one of the trial drugs in line with the findings from the assessment of 
the risk of bias (see 4.1). For example, regarding the A-B comparison the study from List et 
al. [141] possibly yielded a very moderate effect for Metformin vs. placebo (MD: -0.55%) due 
to the low dose of 1,500mg/d which is usually given in doses up to 3,000mg/d; this study was 
also identified to be at high risk for bias and will be excluded from sensitivity analysis.  
 
As mentioned before due to the incorporated uncertainty for the between-study variance in the 
Bayesian setting for RE models (for example A-D), frequentist CI0.95 yielded sometimes a 
statistically significant effect, that disappeared when the corresponding CrI0.95 were examined. 
Moreover, for contrasts which are only supported by a small number of studies such as B-E,  
B-F, C-F or D-G there is insufficient data for adequately estimating the between-trials 
variation resulting in overly wide CrI0.95 compared to CI0.95. On the one hand this might be 
triggered by the relatively vague uniform prior placed on σ; for example if a tighter gamma 
prior is instead assumed for the inverse variance (τ~gamma(0.001,0.001)) the CrI0.95 for the 
relative treatment effect of B-E narrows from [-5.5;5.11] to [-1.29;1.16]. In addition, when the 
information increases for estimating the heterogeneity parameter as for the comparison A-G 
CrI0.95 and CI0.95 are almost of the same width. On the other hand, when there are only a few 
trials available one should take a sceptical view towards the frequentist CI which might 
produce too narrow interval estimates.  
 
Body weight 
 
In comparison to placebo and Metformin both sulfonylureas and Pioglitazone led to a 
substantial weight gain that reached statistical significance for all models except for the RE 
Bayesian model for A-D (which was informed only by three studies) being in accordance with 
earlier findings [6,45]. The weight gain was more pronounced compared to Metformin rather 
than placebo even if this was not evidenced by the direct comparison A-B. Meglitinides that 
tend to induce clinically relevant weight gain, too [6], showed an increased weight compared 
with placebo (Nateglinide), whereas this effect was not paralleled in the direct comparison of 
Repaglinide vs. Metformin.  Although incretin based therapies are claimed to be beneficial 
regarding obese diabetics propagating a weight loss under GLP-1 analogues and a weight 
neutral effect of gliptins this might not hold for the latter since in this work gliptins induced 
moderate significant weight gain compared to placebo and Metformin [142]. The fact that 
alpha-glucosidase inhibitors induced weight loss in some comparisons might be attributed to 
their gastrointestinal side effects like nausea, diarrhea and flatulence which might in turn 
influence the eating behaviour of patients rather than a real beneficial effect on weight.  
 
According to the statistical test and I2 heterogeneity was present for the pooled treatment 
effects for comparisons A-C, B-C, B-E, B-G and C-F with values for I2 ranging from 0.7-0.84.  
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Appraisal of potential outliers of forest plots revealed that some but not all of these studies 
were also identified before to bear a high risk for bias mainly due to high doses near the 
ceiling dose or insufficient dose escalation, pre-therapy with the trial drug or unusual high 
weight losses possibly caused by different adherence to diet or exercise between intervention 
arms.  
Again, compared with frequentist models Bayes estimates for RE models with a small number 
of studies led to widerCrI0.95 (in some cases non-significant e.g. A-D and B-E), whereas 
contrasts informed by a large study set, for example B-G yielded similar CrI0.95. High levels 
of heterogeneity may partly be induced by the vague uniform prior; anew, with a tighter 
gamma prior for the inverse variance (τ~gamma (0.001,0.001)) the CrI0.95 for the relative 
treatment effect of C-G shrinks from [-3.46;1.07] to [-1.97;-0.49]. 
 
Hypoglycemia 
 
It is known that sulfonylureas and meglitinides bear the highest risk for suffering 
hypoglyemic events [6]. These results were confirmed regarding the pooled estimates of 
sulfonylureas and meglitinides vs. almost all other comparators resulting in mostly significant 
OR ranging from 3.7-7.93 and 3.57-5.69 depending on the applied model, respectively. 
However, for the comparisons of Nateglinide vs. placebo and sulfonylureas vs. Metformin, 
the direct evidence couldn´t detect a harmful effect with non-significant OR around 1.  
 
Statistically significant heterogeneity wasn´t detectable for any comparison; merely the C-D 
contrast exhibited borderline heterogeneity (p=0.057; I2=0.6). Moreover, comparisons like  
C-F and C-G displayed moderate heterogeneity reflected by I2 values of 0.42 and 0.49, 
respectively questioning again the power of the heterogeneity test if the amount of evidence is 
low. Potential outliers from the forest plots were not identified by the assessment of risk of 
bias.  
 
Interestingly, point and interval estimates of frequentist and Bayesian models didn´t match so 
well compared to the endpoints HbA1c and body weight which might due to the zero cell 
correction and unstable Bayesian posteriors in case of few, small studies were several trials 
have zero cells (e.g. Repaglinide vs. Metformin). Moreover, some Bayesian models like  
A-C (σ= 1.02) or A-G (σ=0.38) were heterogeneous whereas the frequentist models were not 
(I2=0); this might be explained by the fact that the deviant studies were small and contributed 
minor weights to the summary estimate. Just as for HbA1c and body weight, tighter priors 
resulted in narrower credible intervals. Considering the contrast C-G if the original uniform 
prior (σ~unif (0,10)) is substituted by a more informative one (σ~unif(0,2)) the CrI0.95 
diminished from [0.01;3.3] to [0.06;0.71]. In light of these findings it must be conceded that 
the original prior might have been determined too vague and a tighter uniform prior might 
have been more adequate. For example for a mean treatment effect of an odds ratio of 1.5 a 
uniform prior of (σ~unif (0,10)) assumes a CrI0.95 of [0.0008;27,050], whereas a uniform prior 
of (σ~unif(0,2)) yields an CrI0.95 of  [0.2;11], the former emanating from an unrealistic belief 
and the latter seeming to provide an reasonable prior [77]. 
 
In summary, regarding all endpoints some comparisons exhibit heterogeneity to a 
considerable extent. Some reasons like the uncommon dosing of drugs or pre-therapy with the 
trial drug could be identified beforehand by means of the risk of bias assessment. 
Even if existent heterogeneity wasn´t further explored in meta-analysis the impact will be 
evaluated for the network by performing meta-regression and removing outliers from 
sensitivity analyses (see 4.2.2.3 and 4.2.2.4). 
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However there might be other reasons contributing to clinical and methodological diversity 
which are not covered by the bias appraisal, meta-regression or sensitivity analysis. 
Therefore, it must be considered that a certain degree of residual heterogeneity will be 
immanent in these comparisons. Thus, estimates of RE models must be interpreted with 
caution and the assumption of lumping treatments for analysis - such as sulfonylureas, 
meglitinides or gliptins - might not always be fully justified, if this aggregation into drug 
classes is causing the heterogeneity. 
4.2.1.2 Assessment of publication bias  
 
Contour-enhanced funnel plots for the comparisons A-G and B-G (number of observations > 
10) for all outcomes are presented in Figure 9 of the appendix. The dashed and dotted lines 
represent the summary effects for FE and RE models, respectively. In the graphical 
visualization of the test for funnel plot asymmetry, the horizontal line represents the null 
hypothesis of no association between estimated effects and the measure of uncertainty; thus, if 
the line moves towards the vertical this may be interpreted as a clue for asymmetry that might 
be caused by publication bias. 
 
From the visual inspection of the comparisons A-G (for body weight and hypoglycemia) and 
B-G (for HbA1c and hypoglycemia)  an asymmetrical scattering was deemed unlikely; the p-
values of the Eggers test for funnel plot asymmetry were likewise not statistically significant 
(p(A-G body weight)=0.56; p(A-G hypoglycemia)=0.25; p(B-G HbA1c)=0.18; p(B-G hypoglycemia)=0.53). The 
pooled relative treatment effects of A-G (for HbA1c) and B-G (for body weight) appear 
somehow asymmetrically with borderline p-values of 0.08 and 0.09, respectively. However, 
the asymmetry of the funnel plot of comparison A-G seems not be caused by a gap of 
unpublished studies. For the comparison B-G there might be a gap at the left bottom of the 
funnel plot in the area of non-significant results indicating no weight gain under gliptins vs. 
Metformin which could be caused by unpublished results. However, since body weight was 
usually not the primary endpoint in these clinical trials and effect estimates located in the gap 
would support weight neutrality of gliptins, it is more likely that other reasons than 
publication bias triggered asymmetry or it occurred just by chance.  
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4.2.2 Mixed treatment comparison analysis 
 
Figure 10 pictures the network diagram of the full MTC models. 
 
 
Figure 10: Network diagram of full mixed treatment comparison models. 
Treatments and direct comparisons are represented by nodes and edges, respectively. Bold lines represent the 
basic parameters connecting all other treatments to the overall baseline (placebo). 
 
The nodes and the edges represent the interventions and the direct comparisons, respectively 
and the numbers above the edges indicate the numbers of direct comparisons supporting the 
two linked treatments. Overall 62 studies comprising 130 arms (thereof 6 three arm trials) 
constitute the body of evidence. The network is well connected and only three contrasts (D-E, 
D-F and E-G) are not informed by head to head trials. The nodes placebo and Metformin are 
connected with all other treatments in the network (spanning tree) and are suited as overall 
baseline; in addition, with 77% of all direct comparisons these nodes account for the largest 
share of evidence reflecting the fact that most pivotal trials for approval were conducted 
against placebo and thereafter, Metformin was the second most common drug since it 
represents the standard of care. However, the number of placebo trials (n=37) outnumbered 
the Metformin trials (n=20); thus it was selected as overall baseline for analyses (bold lines). 
Therefore according to section 3.2.2.1 for K=7 treatments there are T=7(7-1)/2=21 potential 
comparisons, 7-1=6 basic parameters and 21-7+1=15 functional parameters. Taking placebo 
as overall baseline the vector of baseline parameters db and functional parameters df is 
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   )d,d,d,d,d,(dd AGAFAEADACABb =   
  )d,d,d,d,d,d,d,d,d,d,d,d,d,d,(dd FGEGEFDGDFDECGCFCECDBGBFBEBDBCf =  
 
The functional parameters are derived from the basic parameters through the consistency 
equations: 
 
  
AFAGFG
ABADBD
ABACBC
ddd
ddd
ddd
−=
−=
−=

 
 
Of course, the remaining evidence is not ignored in the network. For example, the relative 
treatment effect of dBC is not only estimated by the indirect evidence from the overall baseline 
A; in fact all other possible bridging comparators (D-G) which are in turn estimated via the 
basic parameters plus the direct evidence yield the MTC estimate of dBC. 
 
4.2.2.1 Fixed effects and random effects models 
 
The results of the MTC analysis contrasted with the results from direct pairwise MA are 
displayed in Table 16.
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Table 16: Fixed- and random effects Bayesian mixed treatment comparison analysis 
1. HbA1c, % 
FE: MD [CrI0.95]; 
RE: MD [CrI0.95]  
      Dir 
MTC 
A B C D E F G 
A  -1.14 [-1.28;-1.01]; 
-1.18 [-1.95;-0.39] 
-1.07 [-1.21;-0.93]; 
-1.2 [-1.73;-0.74] 
-0.96 [-1.21;-0.74]; 
-1.03 [-3.02;0.76] 
-0.6 [-0.95;-0.25]c -0.7 [-0.91;-0.49]; 
-0.8 [-2.1;0.47] 
-0,73 [-0,76;-0,68]; 
-0.69 [-0.81;-0.56] 
B -1 [-1.06;-0.94]; 
-1.05 [-1.2;-0.91] 
 0.23 [0.06;0.4]; 
0.09 [-0.58;0.7] 
-0.15 [-0.36;0.06]c -0.15 [-0.41;0.11]; 
-0.17 [-5.5;5.11] 
0.5 [0.26;0.74]; 
0.39 [-6.35;7.12] 
0,23 [0,18;0,28]; 
0.26 [0.16;0.37] 
C -0.94 [-1.02;-0.86]; 
-1 [-1.16;-0.84] 
0.06 [-0.02;0.14]; 
0.06 [-0.11;0.22] 
 -0.05 [-0.2;0.1]; 
-0.05 [-0.35;0.23] 
-0.03 [-0.13;0.09]; 
-0.09 [-0.81;0.6] 
0.51 [0.19;0.83]; 
0.52 [-1.41;2.34] 
0,2 [0,1;0,31]; 
0.16 [-1.46;1.72] 
D -1.05 [-1.16;-0.94]; 
-1.06 [-1.27;-0.86] 
-0.05 [-0.16;0.06]; 
-0.01 [-0.23;0.22] 
-0.11 [-0.22;0]; 
-0.07 [-0.27;0.14] 
 -b -b 0,41 [0,24;0,58]; 0.38 [-4.99;5.7] 
E -0.92 [-1.03;-0.81]; 
-0.99 [-1.22;-0.76] 
0.08 [-0.03;0.19]; 
0.06 [-0.17;0.29] 
0.02 [-0.08;0.11]; 
0 [-0.21;0.21] 
0.13 [-0.01;0.26]; 
0.07 [-0.21;0.35] 
 0.07 [-0.16;0.3]c -b 
F -0.62 [-0.75;-0.48]; 
-0.65 [-0.89;-0.42] 
0.39 [0.25;0.52]; 
0.4 [0.15;0.65] 
0.33 [0.19;0.46]; 
0.35 [0.1;0.59] 
0.43 [0.27;0.6]; 
0.41 [0.12;0.71] 
0.31 [0.16;0.45]; 
0.34 [0.07;0.63] 
 -0,1 [-0,38;0,18]c 
G -0.75 [-0.79;-0.7]; 
-0.73 [-0.85;-0.62] 
0.25 [0.2;0.3]; 
0.32 [0.19;0.45] 
0.19 [0.12;0.26]; 
0.26 [0.1;0.42] 
0.3 [0.2;0.41]; 
0.33 [0.12;0.54] 
0.17 [0.07;0.28]; 
0.26 [0.03;0.49] 
-0.13 [-0.27;0]; 
-0.09 [-0.33;0.16] 
 
SDa 0.24 [0.18;0.31]  
Model 
fit res
D  
 
pD DIC  
FE 301 59.44 359.46 
RE 132.47 107.15 239.62 
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2. Body weight, kg 
FE: MD [CrI0.95]; 
RE: MD [CrI0.95] 
      Dir 
MTC 
A B C D E F G 
A  0.04 [-0.35;0.43]; 
0.01 [-0.67;0.63] 
1.95 [1.61;2.29]; 
2.34 [0.78;4.07] 
2.53 [1.96;3.09]; 
2.55 [-0.33;5.49] 
0.1 [-0.48;0.68]c -0.03 [-0.6;0.51]; 
-0.13 [-2.1;1.68] 
0,53 [0,4;0,66]; 
0,52 [0,34;0,68] 
B -0.61 [-0.79;-0.43]; 
-0.63 [-0.97;-0.28] 
 2.66 [2.3;3.02]; 
2.57 [1.19;4.02] 
3.5 [2.81;4.21]c 2.16 [1.49;2.87]; 
2.67 [-4.93;10.27] 
0.13 [-0.56;0.81]; 
0.06 [-6.28;6.28] 
1,21 [1,01;1,41]; 
1,37 [0,86;1,95] 
C 1.78 [1.58;1.99]; 
1.82 [1.47;2.19] 
2.39 [2.18;2.61]; 
2.45 [2.08;2.83] 
 1.3 [0.68;1.9]; 
1.2 [-0.68;2.9] 
-0.32 [-0.68;0.05]; 
-0.3 [-1.09;0.55] 
-2.52 [-3.22;-1.83]; 
-2.25 [-6.63;2.32] 
-1,14 [-1,47;-0,8]; 
-1.2 [-3.46;1.07] 
D 2.67 [2.33;3]; 
2.7 [2.19;3.22] 
3.28 [2.93;3.62]; 
3.33 [2.79;3.88] 
0.88 [0.53;1.23]; 
0.88 [0.35;1.4] 
 -b -b -1,8 [-2,4;-1,22]; -1.82 [-8.46;4.77] 
E 1.11 [0.83;1.39]; 
1.29 [0.77;1.83] 
1.72 [1.43;2.01]; 
1.92 [1.4;2.46] 
-0.67 [-0.94;-0.41]; 
-0.53 [-1.01;-0.04] 
-1.56 [-1.97;-1.14]; 
-1.41 [-2.07;-0.72] 
 -1.4 [-1.88;-0.92]c -b 
F -0.45 [-0.74;-0.16]; 
-0.35 [-0.88;0.18] 
0.16 [-0.14;0.46]; 
0.27 [-0.28;0.84] 
-2.23 [-2.54;-1.94]; 
-2.18 [-2.72;-1.63] 
-3.12 [-3.54;-2.69]; 
-3.05 [-3.75;-2.36] 
-1.56 [-1.88;-1.24]; 
-1.65 [-2.28;-1.02] 
 1.3 [0.86;1.74]c 
G 0.58 [0.46;0.7]; 
0.62 [0.35;0.89] 
1.2 [1.03;1.36]; 
1.24 [0.93;1.57] 
-1.2 [-1.4;-1]; 
-1.21 [-1.57;-0.84] 
-2.08 [-2.41;-1.74]; 
-2.08 [-2.61;-1.55] 
-0.52 [-0.81;-0.25]; 
-0.68 [-1.22;-0.14] 
1.04 [0.75;1.32]; 
0.97 [0.43;1.51] 
 
SDa 0.53 [0.37;0.71]  
Model 
fit res
D  
 
pD DIC  
FE 237.8 67.91 305.71 
RE 137.43 105.45 242.88 
3. Hypoglycemia  
FE: OR [CrI0.95]; 
RE: OR [CrI0.95] 
      Dir 
MTC 
A B C D E F G 
A  1.49 [0.69;3.34]; 
1.61 [0.38;8.2] 
7.03 [3.44;15.36]; 
7.93 [2.08;40.37] 
2.42 [0.4;26.66]; 
2.74 [0.02;470.6] 
1.02 [0.001;665.8]c 1.18 [0.52;2.64]; 
1.18 [0.16;7.9] 
1.16 [0.72;1.93]; 
1.13 [0.64;2.05] 
B 2.3 [1.47;3.49]; 
2.34 [1.47;3.66] 
 1.41 [0.81;2.49]; 
1.35 [0.42;3.5] 
0.87 [0.28;2.5]c 3.4 [1.86;6.35]; 
5.69 [0.01;10,667] 
0.88 [0.3;2.53]; 
0.87 [0.001;1,458] 
0.54 [034;0.84]; 
0.55 [0.31;0.97]  
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C 5.79 [3.76;8.67]; 
5.8 [3.7;8.79] 
2.56 [1.82;3.51]; 
2.53 [1.73;3.57] 
 0.21 [0.14;0.31]; 
0.2 [0.03;1.5] 
0.94 [0.73;1.22]; 
0.92 [0.49;1.62] 
0.2 [0.09;0.44]; 
0.15 [0.002;9.37] 
0.21 [0.13;0.33]; 
0.21 [0.01;3.3] 
D 1.34 [0.77;2.2]; 
1.35 [0.74;2.29] 
0.59 [0.36;0.91]; 
0.59 [0.33;0.96] 
0.23 [0.16;0.33]; 
0.23 [0.15;0.35] 
 -b -b 0.85 [0.27;2.67]; 0.94 [0.001;873] 
E 5.73 [3.55;8.98]; 
5.73 [3.34;9.32] 
2.52 [1.74;3.57]; 
2.48 [1.6;3.7] 
0.99 [0.77;1.25]; 
0.99 [0.72;1.35] 
4.4 [2.83;6.73]; 
4.42 [2.54;7.23] 
 0.25 [0.05;0.92]c -b 
F 1.39 [0.71;2.45]; 
1.38 [0.67;2.5] 
0.62 [0.33;1.04]; 
0.6 [0.31;1.05] 
0.24 [0.13;0.4]; 
0.24 [0.13;0.41] 
1.08 [0.53;1.94]; 
1.07 [0.49;2.05] 
0.25 [0.13;0.42]; 
0.25 [0.12;0.44] 
 0.51 [0.001;339]c 
G 1.24 [0.83;1.82]; 
1.26 [0.82;1.87] 
0.55 [0.39;0.76]; 
0.55 [0.37;0.78] 
0.22 [0.15;0.3]; 
0.22 [0.15;0.31] 
0.97 [0.59;1.51]; 
0.99 [0.57;1.64] 
0.22 [0.15;0.33]; 
0.23 [0.14;0.35] 
0.97 [0.51;1.69]; 
1 [0.5;1.84] 
 
SDa 0.19 [0.01;0.44]  
Model 
fit res
D  pD DIC  
FE 116.86 71.33 188.19 
RE 112.53 76.89 189.42 
Results are cross-tabulated; below and above the diagonal the outcomes for MTC and direct pairwise MA are arranged, respectively. 
a Between-study standard deviation estimated from RE MTC model assuming a homogeneous variance. For variances of pairwise comparisons, see Table 15. The SD for 
hypoglycemia is reported on the log scale. 
b No direct evidence available. 
C Only one study available for direct evidence. 
HbA1c, glycated haemoglobin. MD, difference in means. FE, fixed effects. RE, random effects. CrI, credible interval. Dir, direct evidence. MTC, mixed treatment comparison. 
SD, standard deviation. resD , total residual deviance. pD, effective number of parameters. DIC, deviance information criterion. KG, kilogram. OR, odds ratio. 
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Generally MTC estimates and direct evidence were consistent for most of the pairwise 
comparisons. Since the former are supported by one or several indirect comparisons they 
yield more precise interval estimates compared to the results from direct pairwise MA. 
Moreover, some comparisons gained statistical significance by incorporating the indirect 
comparisons; e.g., the difference in means for HbA1c of Pioglitazone vs. placebo was not 
significant when direct evidence was considered solely whereas the combination of direct and 
indirect evidence (via the bridging comparators B, C and G) reached statistical significance  
(CrI0.95Dir:[-3.02;0.76] vs. CrI0.95MTC:[-1.27;-0.86]). The increase of precision which may even 
lead to statistically significant results is one of the major advantages of MTC compared to 
common pairwise MA as long as the assumption of consistency is fulfilled (see 4.3.2). 
 
HbA1c 
 
For the RE model, the difference in means for the contrasts D-E, D-F and E-G was  
0.07 (CrI0.95:[-0.21;0.35]),  0.41 (CrI0.95:[0.12;0.71]) and  0.26 (CrI0.95:[0.03;0.49]), 
respectively. The statistical significant superiority of Pioglitazone vs. alpha-glucosidase 
inhibitors and meglitinides over gliptins seems reasonable; however these estimates were not 
supported by direct evidence. 
For the contrast A-E the direct estimate yielded a lower efficacy compared to the MTC 
estimate (see 4.2.2.2.1). The posterior mean of the commonly estimated between-study 
standard deviation σ was 0.24 (CrI0.95:[0.18;0.31]); contrasted to the heterogeneity of direct 
pairwise MA it could be estimated with considerable precision; this is another advantage of 
MTC models, namely that the heterogeneity parameter can be estimated relatively exact even 
for comparisons that are not informed by many studies by borrowing strength from other 
contrasts as long as the assumption of homogeneous variance holds. The total residual 
deviance resD  of the RE model is smaller compared to the FE model. Although the effective 
number of parameters penalizes the RE model it nevertheless yields a considerably lower DIC 
(DICRE:239.62 vs. DICFE:359.36) reasoning that the RE model fits the data better. Thus, the 
following analyses were only run for RE models. 
 
Body weight 
 
RE estimates for the difference in means of the comparisons D-E, D-F and E-G which are 
only accessible via indirect evidence were -1.41 (CrI0.95:[-2.07;-0.72]),  
-3.05 (CrI0.95:[-3.75;-2.36]) and -0.68 (CrI0.95:[-1.22;-0.14]), respectively. Since Pioglitazone 
is the drug that induces the heaviest weight gain and alpha-glucosidase inhibitors lead to 
weight loss compared to meglitinides, the direction and magnitude of relative treatment 
effects D-EInd and D-FInd seems plausible as well as the weight gain of meglitinides in 
comparison to gliptins. Since Metformin is known to exert a weight loosing effect compared 
to placebo [42] it is remarkable that this was not reflected by the direct evidence. However, 
the MTC estimate confirmed the beneficial effect of Metformin on weight which was 
statistically significant -0.61 (CrI0.95:[-0.79;-0.43]). Moreover, the result from direct evidence 
that Nateglinide induces no weight gain compared to placebo was refuted by the MTC 
estimate;  driven by the indirect evidence meglitinides yielded a statistically significant 
weight gain contrasted to placebo 1.29 (CrI0.95:[0.77;1.83]) (see. 4.2.2.2.1). The heterogeneity 
parameter σ was 0.53 (CrI0.95:[0.37;0.71]). Again, regarding model fit, the RE model 
performed better than the FE model resulting in a smaller DIC (even though the effective 
number of parameters was larger) and was applied to all remaining analyses. 
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Hypoglycemia 
 
RE indirect estimates for the odds ratios of D-E, D-F and E-G were 4.42 (CrI0.95:[2.54;7.23]), 
1.07 (CrI0.95:[0.49;2.05]) and 0.23 (CrI0.95:[0.14;0.35]), respectively. Even if direct evidence is 
lacking for these comparisons the findings seem realistic since Meglitinides are prone to cause 
hypoglycemic events in contrast to Pioglitazone or Gliptins. Regarding the comparison of 
Meglitinides vs. placebo and sulfonylureas vs. Metformin their harmful effect is underlined 
by the MTC estimates (ORMTC(A-E):5.73; CrI0.95:[3.34;9.32]; ORMTC(B-C):2.53; CrI0.95: 
[1.73;3.57]), whereas this was not reflected by the direct evidence (ORDir(A-E):1.02; CrI0.95: 
[0.001;665.8]; ORDir(B-C):1.35; CrI0.95:[0.42;3.5]). The between-study standard deviation σ 
amounted to 0.19 (CrI0.95: [0.01;0.44]) on the log scale. Overall goodness of fit was slightly 
better for the FE model compared to the RE model yielding a DIC of 188.19 and 189.42, 
respectively; moreover, in case of a comparable goodness of fit the FE model seems 
preferable since it provides the best estimate of the true unknown treatment effect and thus 
was maintained for further analyses. 
 
In summary, the comparison of relative treatment effects for some contrasts revealed a 
discrepancy between the direct evidence and the MTC outcomes. For HbA1c regarding the 
comparison A-E, the disagreement might be due to the fact that administered drugs from the 
class of meglitinides differed between direct and indirect evidence. For body weight and 
hypoglycemia clinical considerations and findings from other studies provide compelling 
reasons that the MTC results driven by the indirect evidence are more trustworthy than the 
direct evidence. This is a key strength of multiple treatment analyses that they are able to 
provide additional information when direct evidence is possibly biased. If inconsistency can 
be detected by statistical means it will be evaluated by the node splitting procedure. 
 
The comparisons D-E, D-F and E-G are only derived through indirect comparisons. Based on 
clinical grounds they are likely to yield reasonable results. Nevertheless, the transitivity 
assumption must be assessed even if consistency can´t be measured statistically. This will be 
evaluated by comparing the distribution of potential effect modifiers between the sets of 
studies informing the indirect comparison. Another way to assess the validity of indirect 
estimates is to quantify how good they predict effects compared to evidence from external 
trials (see 4.2.2.6). 
4.2.2.2 Assessment of consistency and transitivity 
4.2.2.2.1 Consistency 
 
Node splitting was performed for all nodes that were supported by both direct and indirect 
evidence (all contrasts apart from D-E, D-F and E-G). The node split was only performed for 
the MTC models that fitted the data better (RE for HbA1c/body weight and FE for 
hypoglycemia). The results of the node split procedure are summarized in Table 17. 
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Table 17: Node splitting procedure  
 Model fit Source of evidence/ Inconsistency estimate/ Bayesian p-value 
Model 
resD  pD DIC SD  MTC Direct 
Dir
XYd̂  
Indirect 
Ind
XYd̂  
Inconsistency 
estimate 
Ind
XY
Dir
XYXY ddω
ˆˆˆ −=  
Inconsistency 
p-valueb 
1. HbA1c, %  
MTC (RE)a 132.47 107.15 239.62 0.24      
Node split     MD   
1-2 132.56 107.34 239.91 0.23 -1.05 -1.15 -1 -0.15 0.32 
1-3 132.25 106.68 238.93 0.23 -1.00 -1.16 -0.89 -0.28 0.09 
1-4 132.44 107.82 240.26 0.24 -1.06 -1.01 -1.1 0.09 0.7 
1-5 131.97 107.62 239.59 0.24 -0.99 -0.6 -1.06 0.46 0.15 
1-6 132.85 107.79 240.65 0.24 -0.65 -0.67 -0.68 0.01 0.95 
1-7 132.19 107.57 239.76 0.24 -0.73 -0.69 -0.85 0.16 0.19 
2-3 132.69 107.7 240.39 0.24 0.06 0.13 0.02 0.12 0.52 
2-4 133.03 107.84 240.87 0.24 -0.01 -0.15 0.03 -0.17 0.55 
2-5 133.25 107.45 240.7 0.24 0.06 -0.13 0.13 -0.26 0.33 
2-6 131.85 108.82 240.67 0.24 0.40 0.48 0.39 0.09 0.74 
2-7 132.4 107.38 239.78 0.24 0.32 0.28 0.36 -0.08 0.54 
3-4 132.72 107.89 240.6 0.24 -0.07 -0.06 -0.08 0.02 0.92 
3-5 132.05 107.36 239.41 0.24 0.00 -0.09 0.14 -0.23 0.3 
3-6 132.48 108.29 240.78 0.24 0.35 0.53 0.27 0.26 0.34 
3-7 131.94 107.84 239.78 0.24 0.26 0.17 0.3 -0.12 0.48 
4-7 132.42 107.68 240.1 0.24 0.33 0.39 0.32 0.07 0.77 
5-6 132.61 106.53 239.14 0.24 0.34 0.07 0.46 -0.39 0.21 
6-7 132.43 107.84 240.27 0.25 -0.09 -0.1 -0.09 -0.02 0.96 
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2. Body weight, kg 
MTC (RE)a 137.43 105.45 242.88 0.53      
Node split     MD   
1-2 137.2 103.97 241.17 0.5 -0,63 -0.05 -0.89 0.84 0.02 
1-3 135.96 105.58 241.54 0.52 1.82 2.15 1.58 0.57 0.12 
1-4 137.13 105.85 242.98 0.53 2.7 2.53 2.8 -0.27 0.62 
1-5 138.1 103.67 241.77 0.49 1.29 0.1 1.57 -1.47 0.02 
1-6 136.52 106.05 242.57 0.53 -0.35 -0.36 -0.16 -0.2 0.73 
1-7 136.04 105.19 241.23 0.53 0.62 0.49 0.96 -0.48 0.11 
2-3 137.94 105.98 243.91 0.53 2.45 2.55 2.39 0.16 0.69 
2-4 137.75 106.11 243.87 0.53 3.33 3.5 3.28 0.23 0.74 
2-5 136.95 105.61 242.56 0.53 1.92 2.41 1.76 0.65 0.29 
2-6 137.48 105.75 243.23 0.53 0.27 0.19 0.25 -0.06 0.93 
2-7 136.89 106.25 243.14 0.53 1.24 1.35 1.06 0.29 0.37 
3-4 137.5 105.62 243.12 0.52 0.88 1.24 0.63 0.61 0.27 
3-5 138.68 105.11 243.8 0.51 -0.53 -0.28 -0.86 0.59 0.23 
3-6 139.1 106.01 245.11 0.53 -2.18 -2.25 -2.19 -0.06 0.91 
3-7 137.25 106.06 243.31 0.54 -1.21 -1.23 -1.18 -0.05 0.89 
4-7 137.56 105.95 243.51 0.53 -2.08 -1.78 -2.2 0.41 0.47 
5-6 136.75 105.78 242.53 0.53 -1.65 -1.41 -1.75 0.34 0.62 
6-7 136.96 105.53 242.49 0.53 0.97 1.3 0.88 0.43 0.51 
3. Hypoglycemia 
MTC (FE)a 116.86 71.33 188.19       
Node split     log OR   
1-2 117.34 72.46 189.79  0.83 0.72 0.86 -0.14 0.74 
1-3 116.73 72.15 188.88  1.76 1.93 1.61 0.32 0.32 
1-4 117.68 72.37 190.05  0.29 0.91 0.21 0.7 0.54 
1-5 117.34 72.46 189.79  1.75 -0.01 1.74 -1.75 0.52 
1-6 116.08 72.37 188.45  0.33 0.56 -0.24 0.8 0.18 
1-7 115.18 71.9 187.08  0.22 0.04 0.53 -0.49 0.12 
2-3 112.3 72.13 184.44  0.94 0.35 1.18 -0.82 0.02 
2-4 117.1 72.18 189.28  -0.53 -0.26 -0.64 0.39 0.48 
2-5 116.05 72.11 188.16  0.92 1.23 0.73 0.5 0.2 
2-6 117.6 72.2 189.8  -0.48 -0.43 -0.61 0.18 0.76 
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2-7 115.18 71.9 187.08  -0.60 0.04 -0.48 -0.49 0.12 
3-4 117.12 72.35 189.47  -1.47 -1.56 -1.13 -0.42 0.39 
3-5 116.94 72.34 189.29  -0.01 -0.06 0.28 -0.34 0.34 
3-6 117.3 72.06 189.36  -1.43 -1.63 -1.32 -0.3 0.59 
3-7 117.65 72.16 189.8  -1.51 -1.55 -1.54 -0.01 0.97 
4-7 117.43 72.02 189.45  -0.03 0.06 -0.08 0.13 0.78 
5-6 117.66 72.19 189.85  -1.39 -1.39 -1.47 0.09 0.88 
6-7 118.01 72.56 190.58  -0.03 -0.68 -0.07 -0.61 0.81 
a For HbA1c/body weight and hypoglycemia RE  and FE models were split, respectively depending on which model fitted the data better (see 4.2.2.1). 
b The two-sided Bayesian inconsistency p-value is derived as follows p=2xmin (prob,1-prob); p is the probability over all iterations that 
Dir
XYd̂  exceeds 
Ind
XYd̂  (or XYω̂  > 0). 
resD , total residual deviance. pD, effective number of parameters. DIC, deviance information criterion. SD, between-study standard deviation. MTC, mixed treatment 
comparison. RE, random effects. FE, fixed effects. MD, difference in means. OR, odds ratio.  
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The left hand side of the table contains resD , pD, DIC and the between-study standard 
deviation σ for model comparison between full MTC models and the node split models.  A 
decrease of the DIC or σ indicates that a certain node that is freed from the consistency 
equation results in a better overall fit [129]. On the right hand side of the table the relative 
treatment effects of the full MTC models and the node split models separating the whole 
evidence into direct and indirect parts are compared together with the inconsistency estimate 
XYω̂ and the two-sided Bayesian p-value. Moreover it becomes clear how the MTC estimate is 
influenced by both sources of evidence.  
 
HbA1c 
 
Model comparison via the DIC revealed that no splitted node remarkably improved model fit 
(changes in σ weren´t detectable, either). This is paralleled by the inconsistency p-value 
which reached never statistical significance implicating that the null hypothesis of consistency 
can´t be rejected. However, for some comparisons like A-E, A-C or A-G the p-value came 
very close to the threshold of 0.05 suggesting that some degree of inconsistency might exist. 
Since this test suffers from low power if both sources of evidence are only supported from a 
small number of studies and since present heterogeneity may hinder to detect inconsistency a 
non-significant p-value should not be interpreted like inconsistency can be ruled out 
definitely. Moreover, for A-E the relative treatment effect showed that the MTC estimate is 
dominated by the indirect evidence.  
 
Although proof or hint of inconsistency suggests that pooling of direct and indirect evidence 
might be doubtful it doesn´t settle the question which one is more reliable. This must be 
carefully contemplated by reconsidering all the evidence from a clinical perspective. 
Examination of baseline characteristics between the sets of evidence might yield obvious 
reasons for discrepancy but there may be unknown covariates which might cause 
inconsistency as well.  
However, post-hoc explanations for inconsistency are of limited value and suitable measures 
like adjusting for potential effect modifiers and accounting for bias possibly introducing 
inconsistency should be determined prior to synthesis [129]. 
For the comparison A-E, the inconsistency might be attributed to the fact that the node 
meglitinides was differently defined between direct and indirect comparisons. Whereas the 
direct RCT was undertaken with Nateglinide, all other bridging trials (study No. 38,39, 52-55) 
apart from one (No. 61) included Repaglinide which seems to be superior to Nateglinide; thus 
indirect evidence yields more favourable results than direct evidence. In this case 
inconsistency is more a subject of node definition rather than which source of evidence is 
more trustworthy. 
This highlights again the importance that nodes in a network have to be reasonably specified; 
separating the drug class meglinitindes into two independent nodes Nateglinide and 
Repaglinide might resolve inconsistency but increases complexity. 
 
Body weight  
 
For body weight, neither comparing the DIC nor σ between the full MTC model and the node 
split models yielded a model that could benefit from separation direct and indirect evidence. 
The apparent conflict comparing MTC and direct estimates (see 4.2.2.1) for the comparison 
A-B and A-E was confirmed by the node splitting procedure, resulting in an inconsistency 
estimate of 0.84 (p=0.02) and -1.47 (p=0.02), respectively; anew, both MTC estimates are 
driven by indirect comparisons contributing more information to the pooled estimate. Some 
other contrasts, e.g. B-E or C-D yielded a certain degree of discrepancy 
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regarding the inconsistency estimate XYω̂ with values of 0.65 and 0.61, respectively but p-
values were not significant underlining again the issue of low power.  
For the comparison A-B no baseline characteristics could be identified that might have caused 
inconsistency; however indirect evidence seems to be more reliable since Metformin is likely 
to induce weight loss. This possibility to draw conclusions based on indirect comparisons if 
direct evidence might be biased is another appealing feature of MTC models. 
For the A-E comparison inconsistency might again be explained by the differing node 
definition; therefore the more potent Repaglinide is likely to trigger weight gain in indirect 
comparisons more intensively than Nateglinide in the placebo-controlled trial. 
 
Hypoglycemia 
 
The comparison of the DIC demonstrated that the node split model B-C exhibited a better 
model fit after cancelling the consistency equation on that node resulting in a DIC of 184.44 
vs. a DIC of 188.19 for the full MTC model. This was paralleled by a significant 
inconsistency estimate of -0.82 (p=0.02). Strikingly, the other discrepancy for the node A-E 
(see 4.2.2.1) yielded a very high inconsistency estimate of -1.75 but a p-value which is far 
from significance (p=0.52). Even if the ratio of odds ratios for indirect vs. direct evidence of 
5.75 is overly inconsistent the statistical test failed to detect it; this may be due to the fact, that 
the test is underpowered since there is only one direct RCT. Both MTC estimates were again 
controlled by the indirect evidence. 
 
For the contrast B-C no obvious reason could be detected by comparing trial characteristics; 
however, the indirect evidence is likely to be more valid than the direct evidence since 
sulfonylureas commonly cause hypoglycemias in contrast to Metformin. Since for the node 
sulfonylureas five different drugs were administered in the whole study set and some of the 
pairwise comparisons were heterogeneous, inconsistency might be linked again to the 
question of how nodes were determined. 
For the comparison A-E, the higher OR for hypoglycemic events from the indirect evidence 
compared to the direct evidence might again be caused by the stronger efficacy of 
Repaglinide which is accompanied by a higher potency to cause more harmful effects, too.  
 
In summary, post-hoc explanations for inconsistency could hardly be identified apart from the 
fact that the node definition for some aggregated drug classes might be questionable. If the 
meta-regression models and the planned sensitivity analyses are able to reduce inconsistency 
in the network this will be evaluated by performing the node splitting procedure for the 
inconsistent nodes again thereafter. 
4.2.2.2.2 Transitivity 
 
For indirect comparisons without direct evidence, the transitivity assumption that an indirect 
comparison validly estimates an unobserved head-to head comparison must be explored on 
clinical grounds by assessing bridging comparators and baseline characteristics. For the 
comparisons of D-E, D-F and E-G Table 18 summarizes the potential effect modifiers for 
each relevant bridging comparator.
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Table 18: Assessment of the transitivity assumption of indirect comparisons  
Indirect 
comparison 
Anchor treatment 
(drug,dose/d) 
Follow 
-up, 
 wk 
Mean 
age 
 (SD), 
y 
Men,  
% 
Mean 
duration 
of  
existing 
T2DM 
(SD), y 
Mean bl 
HbA1c 
(SD), % 
Mean bl 
body 
weight 
(SD), kg 
Previous  
therapy 
Definition Hypoglycemia Heterogeneityb 
 
1.  Meglitinides (E) vs. Pioglitazone (D) 
1.1 Anchor: Placebo (A) 
A-D (12-14) Placebo 16-26 55.5 
(9.6) 
49 NR 9.9 
(1.9) 
90.4 
(15.8) 
3 14: probably symptomatic  HbA1c 
A-E (15) 
 
Placebo 12 58.6 
(10.7) 
59.6 NR 7.2 
(0.7) 
77.4 1 Confirmed  NA 
1.2 Anchor: Metformin (B) 
B-D (37) Metformin (up to 
2500mg) 
26 53.7 
(11) 
60.3 2.7 
(3.7) 
8.5 
(1.2) 
86.8 
(18.9) 
2 Symptomatic  NA 
B-E (38,39) Metformin (500-
3000mg) 
16-20 60.5 
(9.1) 
69.5 5.3 
(NR) 
8.3 
(1.3) 
74.5 
(9.8) 
3 Symptomatic  Body weight 
1.3 Anchor: Sulfonylureas (C) 
C-D (48-51) 48:Gliclazide (160-
320mg; mean dose: 
184mg); 
49,50: 
Glibenclamide 
(1.75-15mg); 
51:Glimepiride (2-
8mg) 
52 55.6 
(10.4) 
53.8 4.6 
(5.4) 
8.8 
(1.1) 
86.2 
(17.8) 
49: 2; 
48,50,51: 
3 
Symptomatic, measured or 
confirmed 
Hypoglycemia 
C-E (52-55) 52: Glipizide 
(515mg); 
53,54: 
Glibenclamide 
(1.75-15mg); 
55: Gliclazide (80-
160mg) 
16-60 58.2 
(9.6) 
60.5 5.4 
(NR) 
7.7 
(NR) 
76.8 
(NR) 
55:1; 
52-54: 3 
52: not specified; 53: 
symptomatic, measured or 
confirmed; 54, 55: 
probably symptomatic  
HbA1c 
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2. Alpha Glucosidase Inhibitors (F) vs. Pioglitazone (D) 
2.1 Anchor: Placebo (A) 
A-D (12-
14) 
See 1.1 
A-F 
(3,4,10,16) 
Placebo 12-
108 
57 
(NR) 
55.1 3.8 
(NR) 
7.7 
(NR) 
82.7 
(NR) 
4, 16: 1; 3:2; 10: 3 10: probably symptomatic  HbA1c 
2.2 Anchor: Metformin (B) 
B-D (37) See 1.2 
B-F (3,4) Metformin (1500-
1700mg) 
24-
36 
57.8 
(9) 
61.9 4.8 
(5.3) 
8.7 
(0.9) 
85.7 
(15.6) 
4:1; 3:2 Not specified HbA1c 
2.3 Anchor: Sulfonylureas (C) 
C-D (48-
51) 
See 1.3 
C-F 
(10,56,57) 
10: Tolbutamide 
(750mg); 56: 
Glimepiride (1-
6mg); 57: Gliclazide 
(80-160mg) 
24-
26 
56.4 
(NR) 
53.5 4.3 
(NR) 
8.2 
(NR) 
84 
(NR) 
57:1; 
56:2;  
10: 3 
Probably symptomatic Body 
weight 
2.4 Anchor: Gliptins (G) 
D-G 
(37,60) 
37: Sitagliptin 
(100mg);  
60: Vildagliptin 
(100mg) 
24-
26 
53.1 
(10.9) 
61.5 2.4 
(3.5) 
8.6 
(1.1) 
84.9 
(NR) 
2 37: symptomatic; 60: confirmed Body 
weight 
F-G (62) Vildagliptin 
(100mg) 
24 51.8 
(10.2) 
61.1 1.2 
(2.4) 
8.6 
(0.9) 
72 
(NR) 
2 Confirmed NA 
3. Gliptins (G) vs. Meglitinides (E) 
3.1 Anchor: Placebo (A) 
A-E (15) See 1.1 
A-G 
(5,11,17-
31) 
Placebo 12-
108 
57.1 
(10.7) 
55.1 3.8 
(NR) 
7.9 
(0.9) 
80.5 
(NR) 
19: 1; 11,30,31,20-29: 
2; 
5,17,18:3 
5,11,17,18,20,21,25,27,28: not 
specified; 19,22,26: symptomatic; 
30,31,23,24: confirmed; 29: 
symptomatic, measured or confirmed 
HbA1c 
3.2 Anchor: Metformin (B) 
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B-E (38,39) See 1.2          
B-G 
(5,37,40-47) 
Metformin (500-2500mg) 24-
104 
55.1 
(11.1) 
50.7 2.3 
(NR) 
8.4 
(1.2) 
86.6 
(NR) 
5: 3; all other 
studies: 2 
5: not specified; 37, 41, 44, 45,: 
symptomatic; 
40,42,46,47: confirmed;  
43: symptomatic and confirmed 
Body 
weight 
3.3 Anchor: Sulfonylureas (C) 
C-E (52-55) See 1.3 
C-G 
(11,58,59) 
11, 58: Glipizide (2,5-10mg); 59: 
Gliclazide (80-320mg) 
12-
104 
56.7 
(10.7) 
56.1 3.2 
(NR) 
8.2 
(1) 
84.3 
(NR) 
2 11: not specified; 58: 
symptomatic; 59: confirmed 
HbA1c 
3.4 Anchor: Alpha-glucosidase Inhibitors (F) 
E-F (61) Acarbose (up to 300mg) 12 54.8 62.9 2.6 7.8 70.3 3 Not specified NA 
F-G (62) Acarbose (up to 300mg) 24 51.8 61.1 1.2 8.6 72 2 Confirmed NA 
For coding of covariates, see Table 12. 
a Data was aggregated for all studies that provided the required data. 
b Reported for outcomes that display a considerable heterogeneity (I2>50%) in pairwise meta-analysis. 
Wk, week. SD, standard deviation. Y, year. T2DM, diabetes mellitus type 2. Bl, baseline. HbA1c, glycated haemoglobin. Kg, kilogram. NR, not reported. NA, not applicable. 
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Meglitinides vs. Pioglitazone 
 
Indirect comparisons were pooled over the bridging nodes placebo, Metformin and 
sulfonylureas.  
 
HbA1c 
 
In A-D (vs. A-E) and D-C (vs. E-C) studies patients had higher HbA1c baseline levels which 
may bias indirect estimates in favour of Pioglitazone. On the other hand, patients in A-E trials 
were therapy naïve whereas patients in A-D studies had OAD discontinued only eight weeks 
or shorter before randomization which could benefit the meglitinides in the indirect 
comparison. Heterogeneity was present in comparisons of A-D and C-E studies which 
compromises the precision of the indirect estimate and might violate the transitivity relation.  
 
Body weight 
 
Baseline body weight was higher regarding all bridging comparators in trials where patients 
received Pioglitazone; due to co-administered diet and physical exercise in most trials the 
potential for weight loss might be higher in patients on Pioglitazone; thus the indirect 
comparison possibly underestimated the weight loss of meglitinides vs. Pioglitazone; 
moreover heterogeneity in B-E studies might serve as further factor affecting the validity of 
the indirect estimate.   
 
Hypoglycemia 
 
The definition of hypoglycemic events was especially inconsistent in the set of trials via the 
bridging node placebo and sulfonylureas. Moreover, heterogeneity was present in the pairwise 
comparison of C-D studies. However, it is difficult to say in which direction potential 
violations of the transitivity assumption might have biased the indirect estimate. 
 
Alpha-glucosidase inhibitors vs. Pioglitazone 
 
Indirect estimates were derived via placebo, Metformin, sulfonylureas and gliptins.  
 
HbA1c 
 
The indirect estimate might overestimate the increase in HbA1c levels of alpha-glucosidase 
inhibitors vs. Pioglitazone since baseline HbA1c levels were unevenly distributed in favour of 
Pioglitazone in the indirect comparisons via placebo and sulfonylureas. Present heterogeneity 
in the pairwise comparisons of A-D, A-F and B-F might interfere with transitive effects. 
 
Body weight 
 
The indirect evidence might be biased downwards; since patients on Pioglitazone had a higher 
baseline body weight compared to patients on alpha-glucosidase inhibitors especially in the 
set of trials via placebo and gliptins as linkage weight increase of Pioglitazone against alpha-
glucosidase inhibitors might even be larger if baselines would have been balanced. 
Heterogeneity in contrasts of C-F and D-G might act as another factor influencing the indirect 
estimate. 
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Hypoglycemia 
 
Definitions of hypoglycemia were not overly deviant within the indirect comparisons. 
Heterogeneity was present in the pairwise comparison of C-D. 
 
Gliptins vs. Meglitinides 
 
Indirect evidence was synthesized by means of placebo, Metformin, sulfonylureas and alpha-
glucosidase inhibitors serving as linking treatments.    
 
HbA1c 
 
Unbalanced HbA1c levels in favour of gliptins in the indirect comparisons via placebo, 
sulfonylureas and alpha-glucosidase inhibitors might underestimate the weaker glycemic 
control of gliptins vs. meglitinides. Heterogeneity in pairwise comparisons of A-G, C-E and 
C-G might impact on the transitivity hypothesis. 
 
Body weight 
 
The indirect estimate might potentially exaggerate the weight loosing effect of gliptins against 
meglitinides since patients on gliptins had a higher baseline body weight compared to patients 
on meglitinides in trials with the bridging comparator Metformin and sulfonylureas, 
respectively. Apparent heterogeneity in the summary estimates of B-E and B-G might have 
influenced transitivity as well.  
 
Hypoglycemia 
 
Hypoglycemic events were inconsistently defined over the whole set of trials involved in 
indirect comparisons potentially impacting transitivity.  
 
In conclusion, some differences in potential effect modifiers across trials included in the 
estimate of indirect evidence could be identified which may have violated the transitivity 
assumption in some circumstances. However, as mentioned before from a clinical perspective 
(see 4.2.2.1) most of the indirect estimates were plausible so that potential bias might occur in 
the magnitude of relative treatment effects but is unlikely to affect the direction of results. The 
validation against external evidence will deliver further insights if indirect estimates may be 
valid. 
4.2.2.3 Meta-regression of potential effect modifiers 
 
Meta-regression MTC models were only run for the models that fitted the data better 
(HbA1c/body weight: RE, hypoglycemia: FE). The number of observations (62 studies) 
appeared large enough to include the pre-specified covariates in the full models in order to 
detect significant effects of the regression coefficients (the rule of thumb of having at least 10 
observations for each included covariate was achieved). For studies that didn´t report the 
baseline body weight the mean of the remaining studies was imputed ( 64.82=m kg). 
 
The regression coefficients of the pre-specified covariates for the full MTC models for each 
outcome are reported in Table 19. 
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Table 19: Regression coefficients for meta-regression MTC models 
1. HbA1c (covariate) Mean [CrI0.95] 
ß0  (baseline HbA1c)a -0.19 [-0.32;-0.06] 
ß1 (length of follow-up)a -0.008 [-0.004;0.006] 
ß2 (previous therapy )b 0.22 [-0.06;0.51] 
ß3 (previous therapy )b 0.21 [-0.1;0.52] 
2. Body weight  
ß0  (baseline body weight)a 0.007 [-0.007;0.02] 
ß1 (length of follow-up)a 0.003 [-0.003;0.009] 
ß2 (previous therapy )b 0.1423 [-0.15;0.44] 
ß3 (previous therapy )b 0.1 [-0.21;0.42] 
3. Hypoglycemia  
ß0 (year of study)a -0.02 [-0.1;0.05] 
ß1 (length of follow-up)a -0.03 [-0.07;-0.005] 
a For continuous covariates ß indicates how the outcome variable changes with a unit increase in the explanatory 
variable. 
b For categorical covariates ß indicates how the outcome variable differs from a reference group, respectively. 
Reference category: therapy naïve; ß2: no OAD at least 8 weeks before randomization; ß3: else. 
HbA1c, glycated haemoglobin. MTC, mixed treatment comparison. CrI, credible interval. 
 
For HbA1c, the regression coefficient for the covariate baseline HbA1c yielded a significant 
result denoting that for each increase of the baseline HbA1c by 1% the difference in means of 
treatments relative to placebo decreases by -0.19%. The finding sounds reasonable since it is 
known that the glucose lowering potential of OAD increases the higher the baseline HbA1c is. 
Moreover, this relationship was confirmed, if the crude differences in means of all direct 
comparisons were plotted against baseline levels of HbA1c and the assumption of a common 
regression coefficient applying to relative effects of all the treatments relative to the overall 
baseline placebo seemed to fit the data well (see Figure 11, appendix).  
 
For the categorical variable previous therapy both regression coefficients indicated that 
compared to the reference category „therapy naive“, both categories (ß2, no OAD at least 8 
weeks before randomization; ß3, else) led to an increase of HbA1c of approximately 0.2%. 
This implicates that the treatments relative to placebo are less efficacious if patients that got 
some kind of pre-therapy (including wash-out or continuous therapy until randomization) 
compared to therapy naive patients, which seems reasonable since patients without any kind 
of therapy exhibit higher baseline HbA1c levels and are more responsive for drug therapy. 
However, the CrI0.95 of the regression coefficients for previous therapy still included the null 
effect so that the observed trend for previous therapy did not reach statistical significance and 
for the adjusted model with both covariates baseline HbA1c and previous therapy 
heterogeneity did not further decrease; thus the covariate previous therapy was dropped.  
 
For body weight, all regression coefficients of the covariates were not statistically significant 
so that no treatment by covariate interaction could be identified. 
 
For hypoglycemia the regression coefficient for the covariate length of follow-up  was 
statistically significant; the value suggests that for each week of follow-up the log odds ratios 
of treatments relative to placebo decrease by -0.02 which seems somehow spurious and is in 
contrast to the hypothesis that a longer drug exposure enforces the harmful effect. A plot of  
the crude log odds ratios against the length of follow-up confirms that this treatment 
interaction might have occurred just by chance since the prediction of odds ratios smaller than 
one suggesting a protective effect of sulfonylureas and meglitinides vs. placebo (if follow-up 
is approximately longer than 80 weeks)  is not plausible. This suggests that the meta-
regression model is not appropriate for explaining heterogeneity and an adjustment for the 
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covariate length of follow is meaningless; thus no covariate was maintained for the outcome 
hypoglycemia.  
 
The adjusted relative treatment effects (reported at the mean value of the covariate of 8.21%) 
for baseline HbA1c of the RE MTC model are depicted in Table 20. 
 
Table 20:  RE MTC meta-regression model for HbA1c adjusted for baseline HbA1c 
1. HbA1c, %  
Comparison MD [CrI0.95] 
A-B -1.07 [-1.21;-0.93] 
A-C -1.01 [-1.16;-0.85] 
A-D -1.01 [-1.21;-0.81] 
A-E -1.03 [-1.26;-0.81] 
A-F -0.69 [-0.92;-0.46] 
A-G -0.78 [-0.89;-0.67] 
B-C 0.07 [-0.09;0.23] 
B-D 0.06 [-0.15;0.28] 
B-E 0.04 [-0.18;0.26] 
B-F 0.39 [0.14;0.62] 
B-G 0.3 [0.17;0.43] 
C-D -0.01 [-0.21;0.2] 
C-E -0.02 [-0.23;0.18] 
C-F 0.32 [0.08;0.56] 
C-G 0.23 [0.08;0.39] 
D-E -0.02 [-0.29;0.25] 
D-F 0.33 [0.03;0.61] 
D-G 0.24 [0.03;0.45] 
E-F 0.34 [0.07;0.61] 
E-G 0.25 [0.03;0.48] 
F-G -0.09 [-0.32;0.15] 
SD 0.22 [0.17;0.29] 
ß0 (baseline HbA1c) -0.18 [-0.3;-0.07] 
Model fit 
resD  pD DIC 
 129.62 107.35 236.97 
Relative treatment effects for HbA1c are reported at the mean covariate value (8.21%). 
MTC, mixed treatment comparison. HbA1c, glycated haemoglobin. RE, random effects. MD, difference in 
means. CrI, credible interval. SD, standard deviation. resD , total residual deviance. pD, effective number of 
parameters. DIC, deviance information criterion.  
 
Contrasted to the unadjusted model the DIC and SD decreased slightly arguing that 
adjustment for baseline HbA1c might explain heterogeneity to some content and improves 
model fit. However, even if baseline HbA1c is considered as covariate there are only minor, 
clinically irrelevant differences between the adjusted and the crude relative treatment effects 
(see Table 16).
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In summary, only one pre-specified covariate (baseline HbA1c) could be identified as 
treatment modifier and the amount of heterogeneity explained by it was moderate. Thus, 
it remains a certain degree of residual heterogeneity which might be caused by other 
(unobserved) covariates. Moreover, since meta-regression is observational the observed 
association might be confounded by another covariate so that a causal relationship can´t be 
concluded. Another limitation is that without individual patient data it can´t be excluded that 
the finding is susceptible to ecological bias; if the interaction of baseline HbA1c and 
treatment effect is not present within each trial than the treatment-by-covariate interaction 
across trials is confounded and adjusted results might be misleading. 
4.2.2.4 Sensitivity analyses  
 
Overall baseline 
 
For each treatment  a FE and RE Bayesian meta-analysis was carried out for the arms 
containing the corresponding baseline and the better fitting model was selected based upon 
the DIC (data not shown, see electronic data carrier: Ancillary output\Sensitivity 
analyses\Different overall baselines); for all baselines, the RE models fitted better.  The mean 
and the between-study standard deviation were used to sample predictive distributions for the 
estimation of the absolute efficacy and the ranking of treatments for each baseline (see Table 
21).
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Table 21: Sensitivity analysis for HbA1c: absolute efficacy and ranking of treatments with different overall baselines 
 Overall baseline 
 A 
(0.189;13.53)a 
B 
(-0.905;3.809)a 
C 
(-0.782;1.427)a 
D 
(-0.939; 2.702)a 
E 
(-0.27; 3.871)a 
F 
(-1.021;3.265)a 
G 
(-0.708;7.749)a 
Parameter Mean  SD Mean  SD Mean  SD Mean  SD Mean  SD Mean  SD Mean  SD 
T [A] 0.189 0.273 0.132  0.517 0.214 0.844 0.035  0.624 0.767  0.534 -0.372 0.57 0.04  0.363 
T [B] -0.885 0.282 -0.911 0.512 -0.83  0.845 -1.01  0.624 -0.289 0.532 -1.426  0.571 -1.025 0.365 
T [C] -0.816  0.283 -0.854 0.519 -0.788  0.84 -0.953  0.622 -0.228  0.531 -1.366  0.571 -0.963 0.368 
T [D] -0.824 0.291 -0.93 0.524 -0.876 0.846 -0.95 0.607 -0.298 0.539 -1.437  0.578 -1.034  0.373 
T [E] -0.841 0.296 -0.854  0.525 -0.744 0.848 -0.951  0.631 -0.267  0.514 -1.36  0.575 -0.96  0.377 
T [F] -0.499  0.298 -0.515  0.525 -0.427  0.85 -0.606  0.632 0.117  0.538 -1.021 0.556 -0.617  0.377 
T [G] -0.587  0.279 -0.603 0.516 -0.518  0.844 -0.693  0.623 0.032  0.534 -1.107 0.571 -0.704  0.357 
Best [A] 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Best [B] 0.457 0.498 0.312  0.463 0.257  0.437 0.427  0.495 0.263  0.44 0.335  0.472 0.341  0.474 
Best [C] 0.071 0.256 0.054 0.226 0.075  0.263 0.1  0.3 0.054  0.225 0.0616 0.24 0.058  0.233 
Best [D] 0.205  0.404 0.464  0.499 0.567  0.496 0.267  0.443 0.376 0.484 0.441  0.497 0.433 0.495 
Best [E] 0.267  0.4424 0.171  0.377 0.101  0.302 0.205  0.404 0.307 0.461 0.163  0.37 0.168  0.374 
Best [F] 2.897e-4 0.0169 7.143e-5  0.008 1.437e-4 0.012 3.571e-4  0.019 2.143e-4 0.015 1.429e-4  0.012 2.143e-4  0.015 
Best [G] 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
The random effects MTC meta-regression model with adjustment for baseline Hba1c was used for sensitivity analysis. 
a Values in brackets (mean, tau) are the RE estimates from the Bayesian meta-analyses for all arms of the corresponding baseline that were used to draw predictive distributions. 
T [i] is the absolute efficacy of the corresponding treatment (mean change in HbA1c, %). 
Best [i] is the probability that the i-th treatment is the best averaged over all iterations. 
HbA1c, glycated haemoglobin. RE, random effects. MTC, mixed treatment comparison. SD, standard deviation.  
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It can be noticed that even if the sequence is similar the ranking of the best treatments doesn´t 
automatically parallel the ranking of the absolute efficacy since T [i] is the mean absolute 
efficacy of each treatment whereas the probability of being the best treatment is assigned for 
each iteration; for example for placebo as overall baseline the mean change of HbA1c for 
gliptins (-0.587) is superior to alpha-glucosidase inhibitors (-0.499); nevertheless, gliptins 
were never the best treatment compared to alpha-glucosidase inhibitors (pbest=2.8e-4), even 
though the probability was very low. 
The absolute efficacy is depending on the overall baseline. For example if alpha-glucosidase 
inhibitors as baseline were compared to placebo as baseline (apparently the single arms of 
alpha-glucosidase inhibitors exhibited a high glucose lowering potential) the mean change for 
placebo was -0.372 and 0.189, respectively; however the relative treatment effects were not 
affected therefrom. Placebo, Metformin and sufonylureas are fully connected to all other 
treatments and fulfill the assumption of a spanning tree; however placebo appears most 
appropriate, since estimates for absolute efficacy were more precise for placebo as more 
studies were involved in the calculation of the baseline. The remaining treatments were less 
appropriate since the baseline estimates were estimated with a smaller precision, too.  
Different baselines also influenced the ranking. Although Metformin, Pioglitazone and 
meglitinides always were between the first three treatments of the ranking for the best 
treatment the rank and probabilities differed considerably.  
 
Summed up the absolute efficacy and ranking of treatments were susceptible regarding 
different overall baselines in terms of the sequence of treatments and the magnitude and 
precision of effects. Therefore, it is advisable that the spanning tree assumption is fulfilled 
and if this holds for several options the alternative that is supported by the largest evidence 
base should be selected to provide reliable estimates. 
 
Risk of bias 
 
The network diagrams for the set of studies for the corresponding outcomes when potentially 
biased studies (see 3.1.4.4) were excluded are depicted in Figure 12 of the appendix. 
 
For all networks the contrast E-F wasn´t supported anymore by direct evidence and was only 
estimated via indirect comparisons. 
The removal of studies for the particular endpoints bearing a high risk of bias improved model 
fit for HbA1c as the between-study heterogeneity decreased from 0.22 (see Table 20) to 0.16 
(see Table 22); the DIC couldn´t be used for model comparison since the number of studies 
differed.
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Table 22: Sensitivity analyses for risk of bias, removal of outliers and different priors for the between-study standard deviation 
 Sensitivity analyses 
 Risk of biasa Removal of outliersb Prior between- study standard deviationc 
   unif (0,5) unif (0,2) gamma (0.001,0.001) 
1. HbA1c , %  
(RE) 
MD [CrI0.95] 
Comparison  
A-B -1.1 [-1.23;-0.97] -1.02 [-1.13;-0.91] -1.02 [-1.13;-0.91] -1.02 [-1.13;-0.91] -1.02 [-1.14;-0.91] 
A-C -1.04 [-1.19;-0.88] -1.01 [-1.15;-0.87] -1.01 [-1.15;-0.87] -1.01 [-1.15;-0.87] -1.01 [-1.14;-0.88] 
A-D -1.11 [-1.28;-0.93] -1.08 [-1.24;-0.93] -1.08 [-1.24;-0.93] -1.08 [-1.24;-0.93] -1.08 [-1.24;-0.93] 
A-E -0.99 [-1.21;-0.77] -0.96 [-1.15;-0.78] -0.96 [-1.15;-0.78] -0.96 [-1.15;-0.78] -0.97 [-1.15;-0.78] 
A-F -0.52 [-0.76;-0.28] -0.49 [-0.71;-0.28] -0.49 [-0.71;-0.28] -0.49 [-0.71;-0.28] -0.49 [-0.7;-0.28] 
A-G -0.78 [-0.87;-0.69] -0.76 [-0.83;-0.68] -0.76 [-0.83;-0.68] -0.76 [-0.83;-0.68] -0.76 [-0.83;-0.68] 
B-C 0.05 [-0.11;0.22] 0.01 [-0.13;0.15] 0.01 [-0.13;0.15] 0.01 [-0.13;0.15] 0.01 [-0.12;0.15] 
B-D -0.01 [-0.2;0.17] -0.06 [-0.22;0.1] -0.06 [-0.22;0.1] -0.06 [-0.22;0.1] -0.06 [-0.22;0.1] 
B-E 0.1 [-0.11;0.32] 0.06 [-0.13;0.25] 0.06 [-0.13;0.25] 0.06 [-0.13;0.25] 0.06 [-0.12;0.24] 
B-F 0.57 [0.33;0.82] 0.53 [0.31;0.75] 0.53 [0.31;0.75] 0.53 [0.31;0.75] 0.53 [0.32;0.75] 
B-G 0.31 [0.21;0.42] 0.27 [0.18;0.36] 0.27 [0.18;0.36] 0.27 [0.18;0.36] 0.27 [0.18;0.36] 
C-D -0.07 [-0.26;0.12] -0.07 [-0.23;0.09] -0.07 [-0.23;0.09] -0.07 [-0.23;0.09] -0.07 [-0.23;0.09] 
C-E 0.05 [-0.14;0.25] 0.05 [-0.12;0.21] 0.05 [-0.12;0.21] 0.05 [-0.12;0.21] 0.04 [-0.11;0.2] 
C-F 0.52 [0.25;0.78] 0.52 [0.28;0.75] 0.52 [0.28;0.75] 0.52 [0.28;0.75] 0.52 [0.29;0.75] 
C-G 0.26 [0.11;0.41] 0.25 [0.12;0.39] 0.25 [0.12;0.39] 0.25 [0.12;0.39] 0.25 [0.13;0.38] 
D-E 0.12 [-0.13;0.37] 0.12 [-0.1;0.33] 0.12 [-0.1;0.33] 0.12 [-0.1;0.33] 0.12 [-0.09;0.33] 
D-F 0.58 [0.3;0.87] 0.59 [0.34;0.84] 0.59 [0.34;0.84] 0.59 [0.34;0.84] 0.59 [0.35;0.84] 
D-G 0.33 [0.15;0.5] 0.33 [0.17;0.48] 0.33 [0.17;0.48] 0.33 [0.17;0.48] 0.33 [0.18;0.48] 
E-F 0.47 [0.16;0.78] 0.47 [0.2;0.73] 0.47 [0.2;0.73] 0.47 [0.2;0.73] 0.47 [0.21;0.73] 
E-G 0.21 [-0.01;0.43] 0.21 [0.02;0.39] 0.21 [0.02;0.39] 0.21 [0.02;0.39] 0.21 [0.03;0.39] 
F-G -0.26 [-0.5;-0.02] -0.26 [-0.47;-0.05] -0.26 [-0.47;-0.05] -0.26 [-0.47;-0.05] -0.26 [-0.47;-0.06] 
SD 0.16 [0.11;0.23] 0.12 [0.07;0.18] 0.12 [0.07;0.18] 0.12 [0.07;0.18] 0.12 [0.06;0.17] 
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2. Body weight , kg 
(RE) 
MD [CrI0.95] 
Comparison  
A-B -0.64 [-0.99;0.29] -0.53 [-0.81;-0.25] -0.53 [-0.81;-0.24] -0.53 [-0.81;-0.24] -0.52 [-0.8;-0.25] 
A-C 1.42 [1;1.86] 1.17 [0.79;1.54] 1.17 [0.79;1.54] 1.17 [0.79;1.54] 1.18 [0.81;1.53] 
A-D 2.53 [2.02;3.05] 2.47 [2.02;2.91] 2.47 [2.02;2.91] 2.47 [2.02;2.91] 2.48 [2.05;2.9] 
A-E 1 [0.45;1.57] 0.66 [0.19;1.12] 0.66 [0.19;1.12] 0.66 [0.19;1.12] 0.66 [0.22;1.1] 
A-F -0.91 [-1.57;-0.26] -0.73 [-1.37;-0.09] -0.73 [-1.37;-0.09] -0.73 [-1.37;-0.09] -0.73 [-1.31;-0.12] 
A-G 0.58 [0.32;0.82] 0.57 [0.37;0.77] 0.57 [0.38;0.77] 0.57 [0.38;0.77] 0.57 [0.39;0.76] 
B-C 2.06 [1.59;2.54] 1.7 [1.29;2.11] 1.7 [1.29;2.1] 1.7 [1.29;2.1] 1.7 [1.32;2.09] 
B-D 3.17 [2.63;3.74] 3 [2.52;3.47] 2.99 [2.53;3.46] 2.99 [2.53;3.46] 3 [2.54;3.45] 
B-E 1.64 [1.08;2.23] 1.18 [0.7;1.68] 1.18 [0.69;1.68] 1.18 [0.69;1.68] 1.18 [0.71;1.65] 
B-F -0.28 [-0.96;0.41] -0.2 [-0.85;0.45] -0.2 [-0.84;0.45] -0.2 [-0.84;0.45] -0.2 [-0.8;0.42] 
B-G 1.21 [0.9;1.53] 1.1 [0.85;1.35] 1.1 [0.85;1.35] 1.1 [0.85;1.35] 1.09 [0.85;1.33] 
C-D 1.11 [0.56;1.66] 1.3 [0.82;1.79] 1.3 [0.81;1.78] 1.3 [0.81;1.78] 1.3 [0.83;1.77] 
C-E -0.42 [-0.93;0.11] -0.51 [-0.93;-0.08] -0.51 [-0.94;-0.08] -0.51 [-0.94;-0.08] -0.52 [-0.92;-0.11] 
C-F -2.33 [-3.08;-1.6] -1.9 [-2.61;-1.19] -1.9 [-2.61;-1.17] -1.9 [-2.61;-1.17] -1.91 [-2.57;-1.21] 
C-G -0.85 [-1.29;-0.41] -0.6 [-0.98;-0.21] -0.6 [-0.98;-0.21] -0.6 [-0.98;-0.21] -0.61 [-0.97;-0.24] 
D-E -1.53 [-2.21;-0.84] -1.81 [-2.41;-1.21] -1.81 [-2.4;-1.22] -1.81 [-2.4;-1.22] -1.82 [-2.37;-1.2] 
D-F -3.44 [-4.24;-2.65] -3.2 [-3.96;-2.45] -3.2 [-3.95;-2.45] -3.2 [-3.95;-2.45] -3.2 [-3.91;-2.48] 
D-G -1.96 [-2.49;-1.44] -1.9 [-2.34;-1.44] -1.9 [-2.33;-1.45] -1.9 [-2.33;-1.45] -1.91 [-2.33;-1.48] 
E-F -1.91 [-2.76;-1.1] -1.39 [-2.15;-0.62] -1.39 [-2.14;-0.6] -1.39 [-2.14;-0.6] -1.38 [-2.12;-0.65] 
E-G -0.42 [-1.01;0.14] -0.09 [-0.56;0.39] -0.09 [-0.56;0.39] -0.09 [-0.56;0.39] -0.09 [-0.54;0.36] 
F-G 1.49 [0.85;2.14] 1.3 [0.69;1.91] 1.3 [0.68;1.91] 1.3 [0.68;1.91] 1.3 [0.71;1.87] 
SD 0.43 [0.24;0.65] 0.28 [0.1;0.47] 0.28 [0.09;0.47] 0.28 [0.09;0.47] 0.24 [0.05;0.43] 
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3. Hypoglycemia (FE) OR [CrI0.95] 
Comparison  
A-B 2.27 [1.41;3.54]  
A-C 6.07 [3.73;9.48]  
A-D 1.34 [0.73;2.26]  
A-E 5.67 [3.18;9.5]  
A-F 1.93 [0.86;3.75]  
A-G 1.14 [0.74;1.72]  
B-C 2.71 [1.85;3.87]  
B-D 0.6[0.35;0.94]  
B-E 2.53 [1.6;3.88]  
B-F 0.89 [0.4;1.63]  
B-G 0.51 [0.34;0.74]  
C-D 0.22 [0.15;0.31]  
C-E 0.94 [0.67;1.28]  
C-F 0.36 [0.15;0.62]  
C-G 0.19 [0.13;0.28]  
D-E 4.37 [2.64;6.93]  
D-F 1.52 [0.63;3.02]  
D-G 0.9 [0.53;1.45]  
E-F 0.36 [0.15;0.7]  
E-G 0.21 [0.13;0.33]  
F-G 0.67 [0.3;1.31]  
For model fit, no DIC was calculated since the sensitivity analyses included different numbers of studies.  
a For HbA1c, relative treatment effects are reported for the unadjusted model without baseline HbA1c as covariate, since the regression coefficient was no longer statistically 
significant after studies at high risk of bias were removed. 
b According to the leverage vs. residual plots the following studies were identified as outliers and excluded from further analyses. HbA1c: study No. 2; Body weight: study No. 
10, 38 and 47; for hypoglycemia, no outliers were detected. 
c For sensitivity analyses two uniform priors were placed on the between-study deviation sigma and one gamma prior on the precision (1/between-study variance). 
HbA1c, glycated haemoglobin. RE, random effects. MD, difference in means. CrI, credible interval. SD, standard deviation. Kg, kilogram. FE, fixed effects, OR, odds ratio. 
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Interestingly, the covariate for baseline HbA1c lost significance (see electronic data carrier: 
Ancillary output\Sensitivity analyses\Risk of bias) indicating that the potentially biased and 
removed studies might have caused this heterogeneity; thus the covariate was dropped. For 
body weight, the heterogeneity in the network decreased likewise from 0.53 (see Table 16) to 
0.43 when the possibly biased studies were excluded. For the FE model for hypoglycemia, 
model fit could not be assessed by heterogeneity. Thus the node split on the statistically 
inconsistent node B-C (see Table 17) was repeated to assess if inconsistency resolved, which 
was not the case ( XYω̂ : -1.04; p=0.004). Moreover, relative treatment effects were comparable 
to the core model (see Table 16), which yielded more precise estimates and hence was used 
for further analyses. 
 
Removal of outliers 
 
Outliers were detected from leverage vs. residual plots for HbA1c (study No. 2) and Body 
weight (study No. 10, 38 and 47) (see Figure 13). 
 
a.) 
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b.) 
 
 
 
 
 
 
 
 
 
 
 
c.) 
 
Figure 13: Leverage vs. residual plots  
For a.) HbA1c, b.) body weight and c.) hypoglycemia. 
Points on the black, red and green lines each contribute an amount of c=1, 2, 3, respectively to the DIC. Points 
with c>3 beyond the green line were classified as outliers and excluded from sensitivity analysis.
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The exclusion of outliers further reduced heterogeneity in the network improving model fit 
(see Table 22.) Moreover, for body weight one of the statistically inconsistent nodes (1-5; see 
Table 17) yielded now no more disagreement between direct and indirect evidence  
( XYω̂ = -0.83; p=0.08) reasoning that the outliers introduced some inconsistency in the 
network. 
 
For HbA1c, the MTC estimates from the full model (see Table 16) results were robust to 
sensitivity analyses. The minor differences in lowering HbA1c levels that affected some 
comparisons such as A-F (MDcore model:-0.65 vs. MDSA:-0.49), C-F (MDcore model: 0.35 vs.  
MDSA:0.52) or D-F (MDcore model:0.41 vs. MDSA:0.59) were not clinically relevant. 
 
For body weight, the results from the full MTC core model (see Table 16) were likewise 
unsusceptible for the different assumptions of sensitivity analyses. Changes in body weight 
differed slightly only for a few comparisons, e.g. A-C (MDcore model:1.82 vs. MDSA:1.17),  
B-F (MDcore model:0.27 vs. MDSA:-0.2) or C-D (MDcore model:0.88 vs. MDSA:1.3) but were not 
clinically meaningful.  
 
Thus, even though sensitivity analyses for HbA1c and body weight were able to reduce the 
amount of heterogeneity and/or inconsistency to some extent all core analyses yielded 
comparable results to different assumptions of sensitivity analyses demonstrating that the 
results were robust to them.  
 
For HbA1c and body weight, the RE models excluding possibly biased studies and outliers 
were identified as having the best model fit. For hypoglycemia, the FE core model comprising 
all studies was selected for the remaining analyses. 
 
Different priors for heterogeneity parameter 
 
The different priors for the heterogeneity parameter which were all more informative in terms 
of limiting the belief in the extent of heterogeneity compared to the core model hardly 
influenced the estimate of the between-study heterogeneity; only for body weight, the gamma 
prior on the precision which gives more weight to values of σ near zero slightly decreased the 
between-trial standard deviation demonstrating that due to huge amount of data the posterior 
of the between trial standard deviation is robust to different priors (which was not the case for 
Bayesian pairwise meta-analysis when the number of studies was small, see 4.2.1.1). 
4.2.2.5 Ranking of treatments  
 
For the best fitting models (see 4.2.2.4) the ranking of treatments for every outcome was 
estimated. A new predictive value for the overall baseline placebo was calculated for the 
reduced study set without outliers and observations being at high risk of bias (for HbA1c and 
body weight).  
 
For HbA1c Pioglitazone, Metformin and sulfonylureas were superior with a probability of 
being the best treatment of 0.64, 0.17 and 0.11, respectively (see Table 23).
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Table 23:  Ranking of treatments and number needed to harm for Hypoglycemia 
1. HbA1c 
                               Ranking 
Treatment 
1 2 3 4 5 6 7 Absolute 
efficacy T[i]a 
Placebo 0 0 0 0 0 0 1 0.19 
Metformin 0.17 0.38 0.29 0.17 0 0 0 -0.84 
Sulfonylureas 0.1 0.3 0.43 0.18 2.14e-04 0 0 -0.82 
Pioglitazone 0.65 0.19 0.1 0.06 0 0 0 -0.9 
Meglitinides 0.08 0.14 0.19 0.58 0.02 5.71e-04 0 -0.78 
Alpha-glucosidase inhibitors 0 0 7.14e-05 5.0e-04 0.08e-01 0.99 0 -0.31 
Gliptins 0 0 7.14e-05 0.02 0.98 0.08e-01 0 -0.57 
2. Body weight 
Ranking 
Treatment 
1 2 3 4 5 6 7 Absolute 
efficacy T[i]a 
Placebo 0 0.13e-01 0.98 0.03e-01 0 0 0 -0.65 
Metformin 0.26 0.74 3.57e-04 0 0 0 0 -1.18 
Sulfonylureas 0 0 0 2.86e-04 0.01 0.99 0 0.52 
Pioglitazone 0 0 0 0 0 0 1 1.82 
Meglitinides 0 1.43e-04 0.04e-01 0.36 0.63 0.01 0 0.05e-01 
Alpha-glucosidase inhibitors 0.74 0.25 0.01 5.71e-04 2.14e-04 0 0 -1.38 
Gliptins 0 0 1.43e-04 0.64 0.36 0.01e-01 0 -0.08 
3. Hypoglycemia 
Ranking 
Treatment 
1 2 3 4 5 6 7 Absolute 
efficacy T[i]a 
Placebo 0.64 0.24 0.1 0.03 7.14e-05 0 0 0.13e-01 
Metformin 0 0 0.01e-01 0.04 0.96 0 0 0.03 
Sulfonylureas 0 0 0 0 0 0.45 0.55 0.07 
Pioglitazone 0.12 0.21 0.33 0.33 0.07e-01 0 0 0.18e-01 
Meglitinides 0 0 0 0 0 0.55 0.45 0.07 
Alpha-glucosidase inhibitors 0.15 0.19 0.22 0.41 0.04 0 0 0.18e-01 
Gliptins 0.1 0.37 0.35 0.19 2.86e-04 0 0 0.16e-01 
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NNH Placebo  Metformin  Sulfonylurea
s 
 
Pioglitazone  Meglitinides  Alpha-
glucosidase  
inhibitors  
Gliptins   
Placebo (A)         
Metformin (B) 61        
Sulfonylureas (C) 17 24       
Pioglitazone (D) 235 82b 19b      
Meglitinides (E) 18 25 1351b 19     
Alpha-glucosidase inhibitors (F) 202 87b 19b 1449 19b    
Gliptins (G) 324 75b 18b 855b 19b 538b   
For 1.) HbA1c 2.) body weight and 3.) hypoglycemia the estimated probability denotes that each treatment is ranked first (best), second, third,…,seventh (worst) in terms of 
reducing HbA1c, avoiding an increase in body weight and having the lowest risk for experiencing a hypoglycemic event.  
The number needed to harm NNHbk is derived as follows: NNHbk=1/(probk-probb)*100, where probk/b is the probability of suffering a hypoglycemic event on treatment k and b, 
respectively. It indicates how many patients need to be treated with  treatment k compared to treatment b over a specific period to cause harm in one patient that would not 
otherwise have been harmed, as long as k is alphabetically after b. 
a T [i] is the absolute efficacy of the corresponding treatment (mean change in HbA1c (%) and body weight (kg) and proportions of patients experiencing at least one event of any 
hypoglycemia, respectively). 
b For these comparisons the NNHkb is inversed denoting how many patients need to be treated with  treatment b compared to treatment k over a specific period to cause harm in 
one patient that would not otherwise have been harmed. 
HbA1c, glycated haemoglobin. NNH, number needed to harm.
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The second and third rank was dominated by Metformin and sulfonylureas, respectively. For 
the fourth and fifth rank, meglitinides and gliptins were the prevailing drug class.  
Apart from placebo the therapeutic efficacy was worst for alpha-glucosidase inhibitors having 
a 0.99 probability of being the second worst treatment. 
 
With respect to body weight alpha-glucosidase inhibitors and Metformin were most effective 
in avoiding an increase of weight with a probability of 0.74 and 0.26, respectively. Whereas it 
is known that Metformin has a positive impact on weight loss, the apparently high effect of 
alpha-glucosidase inhibitors might be attributed to gastrointestinal side effects such as 
diarrhea and flatulence; thus this weight loss comes at the price of a worse tolerability and 
impaired compliance. In accordance with the MTC estimates gliptins were inferior to placebo 
and Metformin exhibiting a high probability of ranking fourth or fifth. 
The weight gaining effect of sulfonylureas, meglitinides and especially Pioglitazone is 
reflected by the fact that they performed badly and were ranked among the worst options.  
 
Regarding hypoglycemia placebo, alpha-glucosidase inhibitors and Pioglitazone were the 
safest drugs inducing the fewest hypoglycemic events with a probability of 0.64, 0.15 and 
0.12, respectively. Obviously, therapeutic nihilism (placebo) can´t be really considered as an 
alternative. Moreover, one has to consider all relevant side effects and not only hypoglycemia. 
Although alpha-glucosidase inhibitors rank second after placebo with regard to being the 
safest treatment health care professionals must balance this benefit against other side effects 
as mentioned before. For Pioglitazone several serious side effects (like weight gain, fluid 
retention, edema, heart failure, fractures and a possible association with an increased risk for 
bladder carcinoma; see 1.4) surely outweigh its favourable effect on hypoglycemia. Thus, if 
these three treatments are ignored, gliptins and Metformin are likely to be the next best 
alternatives. For dichotomous outcomes the number needed to harm (NNH) is a helpful 
clinical measure to describe detrimental effects of drugs. It is defined as the inverse of the 
absolute risk reduction and indicates how many patients need to be exposed to a drug 
compared to the control over a specific period (which differs due to differences in length of 
follow-up of the included studies) to cause harm in one patient that would not otherwise have 
been harmed (the higher, the better the side effect profile of the corresponding drug). Just as 
the number to treat these measures are able to detect differences in absolute baseline risk 
whereas relative effect measures ignore them and yield identical results. Table 23 displays all 
pairwise NNHs; whereas some drugs like sulfonylureas and meglitinides exhibited low 
NNH´s compared to the other alternatives mirroring their high potential for inducing 
hypoglycemias, other drugs like gliptins, alpha-glucosidase inhibitors and Pioglitazone 
yielded relatively high NNH´s reflecting their good tolerability with respect to 
hypoglycemias.  
 
The ranking of treatments apparently yields very distinct differences; e.g. for HbA1c, the 
probability for Metformin (p=0.17) being best is considerably lower than for Pioglitazone 
(p=0.64). However, the results must be scrutinized. On the one hand it is important how 
treatments rank over all ranks (e.g. what is the probability of ranking second best, third best, 
etc.) to get the whole picture. Hence, Metformin has the highest probability of ranking second 
(and a high chance to rank third or fourth) if Pioglitazone might not be chosen due to side 
effects. In addition, one must consider the relative treatment effects; the difference in means 
of Pioglitazone vs. Metformin is -0.06 (CrI0.95:[-0.15;0.27]) which is clinically meaningless. 
Thus, in this case the ranking pretends a clear superiority of Pioglitazone which is not 
supported by the relative treatment effect.  
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Another example are hypoglycemias; Metformin seems to be inferior to gliptins since gliptins 
have a probability of ranking second of 0.37 whereas it is zero for Metformin. 
Although gliptins cause less hypoglycemic events than Metformin (OR:0.55; 
CrI0.95:[0.39;0.76]), the baseline risk for Metformin is still low (the pooled incidence of 
experiencing such events was 0.03) which is reflected by a comparatively high NNH of 75. 
Alike, the benefit of gliptins compared to Metformin based only on the ranking for 
hypoglycemic events diminishes if the NNH is examined.  
 
Thus, for drug choice the ranking alone might be misleading and relative and absolute 
treatment effects should be considered, too. Moreover, all relevant endpoints (not only the 
ones reported in this thesis) must of course be considered simultaneously in order to base the 
decision on a comprehensive benefit-risk assessment. 
4.2.2.6 Validation of the mixed treatment comparison models 
 
The contrasts D-E, D-F and E-G plus E-F (only for HbA1c and body weight) were not 
supported by direct evidence. From the list of excluded studies only the one by Göke et al. 
(record No. 9361, see Table 11 of the appendix) [143] was identified to serve as external 
reference and provided results for HbA1c and body weight for model prediction purposes for 
the contrast D-F (see Table 24). 
 
Table 24: Validation for predictive effects of MTC models 
 MC 
controla 
MDnewb [CrI0.95] MC 
experimentalc 
P-value MD [CrI0.95]d 
1. HbA1c (%) -1.16 0.6 [0.34;0.84] -0.57 0.7 0.68 [0.28;1.08] 
2. Body weight 
(kg) 
1.23 -3.2 [-3.94;-2.44] -1.96 0.84 -3.32 [-4.39;-2.25] 
Predictive effects of the best fitting MTC models for contrasts that were estimated based on indirect evidence 
only and for which evidence from the excluded studies was available; this applied only for the contrast 
Pioglitazone vs. alpha-glucosidase inhibitors where one trial (record No. 9361, see Table 11 of the appendix) 
reported data for HbA1c and body weight for cross-validation [143]. 
a Predictive mean change for HbA1c and body weight for the control arm (Pioglitazone) of the external trial in a 
new study. 
b Predictive effect of the MTC models for the difference in means for HbA1c and body weight. 
c Predicted mean change for HbA1c and body weight for the experimental arm (alpha-glucosidase inhibitors). 
d CrI0.95 for the difference in means of the external trial for HbA1c and body weight. 
HbA1c, glycated haemoglobin. MTC, mixed treatment comparison, MC, mean change. MD, difference in 
means. CrI, credible interval. 
 
For HbA1c (MDnew:0.6; CrI0.95new:[0.34;0.84] vs. MDext:0.68; CrI0.95ext:[0.28;1.08]) and body 
weight (MDnew:-3.2; CrI0.95new:[-3.94;-2.44] vs. MDext:-3.32; CrI0.95ext:[-4.39;-2.25]) the 
predictive treatment effects were consistent compared to the treatment effect of the external 
trial. In addition, the Bayesian p-values (HbA1c: p=0.7; body weight: p=0.84) confirmed the 
good agreement and indicated that it is unlikely that predictive values from the MTC models 
differ from future trials.  
 
In summary, even if only one trial was available for the validation of the indirect D-F MTC 
estimates for HbA1c and body weight results were satisfying in assuming that the models 
accurately predict these relative treatment effects in future studies. 
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5. Conclusion 
 
In this systematic review the comparative effectiveness and safety of oral antihyperglycemic 
drugs as monotherapy in patients with type 2 diabetes mellitus in terms of HbA1c, body 
weight and hypoglycemia was assessed by a mixed treatment comparison analysis.  
 
In summary, Metformin appeared to be the best OAD as first-line monotherapy in T2DM 
patients; it exhibited comparable glycemic control compared to sulfonylureas and 
Pioglitazone and induced the strongest weight loss. Even if Metformin might cause more 
hypoglycemias than gliptins the absolute incidence is low. Moreover, it is the only drug 
positively affecting micro- and macrovascular complications [35]. Contraindications like 
severe renal disorders must be taken into account.  
 
If Metformin is not suitable meglitinides and sulfonylureas might be the second best option. 
The former might be more beneficial since both lower HbA1c and trigger hypoglycemias to a 
similar extent but the weight gain of meglitinides is less pronounced compared to 
sulfonylureas. However, their weight gaining effect and their disposition for hypoglycemias 
makes them a less attractive option for obese patients, elderly patients with comorbidities and 
patients with irregular eating behavior or increased physical activity.  
 
If meglitinides and sulfonylureas are not an option gliptins might be considered as an 
alternative. Even though their HbA1c lowering effect is moderate they result in a weight loss 
compared to sulfonylureas and are weight neutral compared to meglinitides; moreover they 
cause less frequently hypoglycemias than both classes.  
 
Finally, Pioglitazone and alpha-glucosidase inhibitors seem less appropriate. Although 
Pioglitazone demonstrated a promising glucose lowering efficacy, its strong weight gain and 
cardiovascular risk limit its use in diabetics. Alpha-glucosidase inhibitors were worst at 
lowering HbA1c levels and even though they don´t cause hypoglycemias very often their 
weight losing effect is offset particularly by the frequent gastrointestinal side effects which 
affect compliance negatively and can lead to discontinuation of drug therapy [6]. 
 
The analysis has some limitations which need to be addressed. One is that hypoglycemias 
were reported inconsistently and incompletely in the included studies. Consequently, this 
endpoint couldn´t be analyzed as planned for separate categories reflecting the severity of 
events; as a trade off any kind of hypoglycemia was used instead making it difficult to draw 
conclusions about the clinical relevance of this finding. Due to the heterogeneous definitions 
of events within the network it is unknown if differences were caused by more meaningful 
events like documented symptomatic hypoglycemias or less important ones such as probable 
symptomatic or relative hypoglycemia. Thus, it remains unclear if the elevated risk, especially 
for meglitinides and sulfonylureas is really a drawback or is of minor importance. Therefore it 
would be desirable that future clinical trials adhere stronger to the recommendations of 
regular approval authorities and scientific associations to improve reporting on hypoglycemic 
events [79,82].  
 
A second limitation is that some residual inconsistency persisted in the network even after 
meta-regression and sensitivity analyses were performed as countermeasures to get rid of it. 
For HbA1c there were no statistically inconsistent comparisons. Even though the 
inconsistency estimate was close to statistical significance for some contrasts the differences 
were not clinically relevant. 
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For body weight, regarding the comparison of meglitinides vs. placebo statistically 
inconsistency could be overcome by sensitivity analyses, even though the inconsistency 
estimate remained considerably large. The conflict between direct and indirect evidence of 
Metformin against placebo persisted.  
For hypoglycemia inconsistency on the node sulfonylureas vs. Metformin couldn´t be 
remedied and remained unchanged. Moreover, for the contrast meglitinides vs. placebo direct 
and indirect estimates were obviously not in agreement although this phenomenon couldn´t be 
confirmed statistically probably due to the underpowered test. 
 
Although for body weight and hypoglycemia the mentioned discrepancies question the 
pooling of the direct and indirect evidence for all nodes besides the comparison of 
meglitinides vs. placebo indirect evidence was likely to yield more reliable results and drove 
clearly the MTC estimates. Thus, inference based on the MTC estimates and the ranking of 
treatments might be regarded as valid even though (statistically proven) inconsistency on 
some nodes in the network is evident.  
The present inconsistency for the comparison of meglitinides vs. placebo is probably caused 
by the lumping of the heterogeneous drugs Nateglinide and Repaglinide into one drug class 
rather than by differences in the validity of direct and indirect evidence. Therefore, it would 
be interesting to see if inconsistency dissolves if the assumption of modeling a joint drug class 
of meglitinides is relaxed and both drugs are treated as independent nodes in the network. 
 
Hence, it is very crucial to give considerable consideration prior to the evidence synthesis to 
the question how the treatment nodes in the network are defined and which steps will be taken 
to address heterogeneity and inconsistency. One the one hand, if single drugs are similar 
enough to aggregate them into one drug class this keeps the complexity of the network at a 
reasonable level and facilitates interpretation of the results. On the other hand, if this 
assumption might be violated the lumping of treatments may lead to imprecisely defined 
nodes and as a consequence heterogeneity or inconsistency might be introduced into the 
network.  
 
Apart from assessing inconsistency between closed loops of evidence it is important that the 
transitivity assumption is also appraised for contrasts that are not informed by direct head- to- 
head- trials. Generally this can only be evaluated by exploring potential effect modifiers that 
might be unevenly distributed between the set of studies involved in the indirect comparisons. 
In this work some findings indicated that the transitivity relation might not always hold. 
However, from a clinical view, indirect estimates appeared to be reasonable and the partial 
validation confirming that MTC models reliably predicted results reinforced confidence in 
them.  
 
Meta-regression was a helpful approach to detect and reduce heterogeneity and maybe 
inconsistency to a certain extent. However, the magnitude of effect was moderate and some 
residual heterogeneity remained although the MTC models already yielded relatively precise 
results of the between-study heterogeneity. Moreover, it needs to be borne in mind that meta-
regression is of observational nature and can introduce ecological bias as long as no 
individual patient data is available [136]. 
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The sensitivity analysis for the overall baseline revealed that it should be carefully chosen 
since it affects the ranking of treatments. Thus, the assumption of a spanning tree connecting 
the reference treatment to any other node in the network should be fulfilled to provide valid 
results. Although the ranking of treatments is an appealing feature of Bayesian MTC models it 
must be interpreted with caution. The probability statements seem to provide clear answers 
which treatment might be the best; however, in some cases this is not reflected by the relative 
or absolute treatment effects. Thus, the choice of treatment should always be based on a 
holistic review of all the evidence. 
 
Furthermore, sensitivity analyses demonstrated that the exclusion of possibly biased studies 
and obvious outliers improved the model fit by decreasing the between-trial heterogeneity and 
eliminating some inconsistency in the network. However, some of the assessed domains of the 
risk of bias, especially the sequence generation for randomization and the allocation of 
concealment were very poorly reported in included studies, even in recent ones and despite 
well-known recommendations like the CONSORT statement [140] ; thus it couldn´t be 
resolved if selection bias might be present in the study set and how this might affect the 
findings.  
Although sensitivity analyses yielded some improvements in terms of reducing the amount of 
heterogeneity and inconsistency in the network, the full MTC models were likely to yield 
comparable results exhibiting only slight but not clinically relevant differences and hence 
were deemed to be robust to the different assumptions made in sensitivity analyses.  
 
In the end, the advantages of mixed treatment comparisons became evident in this work. 
First of all, based upon the consistency assumption indirect evidence could be obtained for 
comparisons that were not informed by direct evidence. Moreover, by pooling of the direct 
and indirect evidence MTC models improved the precision of results leading to narrower 
interval estimates that in some cases without indirect evidence would not have reached 
statistical significance. In addition, direct evidence appeared to be biased for some contrasts 
and indirect comparisons provided another piece of evidence which might be considered 
instead. Finally, interpretation of pairwise meta-analyses can become very confusing and 
complex if several treatment options are compared against each other; by means of an overall 
reference treatment the Bayesian MTC analysis allowed to generate rankings of the 
probability that each treatment is among the n best options which might ease choice of 
treatment for health care professionals.  
 
If inference based on mixed treatment comparisons is made prudently and its limitations are 
adequately considered this method will become increasingly important and popular and has 
the potential to serve as the “next generation evidence synthesis tool” within the framework of 
comparative effectiveness research, benefit and health economic assessment of 
pharmaceuticals going beyond the requirements of drug approval [60]. 
 
 
 
 
 
 
 
 
 
 
 
 108                 Conclusion 
Zusammenfassung 
 
Die vorliegende systematische Übersichtsarbeit befasst sich mit der Untersuchung der 
Wirksamkeit und Sicherheit oraler Antidiabetika als Monotherapie bei Patienten mit Diabetes 
Mellitus Typ 2; die Evidenzsynthese der untersuchten Endpunkte glykosyliertes Hämoglobin, 
Körpergewicht und Hypoglykämien erfolgte im Rahmen einer Netzwerk Meta-Analyse. 
 
Metformin erscheint das geeignetste orale Antidiabetikum im Hinblick auf die Erstlinien-
Monotherapie bei Patienten mit T2DM zu sein. Während die antihyperglykämische Wirkung 
von Metformin vergleichbar mit der der Sulfonylharnstoffe und Pioglitazon ist, induziert es 
neben alpha- Glukosidase Inhibitoren den stärksten Gewichtsverlust unter allen 
Netzwerkkomparatoren. Obwohl Metformin mit mehr Hypoglykämien als die 
Wirkstoffgruppe der Gliptine assoziiert zu sein scheint, ist die absolute Inzidenz für diese 
Ereignisse gering; die klinische Relevanz dieses Befundes spielt somit eine untergeordnete 
Rolle. Darüber hinaus ist es das einzige Pharmakon, für das ein positiver Effekt auf die 
Verhinderung mikro- und makrovaskulärer Komplikationen belegt ist [35]. Bei dem Einsatz 
von Metformin müssen Kontraindikationen wie z.B. Nierenversagen oder Störung der 
Nierenfunktion (Kreatinin-Clearance < 60ml/min) berücksichtigt werden. 
 
Wenn Metformin nicht in Frage kommt, bieten sich Glinide und Sulfonylharnstoffe als 
weitere Alternativen an; dabei erscheinen die Glinide im Vergleich zu den 
Sulfonylharnstoffen einen größeren klinischen Benefit zu haben, da sie bei vergleichbarer 
glykämischer Kontrolle und einem ähnlichen Schadenspotential bezüglich hypoglykämischer 
Episoden eine geringere Gewichtszunahme erzeugen.  
 
Allerdings schränken deren negativen Effekte auf das Körpergewicht sowie die Neigung zu 
Hypoglykämien den Einsatz insbesondere bei adipösen Patienten, älteren Patienten mit 
Komorbiditäten sowie Patienten mit unregelmäßigem Essverhalten und starker körperlicher 
Aktivität ein. Bei diesen Patientengruppen kommen Gliptine als weitere Therapieoption für 
die orale Monotherapie in Betracht. Obwohl der HbA1c- senkende Effekt eher moderat 
ausgeprägt ist, bewirken sie gegenüber Sulfonylharnstoffen eine Gewichtsabnahme und sind 
gewichtsneutral, was den Vergleich mit den Gliniden anbelangt. Zudem sind sie durch ihr 
vermindertes Risiko für Hypoglykämien beiden Wirkstoffklassen überlegen.  
 
Abschließend scheinen Pioglitazon und alpha- Glukosidase Inhibitoren für die orale 
Ersttherapie weniger angebracht zu sein. Wenngleich der Insulinsensitizer Pioglitazon einen 
sehr vielversprechenden antihyperglykämischen Effekt besitzt und in der Netzwerk Meta-
Analyse den stärksten HbA1c Abfall demonstrierte, überwiegen vor allem Bedenken im 
Hinblick auf das kardiovaskuläre Risiko, Gewichtszunahme, eine erhöhte Frakturinzidenz 
sowie die im Raum stehende Assoziation mit der Entstehung von Blasenkarzinomen, so dass 
die Nutzen-Schaden Bilanz negativ ausfällt. Unter allen Netzwerkkomparatoren senkten 
alpha- Glukosidase Inhibitoren den HbA1c am geringsten. Diese Wirkstoffgruppe verursacht 
zwar selten hypoglykämische Episoden, allerdings scheint der Gewichtsverlust auf 
gastrointestinale Nebenwirkungen wie Flatulenz oder Meteorismus zurück zu führen zu sein, 
welche die Compliance negativ beeinflussen und Therapieabbrüche zur Folge haben  
können [6]. 
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Die Arbeit weist einige Limitationen auf, die nachfolgend diskutiert werden. Ein Aspekt, der 
die Aussagekraft der Netzwerk Meta-Analyse einschränkt, ist dass der Sicherheitsendpunkt 
Hypoglykämien inkonsistent und unvollständig in den einzelnen Studien des Studienpools 
berichtet ist. In der Konsequenz konnte der Endpunkt nicht wie ursprünglich geplant für 
verschiedene Ereigniskategorien unterschiedlicher Schweregrade analysiert werden und es 
wurde auf die Kategorie jegliche Art von Hypoglykämien zurückgegriffen, was die 
Interpretation der klinischen Relevanz erschwert. Aufgrund der äußerst heterogenen 
Endpunktspezifizierung dieses Outcomes in den einzelnen Studien des Netzwerkes lässt sich 
nicht abschließend klären, ob Differenzen in den relativen Behandlungseffekten durch 
klinisch bedeutsame Ereignisse wie z.B. schwere oder dokumentierte symptomatische 
Hypoglykämien oder weniger relevante Episoden wie z.B. symptomatische oder 
Pseudohypoglykämien verursacht werden. Demzufolge ist es auch schwierig, das tatsächliche 
Schadenspotential der Sulfonylharnstoffe und Glinide, die ein erhöhtes Risiko für 
Hypoglykämien im Vergleich zu den anderen Interventionen besitzen, adäquat zu bewerten. 
Es wäre somit wünschenswert, wenn zukünftige randomisierte, kontrollierte 
Interventionsstudien stringenter auf die entsprechenden Empfehlungen der 
Zulassungsbehörden und Fachgesellschaften bei der Berichterstattung von Hypoglykämien in 
Publikationen achten [79,82]. 
 
Die Diskrepanz zwischen direkter und indirekter Evidenz (Inkonsistenz), die trotz Meta-
Regression und Sensitivitätsanalysen für einige Ergebnisschätzer im Netzwerk persistierte, 
stellt eine weitere Einschränkung dar. Für den Endpunkt HbA1c war keiner der gepoolten 
Ergebnisschätzer statistisch signifikant inkonsistent; selbst die Inkonsistenzschätzer, deren 
Bayesianischer p-Wert nahe dem Signifikanzniveau lag, wiesen lediglich klinisch marginale 
Unterschiede auf, so dass die Konsistenzannahme gerechtfertigt erscheint.  
Für den Endpunkt Körpergewicht konnte die primär vorhandene statistisch signifikante 
Inkonsistenz für den Behandlungsvergleich Glinide vs. Placebo mit Hilfe der durchgeführten 
Sensitivitätsanalysen eliminiert werden, allerdings ist der numerische Mittelwertsunterschied 
immer noch beträchtlich, was bei der Interpretation der Ergebnisse berücksichtigt werden 
sollte. Die Nichtübereinstimmung bezüglich direkter und indirekter Evidenz für den Vergleich 
Metformin vs. Plazebo blieb bestehen.  
Auch für den Endpunkt Hypoglykämien war die Inkonsistenz des Vergleiches 
Sulfonylharnstoffe vs. Metformin nicht zu beheben. Darüber hinaus erweckt der Vergleich 
von direkter und indirekter Evidenz für Glinide vs. Plazebo trotz statistischer Unauffälligkeit 
den Anschein von Inkonsistenz, was vermutlich durch einen unterpowerten Test bedingt ist. 
 
Für die inkonsistenten Netzwerkkontraste muss die Evidenzsynthese aus direkten und 
indirekten Vergleichen kritisch hinterfragt werden. Aus einer klinischen Perspektive 
(abgesehen von dem Vergleich Glinide vs. Plazebo) erscheint die indirekte Evidenz reliablere 
Ergebnisse als die head to head- Studien zu liefern und dominiert zudem die kombinierten 
Schätzer in ihrer Gewichtung. Insofern erscheint es angemessen, die Inferenz aus der 
Netzwerk Meta-Analyse trotz vorhandener Inkonsistenzen als valide zu betrachten.  
Für den Vergleich Glinide vs. Plazebo ist die Inkonsistenz vermutlich weniger durch eine 
Diskrepanz von direkter und indirekter Evidenz bedingt als durch die Modellierung einer 
gemeinsamen Wirkstoffklasse. In diesem Fall mag die Annahme ähnlicher Effekte für die 
einzelnen Wirkstoffe Nateglinid und Repaglinid unzutreffend sein und die Inkonsistenz ist 
wohl eher “technischer” Natur, bedingt durch die zu Grunde liegende Netzwerkstruktur. 
Eventuell lässt sich ein Konsistenzgewinn durch eine Aufspaltung der potentiell heterogenen 
Wirkstoffklasse Glinide in die einzelnen Wirkstoffe erzielen, was allerdings nicht im Rahmen 
dieser Arbeit untersucht wurde.  
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Demnach ist es von großer Relevanz, im Vorfeld der Evidenzsynthese ein klinisch plausibles 
Netzwerk zu definieren; dabei sollten vor allem die Vorteile (überschaubares Netzwerk und 
leichtere Vermittelbarkeit der Ergebnisse) und Nachteile (etwaige Verletzung der 
Konsistenzannahme bei Gruppenaggregation heterogener Wirkstoffe) einer Analyse von 
Wirkstoffklassen gegeneinander abgewogen werden. Außerdem sollten a priori in einem 
Studienprotokoll die Maßnahmen festgelegt werden, um mit Heterogenität und Inkonsistenz 
umzugehen. 
 
Für Vergleiche, die lediglich durch indirekte Evidenz gestützt sind, muss die 
Transitivitätsannahme ebenso evaluiert werden. In der Regel kann dies nur durch eine 
klinische Exploration potentieller Effektmodifikatoren, deren Verteilung zwischen den 
involvierten Studien differiert, untersucht werden. In dieser Arbeit ergaben sich 
Anhaltspunkte, dass die Annahme einer Transitivität der Effekte nicht für jeden Vergleich  
gleichermaßen gerechtfertigt sein mag. Allerdings erscheinen die Ergebnisse unter klinischer 
Betrachtung plausibel und die partielle Kreuzvalidierung mit Studien, die nicht in die Analyse 
mit einbezogen wurden, mag als Beleg für eine valide Prädiktion dieser Ergebnisschätzer der 
Netzwerk Meta-Analyse herangezogen werden.  
 
Die durchgeführte Meta-Regression für potentielle Effektmodifikatoren erwies sich als ein 
hilfreicher Ansatz im Hinblick auf den Endpunkt HbA1c unter Einschluss des baseline 
HbA1c Wertes als erklärende Variable, um die Netzwerkheterogenität zu reduzieren; 
eventuell mag die Adjustierung auch dazu beigetragen haben, die Inkonsistenz positiv zu 
beeinflussen. Allerdings hatte die Adjustierung nur einen geringen Einfluss auf die 
Effektstärke, die Effektrichtung war davon nicht betroffen.  Das Ausmaß der Reduktion des 
Heterogenitätsparameters war moderat und es verblieb eine residuale Heterogenität, die sich 
nicht durch die untersuchten Kovariablen erklären ließ. Allerdings war die Heterogenität 
bereits in den unadjustierten MTC Analysen zuvor relativ gering, so dass kein ausgeprägter 
Effekt durch die Adjustierung um potentielle Effektmodifikatoren zu erwarten war. 
Unabhängig davon ist bei der Auslegung der Ergebnisse einer Meta-Regression zu bedenken, 
dass sie observationeller Natur ist und ein potentieller ökologischer Bias ohne 
patientenindividuelle Daten nicht ausgeschlossen werden kann [136]. 
 
Die Robustheit der Wahl verschiedener Referenzbehandlungen wurde in einer 
Sensitivitätsanalyse untersucht. Dabei zeigte sich, dass das Ranking der Interventionen in 
Bezug auf Reihenfolge und Ausmaß der Wahrscheinlichkeit, welche Behandlung die n-beste 
ist, für verschiedene Annahmen anfällig ist und somit die Wahl der Referenzbehandlung 
umsichtig getroffen werden sollte; dabei sollte die Referenzbehandlung einen “spanning tree” 
formen, das heißt, mit allen anderen Netzwerkkomparatoren verbunden sein. Obwohl das 
Ranking der Behandlungsinterventionen mit Hilfe von Bayesianischen MTC Modellen 
aufschlussreich sein kann, müssen diese Wahrscheinlichkeitsaussagen mit Bedacht 
interpretiert werden; für eine umfassende Evidenzbewertung sollten sie daher nicht isoliert 
betrachtet werden, sondern immer in der Gesamtschau aller relativen und absoluten 
Behandlungseffekte. 
 
 111                 Conclusion 
Die Sensitivitätsanalysen, die Studien mit einem hohen Verzerrungspotential auf Endpunkt- 
oder Studienebene sowie potentielle Ausreißer (Devianzresiduen + Leverage > 3) 
ausschlossen, führten zu einer Verbesserung der Güte der Modellanpassung, was sich in einer 
reduzierten Heterogenität und einem Konsistenzgewinn manifestierte. Allerdings sind selbst 
in aktuellen Publikationen manche Domänen des Verzerrungspotentials, insbesondere die 
Erzeugung der Randomisierungssequenz und die Verdeckung der Gruppenzuteilung 
bedauerlicherweise äußerst unzureichend berichtet, obwohl dazu einschlägige Empfehlungen 
wie z.B. das CONSORT Statement existieren [140].  Somit kann nicht bewertet werden, ob 
ein Selektionsbias in dem Studienpool vorliegt und welchen Einfluss dies auf die Validität der 
Ergebnisse hat.  
 
Sämtlichen Sensitivitätsanalysen ist gemein, dass deren Ergebnisschätzer nur marginale, 
klinisch irrelevante Unterschiede verglichen mit denen der ursprünglichen MTC Modellen 
aufweisen. Somit kann davon ausgegangen werden, dass die initialen MTC Modelle valide 
Ergebnisschätzer liefern und robust gegenüber den unterschiedlichen Annahmen in den 
durchgeführten Sensitivitätsanalysen sind.  
 
Die diversen Vorteile von MTC Modellen gegenüber paarweisen Meta-Analysen einzelner 
Wirkstoffvergleiche lassen sich auch anhand dieser Arbeit belegen. Zunächst konnten drei der 
insgesamt 21 relativen Behandlungseffekte, für die keine direkten randomisierten 
kontrollierten Studien vorliegen basierend auf der Konsistenzannahme aus indirekten 
Vergleichen über die jeweiligen Brückenkomparatoren geschätzt werden. Zudem lässt sich 
durch die Synthese aus direkter und indirekter Evidenz ein erheblicher Präzisionsgewinn der 
Ergebnisschätzer feststellen, was sich in einer geringeren Standardabweichung und engeren 
Glaubwürdigkeitsintervallen niederschlägt. Folglich erreichten einige relative 
Behandlungseffekte statistische Signifikanz, die unter alleiniger Betrachtung der direkten 
Vergleiche nicht gegeben war. Darüber hinaus scheint die direkte Evidenz für einige 
Vergleiche keine validen Ergebnisse zu liefern; für diese halten indirekte Vergleiche eine 
weitere Informationsquelle bereit, die anstelle der direkten Evidenz betrachtet werden kann.  
Letztendlich erlauben die Methoden der klassischen paarweisen Meta-Analyse keine Aussage 
über eine Rangfolge im Hinblick auf Nutzen oder Schaden einer Therapie; ferner kann sich 
insbesondere bei großen Netzwerken die Interpretation der Ergebnisse reichlich kompliziert 
gestalten. Bayesianische MTC Modelle hingegen ermöglichen unter Bezugnahme auf eine 
Referenzbehandlung ein Ranking der Interventionen und erlaubenWahrscheinlichkeitsaus-
sagen, dass die jeweilige Behandlung die n-beste Option ist und stellen somit eine weitere 
nützliche Entscheidungshilfe im Rahmen der Evidenzbewertung dar.  
 
In der Zusammenschau erweisen sich Netzwerk Meta-Analysen als eine wertvolle 
Erweiterung des klassischen Methodenspektrums. Solange die Inferenz sorgfältig abgeleitet 
wird und ihre Limitationen entsprechend in Erwägung gezogen werden, stellen sie 
insbesondere im Bereich der Nutzenbewertung und gesundheitsökonomischen Evaluation von 
Arzneimitteln, deren Erfordernisse über die der Zulassung hinausgehen, einen integralen 
Bestandteil der Evidenzsynthese dar.   
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A Tables 
A.1 Table 10 
 
Table 10: Literature search strategy 
I. Medline 
Interface PubMed 
Date of search 2012/04/02 and 2012/07/30 (update) 
Limits None 
Records retrieved 2012/04/02: n=7,648 
201/07/30:   n=315 
Syntax guide 
[mh] Medical Subject Heading (MeSH); Thesaurus, controlled vocabulary of 
biomedical terms issued by National Library of Medicine. 
[tw] Text word 
[nm] Supplementary concept; includes chemical, protocol or disease terms. 
[pt] Publication type 
* Truncation; use to search for one or more characters. 
[mh:noexp] Turn of feature of including more specific MeSH terms beneath the 
original one. 
Search 
Condition (((diabetes mellitus, type 2[MeSH Terms]) OR mody[Text Word]) OR 
niddm[Text Word]) OR T2DM[Text Word] 
Boolean operator AND 
Drugs (((((((((((((((((((((((((((((((((((((acarbose[MeSH Terms]) OR acarbose byproduct, 
component C[Supplementary Concept]) OR acarbose 7-phosphotransferase) OR 
acarbose 7-phosphate) OR miglitol[Supplementary Concept]) OR alpha 
glucosidases/ antagonists and inhibitors[MeSH Terms]) OR gliclazide[MeSH 
Terms]) OR gliquidone[Supplementary Concept]) OR 
glimepiride[Supplementary Concept]) OR hydroxyglimepiride[Supplementary 
Concept]) OR glyburide[MeSH Terms]) OR 4-transhydroxy 
glyburide[Supplementary Concept]) OR Glucovance[Supplementary Concept]) 
OR glibenclamide[MeSH Terms]) OR glibenclamide receptor[Supplementary 
Concept]) OR chlorpropamide[MeSH Terms]) OR glipizide[MeSH Terms]) OR 
tolbutamide[MeSH Terms]) OR tolbutamide 4-hydroxylase[Supplementary 
Concept]) OR carboxytolbutamide[Supplementary Concept]) OR 
tolazamide[MeSH Terms]) OR sulfonylurea compounds[MeSH Terms]) OR 
pioglitazone[Supplementary Concept]) OR nateglinide[Supplementary Concept]) 
OR repaglinide[Supplementary Concept]) OR 2-methoxy-4-(3-methyl-1-(2-
piperidin-1-ylphenyl)butylcarbamoyl)benzoic acid[Supplementary Concept]) OR 
meglitinide*[Supplementary Concept]) OR sitagliptin[Supplementary Concept]) 
OR vildagliptin[Supplementary Concept]) OR lipoyl vildagliptin[Supplementary 
Concept]) OR linagliptin[Supplementary Concept]) OR 
saxagliptin[Supplementary Concept]) OR 5-hydroxysaxagliptin[Supplementary 
Concept]) OR dipeptidyl peptidase iv inhibitors[MeSH Terms]) OR LC15-
0444[Supplementary Concept]) OR metformin[MeSH Terms]) OR 
tetrachloro(metformin)platinum(IV)[Supplementary Concept]) OR drugs, 
hypoglycemic[MeSH Terms] 
Boolean operator AND 
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Filter for randomized 
controlled trialsa 
(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized 
controlled trials[mh] OR random allocation[mh] OR double-blind method[mh] 
OR single-blind method[mh] OR clinical trial[pt] OR clinical trials[mh] OR 
(“clinical trial”[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR 
tripl*[tw]) AND (mask*[tw] OR blind*[tw])) OR (“latin square”[tw]) OR 
placebos[mh] OR placebo*[tw] OR random*[tw] OR research design[mh:noexp] 
OR follow-up studies[mh] OR prospective studies[mh] OR cross-over 
studies[mh] OR control*[tw] OR prospectiv*[tw] OR volunteer*[tw]) NOT 
(animal[mh] NOT human[mh]) 
 
II. Embase 
Interface OVID 
Date of search 2012/04/02 and 2012/07/30 (update) 
Limits None 
Records retrieved 2012/04/02: n=5,298 
201/07/30:   n=653 
Syntax guide 
? Truncation symbol for one or no characters only 
$ Truncation symbol, or wildcard: retrieves plural or variations of a word 
adj# Proximity operator; adjacency within # number of words (in any order) 
* Indicates that the marked subject heading is a primary topic 
tw Text word 
sh EMTREE Thesaurus terms; controlled vocabulary of biomedical terms used by Embase for indexing 
rn CAS Registry Numbers (RN); contains the Chemical Abstracts Service Registry number in an 
association with chemical name for a compound mentioned in an article. 
Search 
Condition (diabetes mellitus or maturity onset diabetes mellitus or non insulin dependent 
diabetes mellitus or lipoatrophic diabetes mellitus).sh. or ((adult or ketosis-
resistant or matur* or late or non-insulin depend* or slow or stable or type 2 or 
type II or lipoatrophic) adj3 diabet$).tw. or (mody or niddm or T2DM).tw. 
Boolean operator AND 
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Drugs metformin.sh. or metformin.tw. or (dimethylguanylguanidine or 
dimethylbiguanidine or glucophage).tw. or (657-24-9 or 1115-70-4).rn. or (apo-
metformin or apotex or genmetformin or glucophage or glumetza or novo-
metformin or nu-metformin or pms-metformin or ran-metformin or ratio-
metformin or rhoxal-metformin or sandoz metformin).tw. or (Glycon or Fortamet 
or Riomet or Venez or Diaformina or Dimefor or Glafornil or Glucaminol or 
Glucofage or Diabex or Diaformin or Glucohexal or Glucomet or Novomet or 
Metomin or Glucamet or Metsol or Orabet).tw. or (Aron or Diabetosan or Diabex 
or Diformin or Diformin Retard or Dimethylbiguanide or Dmgg or Fluamine or 
Fortamet or Gliguanid or Glucoformin or Haurymellin or La 6023 or La6023 or 
Meguan or Mellittin or Metaformin or Methformin or Metiguanide or 
Metphormin or Dimethylguanylguanide or Nndg or Dimethylbiguanide or 
Dimethyl Biguanidine or Dimethylbiguanidine or Dimethyldiguanide).tw. or 
gliclazide.sh. or gliclazide.tw. or gliquidone.sh. or gliquidone.tw. or 
glimepiride.sh. or glimepiride.tw. or glyburide.sh. or glyburide.tw. or 
glibenclamide.sh. or glibenclamide.tw. or glybenclamide.sh. or 
glybenclamide.tw. or chlorpropamide.sh. or chlorpropamide.tw. or glipizide.sh. 
or glipizide.tw. or tolbutamide.sh. or tolbutamide.tw. or tolazamide.sh. or 
tolazamide.tw. or (64-77-7 or 1156-19-0 or 94-20-2 or 29094-61-9 or 10238-21-8 
or 93479-97-1 or 21187-98-4).rn. or (Orinase or glyconon or Tolinase or 
Diabinese or glymese or Glucotrol or Diabeta or Micronase or Glynase or gen-
glybe or euglucon or Amaryl or Diamicron or diaglyk or glibenese or minodiab 
or gen-gliclazide).tw. or sulfonylurea.sh. or sulfonylurea.tw. or pioglitazone.sh. 
or pioglitazone.tw. or actos.tw. or repaglinide.sh. or repaglinide.tw. or 
nateglinide.sh. or nateglinide.tw. or meglitinide.sh. or meglitinide.tw. or 
(135062-02-1 or 105816-04-4).rn. or (prandin or gluconorm or starlix or 
novonorm).tw. or miglitol.sh. or miglitol.tw. or acarbose.sh. or acarbose.tw. or 
(56180-94-0 or 72432-03-2 or 83480-29-9).rn. or (acarbose or glucobay or 
precose or prandase or akarbose or miglitol* or glyset or diastabol or 
voglibose).tw. or alpha glucosidase inhibitor.sh. or alpha glucosidase 
inhibitor.tw. or (((alph* adj glucos* adj inhibit*) or alf*adj glucos*) adj 
inhibit*).tw. or (((((sitagliptin or vildagliptin or linagliptin or saxagliptin).sh. or 
(sitagliptin or vildagliptin or linagliptin or saxagliptin).tw. or (januvia or galvus 
or trajenta or onglyza or gliptin).tw. or (486460-32-6 or 274901-16-5 or 141758-
74-9 or 204656-20-2).rn. or dipeptidyl peptidase IV inhibitor.sh. or dipeptidyl 
peptidase IV inhibitor.tw. or dpp.mp.) adj IV.mp. adj inhibitor*.tw.) or 
Dipeptidyl-Peptidase.mp.) adj IV.mp. adj inhibitor*.tw.) or DPP-4 inhibitors.tw. 
or dipeptidyl peptidase-4 inhibitors.tw. or oral antidiabetic agent.sh. or 
(((Antidiabetic or anti diabetic or antihyperglycemic or anti-hyperglycemic or 
oral hypoglycemic or anti-diabetes or antidiabetes) adj agent) or agents or drug or 
drugs or compound or compounds).tw.  
Boolean operator AND 
Filter for randomized 
controlled trialsb 
((clinical trial or randomized controlled trial or randomization or single blind 
procedure or double blind procedure or crossover procedure or placebo).sh. or 
randomi?ed controlled trial$.tw. or rct.tw. or random allocation.tw. or randomly 
allocated.tw. or allocated randomly.tw. or allocated ajd2 random.tw. or single 
blind$.tw. or double blind$.tw. or (treble or triple blind$).tw. or placebo$.tw. or 
prospective study.sh.) not (case study or abstract report or letter).sh. 
 
III.  Cochrane Central Register for Controlled Trials (CENTRAL) 
Interface Cochrane Library 
Date of search 2012/04/02 and 2012/07/30 (update) 
Limits Exclusion of records that have been sourced from Medline and Embase 
Records retrieved 2012/04/02: n=22 
201/07/30:   n=22 
Syntax guide 
* Truncation; use to search for one or more characters 
adj#/near# Proximity operator; finds the terms when they are within # words of each 
other where # = the maximum number of words between search terms. 
Terms can appear in either order 
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ti Title 
ab Abstract 
kw Keyword; limit includes MeSH terms but does not allow for MeSH term explosion. Also searches 
EMBASE keyword fields 
exp Explode search to include more specific MeSH terms beneath the original one; by default, a MeSH 
term will be exploded and searched in all trees 
MeSH descriptor Medical Subject Heading (MeSH); Thesaurus, controlled vocabulary of 
biomedical terms issued by National Library of Medicine 
Search 
Condition ((adult or ketosis-resistant or matur* or late or non-insulin depend* or noninsulin 
depend* or slow or stable or type 2 or type II or lipoatrophic) adj3 
diabet$):ti,ab,kw OR (mody or niddm or T2DM):ti,ab,kw or  
MeSH descriptor: [Diabetes Mellitus, Type 2] explode all trees 
Boolean operator AND 
Drugs (hypoglycemic drugs) or ((Antidiabetic or anti diabetic or antihyperglycemic or 
anti-hyperglycemic or oral hypoglycemic or anti-diabetes or antidiabetes) adj 
(agent or agents or drug or drugs or compound or compounds)) or (pioglitazone or 
actos) or (155141-29-0) or MeSH descriptor Metformin explode all trees or 
(metformin) or (dimethylguanylguanidine or dimethylbiguanidine or glucophage) 
or (apo-metformin or apotex or genmetformin or glucophage or glumetza or novo-
metformin or nu-metformin or pms-metformin or ran-metformin or ratio-
metformin or rhoxal-metformin or sandoz metformin) or (Glycon or Fortamet or 
Riomet or Venez or Diaformina or Dimefor or Glafornil or Glucaminol or 
Glucofage or Diabex or Diaformin or Glucohexal or Glucomet or Novomet or 
Metomin or Glucamet or Metsol or Orabet) or (Aron or Diabetosan or Diabex or 
Diformin or Diformin Retard or Dimethylbiguanide or Dmgg or Fluamine or 
Fortamet or Gliguanid or Glucoformin or Haurymellin or La 6023 or La6023 or 
Meguan or Mellittin or Metaformin or Methformin or Metiguanide or Metphormin 
or Dimethylguanylguanide or Nndg or Dimethylbiguanide or Dimethyl 
Biguanidine or Dimethylbiguanidine or Dimethyldiguanide) or (sitagliptin, 
vildagliptin, linagliptin, saxagliptin) or (januvia or janumet or galvus or eucreas or 
trajenta or onglyza or gliptin) or (486460-32-6 or 274901-16-5 or 141758-74-9 or 
204656-20-2) or MeSH descriptor Dipeptidyl-Peptidase IV Inhibitors explode all 
trees or (Dipeptidyl-Peptidase adj IV adj inhibitor*) or MeSH descriptor Acarbose 
explode all trees or MeSH descriptor alpha-Glucosidases explode all trees or 
((alph* adj glucos* adj inhibit*) or (alf* adj glucos* adj inhibit*)) or MeSH 
descriptor Sulfonylurea Compounds explode all trees or MeSH descriptor 
Gliclazide explode all trees or MeSH descriptor Glyburide explode all trees or 
MeSH descriptor Chlorpropamide explode all trees or MeSH descriptor Glipizide 
explode all trees or MeSH descriptor Tolbutamide explode all trees or  MeSH 
descriptor Tolazamide explode all trees or (64-77-7 or 1156-19-0 or 94-20-2 or 
29094-61-9 or 10238-21-8 or 93479-97-1 or 21187-98-4) or (repaglinide or 
nateglinide or meglitinide*) or (135062-02-1 or 105816-04-4) or (prandin or 
gluconorm or starlix or novonorm) or (gliclazide or gliquidone or glimepiride or 
glyburide or glibenclamide or glybenclamide or chlopropamide or glipizide or 
tolbutamide or tolazamide) or (sulfonylurea* or Orinase or glyconon or Tolinase 
or Diabinese or glymese or Glucotrol or Diabeta or Micronase or Glynase or gen-
glybe or euglucon or Amaryl or Diamicron or diaglyk or glibenese or minodiab or 
gen-gliclazide) or (56180-94-0 or 72432-03-2 or 83480-29-9) 
Boolean operator NOT 
Exclusion of records 
sourced from Medline 
and Embase 
"accession number" near pubmed OR "accession number" near/2 embase 
 
IV. Drug regulatory approval authorities 
Food an Drug 
Administration (FDA) 
[94] 
Drugs@FDA provides information about most of the drugs approved in the US since 1939. Medical 
and statistical reviews for the eligible drugs were searched to find unpublished data or missing data 
from publications. 
Date of search 2012/07/16 
Records retrieved n=7 
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European Medicines 
Agency (EMA) [93] 
The publicly available European Public Assessment Reports (EPAR) for the eligible drugs were 
searched to find unpublished data or missing data from publications.. 
Date of search 2012/07/17 
Records retrieved n=11 
 
V. Clinical trial registers (public and pharmaceutical) 
Clinical Trials.gov ClinicalTrials.gov is a Web-based resource that provides access to clinical studies maintained by the 
National Library of Medicine and the National Institutes of Health. Each record presents summary 
information about a study protocol and includes the following: disease or condition, intervention, title, 
description, and design of the study, requirements for participation (eligibility criteria), locations where 
the study is being conducted, contact information for the study locations. Some records also include 
information on the results of the study, such as: description of study participants, outcomes of the study 
and summary of adverse events experienced by study participants. The register was searched for the 
eligible drugs to find unpublished data or missing data from publications 
Date of search 2012/08/01 
Records retrieved n=15 
 
Limits Closed studies; studies with results; interventional studies; age 
group=adults 
Pharmaceutical industry 
trials registers:  
• Astra Zeneca [87] 
• Bristol Myers 
Squibb [88] 
• Eli Lilly [89] 
• GlaxoSmithKline 
[90] 
• Novartis [91] 
• Roche [92] 
The clinical trial registers of the mentioned manufacturers were searched for 
the eligible drugs to find unpublished data or missing data from publications 
Date of search 2012/08/10 
Records retrieved n=9 
a To follow a highly sensitive search strategy for randomized controlled trials a validated filter for Medline using 
PubMed format was used [95]. 
b To follow a highly sensitive search strategy for randomized controlled trials a validated filter for Embase was 
used  [96].
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A.2 Table 11 
 
Table 11: List of excluded full-text articles 
No. Reference Reason for exclusiona Rationale 
9 
Arjona Ferreira JC, Corry D, Mogensen CE, Slone L, Xu L, Gonzalez EJ, et al. 
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-
Stage Renal Disease. Diabetes, Stoffwechsel und Herz 2011; 6: 430. 
5 
Missing data for body weight.b 
24 
Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin 
in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled 
trial. Diabetes Metab Res Rev 2012 Mar;28(3):268-75. 
5 
Missing data for HbA1c and body weight.b 
153 
Rokeya B, Parvin M, Bhowmik A, Chowdury AK. Randomized Double-Blind 
Clinical Trial Comparaing Efficacy and Safety of Pioglitazone and Metformin in 
Patients with Type 2 Diabetes. Diabetes 2011;60 (Suppl 1): A618. 
5 
Missing data for HbA1c and body weight; 
hypoglycemia not reported. 
206 
Rosenstock J, Gross JL, Salinas CAA, Hissa M, Berglind N, Ravichandran S, et  al. 
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and dose-response characteristics of glipizide gastrointestinal therapeutic system on 
glycemic control and insulin secretion in NIDDM. Results of two multicenter, 
randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal 
Therapeutic System Study Group. Diabetes Care 1997 Apr;20(4):597-606. 
4 
Duplicate see record number 4829. 
11558 
Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM 
in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm 
Metab Res 1996 Sep;28(9):426-9. 
4 
Duplicate see record number 4872. 
11591 
Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ, Calle JR, Maranes JP. 
Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in 
obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-
blind comparison study with placebo. Diabetes Metab 1996;22(3):201-2. 
5 
Hypoglycemia not reported. 
11660 
Rodger NW, Chiasson JL, Josse RG, Hunt JA, Palmason C, Ross CA et al. Clinical 
experience with acarbose: results of a Canadian multicentre study. Clin Invest Med 
1995;18(4):318-24. 
4 
Duplicate see record number 4923. 
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11665 
Tsumura K. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a 
double blind comparative study versus gliclazide. Diabetes Res Clin Pract 1995 
Aug;28 Suppl:S147-9. 
4 
Duplicate see record number 1144. 
11699 
Wolever TM, Radmard R, Chiasson JL, Hunt JA, Josse RG, Palmason C et al. One-
year acarbose treatment raises fasting serum acetate in diabetic patients. Diabet Med 
1995;12(2):164-72. 
4 
Duplicate see record number 4998. 
11711 Harrower AD. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications 1994 Oct-Dec;8(4):201-3. 2 
Review (single studies were assessed; see 
11935, 11711_1 and 11711_2). 
11754 
de Leiva A, Pinon F, Tebar J, Escobar-Jimenez F, de la Calle H, Herrera-Pombo JF et 
al. Clinical efficacy and tolerance to acarbose in the treatment of non-insulin-
dependent diabetic patients. MedClin-Barcelona 1993; 
100(10):368-71. 
4 
Duplicate see record number 5041. 
11797 
Spengler M, Hansel G, Boehme K. Efficacy of 6 months monotherapy with 
glucosidase inhibitor Acarbose versus sulphonylurea glibenclamide on metabolic 
control of dietary treated type II diabetics (NIDDM). Horm Metab Res Suppl 1992; 
6 
Not available. 
11833 Harrower AD. Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM. Diabetes Res Clin Pract 1991;14 Suppl 2:S65-7. 2 
Review (single studies were assessed). 
11931 
U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin 
supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A 
multicenter study. Diabetes 1984;34(8):793-798 
5 
Body weight and hypoglycemia not reported. 
11935 
Harrower AD. Comparison of diabetic control in type 2 (non-insulin dependent) 
diabetic patients treated with different sulphonylureas. Curr Med Res Opin 
1985;9(10):676-80. 
1 
Five drugs from within the same drug class. 
11950 Borthwick LJ, Wilson S. Diabetic control with gliquidone--a short acting sulphonylurea. Eur J Clin Pharmacol 1984;26(4):475-9. 3 
Cross over periods only 10 weeks. 
11966 Toyota T. Sulfonylurea drug--a new sulfonylurea drug for type 2 diabetes. Nihon Rinsho 1999 Mar;57(3):695-701. 5 
Hypoglycemia not reported. 
11967 Kaneko T, Sakamoto N. Clinical efficacy of glimepiride. Nihon Rinsho 1997 Nov;55 Suppl:152-7. 2 
Review. 
11978 
Kaneko T, Sakamoto N, Nakagawa S, Goto Y, Hirata Y, Akanuma Y et al. Clinical 
evaluation of Glimepiride in non-insulin dependent diabetes mellitus – a double blind 
comparative study versus Gliclazide. Nihon Rinsho 1993 Sept;9(5): 167-80. 
1 
Two drugs from within the same drug class. 
11981 
Dalzell GW, Hadden DR, Atkinson B, Kennedy L, Weaver JA.  A randomized trial 
of Tolbutamide and Metformin for persistent severe hpyerglycemia in non-insulin 
dependent diabetes mellitus (NIDDM). Ir J Med Sci  1986;9:341-2. 
5 
HbA1c, body weight and hypoglycemia not 
reported. 
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11711_1 Harrower AD. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications 1994 Oct-Dec;8(4):201-3. 1 
Three drugs from within the same drug class. 
11711_2 
Harrower AD. Comparison of efficacy, secondary failure rate, and complications of 
sulfonylureas. J Diabetes Complications 1994 Oct-Dec;8(4):201-3. 2 
Cross-over without randomization, pre-post 
comparison; treatment follow-up interaction 
could bias the outcomes. 
U1c 
Naka KK, Papathanassiou K, Bechlioulis A, Pappas K, Kazakos N, Kanioglou C et 
al. Effects of pioglitazone and metformin on vascular endothelial function in patients 
with type 2 diabetes treated with sulfonylureas. Diab Vasc Dis Res 2012 Jan;9(1):52-
8. 
1 
Other OAD as baseline medication allowed. 
U2c 
Uchida T, Kawai J, FujitaniY, Kawamori R, Watada H, Hirose K. Efficacy and 
adverse effects of low-dose Nateglinide in early type 2 diabetes: comparison with 
Acarbose in a cross-over study. Diabetol Int 2010;1:35-41. 
2 
Cross-over study: no wash out after 1st 
sequence; carry over effect could bias the 
outcomes. 
a 1 Non eligible intervention.  
   2 Inadequate study design. 
   3 Study duration inadequate. 
   4 Duplicate data. 
   5 Data required for analysis not reported/ not provided upon request from authors. 
   6 Full text publication not available. 
b Missing data was requested from first author without success. 
c Excluded studies from updated literature research.
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A.3 Table 12 
 
Table 12a: Trial and patients characteristics of included studies  
No. Author, 
y 
Follow-
upa, 
wk 
Previous 
therapyb 
Included study armsc 
 
Rand. 
patients, 
n 
Mean age  
(SD), y 
Men,  
% 
Mean duration of 
existing T2DM  
(SD), y 
Mean bl 
HbA1c (SD), 
% 
Mean bl body 
weight (SD), 
kg 
1 
 
List, 2009 
[141] 
 
12 
 
1 
 
Placebo 54 53 (11) 55.6 NR 7.9 (0.9) 89 (18) 
Metformin 
(1,500mg;q.d.) 
56 54 (9) 48.2 NR 7.6 (0.8) 88 (20) 
2 Defronzo, 
1995 [144] 
 
29 
 
1 Placebo 146 53 (12.1) 42.5 6 (7.2) 8.2 (2.4) 92.2 (14.5) 
Metformin (titration: 
500mg;q.d./ 
maintenance: 
2,550mg;t.i.d.) 
143 53 (11.9) 43.4 6 (6) 8.4 (1.2) 94.4 (13.2) 
3 
 
Chiasson, 
2001 [145] 
 
 
36 
 
2 
 
Placebo 83 57.7 (9.9) 67.5 5.1 (4.9) 8.1 (0.7) 88.6 (14.1) 
Metformin 
(1,500mg;t.i.d.) 
83 57.9 (8.6) 73.5 7.5 (7.4) 8.2 (0.9) 89 (17.8) 
Miglitol (0-4wk: 
25mg;q.d./ 3-12wk: 
50mg;t.id./ 12-36wk: 
100mg;t.i.d.) 
82 57.3 (9) 78 5.2 (4.7) 8.2 (0.9) 91 (15.5) 
4 
 
Hoffmann, 
1997 [146] 
 
 
24 
 
1 
 
Placebo 32 60.2 (8.6) 37.5 3.6 (2.8) 9.4 (0.9) 74.9 (9.7) 
Metformin 
(1,700mg;b.i.d.) 
32 55.9 (7.8) 43.8 2.1 (1.5) 9.7 (0.9) 79 (8.8) 
Acarbose 
(300mg;t.i.d) 
32 58.9 (9.4) 18.8 3.1 (2.3) 9.6 (0.9) 73.9 (10.3) 
5 
 
Haak, 2012 
[147] 
 
24 
 
3 
 
Placebo 72 55.7 (11) 50 NR 8.7 (1) 76.8 (17.5) 
Metformin (500 and 
1,000mg;b.i.d.)d 
291 54.1 (10.5) 55 NR 8.6 (0.9) 80 (18.4) 
 Linagliptin (5mg;q.d.) 142 56.2 (10.8) 56.3 NR 8.7 (1) 79.1 (17.3) 
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6e Simonson, 
1997 [148] 
12 3 Placebo 69 60.2 
(NR) 
76.8 7.5 (NR) 8.3 (1.7) 87 (NR) 
Glipizide (5, 10, 15, 
20, 40, 60mg;q.d.)d 
278 58.2 
(NR) 
64 7.2 (NR) 8.6 (1.5) 85.3 (NR) 
7 
 
Bautista, 
2003 [149] 
 
14 
 
2 
 
Placebo 22 50.7 (10) 50 5.7 (8.4) 10.5 (2.2) 76.3 (18.5) 
Glimepiride (level 1: 
1mg;q.d./level 2: 
2mg;q.d./ level 3: 
4mg;q.d.) 
48 48.4 (11.7) 56.3 4.2 (5.8) 10 (1.8) 83.3 (17) 
8 
 
Madsbad, 
2004 [150] 
 
12 3 
 
Placebo 29 57 (9.4) 69 3.4 (2.9) 7.4 (1.2) NR 
Glimepiride (1-4mg; 
q.d./ mean received 
dose:2.7mg) 
27 57 (9.2) 59.3 3.8 (3.4) 7.8 (0.9) NR 
9 
 
Vray, 1995 
[151] 
 
12 
 
3 
 
Placebo 56 56.8 (6.7) 35.7 3.9 (4.5) 10 (3) NR 
Glibenclamide 
(7.5mg;t.i.d.) 
56 55.8 (7.5) 35.7 2.4 (3) 9.6 (3) NR 
10f 
 
Connif, 
1995 [152] 
 
 
24 
 
3 
 
Placebo 62 56.3 (NR) 51.6 5.5 (NR) 7.1 (NR) 85.8 (NR) 
Tolbutamide 
(750mg;t.i.d./ forced 
titration until 
1000mg;d) 
66 55.4 (NR) 56.1 5.6 (NR) 7 (NR) 84.8 (NR) 
Acarbose 
(600mg;t.i.d.) 
67 56.2 (NR) 38.8 5.1 (NR) 6.9 (NR) 81.6 (NR) 
11 
 
Scott, 2007 
[153] 
 
 
12 
 
 
2 
 
 
Placebo 125 55.3 (9.7) 62.4 4.8 (4.7) 7.9 (1) NR 
Glipizide (5mg;q.d.) 123 54.7 (10.7) 56.9 4.7 (4.2) 7.9 (1) NR 
Sitagliptin (5, 12,5, 25 
and 50mg;b.i.d.)d 
495 55.5 (9.3) 51.9 4.6 (4.6) 7.9 (1) NR 
12 Henry, 
2009 [154] 
 
16 
 
3 
 
Placebo 55 56.5 (8.9) 41.8 NR 8.1 (0.8) NR 
Pioglitazone 
(45mg;q.d.) 
57 54.4 (8.8) 42.1 NR 8 (0.8) NR 
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13 
 
Rosenblatt, 
2001 [155] 
 
16 
 
3 
 
Placebo 96 55.2 (10) 56.3 NR 10.4 (1.7) 87.2 (18.4) 
Pioglitazone 
(30mg;q.d.) 
101 53.8 (10) 50.5 NR 10.7 (1.8) 89.8 (18) 
14 Aronoff, 
2000 [156] 
 
26 
 
3 
 
Placebo 79 NR NR NR 10.4 (2) 90.4 (13.1) 
Pioglitazone (7,5, 15, 
30, 45mg;q.d.)d 
329 NR NR NR 10.2 (2) 91.4 (14.7) 
15 
 
Gonzalez, 
2008 [157] 
 
12 
 
1 
 
Placebo 54 57.2 (10.7) 63 NR 7.1 (0.7) 77.1 (11) 
Nateglinide 
(480mg;t.i.d.) 
55 59.9 (10.6) 56.4 NR 7.2 (0.6) 77.6 (11.5) 
16 
 
Derosa, 
2011 [158] 
 
28 
 
1 
 
Placebo 92 56.7 (7) 48.9 0.4 (0.1) 6.7 (0.5) 76.5 (8.2) 
Acarbose 
(150mg;t.i.d./ 
uptitration after 1 
month to 300mg;t.i.d.) 
96 56.7 (7) 49 0.4 (0.1) 6.8 (0.6) 75.1 (7.7) 
17 
 
Kawamori, 
2012 [159] 
 
12 
 
3 
 
Placebo 80 59.7 (8.9) 71.3 NR 8 (0.7) 65.3 (11.6) 
Linagliptin (5 and 
10mg;q.d.)d 
319 60.8 (9.7) 69.9 NR 8 (0.7) 65.4 (12.2) 
18 
 
Del Prato, 
2011 [160] 
 
24 
 
3 
 
Placebo 167 54.4 (10.3) 47.3 NR 8 (0.9) 79.2 (16) 
Linagliptin (5mg;q.d.) 336 56.4 (10.1) 48.8 NR 8 (0.9) 78.5 (16.7) 
19 
 
Kikuchi, 
2009 [161] 
 
12 
 
1 
 
Placebo 72 60.4 (8.1) 63.9 7.1 (5.5) 7.4 (0.8) 63.8 (10.1) 
Vildagliptin (10, 
25,50mg;b.i.d.)d 
219 58.5 (8.5) 68 4.6 (4.3) 7.4 (0.8) 63.5 (9.8) 
20 Mohan, 
2009 [162] 
 
18 2 
 
Placebo 178 50.9 (9.3) 59.6 1.9 (1.6) 8.8 (1.1) 66.6 (11.4) 
Sitagliptin 
(100mg;q.d.) 
352 50.9 (9.3) 56.8 2.1 (1.7) 8.7 (1) 66.8 (10.2) 
21 
 
Aschner, 
2006 [163] 
 
24 
 
2 
 
Placebo 253 54.3 (10.1) 51.4 4.6 (4.7) 8 (0.8) 85 (18.1) 
Sitagliptin (100 and 
200mg;q.d.)d 
488 54.2 (9.8) 51.8 4.3 (4.8) 8.1 (0.9) 84.3 (18.8) 
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22 
 
Rosen-
stock, 2008 
[164] 
 
12 
 
2 
 
Placebo 67 55.2 (9.8) 62.7 NR 8 (1) 93.1 (19.2) 
Saxagliptin (2.5, 5, 10, 
20 and 40mg;q.d.)d 
271 53.7 (9.7) 57.2 NR 7.9 (1) 89 (16.6) 
23 
 
Dejager, 
2007 [165] 
 
24 
 
2 
 
Placebo 94 52.2 (11.2) 47.9 1.6 (2.5) 8.4 (0.8) NR 
Vildagliptin (50 and 
100mg;q.d./ 
50mg;b.i.d.)d 
286 54 (11.1) 46.9 2.2 (3.7) 8.4 (0.8) NR 
24 Pi-Sunyer, 
2007 [166] 
 
24 
 
2 
 
Placebo 92 52 (12) 54.3 2.5 (3.7) 8.5 (0.8) 93 (23.2) 
Vildagliptin (50 and 
100mg;q.d./ 
50mg;b.i.d.)d 
262 51 (11) 55.3 2.1 (2.9) 8.4 (0.9) 90.4 (20.2) 
25 Barzilai, 
2011 [167] 
 
24 
 
2 
 
Placebo 104 72.1 (6) 47.1 7 (7.5) 7.8 (0.7) 85.8 (16.5) 
Sitagliptin  (50 or 
100mg;q.d./lower 
dose  for patients with 
creatinin clearance 
<50 mL/min) 
102 71.6 (6.1) 47.1 7.2 (7.3) 7.8 (0.8) 85.6 (16.6) 
26 
 
Iwamoto, 
2010 [168] 
 
12 
 
2 
 
Placebo 73 60.2 (8) 68.5 6.4 (5.5) 7.7 (0.9) NR 
Sitagliptin (25, 50, 
100 and 200mg;q.d.)d 
290 59.6 (8.6) 60 5.2 (5.3) 7.6 (0.8) NR 
27 
 
Nonaka, 
2008 [169] 
 
12 
 
2 
 
Placebo 76 55 (8) 65.8 4.1 (4.6) 7.7 (0.9) NR 
Sitagliptin 
(100mg;q.d.) 
76 55.6 (8.6) 59.2 4 (4.1) 7.5 (0.9) NR 
28 
 
Raz, 2006 
[170] 
 
18 
 
2 
 
Placebo 110 55.5 (10.1) 62.7 4.7 (5) 8.1 (0.9) 92.8 (18.8) 
Sitagliptin (100 and 
200mg;q.d.)d 
411 55 (9.6) 52.1 4.5 (4.1) 8.1 (0.9) 89.6 (19.2) 
29 
 
Ristic, 
2005 [171] 
 
12 2 
 
Placebo 58 54.6 (10.6) 56.9 2.3 (3) 7.8 (0.8) 92 (15.6) 
Vildagliptin (25, 50 
and 100mg;q.d./ 
25mg;b.i.d.)d 
221 56.5 (10.3) 53.8 3 (4.2) 7.7 (0.8) 90 (17.1) 
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30 
 
Scher-
baum, 
2008 [172] 
52 2 
 
Placebo 150 62.8 (11) 59.3 2.7 (3.2) 6.8 (0.4) 85 (1.4) 
Vildagliptin 
(50mg;q.d.) 
156 63.3 (10.2) 59.6 2.5 (2.9) 6.7 (0.4) 86 (1.2) 
31 
 
Scher-
baum, 
2008 [173] 
108 
(52/56) 
 
2 
 
Placebo 63 63.2 (10) 58.7 2.5 (2.6) 6.7 (0.4) NR 
Vildagliptin 
(50mg;q.d.) 
68 63.1 (9.6) 60.3 2.1 (2.1) 6.6 (0.4) NR 
32 
 
Defronzo, 
1995 [144] 
 
29 
 
3 
 
Metformin (titration: 
500mg;q.d./ 
maintenance:2,500mg;
five times a day 
210 55 (14.5) 45.7 8.4 (5.8) 8.9 (1.4) 92.6 (14.5) 
Glibenclamide (20mg; 
four times a day) 
209 56 (14.5) 49.3 8.7 (5.8) 8.5 (1.4) 92.6 (14.5) 
33 
 
Charpen-
tier, 2001 
[174] 
 
20 
 
3 
 
Metformin 
(2,550mg;t.i.d.) 
75 56.7 (NR) 60 7 (NR) 6.8 (1.2) 82.2 (NR) 
Glimepiride (1-6mg; 
q.d.) 
150 55.4 (NR) 58 5.3 (NR) 6.5 (1.1) 81 (NR) 
34 Tosi, 2003 
[175] 
 
23 
 
3 
 
Metformin (500-
3,000mg;nr) 
19 NR NR NR 7.7 (0.9) 73 (10.7) 
Glibenclamide (5-
15mg;nr) 
20 NR NR NR 7.9 (1) 71.7 (8.3) 
35 
 
Hermann, 
1994 [176] 
 
24 
 
2 
 
Metformin (1,000-
3,000mg;nr) 
38 NR NR NR 6.9 (1.3) 78.6 (12.6) 
Glibenclamide (3.5-
10.5mg;nr) 
34 NR NR NR 6.7 (1.3) 86.2 (14.4) 
36 
 
Goldstein, 
2003 [177] 
 
18 
 
3 
 
Metformin 
(500mg;q.d./uptitra- 
tion to 2,000mg;  
four times a day) 
76 56.6 (9.7) 61.8 7.3 (4.9) 8.7 (1.2) 93.8 (17) 
Glipizide 
(30mg;b.i.d.) 
84 57.4 (9.2) 64.3 6.5 (4.4) 8.9 (1.1) 89.9 (17.3) 
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37 
 
Russell-
Jones, 
2012 [178] 
 
 
26 
 
2 
 
 
Metformin (up to 
2,500mg; nr) 
246 54 (11) 62.6 2.6 (3.6) 8.6 (1.2) 85.9 (19.6) 
Pioglitazone (up to 
45mg;nr) 
163 55 (11) 59.5 2.7 (3.7) 8.5 (1.2) 86.1 (17.8) 
Sitagliptin 
(100mg;q.d.) 
163 52 (11) 57.7 2.7 (3.7) 8.5 (1.3) 88.7 (18.7) 
38 
 
Moses, 
1999 [179] 
 
20 
 
3 
 
Metformin (1,000-
3,000mg;nr) 
27 57.8 (9.5) 63 8 (6.2) 8.6 (1.1) NR 
Repaglinide (1.5-
12mg;t.i.d.) 
28 60.3 (7.7) 53.6 7 (5.2) 8.6 (1.3) NR 
39 
 
Lund, 2007 
[180] 
 
16 
 
3 
 
Metformin 
(500mg;q.d./ uptitra-
tion to2,000mg;b.i.d.) 
48 59.5 (9.3) 77.1 3 (NR) 8.1 (1.1) 74.5 (9.8) 
Repaglinide 
(1mg;q.d./ uptitration 
to 6mg;t.i.d.) 
48 63.3 (8.9) 75 5 (NR) 8.1 (1.1) 74.5 (9.8) 
40 
 
Bosi, 2009 
[181] 
 
24 
 
2 
 
Metformin 
(500mg;q.d./ uptitra-
tion to 2,000mg; four 
times a day) 
294 52.4 (10.7) 58.2 2.2 (3.3) 8.6 (0.9) 88.4 (17.4) 
Vildagliptin 
(100mg;b.i.d.) 
300 53.5 (11) 60 2.2 (3.3) 8.7 (1) 87.8 (17.4) 
41 
 
Aschner, 
2010 [182] 
 
24 
 
2 
 
Metformin 
(500mg;q.d./ 
uptitration to 
2,000mg;b.i.d.) 
522 55.7 (10.3) 37.2 2.1 (3.5) 7.2 (0.7) 84.6 (17.2) 
Sitagliptin 
(100mg;q.d.) 
528 56.3 (10.7) 41.1 2.6 (3.9) 7.2 (0.7) 84.9 (17.7) 
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42 
 
Schweizer, 
2009 [183] 
 
24 
 
2 
 
Metformin 
(500mg;q.d./ 
uptitration to 
1,500mg;t.i.d.) 
166 70.2 (5.1) 53 3 (4.7) 7.7 (0.6) NR 
Vildagliptin 
(100mg;q.d.) 
169 71.6 (5.2) 44.4 2.9 (4.2) 7.8 (0.6) NR 
43 
 
Jadzinsky, 
2009 [184] 
 
24 
 
2 
 
Metformin 
(500mg;q.d./uptitra-
tion to 2,000mg;four 
times a day) 
328 51.8 (10.7) 49.7 1.7 (3.1) 9.4 (1.3) 82.8 (17.5) 
Saxagliptin 
(10mg;q.d.) 
335 52.1 (10.2) 49.3 1.7 (2.8) 9.6 (1.3) 83.1 (16.9) 
44g 
 
Williams-
Herman, 
2009 [185] 
 
54 
(24/30) 
 
2 
 
Metformin (1,000 and 
2,000mg;b.i.d.)d 
259 54 (9.7) 46.3 4.1 (3.9) 8.6 (0.9) NR 
Sitagliptin 
(100mg;q.d.) 
106 53.5 (9.1) 51.9 3.9 (4.6) 8.7 (1) NR 
45g 
 
Williams-
Herman, 
2010 [186] 
 
104 
(24/30/
50) 
 
2 
 
Metformin (1,000 and 
2,000mg;b.i.d.)d 
153 55 (9.5) 45.1 3.9 (3.9) 8.5 (0.8) NR 
Sitagliptin 
(100mg;q.d.) 
52 54.1 (9.1) 57.7 3.7 (4.9) 8.5 (0.9) NR 
46 
 
Schweizer, 
2007 [187] 
 
52 
 
2 
 
Metformin 
(2,000m;b.i.d) 
254 53.6 (10.2) 57.5 1.03 (NR) 8.7 (1.1) 92.9 (1.2) 
Vildagliptin (100mg; 
q.d.) 
526 52.8 (11.7) 52.9 1.05 (NR) 8.7 (1.1) 91.4 (0.9) 
47 
 
Goke, 2008 
[188] 
 
104 
(52/52) 
 
2 
 
Metformin 
(2,000mg;b.i.d.) 
158 54 (11) NR 2.4 (3.4) 8.8 (0.1) 95.7 (1.6) 
Vildagliptin 
(100mg;q.d.) 
305 54 (11) NR 2.4 (3.4) 8.4 (0.1) 93.1 (1.3) 
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48 
 
Perriello, 
2006 [189] 
 
52 
 
3 
 
Gliclazide (160-
320mg;b.i.d./ mean 
dose: 184mg) 
137 59 (7) 64.2 8.5 (4.1) 8.7 (0.9) 78.8 (10.7) 
Pioglitazone (30-
45mg;q.d./ mean dose: 
40mg) 
146 58 (8) 66.4 9.8 (5.4) 8.8 (0.9) 81.1 (12) 
49 Jain, 2006 
[190] 
 
52 
 
2 
 
Glibenclamide (5-
15mg;nr/ range of 
means during 
maintenance phase 
(wk 16-52):9.9-
10.5mg) 
251 52.1 (12.4) 56.2 0.8 (1.3) 9.2 (1.3) 94.3 (20) 
Pioglitazone (15-
45mg;nr/ range of 
means during 
maintenance phase 
(wk 16-52):34.9-
37.6mg) 
251 52.1 (11.3) 53 0.8 (1.1) 9.2 (1.2) 93.9 (19.7) 
50 Tan, 2004 
[191] 
 
52 
 
3 Glibenclamide (1.75-
10.5mg;nr) 
109 57.9 (9.2) 73.4 5.2 (4.7) 8.5 (0.8) 89 (16) 
Pioglitazone (30-
45mg;q.d.) 
91 60 (8.5) 61.5 4.8 (4.7) 8.4 (0.7) 88.4 (17.5) 
51 
 
Tan, 2004 
[192] 
 
52 
 
3 
 
Glimepiride (2-
8mg;q.d./ mean dose: 
6mg) 
123 55.7 (9.3) 52.8 6.8 (6.9) 8.5 (0.9) 74.5 (10.8) 
Pioglitazone (15-
45mg;q.d./ mean dose: 
27mg) 
121 55.1 (8) 44.6 6.5 (6.6) 8.5 (1) 74.2 (10.5) 
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52 
 
Madsbad, 
2001 [193] 
 
58 
 
3 
 
Glipizide (5-15mg;nr/ 
uptitration) 
81 62 (8.8) 64.2 7 (4.9) 7.2 (1.4) 83.6 (14.5) 
Repaglinide (1.5-
12mg;t.i.d./ 
uptitration) 
175 60.2 (8.1) 61.1 8.1 (6) 7.3 (1.2) 82.9 (13.4) 
53 
 
Marbury, 
1999 [194] 
 
60 
 
3 
 
Glibenclamide (2.5-
15mg;nr) 
193 58.7 (9) 62.2 8.3 (6.8) 8.9 (1.6) NR 
Repaglinide (1.5-
12mg;t.i.d./uptitration) 
383 58.3 (9.4) 63.2 7.2 (6.2) 8.7 (1.7) NR 
54 
 
Wolffen-
büttel, 
1999 [195] 
 
60 
 
3 
 
Glibenclamide (175-
10.5mg;nr) 
139 61 (9) 68.3 6 (NR) 7 (1.2) 81.3 (12.2) 
Repaglinide (1.5-
12mg;t.i.d./uptitration) 
286 61 (9) 62.2 6 (NR) 7.1 (1.4) 81.5 (13.4) 
55 
 
NA [196] 
 
16 
 
1 
 
Gliclazide (80mg;q.d./ 
uptitration to 
160mg;b.i.d.) 
222 53.5 (9.9) 55.4 0.8 (1.8) 7.2 (NR) 68.4 (11.2) 
Repaglinide 
(1mg;b.i.d./ uptitration 
to 12mg;t.i.d.) 
218 54.1 (10) 50.5 1 (2) 7.2 (NR) 68.7 (11.6) 
56 
 
Feinböck, 
2003 [197] 
 
26 
 
3 
 
Glimepiride (1-
6mg;q.d.) 
111 57.7 (10.2) 59.5 3 (3.6) 9.1 (1.9) 85 (12.8) 
Acarbose (150-
600mg;t.i.d.) 
108 57.1 (10.7) 53.7 3.6 (4.8) 9.4 (2) 83 (12.5) 
57 
 
Salman, 
2001h [198] 
 
24 
 
1 
 
Gliclazide (80-
160mg;b.i.d./ 80% of 
patients got 80mg 
b.i.d. 
30 56.1 (8.7) 53.3 4.7 (5.6) 8.7 (0.6) NR 
Acarbose (50mg;q.d./ 
uptitration to 
300mg;t.i.d./ 96% of 
patients got 
300mg;t.i.d.) 
27 52.6 (9.1) 63 4.2 (3.4) 8.9 (0.7) NR 
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58 
 
Ferreira , 
2011 [199] 
 
54 
 
2 
 
Glipizide (2.5mg;q.d./ 
uptitration to 10mg; 
b.i.d.) 
212 64.2 (9.4) 57.5 NR 7.8 (0.7) NR 
Sitgaliptin (severe 
CRI: 25mg;q.d./ 
moderate CRI: 
50mg;q.d.) 
211 64.2 (10.7) 62.1 NR 7.8 (0.7) NR 
59 
 
Foley, 
2009 [200] 
 
104 
 
2 
 
Gliclazide (80-
320mg;nr/ mean dose 
at endpoint:209mg) 
546 54.3 (10.4) 52.7 1.9 (3.1) 8.7 (1.1) 84.3 (17.6) 
Vildagliptin 
(100mg;b.i.d.) 
546 55.2 (10.6) 58.8 2.4 (4.3) 8.6 (1) 84.2 (16.3) 
60 
 
Rosen-
stock, 2007 
[201] 
 
24 
 
2 
 
Pioglitazone 
(30mg;q.d.) 
161 52.4 (10.3) 64 2.2 (3.3) 8.7 (1) 81 (NR) 
Vildagliptin 
(100mg;q.d.) 
154 51.4 (10.8) 63.6 1.9 (3.1) 8.6 (1) 82 (NR) 
61 Pan, 2009 
[202] 
 
12 
 
3 
 
Nateglinide 
(480mg;t.i.d.) 
119 54.4 (9.4) 58.8 2.7 (3.7) 7.8 (1) 69.5 (10.2) 
Acarbose 
(100mg;q.d./ uptitra-
tion to 300mg;t.i.d.) 
118 55.1 (9) 66.9 2.6 (3.8) 7.7 (0.8) 71.2 (9.4) 
62 
 
Pan, 2008 
[203] 
 
24 
 
2 
 
Acarbose (uptitration 
to 300mg;t.i.d.) 
220 51.9 (10.3) 63.2 1.3 (2.4) 8.6 (1) 72 (NR) 
Vildagliptin 
(100mg;b.i.d.) 
441 51.8 (10.1) 60.1 1.2 (2.4) 8.6 (0.9) 72 (NR) 
References for included studies are only indexed once in Table 12a. 
a (core study/ plus extension). 
b Coding of previous therapy: 1: therapy naive; 2: no oral antidiabetic drug at least 8 weeks before randomization; 3: else. For study No. 37 and 43 the exclusion criteria   
  (patients were excluded if treated with any antihyperglycemic drug for > 7 days within 3 months of screening) come pretty close to category 2; thus they were included therein. 
c (dose/d; frequency). 
d Different doses of one drug were aggregated into one arm (see 3.1.3.4). 
e For the two sibling studies from study no. 6 trial and patients characteristics are only reported for the aggregated Placebo and Glipizide arms. 
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f Baseline characteristics are only reported for the patients who were valid for efficacy analysis (on study medication > 35d). 
g Study arms that were switched from placebo to Metformin in these extension studies were not included due to potential confounding of placebo given during core phase. 
hBaseline characteristics are only reported for the patients who completed the study. 
Y, year. Wk, week. D, day. Rand., randomized. SD, standard deviation. T2DM, diabetes mellitus type 2. Bl, baseline. HbA1c, glycated haemoglobin. KG, kilogram. NR, not 
reported. NA, not applicable. Q.d., once daily. B.i.d., twice daily. T.i.d., thrice daily. CRI, chronic renal insufficiency. 
 
Table 12b: Outcome data for HbA1c, body weight and hypoglycemia of included studies  
No. Author, 
y 
Included study 
arms 
HbA1c, % Body weight, kg Hypoglycemia 
n mc SDa n mc SDa r n Definitionb 
1 List, 2009 Placebo 54c -0.18 0.73 54c -1.07 2.61d 2 54 Not further specified; ae were summarized by 
preferred term (MedDRA, version 10). Metformin 56c -0.73 0.75 56c -1.5 2.46d 5 56 
2 Defronzo, 
1995 
Placebo 146c 0.4 1.21 146c -1.1 2.42 0 146 Symptoms compatible with hypoglycemia without 
biochemical documentation. Metformin 143c -1.4 1.2 143c -0.6 3.59 3 143 
3 Chiasson, 
2001 
Placebo 82 0.38 1.09 82 -0.69 2.45 7 83 Not further specified. 
Metformin 81 -0.85 1.08 81 -0.79 2.97 8 83 
Miglitol 80 0.02 0.89 80 -0.42 2.59 7 82 
4 Hoffmann, 
1997 
Placebo 32 0.4 1.16f 32 -0.2 2.36g 0 32 Not further specified. 
Metformin 31 -1 1.21f 31 -0.5 2.14g 0 32 
Acarbose 31 -1.1 1.37f 31 -0.8 2.51g 0 32 
5 Haak, 2012 Placebo 65 0.1 0.81 43 -0.7 2.62 1 72 Not further specified (Hypoglycemic event intensity 
was graded according to the investigator’s 
discretion). 
Metformine 279 -0.85 1.21 239 -0.6 3.27 7 291 
Linagliptin 135 -0.5 1.16 112 0.2 3.17 0 142 
6h Simonson, 
1997 
Placebo 68 0.87 1.5 68c -3.33 2.71 0i 69 Presence of symptoms of hypoglycemia 
alone, a blood glucose level < 3.3 mmol/l 
by home blood glucose monitoring regardless 
of the presence of symptoms or blood glucose 
< 4.4 mmol/l when tested in 
the clinic. 
Glipizidee 272 -0.8 1.49 272c -0.22 2.56 11i 278 
7 Bautista, 
2003 
Placebo 18 -0.7 1.42j 18 -2.1 3.9j 0 22 Hypoglycemic episodes (i.e., self-monitored fasting 
blood glucose < 2.8 mmol/l) recorded in patient 
diaries. 
Glimepiride 42 -2.3 1.42j 42 2.3 3.9j 0 48 
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8 Madsbad, 
2004 
Placebo 29 -0.12 0.65j 29 -0.16 1.83j 0 29 Symptomatic hypoglycemia; not further specified 
(for sensitivity analysis: minor hypoglycemia, 
defined as blood glucose < 2.8 mmol/l). 
Glimepiride 26 -0.86 0.65j 26 0.78 1.83j 5k 26 
9 Vray, 1995 Placebo 56 0.04 2.24 56 -0.66 2.25 0 56c Symptomatic hypoglycemia; not further specified. 
Glibenclamide 52 -1.6 2.16 52 0.81 2.16 9 52c 
10 Connif, 
1995 
Placebo 62 -0.05 1.18 62 -1.38 3.6 4 72 Probably symptomatic hypoglycemia („most 
reported episodes were not verified by plasma 
glucose determinations“). 
Tolbutamide 66 -1.04 0.97 66 2.19 3.44 11 71 
Acarbose 67 -0.6 1.31 67 -1.54 2.52 6 74 
11 Scott, 2007 Placebo 121 0.23 0.76 121l -0.4 2.14j 3 125 Hypoglycemia was assessed by study site 
investigators through reviewing daily glucose logs 
and patient self-report of signs and 
symptoms of hypoglycemia. 
Glipizide 119 -0.76 0.78 119l 0.9 2.23 21 123 
Sitagliptine 485 -0.38 0.79 485 -0.18 2.18j 12 492 
12 Henry, 
2009 
Placebo 54 0.35 0.96 54 -0.85 2.94 0 55 Data not reported, obtained from author upon 
request; not further specified. Pioglitazone 57 -0.35 0.98 57 1.06 3.02 1 57 
13 Rosenblatt, 
2001 
Placebo 93 0.76 1.64 93l -1.87 4.44m 0 55 Not further specified. 
Pioglitazone 100 -0.6 1.7 100l 1.35 3.31m 0 101 
14 Aronoff, 
2000 
Placebo 79 0.7 1.51 79 -1.3 3.2 0 79 Probable symptomatic hypoglycemia, not confirmed 
by blood glucose levels; all of the events were 
considered mild or moderate in intensity and none 
resulted in discontinuation. 
Pioglitazonee 320 -0.32 1.58 326 1.2 3.36 4 329 
15 Gonzalez, 
2008 
Placebo 54c 0.1 0.93j 54c -0.3 1.55j 0 54 Hypoglycemia was defined as a capillary glycemia < 
3.3 mmol/l with signs or 
symptoms of hypoglycemia. 
Nateglinide 55c -0.5 0.93j 55c -0.2 1.55j 0 55 
16 Derosa, 
2011 
Placebo 92c -0.3 1.45m 92c -5.1 24.63
m 
0 92 Not further specified. 
Acarbose 96c -1.1 3.17m 96c -5.9 29.12
m 
0 96 
17 Kawamori, 
2012 
Placebo 80 0.63 0.72 80 -0.39 1.43 0 80 Not further specified. 
Linagliptine 316 -0.25 0.75 316 -0.05 1.51 0 319 
18n Del Prato, 
2011 
Placebo 163 0.25 0.89 124 -0.29 2.12 1 167 Not further specified, events did not require third-
party assistance. Linagliptin 333 -0.44 0.91 288 0 2.21 1 336 
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19 Kikuchi, 
2009 
Placebo 71 0.28 0.57 71 -0.5 1.1 1 72 Grade 1 hypoglycemia: signs or symptoms 
suggestive of hypoglycemia that could be managed 
by the patient either with sucrose or in any other 
appropriate way. 
Vildagliptine 218 -0.71 0.6 218 0.17 1.42 5 219 
20 Mohan, 
2009 
Placebo 169 0.3 1.33 169l 0 2.6 0 178 Not further specified. 
Sitagliptin 339 -0.7 0.94 339l 0.6 1.84 0 352 
21 Aschner, 
2006 
Placebo 244 0.18 0.96 244l -1.1 3.12 2 253 Not further specified. 
Sitagliptine 467 -0.69 0.96 467l -0.15 3.05 5 488 
22 Rosen- 
stock, 2008 
Placebo 62 -0.27 0.87 54 -1.03 2.87 1 67 Symptoms of hypoglycemia (such as confusion 
and dizziness). Saxagliptine 254 -0.81 0.86 216 -0.48 2.47 17 271 
23 Dejager, 
2007 
Placebo 94 -0.3o 0.97 94 -1.4 3.88 0 157 Symptoms suggestive of low blood glucose con-
firmed by self-monitored blood glucose 
measurement <  3.1 mmol /l. 
Vildagliptine 286 -0.83 0.98 286 -1.01 3.95 3 468 
24 Pi-Sunyer, 
2007 
Placebo 88 0 0.94 88 -1.4 3.75 0 92 Confirmed hypoglycemia was defined as symptoms 
suggestive of low blood glucose confirmed by self-
monitored blood glucose (SMBG) measurement 
<3.1 mmol/L plasma glucose equivalent. Instances 
of SMBG measurement <3.1 mmol/L plasma 
glucose equivalent without accompanying symptoms 
were recorded as asymptomatic low blood glucose. 
Vildagliptine 252 -0.67 0.92 252 -0.27 3.35 0 260 
25 Barzilai, 
2011 
Placebo 91 0.2 1.22 91l -1.7 6.33 0 104 Not further specified. 
Sitagliptin 101 -0.5 1.28 101l -1.1 6.41 0 102 
26 Iwamoto, 
2010 
Placebo 73 0.28 0.52 73l -0.5 1.52 2 73 Symptomatic hypoglycemia not necessary 
confirmed by fingerstick blood glucose 
determination. 
Sitagliptine 290 -0.63 0.54 290l 0.28 1.37 10 290 
27 Nonaka, 
2008 
Placebo 75 0.41 0.66 76 -0.7 1.33 0 76 Not further specified. 
Sitagliptin 75 -0.65 0.66 75 -0.1 1.55 0 75 
28 Raz, 2006 Placebo 103 0.12 0.91 103l -0.7 3.11 0 110 Not further specified. 
Sitagliptine 392 -0.42 0.91 392l -0.4 3.05 5 411 
29 Ristic, 
2005 
Placebo 55 -0.13 0.74 55 -0.73 2.45 3 56 Symptomatic, asymptomatic (plasma glucose 
< 3.7 mmol/l ) and symptomatic confirmed 
hypoglycemia. 
Vildagliptine 217 -0.42 0.76 218 -0.13 2.38 14 220 
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30 Scher- 
baum, 2008 
Placebo 149 0.1 1.22 149 -0.2 3.66 1 150 Symptoms suggestive of low blood glucose 
confirmed by self-monitored blood glucose 
measurement < 3.1 mmol/l. 
Vildagliptin 153 -0.2 1.24 153 -0.5 3.71 0 156 
31 Scher- 
baum, 2008 
Placebo 61 0.5 0.78 61l -0.3 3.12 2 63 Symptoms suggestive of low blood glucose 
confirmed by self-monitored blood glucose 
measurement < 3.1 mmol/l. 
Vildagliptin 67 0.1 0.82 67l -1.1 4.09 0 68 
32 Defronzo, 
1995 
Metformin 210c -0.4 1.45 210c -3.8 2.9 4 210 Symptoms compatible with hypoglycemia without 
biochemical documentation. Glibenclamide 209c 0.2 1.45 209c -0.3 2.89 6 209 
33 Charpen- 
tier, 2001 
Metformin 75c 0.07 1.21 75c -0.74 2.58 8 75 Symptomatic hypoglycemia, including severe 
hypoglycemia (symptoms necessitating assis-tance 
from another person and loss of conscious-ness 
and/or medical intervention). 
Glimepiride 150c 0.27 1.1 150c 0.78 2.98 20 150 
34p Tosi, 
2003 
Metformin 19 -0.49 1.11 19 -1.48 1.75g 2 19 Symptomatic and severe hypoglycemia. 
Glibenclamide 20 -0.5 1.5 20 0.7 1.28g 2 20 
35 Hermann, 
1994 
Metformin 19 -0.9 0.87 19 -0.8 2.18 8 38 Interpreted by the investigator on the basis 
of clinical findings and any available 
blood glucose measurements. 
Glibenclamide 19 -1.3 0.87 19 2.8 3.05 12 34 
36 Goldstein, 
2003 
Metformin 71 -0.3 1.24g 75 -2.7 2.6 1 75 Symptoms of hypoglycemia were confirmed by a 
fingerstick blood glucose level < 2,8 mmol/l. Glipizide 79 -0.4 1.19g 83 -0.4 2.73 0 84 
37 Russell-Jones, 
2012 
Metformin 246c -1.48 1.1 246c -2 3.14 10 246 Symptoms of hypoglycemia, not confirmed by 
blood glucose measurement. Pioglitazone 163c -1.63 1.02 163c 1.5 3.83 6 163 
Sitagliptin 163 -1.15 1.02 163 -0.8 3.83 5 163 
38 Moses, 
1999 
Metformin 27 -0.33 1.25 27 -0.86 2.65 0 27 Symptomatic hypoglycemia; not further specified. 
Repaglinide 28 -0.38 1.22 28 2.98 2.59 3 29 
39 Lund, 
2007 
Metformin 83 -0.16 0.93 82 -0.88 2.67 23k 92 Mild hypoglycemic symptoms treated by the patient 
(for sensitivity analysis: biochemical hypoglycemia, 
defined as plasma glucose < 3.5 mmol/l). 
Repaglinide 82 -0.33 0.92 82 0.7 2.68 46k 89 
40 Bosi, 2009 Metformin 285 -1.4 1.01 285l -1.62 3.71 2 292 Symptoms suggestive of hypoglycemia and 
confirmed by self-monitored 
plasma glucose < 3.1 mmol/l. 
Vildagliptin 287 -1.1 1.02 287l -0.59 3.73 2 297 
41 Aschner, 
2010 
Metformin 498 -0.55 0.63 446 -1.9 2.65 17 522 Symptomatic hypoglycemia; not further specified. 
Sitagliptin 512 -0.38 0.64 458 -0.6 2.73 9 528 
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42 Schweizer, 
2009 
Metformin 166c -0.75 0.9 166c -1.25 2.45 2 165 Symptoms suggestive of hypoglycemia and 
confirmed by self-monitored plasma glucose < 3.1 
mmol/l. 
Vildagliptin 169c -0.64 0.91 169c -0.45 2.6 0 167 
43 Jadzinsky, 
2009 
Metformin 313 -2 1.47q 313l -1.6 3.18 13 328 Reported hypoglycemia was defined as events 
consistent with signs or symptoms of hypoglycemia 
with or without documented blood glucose levels  
< 2,8 mmol/l. 
Saxagliptin 317 -1.7 2.23q 317l -1.1 3.74 5 335 
44 Williams-
Herman, 
2009 
Metformine 251 -1.16 1.02 248 -1.27 3.98 4 364 Symptomatic hypoglycemia, documentation of a 
glucose determination at the time the patient had 
symptoms was not required. Events of hypo-
glycemia were defined as follows: those not 
requiring assistance or  those requiring the 
(nonmedical) assistance of others. 
Sitagliptin 106 -0.8 1.05 100 0.6 4.08 2 179 
45 Williams-
Herman, 
2010 
Metformin 151 -1.22 0.76 140 -1.73 4.24m 7 364 See study No. 1919. 
Sitagliptin 50 -1.2 0.9 50 0.5 4.22m 2 179 
46 Schweizer, 
2007 
Metformin 249 -1.4 1.58 249 -1.9 4.73 1 252 Symptoms suggestive of hypoglycemia and 
confirmed by self-monitored plasma glucose 
 < 3.1 mmol/l. 
Vildagliptin 511 -1 2.26 511 0.3 4.52 3 519 
47 Goke, 2008 Metformin 158 -1.5 1.26 158l -2.5 6.28 0 159 See study No. 2862. 
Vildagliptin 300 -1 1.73 300l 0.5 6.93 1 304 
48 Perriello, 
2006 
Gliclazide 135 -0.79 1.21g 135l 2 8.14m 2 137 Not specified. 
Pioglitazone 140 -0.79 1.3g 140l 2 8.3m 1 146 
49 Jain, 2006 Glibenclamide 251 -2.02 1.31j 251l 1.95 5.35 61 251 Hypoglycemic events were defined as follows: two 
or more simultaneous symptoms of hypoglycemia, 
one symptom before ingesting a glucose- or lactose- 
containing substance, a blood glucose level < 
3,3mmol/l (home monitoring) or < 3.9 mmol/l 
(clinical laboratory test). 
Pioglitazone 251 -2.07 1.31j 251l 3.66 6.14 11 251 
50 Tan, 2004 Glibenclamide 96 -0.4 1.23 108 1.1 4.16 32 109 Hypoglycemic episodes were defined by either 
signs or symptoms of hypoglycemia as reported by 
the patient, or blood glucose levels ≤ 2.8 mmol/ l, 
regardless of the presence of hypoglycemic signs or 
symptoms. 
Pioglitazone 83 -0.5 1.34 90 3 4.74 4 91 
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51 Tan, 2004 Glimepiride 99 -0.68 1.68 99l 0.79 3.87m 38 123 Hypoglycemic episodes were defined either 
subjectively (ie, in terms of reported signs or 
symptoms) or by a blood glucose level ≤ 2.8 
mmol/L, regardless of the presence of subjective 
symptoms. 
Pioglitazone 109 -0.78 1.69 109l 1.49 4.6m 19 121 
52 Madsbad, 
2001 
Glipizide 81 0.78 0.96 81 -0.9 3.93g 15 81 Minor hypoglycemic events, not further specified. 
Repaglinide 175 0.19 2.16 175 -0.7 3.64g 26 175 
53 Marbury, 
1999 
Glibenclamide 171 0.1 1.44 171l 0.05 4.09q 37 193 Mild-to-moderate hypoglycemic events were 
defined as symptoms of sweating, strong hunger, 
dizziness, tremors, and/or a blood glucose level 
< 3,9mmol/l. 
Repaglinide 338 0.08 1.29 338l -0.22 3.85q 59 383 
54 Wolffen-
büttel, 1999 
Glibenclamide 139 0.45 1.41 139l 0.7 3.28g 13 139 Not further specified, probably mild and mode-rate 
symptoms that could be treated/corrected by the 
patient without the assistance of other individuals. 
Repaglinide 286 0.58 1.51 286l 0 3.65g 26 286 
55 NA Gliclazide 202 -0.87 0.72 194 -0.51 2.99 68 219 Hypoglycemic episodes based on subjects self-
reports. Repaglinide 206 -0.86 0.73 196 -0.75 3.05 74 216 
56 Feinböck, 
2003 
Glimepiride 111c -2.5 2.2 111c -0.4 5.2 20 111 Mild-to-moderate hypoglycemic episodes, not 
further defined. Acarbose 108c -1.8 2.2 108c -1.9 3.9 2 108 
57 Salman, 2001 Gliclazide 30 -2.2 3.29m 30 0.4 2.83j 3 30 Mild-to-moderate hypoglycemic episodes, not 
further defined. Acarbose 27 -1.8 2.38m 27 -1.1 2.83j 0 27 
58n Ferreira, 2011 Glipizide 142 -0.62 0.91 148 1.2 3.65 36 212 Symptomatic hypoglycemia, not further specified. 
Sitgaliptin 135 -0.7 0.8 143 -0.6 3.59 13 210 
59n Foley, 
2009 
Gliclazide 545 -0.71 1.63 409 1.6 4.65 14 545 Grade 1 hypoglycemia: symptoms suggestive of 
hypoglycemia and confirmed by self-monitored 
plasma glucose < 3.1 mmol/l not requiring the 
assistance of another party. 
Vildagliptin 543 -0.51 1.63 409 0.75 4.85 4 545 
60 Rosen-stock, 
2007 
Pioglitazone 157 -1.4 1.25 157l 1.5 3.76 1 161 Symptoms suggestive of hypoglycemia and 
confirmed by self-monitored 
plasma glucose < 3.1 mmol/l. 
Vildagliptin 150 -1.1 1.22 150l 0.2 3.67 1 153 
61 Pan, 
2009 
Nateglinide 119 -0.9 0.98 119 -0.66 1.79 10 119 Not further specified. 
Acarbose 118 -0.83 0.81 118 -2.06 2 3 118 
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62 Pan, 
2008 
Acarbose 216 -1.3 1.47 216l -1.7 2.94 0 220 Hypoglycemia was defined as symptoms suggestive 
of low blood glucose confirmed by SMBG 
measurement < 3.1 mmol/l plasma glucose 
equivalent. 
Vildagliptin 431 -1.4 2.08 431l -0.4 2.08 0 440 
N denotes the numbers of patients analyzed for HbA1c and body weight, respectively; regarding hypogylcemia r indicates the number of patients experiencing at least one 
hypoglycemic episode and n indicates the number of patients at risk in the safety population. 
a For quantitative synthesis the standard error of the mean was extracted or calculated (see 3.1.3.4). 
b Unfortunately the reporting of hypoglycemic episodes - despite existing guidelines and recommendations of regulatory bodies (ADA working paper 2005, EMA) – lacks 
consistency and completeness and differs considerably between trials.  According to the working paper of  the ADA working group on hypoglycemia data was extracted for the 
following categories to account for differences in severity of hypoglycemic episodes: 1, severe hypoglycemia; 2, documented symptomatic hypoglycemia; 3, asymptomatic 
hypoglycemia; 4, probable symptomatic hypoglycemia; 5, relative hypoglycemia. Due to the scarcity of data within each category and the fact that the categories of clinical 
relevance (1 and 2) were rare in all trials (most trials reported zero event rates) the original approach to analyze this outcome for each category was abandoned. Therefore any 
hypoglycemia was taken as outcome and its trial specific definition (if available) was detailed to facilitate interpretability. 
c Sample size not reported. For analysis or necessary transformations requiring the sample size the number of randomized patients was taken as an approximation. 
d The standard deviation was derived from the corresponding confidence interval, unless other indicated a 0.95 % confidence interval (see 3.1.3.4). For sample sizes smaller than 
60 a t-distribution was used instead of standardized normal distribution. 
e Different doses of one drug were aggregated into one arm (see 3.1.3.4). 
f Measure of uncertainty for mean change from baseline not reported; since imputation by means of a correlation coefficient wasn´t possible and final values couldn´t be analyzed 
due to imbalanced baseline values the averaged standard deviation from similar studies with the same intervention, the same degree of measurement error and a similar time 
period was used instead. However, the appropriateness of this method is unclear, thus these studies were excluded from sensitivity analysis to account for the potential bias 
introduced by this approach. 
g Measure of uncertainty for mean change from baseline not reported; the standard deviation for each arm was imputed by using correlation coefficients from similar studies with 
the same intervention, the same degree of measurement error and a similar time period (see 3.1.3.4). For study No. 4 (5), 34 (2, 35), 36 (3, 33), 48 (49, 51), 52 (55) and 54 (55) a 
correlation coefficient was calculated from a similar set of studies consisting of the studies in brackets; most of the correlation coefficients were greater than 0.9 indicating a 
reasonable measure of the similarity of baseline and final measurements for imputation. 
h For the two sibling studies from study number 6, trial outcome data was aggregated into one single study. 
i The section of adverse events usually covers all kinds of events independent of withdrawals. Consequently the number of hypoglycemic events reported as adverse events should 
exceed the number of withdrawals due to hypoglycemic events. If this relationship is the other way around, categories may be reported separately or a data error occurred. For the 
core analysis the greater proportion is extracted (withdrawals) and this issue of ambiguous reporting will be subjected to sensitivity analysis (see Table 14). 
j Measure of uncertainty for mean change from baseline not reported; the average standard deviation for each arm was derived from the confidence interval, the exact p value or 
its threshold of the differences of means (see 3.1.3.4). For sample sizes smaller than 60 a t distribution was used instead of standardized normal distribution.   
k Hypoglycemias are separately reported for different categories of hypoglycemia; aggregation of events is inappropriate since it is unknown if single patients experienced events 
of both categories; to ensure a certain degree of comparability symptoms of hypoglycemia was chosen for the core analysis since this definition of hypoglycemia was most often 
used in the included studies; to account for the potential bias, the other reported category was explored in sensitivity analysis. 
l Sample size not reported. For analysis or necessary transformations requiring the sample size the number of patients from the intention-to-treat population was taken as an 
approximation. 
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A.4 Table 13 
 
Table 13: Further Trial and patients characteristics of included studies (arm level) 
No. Included study armsa T2DMb 
 
Dietc Other 
condi-
tionsd 
HbA1ce Body weighte Hypoglycemiae AE D AEf SAE D SAEf 
1 Placebo 7 3 4 All randomly 
assigned and 
treated patients 
All randomly 
assigned and 
treated patients 
All randomly 
assigned and 
treated patients 
29 1 0 NR 
Metformin 
(1500mg;q.d.) 
38 1 1 NR 
2 Placebo 8 1 4 ITT, LOCF ITT, LOCF ITT, as 
randomized 
NR NR NR NR 
Metformin (titration: 
500mg;q.d./mainte-
nance: 2,550mg;t.i.d.) 
NR NR NR NR 
3 Placebo 7 1 4 ITT, LOCF ITT, LOCF Safety set, 
received at least 
one trial dose 
71 2 NR NR 
Metformin 
(1,500mg;t.i.d.) 
78 5 NR NR 
Miglitol (0-4wk: 
25mg;q.d./ 3-12wk: 
50mg;t.id./ 12-36wk: 
100mg;t.i.d.) 
79 11 NR NR 
4 Placebo 7 1 4 ITT, presumably 
LOCF for drop 
outs with drug 
exposure of at 
least 18 weeks 
ITT, presumably 
LOCF for drop 
outs with drug 
exposure of at 
least 18 weeks 
Safety set; all 
randomized 
patients 
NR NR NR NR 
Metformin 
(1,700mg;b.i.d.) 
NR NR NR NR 
Acarbose (300mg;t.i.d) NR NR NR NR 
5 Placebo 7 3 4 ITT, FAS (>1 
drug &post bl 
meas);LOCF, 
rescue 
medication 
excluded 
FAS; observed 
cases (exclusion 
of rescue 
medication and 
drop outs) 
Treated set (> 
drug once) 
39 5 1 NR 
Metformin (500 and 
1,000mg;b.i.d.)g 
149 9 9 NR 
Linagliptin (5mg;q.d.) 80 6 3 NR 
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6 Placebo 7 1 4 Some imputation 
method ,since 
analyzed patients 
> rand.-drop outs 
Some imputation 
method ,since 
analyzed patients 
> rand.-drop outs 
Safety set, as 
randomized 
NR NR NR NR 
Glipizide (5, 10, 15, 20, 
40, 60mg;q.d.)g 
NR NR NR NR 
7 Placebo 1 1 4 ITT, imputation 
done method 
unclear 
ITT, imputation 
done method 
unclear 
Treated set (> 
drug once) 
13 NR 1 NR 
Glimepiride (level 1: 
1mg;q.d./level 2: 
2mg;q.d./ level 3: 
4mg;q.d.) 
27 NR 1 NR 
8 Placebo 7 3 4 ITT, imputation 
unclear 
ITT, imputation 
unclear 
ITT, imputation 
unclear 
16 0 NR NR 
Glimepiride (1-4mg; 
q.d./ mean received 
dose:2.7mg) 
9 0 NR NR 
9 Placebo 7 3 4 ITT, imputation 
method NR 
ITT, imputation 
method NR 
All patients, 
presumably 
safety set, equals 
at least ITT 
population 
NR NR NR NR 
Glibenclamide 
(7.5mg;t.i.d.) 
NR NR NR NR 
10 Placebo 7 1 4 ITT, LOCF ITT, LOCF Presumably all 
patients treated 
 
31 4 NR NR 
Tolbutamide 
(750mg;t.i.d./ forced 
titration until 
1,000mg;d) 
42 3 NR NR 
Acarbose (600mg;t.i.d.) 67 7 NR NR 
11 Placebo 7 1 4 ITT, LOCF NR Treated set (> 
drug once) 
67 0 4 0 
Glipizide (5mg;q.d.) 77 7 6 3 
Sitagliptin (5, 12.5, 25 
and 50mg;b.i.d.) g 
284 7 10 0 
12 Placebo 7 1 4 ITT, LOCF ITT, LOCF Treated set (> 
drug once) 
25 3 0 NR 
Pioglitazone 
(45mg;q.d.) 
30 2 1 NR 
13 Placebo 8 1 4 ITT, LOCF ITT, LOCF Treated set (> 
drug once) 
NR NR NR NR 
Pioglitazone 
(30mg;q.d.) 
NR NR NR NR 
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14 Placebo 7 1 4 ITT, LOCF ITT, LOCF Treated set (> 
drug once) 
60 2 NR NR 
Pioglitazone (7.5, 15, 
30, 45mg;q.d.) g 
280 13 NR NR 
15 Placebo 7 1 1 ITT, imputation 
method NR 
ITT ITT NR 1 NR NR 
Nateglinide 
(480mg;t.i.d.) 
NR 1 NR NR 
16 Placebo 8 1 4 ITT, imputation 
method NR 
ITT, imputation 
method NR 
ITT NR NR NR NR 
Acarbose (150mg;t.i.d./ 
uptitration after 1month 
to 300mg;t.i.d.) 
NR NR NR NR 
17 Placebo 7 3 4 ITT (FAS); 
LOCF 
ITT (FAS); 
LOCF 
Treated set, 
observed cases 
45 7 1 0 
Linagliptin (5 and 
10mg;q.d.) g 
174 7 5 2 
18 Placebo 7 3 4 FAS /ITT 
(LOCF) 
OC (exclusion of 
rescue medi-
cation, no 
imputation) 
Treated set (> 
drug once) 
98 4 7 NR 
Linagliptin (5mg;q.d.) 176 5 10 NR 
19 Placebo 7 1 4 ITT (FAS), 
imputation 
method NR 
ITT(FAS), 
imputation 
method NR 
Treated set (> 
drug once), as 
randomized 
53 1 2 1 
Vildagliptin (10, 
25,50mg;b.i.d.) g 
136 3 1 0 
20 Placebo 7 1 4 ITT, LOCF NR APAT 27 2 2 2 
Sitagliptin (100mg;q.d.) 82 5 6 3 
21 Placebo 8 1 4 ITT, LOCF NR Treated set (> 
drug once), as 
randomized 
167 4 9 3 
Sitagliptin (100 and 
200mg;q.d.) g 
317 9 24 6 
22 Placebo 7 3 4 m-ITT: at least 6 
weeks treatment 
+ post bl 
measurement, 
LOCF 
m-ITT: at least 6 
weeks treatment 
+ post bl 
measurement, 
LOCF 
Treated set (> 
drug once), as 
randomized 
53 1 1 NR 
Saxagliptin (2.5, 5, 10, 
20 and 40mg;q.d.) g 
215 5 3 NR 
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23 Placebo 7 1 4 Primary ITT, 
LOCF 
Primary ITT, 
LOCF 
Treated set (> 
drug once) 
108 NR 9 NR 
Vildagliptin (50 and 
100mg;q.d./ 
50mg;b.i.d.) g 
312 NR 23 NR 
24 Placebo 7 3 4 ITT, LOCF ITT, LOCF Treated set (> 
drug once) 
53 3 1 NR 
Vildagliptin (50 and 
100mg;q.d./ 
50mg;b.i.d.) g 
150 2 10 NR 
25 Placebo 7 3 4 ITT, LOCF ITT, LOCF Treated set (> 
drug once) 
55 3 14 NR 
Sitagliptin  (50 or 
100mg;q.d./lower dose  
for patients with 
creatinin clearance <50 
mL/min) 
47 5 7 NR 
26 Placebo 7 3 4 ITT, LOCF APAT with at 
least one drug 
exposure 
Treated set (> 
drug once), as 
randomized 
39 0 0 0 
Sitagliptin (25, 50, 100 
and 200mg;q.d.)g 
189 1 3 0 
27 Placebo 7 3 4 ITT, LOCF ITT, LOCF Treated set (> 
drug once) 
49 2 3 NR 
Sitagliptin (100mg;q.d.) 44 0 1 0 
28 Placebo 7 1 4 ITT, LOCF APAT, 
imputation 
method NR 
Treated set (> 
drug once), as 
randomized 
57 4 3 0 
Sitagliptin (100 and 
200mg;q.d.)g 
194 5 12 3 
29 Placebo 7 1 4 ITT, LOCF ITT, LOCF ITT, treated set 33 3 3 NR 
Vildagliptin (25, 50 and 
100mg;q.d./ 
25mg;b.i.d.)g 
126 11 2 NR 
30 Placebo 7 1 4 ITT, LOCF ITT, LOCF Treated set, as 
randomized 
109 6 13 NR 
Vildagliptin 
(50mg;q.d.) 
114 14 13 NR 
31 Placebo 7 3 4 ITT, LOCF NR Treated set (> 
drug once), as 
randomized 
56 4 12 NR 
Vildagliptin 
(50mg;q.d.) 
57 4 14 NR 
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32 Metformin (titration: 
500mg;q.d./ 
maintenance:2,500mg; 
five times a day) 
8 1 4 ITT, LOCF ITT, LOCF ITT NR NR NR NR 
Glibenclamide 
(20mg;four times a 
day) 
NR NR NR NR 
33 Metformin 
(2,550mg;t.i.d.) 
7 1 4 ITT, imputation 
by taking into 
account FBG 
ITT, imputation 
by taking into 
account FBG 
Treated set (> 
drug once) 
NR NR NR NR 
Glimepiride (1-6mg; 
q.d.) 
NR NR NR NR 
34 Metformin (500-
3,000mg;nr) 
7 1 4 ITT, imputation 
method NR 
ITT, imputation 
method NR 
ITT, imputation 
method NR 
NR NR NR NR 
Glibenclamide (5-
15mg;nr) 
NR NR NR NR 
35 Metformin (1,000-
3,000mg;nr) 
4 1 4 OC, visit-wise OC, visit-wise Safety set, as 
rand. 
32 NR NR NR 
Glibenclamide (3.5-
10.5mg;nr) 
26 NR NR NR 
36 Metformin 
(500mg;q.d./ uptitration 
to 2,000mg; four times 
a day) 
7 3 4 ITT, LOCF ITT, LOCF Safety set 55 4 NR NR 
Glipizide (30mg;b.i.d.) 57 3 NR NR 
37 Metformin (up to 
2,500mg; nr) 
7 1 4 m-ITT, LOCF m-ITT, 
imputation 
method NR 
Safety set, as 
rand. 
NR 6 13 NR 
Pioglitazone (up to 
45mg;nr) 
NR 5 9 NR 
Sitagliptin (100mg;q.d.) NR 1 3 NR 
38 Metformin (1,000-
3,000mg;nr) 
7 3 4 ITT, imputation 
method NR 
ITT, imputation 
method NR 
Safety set, as 
rand. 
NR NR NR NR 
Repaglinide (1.5-
12mg;t.i.d.) 
NR NR NR NR 
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39 Metformin 
(500mg;q.d./ uptitration 
to2,000mg;b.i.d.) 
7 3 4 ITT, imputation 
method NR; all 
patients who 
completed at 
least one period 
ITT, imputation 
method NR; all 
patients who 
completed at 
least one period 
safety set; at least 
drug > once 
NR NR NR NR 
Repaglinide (1mg;q.d./ 
uptitration to 6mg;t.i.d.) 
NR NR NR NR 
40 Metformin 
(500mg;q.d./ uptitration 
to 2,000mg;  
four times a day) 
7 3 4 ITT, LOCF NR, only for 
primary outcome 
Safety set; at 
least drug > once 
175 14 12 2 
Vildagliptin 
(100mg;b.i.d.) 
153 9 4 4 
41 Metformin 
(500mg;q.d./ uptitration 
to 2,000mg;b.i.d.) 
7 1 4 ITT (FAS), 
LOCF 
APAT with at 
least one post bl 
measurement, 
(LOCF) 
Safety set; at 
least drug > once 
(APAT) 
215 19 8 3 
Sitagliptin (100mg;q.d.) 198 9 10 3 
42 Metformin 
(500mg;q.d./ uptitration 
to 1,500mg;t.i.d.) 
7 3 4 ITT, LOCF ITT, LOCF Safety set: drug 
exposure and at 
least one post bl 
safety 
measurement 
83 13 6 NR 
Vildagliptin 
(100mg;q.d.) 
74 7 5 NR 
43 Metformin (500mg;q.d. 
/uptitration to 2,000mg; 
four times a day) 
7 1 4 ITT, LOCF NR Safety set; at 
least drug > once 
192 11 8 1 
Saxagliptin (10mg;q.d.) 179 8 6 0 
44 Metformin (1,000 and 
2,000mg;b.i.d.)g 
7 1 4 ITT, LOCF: 
continous APT 
(bl measurement; 
no rescue 
medication in 
phase A, at least 
one dose and 
postbl. measure-
ment  in 
extension study 
ITT, LOCF: 
continous APT 
(bl measurement; 
no rescue 
medication in 
phase A, at least 
one dose and 
postbl. measure-
ment  in 
extension study 
APT over 54 
weeks, as rand. 
243 13 9 5 
Sitagliptin (100mg;q.d.) 105 5 12 4 
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45 Metformin (1,000 and 
2,000mg;b.i.d.)g 
7 1 4 ITT, LOCF: 
continous APT 
(bl measurement; 
no rescue 
medication in 
phase A, at least 
one dose and 
postbl. measure-
ment  in 
extension study 
ITT, LOCF: 
continous APT 
(bl measurement; 
no rescue 
medication in 
phase A, at least 
one dose and 
postbl. measure-
ment  in 
extension study 
APT over 
104weeks, as 
rand. 
252 25 16 6 
Sitagliptin (100mg;q.d.) 108 14 13 4 
46 Metformin 
(2,000m;b.i.d) 
7 3 4 ITT, LOCF ITT, LOCF APAT (at least 
one dose of drug) 
209 25 22 NR 
Vildagliptin (100mg; 
q.d.) 
205 14 23 NR 
47 Metformin 
(2,000mg;b.i.d.) 
7 3 4 ITT, LOCF: 
continous APT 
(bl measurement; 
no rescue 
medication in 
phase A, at least 
one dose and 
postbl. measure-
ment  in 
extension study 
ITT, LOCF: 
continous APT 
(bl measurement; 
no rescue 
medication in 
phase A, at least 
one dose and 
postbl. measure-
ment  in 
extension study 
APAT over 104 
weeks, only from 
patients included 
in extension 
study (one dose 
of extension 
study drug and 
one post week 52 
safety 
assessment) 
138 3 11 NR 
Vildagliptin 
(100mg;q.d.) 
250 5 27 NR 
48 Gliclazide (160-
320mg;b.i.d./ mean 
dose: 184mg) 
7 3 4 ITT, LOCF NR Safety set, as 
rand. 
31 11 NR NR 
Pioglitazone (30-45mg; 
q.d./ mean dose: 40mg) 
40 7 NR NR 
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49 Glibenclamide (5-
15mg;nr/ range of 
means during 
maintenance phase (wk 
16-52):9.9-10.5mg) 
7 3 4 ITT, LOCF, as 
rand. 
NR Safety set, as 
rand. 
209 25 22 NR 
Pioglitazone (15-45mg; 
nr/ range of means 
during maintenance 
phase (wk 16-52):34.9-
37.6mg) 
205 14 23 NR 
50 Glibenclamide (1.75-
10.5mg;nr) 
7 1 4 ITT, LOCF Safety set, as 
rand., LOCF 
Safety set, as 
rand. 
91 10 8 NR 
Pioglitazone (30-
45mg;q.d.) 
70 6 7 NR 
51 Glimepiride (2-
8mg;q.d./ mean dose: 
6mg) 
7 1 4 ITT, LOCF NR Safety set, as 
rand. 
95 3 5 NR 
Pioglitazone (15-45mg; 
q.d./ mean dose: 27mg) 
105 5 8 NR 
52 Glipizide (5-15mg;nr/ 
uptitration) 
7 3 4 ITT, imputation 
method NR 
NR NR NR 16 NR NR 
Repaglinide (1.5-
12mg;t.i.d./ uptitration) 
NR 25 NR NR 
53 Glibenclamide (2.5-
15mg;nr) 
5 3 4 ITT, LOCF NR Safety set; at 
least drug > once 
NR NR 12 NR 
Repaglinide (1.5-
12mg;t.i.d./ uptitration) 
NR NR 39 NR 
54 Glibenclamide (1.75-
10,5mg;nr) 
4 3 4 ITT, LOCF NR Safety set equals 
ITT population 
NR NR NR NR 
Repaglinide (1.5-
12mg;t.i.d./ uptitration) 
NR NR NR NR 
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55 Gliclazide (80mg;q.d./ 
uptitration to 
160mg;b.i.d.) 
7 3 4 ITT, LOCF FAS, analysis of 
completers 
Safety set, at 
least one trial 
dose 
38 1 0 NR 
Repaglinide (1mg; 
b.i.d./ uptitration to 
12mg;t.i.d.) 
49 3 3 NR 
56 Glimepiride (1-6mg; 
q.d.) 
7 3 4 NR NR Safety set, as 
rand. 
58 1 NR NR 
Acarbose (150-
600mg;t.i.d.) 
88 5 NR NR 
57 Gliclazide (80-
160mg;b.i.d./ 80% of 
patients got 80mg b.i.d. 
7 1 4 OC, analysis of 
completers 
OC, analysis of 
completers 
Safety set, only 
analysis of 
completers 
NR NR NR NR 
Acarbose (50mg;q.d./ 
uptitration to 300mg; 
t.i.d./ 96% of patients 
got 300mg;t.i.d.) 
NR NR NR NR 
58 Glipizide (2.5mg;q.d./ 
uptitration to 
10mg;b.i.d.) 
7 3 3 PP As treated 
(without rescue 
medication) 
APAT; all 
randomized 
participants who 
took at least one 
dose of study 
therapy 
NR 18 38 NR 
Sitgaliptin (severe CRI: 
25mg;q.d./ moderate 
CRI: 50mg;q.d.) 
NR 16 36 NR 
59 Gliclazide (80-320mg; 
nr/ mean dose at 
endpoint:209mg) 
7 3 4 ITT, LOCF PP, LOCF Safety set; at 
least drug > once 
398 45 66 NR 
Vildagliptin 
(100mg;b.i.d.) 
379 38 80 NR 
60 Pioglitazone 
(30mg;q.d.) 
7 3 4 ITT, LOCF NR Safety set; at 
least drug > once 
83 9 NR NR 
Vildagliptin 
(100mg;q.d.) 
78 4 NR NR 
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61 Nateglinide 
(480mg;t.i.d.) 
7 3 4 ITT, imputation 
method NR 
ITT, imputation 
method NR 
Safety set, as 
rand. 
62 NR 1 1 
Acarbose (100mg;q.d./ 
uptitration to 
300mg;t.i.d.) 
63 NR 1 1 
62 Acarbose (uptitration to 
300mg;t.i.d.) 
7 3 4 ITT, LOCF NR Safety set; at 
least drug > once 
113 7 2 NR 
Vildagliptin 
(100mg;b.i.d.) 
154 11 7 NR 
The NCT number was not extracted.  
a (dose/d;frequency). 
b Diagnostic criteria for T2DM were coded as follows: 1: ADA 1997; 2: ADA 1999; 3: WHO 1980; 4: WHO 1985; 5: WHO 1998; 6: Else (state definition); 7: NR. 
c Diet was coded as follows: 1: Yes; 2: No; 3: NR. 
d Comorbidities were coded as follows: 1: Hypertension; 2: End stage renal disease; 3: Chronic renal insufficiency; 4: Else (state other conditions). 
e Efficacy- and safety populations in which the corresponding outcome was assessed; if reported the imputation method is stated. 
f Patients who were discontinued due to AE or SAE, respectively. 
g Different doses of one drug were aggregated into one arm (see 3.1.3.4). 
T2DM, diabetes mellitus type 2. NR, not reported. (S)AE,  (severe) adverse events. ITT, intention to treat-analysis. LOCF, last observation carried forward. . Q.D., once daily. 
B.I.D., twice daily. T.I.D., thrice daily. FAS, full-analysis set. Bl, baseline. Rand., randomized. OC, observed cases. AP(A)T, all patients as treated. FBG, fasting blood glucose. 
PP, per protocol-analysis. 
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A.5 Table 14 
Table 14a: Risk of bias assessment at study and outcome level 
No. Sequence 
generationa 
Allocation of 
concealmenta 
Selective 
reportinga 
Other biasa Blinding of Incomplete 
outcome datab 
Exclusion  
for sensitivity 
analysisc 
participants and 
personnelb 
outcome assessmentb HbA1c
& 
bw 
Hypogly-
cemia 
 
HbA1c& 
bw 
Hypogly- 
cemia 
HbA1c& 
bw 
Hypogly-
cemia 
1 U U L H(HbA1c) L U L U U L 1 
2 U U L L L U L U U U  
3 U U L H (bw) L U L U U U 4 
4 U U L H(HbA1c) L U L U U U 1 
5 U U L L L U L U U U  
6 U U L H(HbA1c/ 
bw/hypo-
glycemia) 
L U L U U L 1,2,4 
7 U U L H (bw) L U L U U U 4 
8 U U L H(HbA1c/ 
Hypo-
glycemia) 
L H L H U U 1,2 
9 U U U H (HbA1c) L U L U U U 1 
10 U U L L L U L U U U  
11 L U L L L U L U U U  
12 U L L L L H L H U U 2 
13 U U L H (bw) L U L U U U 4 
14 U U L U L U L U U U  
15 U L U U L U L U L L  
16 L L U H (bw) L U L U U U 4 
17 U U L L L U L U U U  
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18 L U L H (hypo-
glycemia) 
L U L U H (bw) L 2,4 
19 U U L L L U L U U L  
20 L U L L L U L U U U  
21 U U L H (hypo-
glycemia) 
L U L U U U 2 
22 U U L L L U L U U U  
23 U U L L L U L U U U  
24 U U L L L U L U U U  
25 L U L U L U L U U U  
26 U L L U L U L U L L  
27 L U L L L U L U U U  
28 U U L U L U L U U U  
29 U U U H (HbA1c) L U L U U U 1 
30 U U L H (HbA1c) L U L U U U 1 
31 U U L H (HbA1c) L U L U U U 1 
32 U U L H(HbA1c/bw) L U L U U U 1,4 
33 U L L U L U L U U U  
34 U U U H (bw) L U L U U U 4 
35 L U U L L U L U H U 1,4 
36 U L L H (bw) L U L U U U 4 
37 L U L L L U L U U U  
38 U U L H(HbA1c/bw) L U L U U U 1 
39 L L U H (hypo- 
glycemia) 
L U L U U U 2 
40 U U L U L U L U U U  
41 L U U U L U L U U U  
42 U U L L L U L U U U  
43 U L L U L U L U U U  
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44 L U U H (hypo- 
glycemia) 
L U L U U U 2 
45 L U L H (hypo- 
glycemia) 
L U L U U U 2 
46 U U L U L U L U U L  
47 U U L U L U L U U U  
48 U U L H L U L U U U 3 
49 U U U U L U L U U U  
50 U U U L L U L U U U  
51 L L U L L U L U U U  
52 U U L H(HbA1c/bw) L U L U U U 1,4 
53 U U U U L U L U U U  
54 U U L U L U L U U U  
55 U U L L L H L H U U 2 
56 U U L H(HbA1c/bw) L H L H U U 3 
57 U U L L L H L H H U 3 
58d NA NA NA H NA NA NA NA NA NA 3 
59 U U L L L U L U H (bw) U 4 
60 U U L U L U L U U U  
61d NA NA NA H NA NA NA NA NA NA 3 
62 U U L U L U L U U U  
The overall risk of bias for an outcome within a study will be deemed high in the presence of high bias in any domain, low if all key domains (all domains except random 
sequence generation and allocation concealment) will be of  low bias, and unclear in all other cases.  
a Study specific assessment. 
b Outcome specific assessment; HbA1c and body weight were assessed together since both represent measured outcomes and are in the same manner susceptible to the      
   specific bias domains. If this assumption doesn´t hold for certain studies, the degree of bias for each outcome is separately evaluated. 
c Entire Studies or outcomes at high risk for bias will be excluded from sensitivity analysis to test the robustness of results as follows: 1=HbA1c; 2=Hypoglycemia; 3=whole   
  study; 4=body weight; in case of studies reporting different categories of hypoglycemia (study No. 8 and 39)  the outcome data from the other category was used   
  in sensitivity analysis. 
d Reports were deemed to be at high risk for bias since they were only available as abstract (study No. 58) or in Chinese language (study No. 61). 
H, high (bold letter). L, low. U, unclear. Bw, body weight. NA, not applicable. 
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Table 14b: Support for judgment of rating the risk of bias 
No. Sequence 
Generation 
Allocation of 
concealment 
Selective 
Reporting 
Other bias Incomplete outcome data 
HbA1c&bw Hypoglycemia 
Quote/ comment Quote/ comment Comment Comment Comment Comment 
1 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
- Metformin dose low 
(1,500mg/d) 
- Adjustment for bl 
value bw nr, balanced. 
Numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; ITT 
analysis (all rand. patients); 
appropriateness of LOCF 
imputation method unclear. 
 
Numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; reasons 
for missing data unlikely to be 
informative; all rand. Patients. 
2 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
LTFU substantial~25%; numbers of 
dropouts balanced, reasons not; 
relation between missing data and 
true outcome (informativeness) 
unclear; ITT analysis (all rand. 
patients); appropriateness of LOCF 
imputation method unclear. 
  
LTFU substantial~25%; numbers 
of dropouts balanced, reasons not, 
informativeness unclear; no safety 
population defined; all rand. 
patients. 
3 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value bw nr, 
imbalanced. 
Dropouts not reported, insufficient 
information for judgement; ITT 
analysis; appropriateness of LOCF 
imputation method unclear. 
 
Dropouts not reported, insufficient 
information for judgement; all 
rand. patients. 
 
4 „..by elecronic 
data“. Unsuffi-
cient information 
for judgement 
NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value bw nr, balanced; 
sd for mean change 
from bl for HbA1c nr; 
average sd was taken 
from a set of similar 
studies. 
Dropouts not reported, insufficient 
information for judgement; (m)-
ITT analysis (only patients with 
post-bl value at 18 weeks were 
included); appropriateness of 
LOCF imputation method unclear. 
 
Dropouts not reported, insufficient 
information for judgement; all 
rand. patients. 
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5 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
Numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; ITT: FAS 
set (received drug at least once and 
had bl plus at least one post-bl 
measurement) for HbA1c; 
appropriateness of LOCF 
imputation method unclear; OC 
analysis for body weight, 
informativeness unlikely. 
Numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; treated 
set: all patients who received at 
least one dose of drug. 
6 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value HbA1c & bw nr, 
imbalanced; 
Hypoglycemic events 
reported as 
withdrawals and ae; 
numbers were 
extracted from 
withdrawals;ne-
vertheless potential 
under-estimation of 
events could bias the 
results. 
Numbers and reasons of dropouts 
imbalanced, informativeness 
unclear; ITT analysis; imputation 
method applied but nr. 
Numbers and reasons of dropouts 
imbalanced, informativeness 
unlikely; patients were 
discontinued for hypoglycemia; 
bias unlikely since outcome 
measure wasn´t count data of 
episodes; all rand. patients. 
7 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Unusually high weight 
loss under placebo 
maybe due to different 
adherence to 
diet/exercise. 
LTFU substantial~20%; numbers of 
dropouts imbalanced, reasons nr; 
ITT analysis (received drug at least 
once and had bl plus at least one 
post-bl measurement); imputation 
for missing data probably done, but 
method is nr. 
LTFU substantial~20%; numbers 
of dropouts imbalanced, reasons 
nr; all rand. patients with drug 
exposure and postrand. 
assessment. 
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8 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Glimepiride dose low 
(mean dose:2.7mg/d); 
hypoglycemias are 
reported in two 
categories; since 
aggregation is me-
thodologically 
inappropriate, 
symptomatic 
hypoglycemia was 
taken for core 
analysis. 
Reasons and numbers of dropouts 
imbalanced, informativeness 
unclear; ITT analysis (received 
drug at least once); no information 
of imputation of missing data. 
Reasons and numbers of dropouts 
imbalanced, informativeness 
unclear; ITT analysis (received 
drug at least once). 
9 NR NR No 
prespecified 
endpoints, 
but 
mentioned 
outcomes of 
data 
collection 
reported. 
Adjustment for bl 
value HbA1c nr, 
imbalanced. 
Reasons and numbers of dropouts 
imbalanced; informativeness 
unclear; ITT (endpoint analysis, 
comparing latest value with bl 
value) analysis; appropriateness of 
LOCF imputation method unclear. 
Reasons and numbers of dropouts 
imbalanced; informativeness 
unclear; no safety population 
reported; all rand. patients were 
taken as approximation. 
10 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
Reasons for exclusion reasonable; 
dropouts not fully reported; 
unbalanced, no reasons; 
informativeness unclear; m-ITT 
(only patients who were at least 35 
days on drug and had a post-bl 
measurement); appropriateness of 
LOCF imputation method unclear. 
Reasons for exclusion reasonable; 
dropouts not fully reported; 
unbalanced, no reasons; 
informativeness unclear; safety 
population not defined 
(presumably patients with drug 
exposure). 
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11 „..computer-
generated random 
allocation 
schedule“. 
Probably done 
adequately 
NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
Reasons and numbers of dropouts 
imbalanced for AE and treatment 
failure: informative-ness unclear; 
ITT analysis (received drug at least 
once and had bl plus at least one 
post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Reasons and numbers of dropouts 
imbalanced for AE and treatment 
failure: informativeness unclear; 
safety population: patients 
received drug at least once. 
12 NR „..via a central 
telephone - 
interactive voice-
response system“. 
Probably done 
adequately. 
Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other bias Reasons and numbers of dropouts 
reported, imbalanced for treatment 
failure: informativeness unclear; 
ITT analysis (received drug at least 
once and had bl plus at least one 
post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Reasons and numbers of dropouts 
reported, imbalanced for treatment 
failure: informativeness unclear; 
safety population: patients 
received drug at least once. 
13 „..in accordance 
with a 
randomization 
schedule“. 
Probably done 
Adequately. 
NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value bw nr, 
imbalanced. 
LTFU substantial~27%; dropouts 
only partly reported, imbalanced 
for therapy failure: informativeness 
unclear; ITT analysis (received 
drug at least once and had bl plus at 
least one post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
LTFU substantial~27%; dropouts 
only partly reported, imbalanced 
for therapy failure: 
informativeness unclear; safety 
population: patients received drug 
at least once. 
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14 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Safety population not 
defined, rand. patients 
were taken as 
approximation. 
LTFU substantial~67% placebo 
group and 42-56% in active control 
group; dropouts partly reported, 
imbalanced for treatment failure 
and ae: informativeness unclear; ; 
ITT analysis (received drug at least 
once and had bl plus at least one 
post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
LTFU substantial~67% placebo 
group and 42-56% in active 
control group; dropouts partly 
reported, imbalanced for treatment 
failure and ae: informativeness 
unclear; safety population: 
patients received drug at least 
once. 
15 NR „..central pharmacy“. 
Probably done 
adequately. 
Adverse 
events as 2nd 
endpoint 
defined but 
not fully 
reported. 
Safety population not 
defined, rand. patients 
were taken as 
approximation. 
Numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; ITT 
analysis, imputation method nr. 
Numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; ITT 
analysis. 
16 „..Randomisation 
was done using a 
drawing of 
envelopes 
containing 
randomisation 
codes prepared by 
a statistician“. 
Probably done 
Adequately. 
„..A copy of the code 
was provided only to 
the responsible 
person performing 
the statistical 
analysis. The code 
was only broken 
after the database 
lock“. Probably done 
adequately. 
No 
prespecified 
endpoints, 
but 
mentioned 
outcomes of 
data 
collection 
reported. 
Adjustment for bl 
value bw nr, 
imbalanced; weight 
loss in both groups 
extremely high maybe 
due to intensive diet/ 
exercise throughout 
the study. 
Numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; ITT 
analysis (received drug at least 
once and had bl plus at least one 
post-bl measurement); imputation 
method nr. 
Numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; safety 
population: patients received drug 
at least once and had undergone a 
subsequent tolerability 
observation. 
17 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
Numbers and reasons of dropouts 
reported, imbalanced  for ae, 
informativeness unclear; 
ITT analysis (FAS set, received 
drug at least once and had bl plus at 
least one post-bl measurement); 
imputation method nr. 
Numbers and reasons of dropouts 
reported, imbalanced  for ae, 
informativeness unclear; treated 
set: patients received drug at least 
once. 
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18 „..computer-
generated sequence 
supplied by 
interactive voice or 
web response 
systems“. Probably 
done 
adequately. 
NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
One hypoglycemic 
event in Placebo arm 
under rescue 
medication; potential 
confounder. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
lack of efficacy, informativeness 
unlear; ITT analysis (FAS set, 
received drug at least once and had 
bl plus at least one post-bl 
measurement) for HbA1c; 
appropriateness of LOCF 
imputation method unclear; OC 
analysis for body weight with 
substantial departure from the 
intervention received from that 
assigned at randomization. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
lack of efficacy, unlikely to be 
informative; treated set: patients 
received drug at least once. 
19 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
Numbers of dropouts reported, 
balanced, reasons not, 
informativeness unclear; ITT 
analysis (FAS set, received drug at 
least once and had bl plus at least 
one post-bl measurement); 
imputation method nr. 
Numbers of dropouts reported, 
balanced, reasons not, 
informativeness unclear; safety 
population: rand. patients, not 
further defined 
20 „..following a 
computer-
generated 
schedule“. 
Probably done 
Adequately. 
NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
Numbers and reasons of dropouts 
reported, imbalanced for 
therapeutic failure and withdrawal 
of consent, informativeness 
unclear; ITT analysis (FAS set, 
received drug at least once and had 
bl plus at least one post-bl 
measurement); appropriateness of 
LOCF imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for 
therapeutic failure and withdrawal 
of consent, informativeness 
unclear; all patients as treated set: 
patients received drug at least 
once. 
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21 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
One hypoglycemic 
event in Sitagliptin 
arm under rescue 
medication; potential 
confounder. 
Numbers and reasons of dropouts 
reported, imbalanced for 
therapeutic failure, informativeness 
unclear; ITT analysis (all patients 
treated set, received drug at least 
once and had bl plus at least one 
post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for 
therapeutic failure, 
informativeness unclear; safety 
population: patients received drug 
at least once. 
22 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
LTFU substantial~20%;numbers 
and reasons of dropouts balanced 
between groups, informativeness 
unclear; m-ITT analysis (received 
drug at least 6 wks and had bl plus 
at least one post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
LTFU substantial~20%;numbers 
and reasons of dropouts balanced 
between groups, informativeness 
unclear; treated patients set: 
patients received drug at least 
once. 
23 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
LTFU substantial~20%; exclusion 
reasonable; dropouts partly 
reported, numbers balanced, 
reasons not, informativeness 
unclear; primary ITT analysis 
(received drug at least once and had 
bl plus at least one post-bl 
measurement; appropriateness of 
LOCF imputation method unclear.  
LTFU substantial~20%; exclusion 
reasonable; dropouts partly 
reported, numbers balanced, 
reasons not, informativeness 
unclear; treated set: patients 
received drug at least once. 
24 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
Neither numbers nor reasons for 
dropouts reported; ITT analysis 
(received drug at least once and had 
bl plus at least one post-bl 
measurement); appropriateness of 
LOCF imputation method unclear. 
Neither numbers nor reasons for 
dropouts reported; treated set: 
patients received drug at least 
once. 
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25 „..computer-
generated sequence 
supplied by 
interactive voice or 
web response 
systems“. Probably 
done 
Adequately. 
NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value bw nr, balanced. 
Numbers and reasons of dropouts 
reported, imbalanced for 
therapeutic failure and withdrawal 
of consent, informativeness 
unclear; ITT analysis (received 
drug at least once and had bl plus at 
least one post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for 
therapeutic failure and withdrawal 
of consent, informativeness 
unclear; safety population: 
patients received drug at least 
once. 
26 NR „..Patients were 
allocated to 
treatment ..created 
by… thirdparty 
vendor.. . 
Numbered containers 
were used to 
implement allocation 
All study personnel, 
including 
investigators, study 
site personnel, 
patients, monitors, 
and central 
laboratory personnel, 
remained blinded to 
treatment allocation 
throughout the 
study“; done 
adequately. 
Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value bw nr,  
balanced. 
Numbers and reasons of dropouts 
balanced between groups; 
informativeness unclear; ITT 
analysis (FAS set: received drug at 
least once and had bl plus at least 
one post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
balanced between groups; 
informativeness unclear; all-
patients-as-treated population: 
patients received drug at least 
once. 
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27 „..computer-
generated sequence 
supplied by 
interactive voice or 
web response 
systems“. Probably 
done 
Adequately. 
NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
Numbers and reasons of dropouts 
reported, imbalanced, 
informativeness unclear; ITT 
analysis (received drug at least 
once and had bl plus at least one 
post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced, 
informativeness unclear; safety 
population: patients received drug 
at least once. 
28 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value bw nr,  
balanced. 
Numbers and reasons of dropouts 
reported, imbalanced, 
informativeness unclear; ITT 
analysis (all patients treated: 
received drug at least once and had 
bl plus at least one post-bl 
measurement); appropriateness of 
LOCF imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced, 
informativeness unclear; all-
patients-as-treated population: 
patients received drug at least 
once. 
29 NR NR No 
prespecified 
endpoints, 
but 
mentioned 
outcomes of 
data 
collection 
reported. 
Dose finding study: 
one low dose of 
Vildagliptin (25mg/d). 
Dropouts not reported, insufficient 
information for judgement; ITT 
analysis, not further defined; 
appropriateness of LOCF 
imputation method unclear. 
Dropouts not reported, insufficient 
information for judgement; ITT 
analysis, not further defined. 
30 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Low dose of 
Vildagliptin 
(50mgm/d). 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
protocol violation, informativeness 
unclear; ITT analysis, not further 
defined; appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
protocol violation, 
informativeness unclear; safety 
population: all rand. patients. 
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31 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Low dose of 
Vildagliptin 
(50mgm/d). 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
protocol violation, informativeness 
unclear; ITT analysis, not further 
defined; appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
protocol violation, 
informativeness unclear; safety 
population: all rand. patients. 
32 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Patients got pretherapy 
with glibenclamide; 
might favour outcome 
of Metformin on 
HbA1c and of 
Glibenclamide on bw. 
LTFU substantial~21%; numbers of 
dropouts balanced, reasons not, 
informativeness unclear; ITT 
analysis (all rand. patients); 
appropriateness of LOCF 
imputation method unclear. 
 
LTFU substantial~21%; numbers 
of dropouts balanced, reasons not, 
informativeness unclear; all rand. 
patients. 
 
33 NR „..central rand. via 
minitel to each study 
site“. 
Probably done 
adequately. 
Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value bw nr,  
balanced. 
Dropouts partly reported, numbers 
balanced, reasons unclear, 
insufficient information for 
judgement; ITT analysis (all 
patients treated: received drug at 
least once and had bl plus at least 
one post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Dropouts partly reported, numbers 
balanced, reasons unclear, 
insufficient information for 
judgement; safety population: 
patients received drug at least 
once. 
34 NR NR No 
prespecified 
endpoints, 
but 
mentioned 
outcomes of 
data 
collection 
reported. 
Addjustment for bl 
value bw nr, 
imbalanced. 
Dropouts partly reported, numbers 
balanced, reasons unclear, 
insufficient information for 
judgement; cross-over design, no 
washout between treatment periods, 
potential bias due to treatment 
period interaction; only data from 
first sequence was analyzed. 
Dropouts partly reported, numbers 
balanced, reasons unclear, 
insufficient information for 
judgement; cross-over design, no 
washout between treatment 
periods, potential bias due to 
treatment period interaction; only 
data from first sequence was 
analyzed; safety population: all 
rand. patients. 
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35 „..computer-
generated sequence 
supplied by 
interactive voice or 
web response 
systems“. Probably 
done 
Adequately. 
NR No 
prespecified 
endpoints, 
but 
mentioned 
outcomes of 
data 
collection 
reported. 
No hints for other 
bias. 
LTFU substantial~52%; dropouts 
only reported for whole population; 
OC analysis of patients who 
completed the study. 
LTFU substantial~52%; dropouts 
only reported for whole 
population; safety population: all 
rand. patients. 
36 NR „..central rand. via 
minitel to each study 
site“. 
Probably done 
adequately. 
Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Patients got pretherapy 
with sulfonylurea; 
might favour outcome 
of Glipizide on bw. 
LTFU substantial~27% 
(Glibenclamide) and 34% 
(Metformin); dropouts partly 
reported, numbers and reasons 
imbalanced, informativeness 
unclear; ITT analysis (all patients 
treated: received drug at least once 
and had bl plus at least one post-bl 
measurement); appropriateness of 
LOCF imputation method unclear. 
LTFU substantial~27% 
(Glibenclamide) and 34% 
(Metformin); dropouts partly 
reported, numbers and reasons 
imbalanced, informativeness 
unclear; safety population: 
patients received drug at least 
once. 
37 „..computer-
generated sequence 
supplied by 
interactive voice or 
web response 
systems“. Probably 
done 
Adequately. 
NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
patients decision, informativeness 
unclear; m-ITT analysis (received 
drug at least once and had bl plus at 
least one (un-) scheduled post-bl 
measurement); appropriateness of 
LOCF imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
patients decision, informativeness 
unclear; safety population: all 
rand. patients. 
38 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Patients got pretherapy 
with Metformin; 
Repaglinide dose high; 
might favour outcome 
of Repaglinide on 
HbA1c and of 
Metformin on bw. 
Numbers of dropouts reported, no 
reasons given, insufficient 
information for judgement; ITT 
analysis (received drug at least 
once and returned for at least one 
visit after the start of treatment); 
imputation method nr. 
Numbers of dropouts reported, no 
reasons given, insufficient 
information for judgement; safety 
population: patients received drug 
at least once. 
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39 „..computer-
generated sequence 
supplied by 
interactive voice or 
web response 
systems“. Probably 
done 
adequately. 
„..doublemasked 
treatment using 
numbered drug 
containers (without 
knowledge of the 
assigned treatment)“. 
Probably done 
adequately. 
No 
prespecified 
endpoints, 
but 
mentioned 
outcomes of 
data 
collection 
reported. 
Moderate weight gain 
under Repaglinide 
unusual; maybe due to 
cross-over design; 
hypoglycemias are 
reported in two 
categories; since 
aggregation is me-
thodologically 
inappropriate, 
symptomatic 
hypoglycemia was 
taken for core 
analysis. 
Numbers and reasons of dropouts 
reported, imbalanced for 
therapeutical failure, 
informativeness unclear; cross-over 
design, wash out period one month; 
default model (only patients who 
completed at least one treatment 
period were evaluated for treatment 
efficacy; dropouts to be included in 
the estimates of treatment effects). 
Numbers and reasons of dropouts 
reported, imbalanced for 
therapeutical failure, 
informativeness unclear; cross-
over design, wash out period one 
month; safety population: patients 
received drug at least once. 
40 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value bw nr,  
balanced. 
Numbers and reasons of dropouts 
reported, imbalanced for 
therapeutical failure, 
informativeness unclear; ITT 
analysis (all patients treated: 
received drug at least once and had 
bl plus at least one post-bl 
measurement); appropriateness of 
LOCF imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for 
therapeutical failure, 
informativeness unclear; safety 
population: patients received drug 
at least once and had at least one 
post-bl measurement. 
41 „..computer-
generated sequence 
supplied by 
interactive voice or 
web response 
systems“. Probably 
done 
adequately. 
NR No 
prespecified 
endpoints, 
but 
mentioned 
outcomes of 
data 
collection 
reported. 
Patients bl 
characteristics are 
reported for PP 
population only and 
might differ from 
analysed ITT 
population. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
lack of efficacy, informativeness 
unclear; ITT analysis (FAS set: all 
patients treated: received drug at 
least once and had bl plus at least 
one post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
lack of efficacy, informativeness 
unclear; safety population: all 
patients as treated, patients 
received drug at least once and for 
laboratory measurements had both 
bl and least one post-bl 
measurement. 
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42 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
No hints for other 
bias. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
lack of efficacy, informativeness 
unclear; ITT analysis (received 
drug at least once and had bl plus at 
least one post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
lack of efficacy, informativeness 
unclear; safety population: 
received at least one dose of study 
medication and had at least one 
postbaseline safety assessment. 
43 NR „..central allocation 
via active response 
system“. Probably 
done adequately. 
Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value bw nr,  
balanced. 
Numbers and reasons of dropouts 
reported, imbalanced for lack of 
efficacy, informativeness unclear; 
ITT analysis (received drug at least 
once and had bl plus at least one 
post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for lack of 
efficacy, informativeness unclear; 
safety population: patients 
received drug at least once. 
44 „..computer-
generated sequence 
supplied by 
interactive voice or 
web response 
systems“. Probably 
done 
Adequately. 
NR No 
prespecified 
endpoints, 
but 
mentioned 
outcomes of 
data 
collection 
reported. 
Safety population: all 
rand. patients instead 
of patients entering 
extension phase: 
potential 
underestimation of 
adverse events (see 
incomplete outcome 
data hypoglycemia). 
Numbers and reasons of dropouts 
reported, imbalanced for lack of 
efficacy and ae, informativeness 
unclear ; ITT analysis (continuation 
all-patients-treated population, all 
randomized patients who had a 
baseline measurement, did not 
receive glycemic rescue therapy in 
phase A, received at least one dose 
of study medication in the 
continuation phase, and had at least 
one efficacy measurement during 
the continuation phase); 
appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for lack of 
efficacy and ae, informativeness 
unclear ; safety population: all-
patients-as-treated (APaT) 
population, which consisted of all 
randomized patients who received 
at least one dose of study 
medication. 
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45 „..computer-
generated sequence 
supplied by 
interactive voice or 
web response 
systems“. Probably 
done 
adequately. 
NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Safety population: all 
rand. patients instead 
of patients entering 
extension phase: 
potential 
underestimation of 
adverse events (see 
incomplete outcome 
data hypoglycemia). 
LTFU substantial~23% 
(Metformin) - 36% (Sitagliptin); 
numbers and reasons of dropouts 
reported, imbalanced for lack of 
efficacy and ae, informativeness 
unclear; ITT analysis (continuation 
all-patients-treated population, all 
randomized patients who had a 
baseline measurement, did not 
receive glycemic rescue therapy in 
phase A, received at least one dose 
of study medication in the 
continuation phase, and had at least 
one efficacy measurement during 
the continuation phase); appropria-
teness of LOCF imputation method 
unclear. 
LTFU substantial~23% 
(Metformin) - 36% (Sitagliptin); 
numbers and reasons of dropouts 
reported, imbalanced for lack of 
efficacy and ae, informativeness 
unclear; safety population: all-
patients-as-treated (APaT) 
population, which consisted of all 
randomized patients who received 
at least one dose of study 
medication. 
46 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value bw nr,  
balanced. 
LTFU substantial~25% 
(Metformin) -28% (Vildagliptin); 
numbers and reasons of dropouts 
reported, imbalanced for lack of 
efficacy, ae and exclusion by 
investigator, informativeness 
unclear; ITT analysis (received 
drug at least once and had bl plus at 
least one post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
LTFU substantial~25% 
(Metformin) -28% (Vildagliptin); 
numbers and reasons of dropouts 
reported, imbalanced for lack of 
efficacy, ae and exclusion by 
investigator, informativeness 
unclear; safety population: 
received at least one dose of study 
medication and had at least one 
postbaseline safety assessment. 
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47 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Adjustment for bl 
value bw nr,  
balanced. 
Numbers and reasons of dropouts 
reported, imbalanced for 
therpeutical failure, 
informativeness unclear; extension 
ITT analysis (all randomized 
patients who had a baseline 
measurement, did not receive 
glycemic rescue therapy in core 
study, received at least one dose of 
study medication in the 
continuation phase, and had at least 
one efficacy measurement during 
the continuation phase);appropria-
teness of LOCF imputation method 
unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for 
therpeutical failure, 
informativeness unclear; 
extension safety population: 
received at least one dose of 
extension study medication 
and had at least one extension 
post-bl safety assessment. 
48 NR NR Prespecified 
endpoints 
adequately 
reported 
(number & 
effect 
measure). 
Unclear if other oral 
antidiabetic agents 
were allowed; authors 
didn´t state in which 
populations analyses 
were done. 
Dropouts only partly reported for 
ae, insufficient information for 
judgement; ITT analysis (not 
further defined); appropriateness of 
LOCF imputation method unclear. 
Dropouts only partly reported for 
ae, insufficient information for 
judgement; safety population: all 
rand. patients. 
49 NR NR No 
prespecified 
endpoints, 
but 
mentioned 
outcomes of 
data 
collection 
reported. 
Adjustment for bl 
value bw nr,  
balanced. 
LTFU substantial~46% 
(Pioglitazone)-49% (Glyburide); 
numbers and reasons of dropouts 
reported, imbalanced for lack of 
efficacy and ae, informativeness 
unclear; ITT analysis (received at 
least one dose of study medication, 
no further definition); appropria-
teness of LOCF imputation method 
unclear. 
LTFU substantial~46% 
(Pioglitazone)-49% (Glyburide); 
numbers and reasons of dropouts 
reported, imbalanced for lack of 
efficacy and ae, informativeness 
unclear; safety population: ITT 
cohort (all rand. patients). 
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50 NR NR No prespecified 
endpoints, but 
mentioned 
outcomes of data 
collection 
reported. 
No hints for other 
bias. 
LTFU substantial~38% 
(Glibenclamide)-40% 
(Pioglitazone); imbalanced for 
lack of efficacy, further reasons 
not stated, informativeness 
unclear; ITT analysis (received 
drug at least once and had bl plus 
at least one post-bl measurement); 
appropria-teness of LOCF 
imputation method unclear 
LTFU substantial~38% 
(Glibenclamide)-40% 
(Pioglitazone); imbalanced for 
lack of efficacy, further reasons 
not stated, informativeness 
unclear; safety population: all 
rand. patients. 
51 „..random number 
table“. 
Probably done 
Adequately. 
„..central allocation 
via active response 
system“. Probably 
done adequately. 
No prespecified 
endpoints, but 
mentioned 
outcomes of data 
collection 
reported. 
No hints for other 
bias. 
LTFU substantial~29%; numbers 
and reasons of dropouts reported, 
imbalanced for lack of efficacy, 
informativeness unclear; 
ITT analysis (received drug at 
least once and had bl plus at least 
one post-bl measurement); 
appropria-teness of LOCF 
imputation method unclear. 
LTFU substantial~29%; numbers 
and reasons of dropouts reported, 
imbalanced for lack of efficacy, 
informativeness unclear; safety 
population: all rand. patients. 
52 NR NR Prespecified 
endpoints 
adequately 
reported (number 
& effect measure). 
Usufficient dose 
escalation of glipizide 
(5-15mg/d); might 
favour outcome of 
Repaglinide on 
HbA1c and of 
Glipizide on bw. 
LTFU substantial~20% 
(Repaglinide) – 28% (Glipizide); 
numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; ITT 
analysis (not further defined); 
imputation method nr. 
LTFU substantial~20% 
(Repaglinide) – 28% (Glipizide); 
numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; no 
safety population reported; all 
rand. patients were taken as 
approximation. 
53 NR NR No prespecified 
endpoints, but 
mentioned 
outcomes of data 
collection 
reported. 
Adjustment for bl 
value HbA1c & bw 
nr,  balanced. 
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54 NR NR Prespecified 
endpoints 
adequately 
reported (number 
& effect measure). 
Adjustment for bl 
value HbA1c & bw 
nr,  balanced; unclear 
in which population 
assessment of bw was 
done. 
LTFU substantial~21% 
(Glyburide) – 26% (Repaglinide); 
numbers of drop outs imbalanced, 
no intervention-specific reasons 
stated, insufficient information for 
judgement; ITT analysis (not 
further defined); appropriateness 
of LOCF imputation method 
unclear. 
LTFU substantial~21% 
(Glyburide) – 26% 
(Repaglinide); numbers of drop 
outs imbalanced, no intervention-
specific reasons stated, 
insufficient information for 
judgement; safety population 
equated to ITT population. 
55 NR NR Prespecified 
endpoints 
adequately 
reported (number 
& effect measure). 
No hints for other 
bias. 
Numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; ITT 
analysis (full analysis set: received 
drug at least once and had bl plus 
at least one post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
balanced between groups, 
informativeness unclear; safety 
population: patients received 
drug at least once. 
56 NR NR Prespecified 
endpoints 
adequately 
reported (number 
& effect measure). 
Adjustment for bl 
value HbA1c & bw 
nr,  imbalanced. 
LTFU substantial~16% 
(Glimepiride) – 45% (Acarbose); 
numbers and reasons of dropouts 
reported, imbalanced for 
withdrawal, ae and lack of 
efficacy; informativeness unclear; 
ITT analysis (not further defined); 
appropriateness of LOCF 
imputation method unclear. 
LTFU substantial~16% 
(Glimepiride) – 45% (Acarbose); 
numbers and reasons of dropouts 
reported, imbalanced for 
withdrawal, ae and lack of 
efficacy; informativeness 
unclear; safety population: all 
rand. patients. 
57 NR NR Prespecified 
endpoints 
adequately 
reported (number 
& effect measure). 
No hints for other 
bias. 
Numbers and reasons of dropouts 
reported, imbalanced for 
noncompliance, informativeness 
unclear; only pp analysis reported. 
Numbers and reasons of dropouts 
reported, imbalanced for 
noncompliance, informativeness 
unclear; safety population: all 
rand. patients.  
 184                 Appendix 
58 NR NR NR Abstract, no 
comprehensive 
assessment possible. 
Abstract, no comprehensive 
assessment possible. 
Abstract, no comprehensive 
assessment possible. 
59 NR NR Prespecified 
endpoints 
adequately 
reported (number 
& effect measure). 
No hints for other 
bias. 
LTFU substantial~25%; numbers 
and reasons of dropouts balanced 
between groups, informativeness 
unclear; ITT analysis for HbA1c 
(received drug at least once and 
had bl plus at least one post-bl 
measurement); appropriateness of 
LOCF imputation method unclear; 
pp analysis for body weight. 
LTFU substantial~25%; numbers 
and reasons of dropouts balanced 
between groups, informativeness 
unclear; safety population: 
patients received drug at least 
once. 
60 NR NR Prespecified 
endpoints 
adequately 
reported (number 
& effect measure). 
Adjustment for bl 
value bw nr,  
balanced. 
Numbers and reasons of dropouts 
reported, imbalanced for 
withdrawal, ae and lack of 
efficacy; informativeness unclear; 
ITT analysis (received drug at 
least once and had bl plus at least 
one post-bl measurement); 
appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for 
withdrawal, ae and lack of 
efficacy; informativeness 
unclear; safety population not 
further defined, presumably all 
patients with exposure to study 
medication. 
61 NR NR NR Chinese publication, 
no comprehensive 
assessment possible. 
Chinese publication, no 
comprehensive assessment 
possible. 
Chinese publication, no 
comprehensive assessment 
possible. 
62 NR NR Prespecified 
endpoints 
adequately 
reported (number 
& effect measure). 
Adjustment for bl 
value bw nr,  
balanced. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
lack of efficacy; informativeness 
unclear; ITT analysis (not further 
defined); appropriateness of LOCF 
imputation method unclear. 
Numbers and reasons of dropouts 
reported, imbalanced for ae and 
lack of efficacy; informativeness 
unclear; safety population: 
patients received drug at least 
once. 
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 The following domains of risk of bias were left out: 
- risk of bias for blinding participants and personnel and for blinding of outcome assessment for HbA1c and body weight: since these outcomes are measured they are deemed to 
be insusceptible to bias of unblinding or open-label studies. Thus, all studies were rated to be at low bias within these domains. 
- risk of bias for blinding participants and personnel and for blinding of outcome assessment for hypoglycemia. Since this is partly a patient reported outcome knowledge of the 
administered drug could possibly bias the reporting of symptoms of hypoglycemia by patients and their evaluation by outcome assessors. Therefore, the risk of bias for blinded 
studies (n=55) was graded to be unclear since adverse reactions of the drugs could lead to unblinding; for the open-label studies (n=5) the risk of bias was judged as high.  
NR, not reported. Bl, baseline. D, day. PP, per protocol analysis. (m) ITT, (modified) intention to treat analysis. FAS, full analysis set. OC, observed cases analysis. LOCF, last 
observation carried forward. LTFU, loss to follow-up. AE, adverse events. SD, standard deviation. 
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B Figures 
 
B.1 Figure 8 
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b.) Body weight 
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c.) Hypoglycemia 
 
D-G 
A-B 
A-C 
 196                 Appendix 
 
 
 
A-D 
A-F 
A-G 
 197                 Appendix 
 
 
 
B-C 
B-E 
B-F 
 198                 Appendix 
 
 
 
B-G 
C-D 
C-E 
 199                 Appendix 
 
 
 
 
Figure 8: Forest plots of direct pairwise frequentist meta- analysis  
For a.) HbA1c b.) body weight and c.) hypoglycemia. No forest plots for comparisons D-E/D-F/E-G and          
A-E/B-D/E-F/F-G since no direct evicende is available and direct evidence is only supported by one study, 
respectively. 
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B.2 Figure 9 
 
a.) Gliptins vs. placebo (A-G) 
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Body weight 
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b.) Gliptins vs. Metformin (B-G) 
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Body weight 
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Hypoglycemia 
 
Figure 9: Contour enhanced funnel plots and test for funnel plot asymmetry  
For the summary estimates of a.) gliptins vs. placebo (A-G) and b.) gliptins vs. Metformin (B-G) for HbA1c, body weight and hypoglycemia, respectively. 
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B.3 Figure 11 
 
a.) 
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b.)
 
Figure 11: Covariate vs. outcome plots 
 Plot of a.) the difference in means against the baseline HbA1c and b.) the log odds ratios against the length of follow-up of the crude estimates of direct comparisons. 
The plotted numbers refer to observations comparing contrasts as follows: 1=A-B, 2=A-C, 3=A-D, 4=A-E, 5=A-F, 6=A-G, 7=B-C, 8=B-D, 9=B-E, 10=B-F, 11=B-G, 12=C-D, 
13=C-E, 14=C-F, 15=C-G, 16=D-G, 17=E-F, 18=F-G. The coloured lines represent the relative effects of the treatments compared to placebo as follows: Metformin (red), 
sulfonylureas (green), Pioglitazone (blue), meglitinides (yellow), alpha-glucosidase inhibitors (black) and gliptins (pink). 
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B.4 Figure 12 
 
a.) HbA1c 
 
b) Body weight 
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c.) Hypoglycemia 
 
Figure 12: Network diagrams for sensitivity analysis for the risk of bias 
For a.) HbA1c, b.) body weight and c.) hypoglycemia without possibly biased studies. 
HbA1c, glycated haemoglobin. 
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